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Abstract:
The nuclear receptor Hepatocyte Nuclear- Factor 4a  (HNF4a; NR2A1) regulates tire 
tr anscription of many genes involved in glucose and lipid metabolism. Genetic linkage 
analyses have implicated HNF4a in the disease processes leading to Type 2 Diabetes 
Mellitus and dyslipidaemia. The aim of this stirdy was to investigate the regulation of target 
genes in the metabolic pathways of glycolysis, lipogenesis and gluconeogenesis by HNF4a.
hiitally, the expression of HNF4a and its splice variants was investigated in three human 
hepatoma cell lines, HuH7, HepG2 and Hep3B, with the latter two cell lines shown to express 
the same range of HNF4a splice variants as human adult liver. The regulation of specific 
HNF4a target genes, L-PK, PEPCK and SREBP-lc, was subsequently investigated in HepG2 
cells using a reporter gene approach. HNF4a was found to induce expression of reporter 
genes containing L-PK, PEPCK and SREBP-lc proximal promoter sequences. Insulin 
(1 pM), but not high glucose (25 mM), was formd to stimulate HNF4a-dr*iven expression of 
the SREBP-lc reporter gene, while co-expression of HNF4a with the nuclear receptor co­
activators, PGC-la or p300, led to a reduction in SREBP-lc reporter gene expression.
The changes in expression of various HNF4a tar get genes in response to physiological . 
mediators of the fasting-fed cycle were characterised in HepG2 cells using a real-time 
quantitative PGR approach. The role of HNF4a, p300 and PGC-la was further investigated 
by plasmid overexpression, HNF4a and PGC-la were found to positively regulate PEPCK 
expression under cell culture conditions simulating fasting (cAMP), whilst overexpression of 
HNF4a, PG Cla and p300 reduced L-PK mRNA expression under fed conditions.
In conclusion, the results indicate that HNF4a is a tr anscriptional activator of both glucagon- 
stimulated gluconeogenic gene expression and insulin-stimulated glycolytic and lipogenic 
gene expression. It is hypothesised HNF4a forms separate multi-protein complexes to 
differentially regulate metabolic pathways under different metabolic states.
rv
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Chapter 1 
Introduction
Chapter 1 :
The increase in Type 2 Diabetes Mellitus (T2DM) over the last century presents a global 
public health problem, with the incidence of T2DM predicted to double by 2025 (Zimmet et 
al., 2001). It is hypothesised tliat a better imderstanding of the intracellular' pathways in the 
liver, pancreas, muscle and adipose tissue, which lead to the state of insulin resistance and 
relative insulin deficiency, will facilitate the development of new therapeutic targets to 
prevent and treat this disease (Moller, 2001). The transcriptional control of metabolic 
pathways is one mechanism by which homeostasis of plasma glucose and lipid levels is 
maintained and elucidation of the molecular mechanisms underlying these processes is vital 
to understanding their dysregulation in metabolic disease (Desvergne et a l , 2006).
Nuclear receptors (NRs) are ligand-activated tr anscription factors involved in integrating a 
wide range of metabolic and hormonal signals, and specific NRs have already been shown to 
have an important role in T2DM. Activation of the NR, peroxisome proliferator-activated 
receptor y (PPARy), by the anti-diabetic thiazolidinedione (TZD) class of drugs increases 
insulin sensitivity by inducing adipocyte differentiation and increasing triacylglycerol 
storage, resulting in decreased plasma non-esterifred fatty acid (NEFA) levels (Kersten et al,
2000). Like tlie PPAR gene family, hepatocyte nuclear factor 4a (HNF4a) binds fatty acid 
metabolites, making HNF4a a potential target for therapeutic intervention (Section 1.7), 
however the regulation of HNF4a target genes under different metabolic conditions is less 
well defined. In view of the genetic evidence that HNF4a has a role in T2DM and related 
disorders (Section 1.6), fur ther investigation of the role HNF4a in regulating genes in key 
metabolic patliways is called for.
Metabolic disorders are characterised by altered levels of hormones and dysregulation of 
metabolic pathways by hormonal stimuli. Therefore the metabolic stimuli (Section 1.1) and 
metabolic patliways (Section 1.3) relevant to disorders such as T2DM, dyslipidaemia and the 
metabolic syndrome (Section 1.2) will be described in the following sections.
1.1 Metabolic stimuli
1.1.1 Insulin and glucagon
Insulin and glucagon are peptide hormones produced by the p-cells and a-cells in the Islets of 
Langerhans, which constitute 2% by mass of the pancreas (Pocock and Richards, 2006). The 
two hormones have counter-regulatory functions on glucose and lipid homeostasis, with 
insulin having an anabolic action on metabolism and glucagon a catabolic role (Table 1.1). 
Insulin secretion occurs in two phases: the first secretory phase lasting a few minutes 
followed by a more sustained release of insulin (Holt and Hanley, 2007). The primary 
stimulus for insulin secretion is increased plasma glucose concentration, however amino 
acids and hormones such as secretin, glucagon and glucagon-like peptide also stimulate 
insulin secretion (Pocock and Richar ds, 2006). Glucagon secretion is stimulated by 
hypoglycaemia, amino acids and the gastrointestinal hormone, cholecystokinin, and inhibited 
by insulin (Pocock and Richards, 2006). Plasma glucagon concentrations vary less than 
insulin concentrations, hence the ratio of insulin to glucagon is important in determining the 
overall effect on cell metabolism (Pocock and Richards, 2006).
Table 1.1: Principle functions of insulin and glucagon.Target organ Insulin Glucagon
Liver Suppresses gluconeogenesis 
and stimulates glycolysis
Stimulates gluconeogenesis
Liver and skeletal muscle Stimuiates glycogen synthesis -
Liver and skeietal muscle Suppresses glycogenolysis Stimulates glycogenolysis
Skeletal muscle Stimuiates glucose uptake -
Adipose tissue Stimulates lipid uptake 
Suppresses lipolysis
Stimulates lipolysis
Liver and adipose tissues Stimulates lipogenesis -
Liver Suppresses fatty acid oxidation Stimulates fatty acid oxidation
Muscle Suppresses protein breakdown -
Key: Dash (-) indicates no direct effect. Based on information in Holt and Hanley (2007) and 
Pocock and Richards (2006).
1.1.2 Glucocorticoids
Glucocorticoids are steroid hormones produced by the adrenal gland, with cortisol being tire 
dominant glucocorticoid in humans and smaller amounts of corticosterone and cortisone 
being produced (Pocock and Richards, 2006). Tire hypothalamic-pituitary-adrerral (HPA) 
axis regulates glucocorticoid secretion, with production of corticotropin releasing hormone 
(CRH) by the hypothalamus stimulating release of adrenocorticotrophic hormone (ACTH) 
from the anterior pituitary which in tunr stimulates glucocorticoid synthesis (Pocock and 
Richards, 2006). Plasma cortisol levels increase during periods of fasting due to amplified
secretory bursts from the adrenal gland (Beer et aL, 1989; Bergendahl et al., 1996). Re­
programming of tlie HPA axis resulting in raised cortisol levels have been proposed to be one 
mechanism by which low birth weight is associated with metabolic syndrome (Section 1.2.3) 
(Phillips et al., 1998). Glucocorticoids are a ligand for the glucocorticoid receptor (GR), a 
member of the NR superfamily (Section 1.4.5).
1.1.3 Signalling pathways
The opposing actions of glucagon and insulin on intracellular processes are mediated by 
different phosphorylation cascades downstream of the respective hormone receptors. The 
glucagon receptor is coupled to a stimulatory G-proteins (Gs) which activate adenylyl 
cyclase, leading to rises in intracellular cAMP concentration and activation of protein kinase 
A (Figure 1.1 A) (Frayn, 2003).
Binding of insulin to the insulin receptor results in receptor autophosphorylation of tyr osine 
residues, association of insulin receptor substrates (1RS) and activation of 
phosphatidylinositol 3-kinase (PI3K). PI3K generates phosphatidylinositol (3% 4% 5’)- 
triphosphate, leading to activation of phosphoinositide-dependent kinase (PDK), which in 
turn activates protein Idnase B (PKB) (Figure I.IB) (Frayn, 2003). Mitogen-activated kinase 
pathways (MAPK) are also modulated by insulin signalling, with the Ras-Raf-MEKl-ERK 
cascade being activated by insulin, whereas the p38 MAPK cascade is antagonized by insulin 
(Keeton et a l, 2002). The PI3K cascade mediates many of the effects of insulin on the 
expression of genes involved in metabolism, whilst the MAPK cascade activates genes 
involved in cell proliferation and the cell cycle (Saltiel and Kalm, 2001).
As well as hormones signalling whole-body metabolite requirements, intiacellulai' energy 
status is signalled by AMP-activated protein kinase (AMPK), which is activated by an 
increase the AMP/ATP ratio (Figure I.IC) (Hardie, 2004). AMPK suppresses energy- 
expending processes such as gluconeogenesis and lipogenesis (Sections 1.3.1 and 1.3.3) and 
stimulates the production of ATP by catabolic pathways such as fatty acid oxidation (Viollet 
et al., 2006). The oral hypoglycaemic drug, metformin, reduces hepatic glucose production 
through activation of AMPK (Zhou et a l, 2001).
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Figure 1.1: Key signalling pathways in the regulation of metabolism: (A) Glucagon 
(B) Insulin and (C) AMPK. (A) Glucagon receptor is coupled to Gs protein which 
activates adenylyl cyclase, raising intracellular cAMP and activating PKA. Diagram 
adapted from Frayn (2003). (B) Insulin receptor autophosphorylation leads to binding 
and activation of 1RS and activation of the PI3K and MAPK cascades. Diagram adapted 
from Saltiel and Kahn (2001). (C) AMPK is raised AMP concentration and inhibited by 
ATP. Adenylate kinase converts ADP to AMP. Diagram from Hardie (2004).
1.2 Metabolic disorders
1.2.1 Diabetes mellitus
Diabetes mellitus is characterised by elevated fasting blood glucose (hyperglycaemia) due to 
an absolute or relative deficiency in insulin secretion by pancreatic p-cells. Prolonged 
hyperglycaemia results in symptoms of polyuria and polydipsia, as the kidneys attempt to 
restore plasma glucose homeostasis by excreting excess plasma glucose. A diagnosis of 
diabetes mellitus is reached after measurement of a fasting plasma glucose concentrations 
exceeding 7.0 mmol/1 or non-fasting plasma glucose concentration gieater than 11.1 imnol/1 
on two separate occasions (American Diabetes Association, 2002). In addition, diabetes 
mellitus can be diagnosed by means of an oral glucose tolerance test (OGTT), whereby a 
glucose load is given orally and blood glucose measurements taken at intervals afterwards. A 
plasma glucose concentration exceeding 11.1 mol/1 at the 2 hour timepoint in the OGTT 
constitutes a diagnosis of diabetes mellitus (American Diabetes Association, 2002). The term 
‘impaired glucose tolerance’ (IGT) refers to an intermediate stage in the development of 
diabetes mellitus where insulin secretion is unable to ftilly compensate for an increase in 
blood glucose, with a definition of a 2 horn' plasma glucose concentration of > 7.8 mmol/1 and 
<11.1 mmol/1 during an OGTT (American Diabetes Association, 2002).
The prognosis for patients with diabetes mellitus is a reduction in life expectancy by about 
one third, with the main cause of premature mortality being cardiovascular disease (CVD) 
(Holt and Hanley, 2007). The increased risk of suffering from CVD or a stroke are the 
macro vascular complications of the disease (Holt and Hanley, 2007). Microvascular 
complications of diabetes mellitus include retinopathy, neplnopathy and neuropathy, wliich 
can result in loss of vision, kidney failure and limb amputation (Holt and Hanley, 2007).
The most conunon forms of diabetes mellitus, types 1 and 2 diabetes mellitus (TIDM and 
T2DM respectively) differ markedly in their aetiology, metabolic alterations and treatment 
(Table 1.2). TIDM develops in childhood and is caused by p-cell destruction by an 
autoimmune process in the majority of cases, whereas T2DM develops in middle/old age and 
is caused by insulin resistance accompanied by the inability of the pancreas to compensate by 
producing increased amoimts of insulin. Insulin resistance is the reduced ability of the liver, 
skeletal muscle and adipose tissue to respond to insulin and maintain glucose homeostasis 
(Reaven, 1988). Obesity is the most conunon cause of insulin resistance (Bogaidus, 1985).
Table 1.2: Comparison of Ty pes 1 and 2 Diabetes Mellitus.
Type 1 Diabetes Mellitus Type 2 Diabetes Mellitus
Defect Auto-immune destruction of 13- 
cells
insulin resistance with defective 
insulin secretion
Age of onset (years) 1-25 >40
Typical bodily physique Lean (weight loss at diagnosis) Obese
Prevalence (whole 
population)
0.5% 2%
Inheritance -  50% ~ 70-80%
Ketoacidosis Develops in untreated T1 DM Not prone to ketoacidosis
T reatment Insulin Diet, oral hypoglycaemic 
agents, insulin at later stages
Table adapted from Frayn (2003).
A feedback loop of hyperglycaemia and increased insulin secretion ultimately leads to 
pancreatic p-cell malfunction in T2DM (Kalin, 2003). First phase insulin secretion is lost in 
T2DM, with second phase secretion also being diminished as the disease progresses (Holt 
and Hanley, 2007).
Type 1 diabetics are normally treated with insulin, whereas Type 2 diabetics are often treated 
initially with diet and exercise guidelines and an oral hypoglycaemic agent. These orally 
ingested drugs include sulfonylureas, metformin and thiazolidinediones, which act by 
stimulating insulin secretion (sulfonylureas) and increasing insulin sensitivity in liver 
(metfoimin) and adipose tissue (thiazolidinediones) (Flolt and Hanley, 2007),
Changes in diet and an increasingly sedentar y lifestyle mean that an epidemic of diabetes 
mellitus (with the majority of cases being T2DM) is being predicted for many westernised 
countries, as well as > 50% increases in diabetes mellitus in developing countries such as 
China and India (Zimmet et a l , 2001). Global prevalence of diabetes mellitus is predicted to 
rise from 2.8% to 4.4% between 2000 and 2030 (Wild et a l, 2004). However, factors such as 
increasmg levels of obesity and decreased mortality may mean that current predictions 
underestimate the increase in T2DM (Lipscombe and Hux, 2007). hicreased prevalence of 
T2DM will place an increased public health burden on affected countries for treatment of 
diabetes and its complications (Zinunet et al., 2001).
1.2.2 Dyslipidaemia
Dyslipidaemias are disorders of lipid metabolism, whereby serum cholesterol or triglyceride 
concentrations, or concentr ations of both, are above (hyperiipidaemias) or below 
(hypolipidaernias) the normal ranges (Durrington, 2003). A major contributing factor to the 
increased risk of developing CHD in diabetics is the dyslipidaemia associated with the
disease (Holt and Hanley, 2007). In fact, it has been suggested that T2DM develops as a 
result of alterations in lipid metabolism rather than glucose metabolism (McGaiTy, 1992). In 
the initial stages of the disease {le. before pancreatic p-cell insufficiency), increased plasma 
non-esterified fatty acids (NEFA) are linked to decreased fatty acid oxidation in muscle, 
hyperinsulinaemia and increased hepatic glucose production, thereby promoting insulin 
resistance (McGairy, 2002). Diabetic dyslipidaemia is characterised by 
hypertriglyceridaemia, low levels of high density lipoprotein (FIDL) cholesterol and the 
presence of small dense low density lipoprotein (LDL) particles (discussed fur ther in Section 
1.3.4) (Durrington, 2003).
1.2.3 The Metabolic Syndrome
The considerable overlap in the aetiologies of T2DM, dyslipidaemia and CVD led to the 
proposal that the development of underlying insulin resistance precedes the development of 
overt disease (Reaven, 1988). The term ‘Metabolic Syndrome’ was therefore coined to refer 
to the clustering of insulin resistance, obesity, dyslipidaemia and hypertension as risk factors 
for developing CVD and T2DM (Reaven, 1988). The International Diabetes Federation 
definition for metabolic syndrome specifies the presence of central adiposity plus two of the 
following four factors: raised plasma triglyceride levels, reduced FIDL cholesterol, raised 
blood pressure or raised fasting plasma glucose (Alberti et a l, 2006). The development of 
non-alcoholic fatty liver disease (NAFLD), a condition marked by intrahepatic triglyceride 
accumulation, has been described as a feature of the metabolic syndrome (Maichesini et a l,
2001), wan anting further investigation of the alterations in hepatic metabolism under 
conditions of insulin resistance or hyperinsulinaemia (Desvergne et a l, 2006).
1.3 Metabolic pathways
The function of metabolic pathways of gluconeogenesis, glycolysis, lipogenesis and 
lipoprotein metabolism and their dysregulation in metabolic disorders will be discussed in 
detail below.
1.3.1 Gluconeogenesis
Gluconeogenesis is the synthesis of glucose from non-caibohydrate precursors, le. lactate, 
amino acids and glycerol (Figme 1.2). Hepatic gluconeogenesis is stimulated by a decrease 
in the ratio of insulin to glucagon and contributes to glucose homeostasis in the post- 
absorptive state {e.g. an overnight fast), alongside the breakdown of liver glycogen stores. In
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tlie case of staiwation (> 24 horns fasting), liver glycogen stores are depleted and hepatic 
glucose output is derived entirely from gluconeogenesis (Frayn, 2003).
The flux thi'ough the gluconeogenic pathway is determined by the enzyme activities of 
phosphoenolpyruvate carboxyldnase (PEPCK), fructose 1,6-bisphosphatase and glucose 6- 
phosphatase (G-6-Pase) (Figure 1.2) (Salway, 2004). PEPCK (EC 4.1.1.32) catalyses the 
first rate-determining step, converting oxaloacetate and GTP to phosphoenolpyruvate and 
GDP witli the release of CO2. Oxaloacetate formed by pyruvate caiboxylase in the 
mitochondrion is converted to mal ate and transported to the cytosol, followed by the 
reconversion of malate to oxaloacetate by malate dehydrogenase (Figuie 1.2). This has the 
net effect of removing carbons fr om the tricarboxylic acid (TCA) cycle, a process laiown as 
cataplerosis (Hakimi et a l, 2005). PEPCK activity is not modified by allosteric regulation, 
therefore its activity is controlled primarily at the level of its gene transcription (Hanson and 
Reshef, 1997) (discussed fruther in Section 1.9.1). The second rate-determining step, 
catalysed by fructose 1,6-bisphosphatase (EC 3.1.3.11), is the hydrolysis of fructose 1,6- 
bisphosphate to form fructose 6-phosphate with the release of inorganic phosphate (Figure
1.2). Fructose 1,6-bisphosphatase activity is subject to allosteric inliibition by fructose 2,6- 
bisphosphate, the concentiation of which is reduced in the fasting state as the glucagon to 
insulin ratio increases (Salway, 2004). The final step of the gluconeogenic pathway, the 
hydrolysis of glucose 6-phosphate to foim glucose and inorganic phosphate, is catalysed by 
G-6-Pase (EC 3.1.3.9). The catalytic site of this enzyme is located in the lumen of the 
endoplasmic reticulum, with its substrate being supplied by a specific translocase (van 
Schaftingen and Gerin, 2002). G-6-Pase is regulated in the short term by the concentration of 
glucose 6-phosphate and G-6-Pase activity is regulated in the long term at the level of its 
gene expression (van Schaftingen and Gerin, 2002).
In T2DM, insulin fails to suppress endogenous glucose production (Firth et a l, 1986; 
Mitrakou et a l, 1990), with increased gluconeogenic rate responsible for the increase in 
hepatic glucose output (DeFronzo et a l, 1989; Consoli et a l, 1989; Magnusson et a l, 1992). 
Hepatic insulin resistance results in lack of inhibition of PEPCK and G-6-Pase expression by 
insulin, as demonstrated in a liver insulin receptor laiockout mouse model (Michael et a l , 
2000). Overexpression of PEPCK in transgenic mice also resulted in T2DM (Valera et a l, 
1994).
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Figure 1.2: The gluconeogenic pathway. The formation of glucose from pyruvate is 
shown with metabolic intermediates. The key regulatory steps (wide arrows) and the 
enzymes which catalyse them are indicated in bold. Intracellular compar tments ar e 
indicated in italics, with the TCA cycle indicated by a circle in the mitochondrion. 
Abbreviations: ER, endoplasmic reticulum.
1.3.2 Glycolysis
The glycolytic pathway is the first pathway in the catabolism of glucose by the cell (Figure 
1.3). It differs horn gluconeogenesis (Figure 1.2) in tlrree differeirt control points in the 
pathways: namely, the phosphorylation of glucose by glucokirrase (EC 2.7.1.2), the 
phosphorylation of fructose-6-phosphate by phosphofructokinase (EC 2.7.1.56) and the 
conversion of phosphoenolpyr uvate to pyr uvate catalysed by liver-type pyr uvate kinase (L-
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Figure 1.3: Glycolytic and lipogenic pathways. Glucose is tiaiisported into the 
hepatocyte by glucose transporter GLUT2, followed by its phosphorylation by 
glucokinase, the first step of the glycolytic pathway (left-hand side). Key control points 
in the glycolytic pathway aie indicated by wide aiTows, namely glucoldnase, 
phosphohuctokinase and the final step of the pathway, L-PK. Fatty acids generated by 
de novo lipogenesis or recycled by the liver are converted to triglycerides and exported 
in the form of very low density lipoprotein (VLDL), Abbreviations: GPAT, glycerol 3- 
phosphate acyl transferase. Diagram adapted from Dentin et al. (2005).
PK) (EC 2.7.1.40), thus ensuring that the two pathways do not become a futile cycle. In the 
liver, the glycolytic pathway in tlie first stage of de novo lipogenesis in the synthesis of fatty 
acids from dietary caibohydrates (Section 1.3.3).
L-PK catalyses the transfer of a phosphoryl group fr om phosphoenolpyruvate to ADP, 
generating pyruvate and ATP (Figure 1.9). The reaction of tliis final step of the glycolytic 
pathway is irreversible and thus controls flux of pyruvate into the TCA cycle. L-PK activity 
is subject to allosteric regulation, with ATP and alanine (a product of downstream pathways) 
inhibiting its activity, and fr uctose 1,6-bisphosphate (a product of upstieam
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phosphofi'uctoldiiase) stimulating its activity (Salway, 2004). L-PK is also phosphorylated 
by PKA downstream of glucagon action, resulting inhibition of its activity in the fasting state, 
whilst insulin stimulates protein phosphatase 2A, wliich dephosphorylates and activates L- 
PK. In the long term, L-PK protein levels are regulated by changes to L-PK niRNA levels 
(Section 1.9.2). Increased L-PK niRNA expression has been demonstrated in several rodent 
models of T2DM and obesity (Sugiyama et a l, 1989; Hotta et a l, 1996; Pérez et a l, 1998; 
Shimomura et a l , 2000).
1.3.3 Lipogenesis
De novo lipogenesis (DNL) is the synthesis of fatty acids from non-lipid precursors {e.g. from 
glucose) (Figuie 1.3). Whereas both the liver and adipose tissue express the enzymes of fatty 
acid synthesis, it is tlie liver that is the primary site of lipogenesis in humans (Ferre and 
Foufelle, 2007). In the metabolism of glucose or fructose, pyruvate generated by the 
glycolytic pathway is tiansported into the mitochondiion, converted to acetyl CoA by 
pyi'uvate dehydrogenase and enters the tiicaiboxylic acid (TCA) cycle. Citrate, an 
intermediate in the TCA cycle, is tiaiisported into the cytosol. Citrate is then converted to 
acetyl CoA by ATP citrate lyase, the first step of tlie lipogenic pathway (Figure 1.3). The 
cai'boxylation of acetyl CoA to form malonyl CoA by acetyl CoA caiboxylase (ACC) (EC
6.4.1.2) is the first committed step in the lipogenic patliway. ACC is subject to allosteric 
control, with citrate inducing polymerization of enzyme protomers and activating the enzyme 
(Brownsey et a l, 2006). Malonyl CoA and free CoA (products of the reaction catalysed by 
ACC), as well a fatty acyl CoA (products of downstream reactions in the lipogenic pathway) 
are inhibitors of ACC (Brownsey et a l, 2006). ACC activity is also regulated by 
phosphorylation, witli insulin activating the enzyme and AMPK inhibiting its activity 
(Brownsey et al., 2006). ACC gene expression regulates protein levels of ACC in the longer 
term, with SREBP-lc (Section 1.4.3) being a key regulator of its transcription (Shimano et 
a l, 1999).
The sequential addition of two-caibon units to malonyl CoA to form palmitic acid is 
catalysed by fatty acid synthase (FAS) (EC 2.3.1.85), the product of a single gene with seven 
different enzyme activities. FAS activity is not subject to allosteric regulation or post- 
translational modification, witli the rate of FAS gene transcription being the primary means 
of controlling its activity (Sul and Wang, 1998) (discussed fruther in Section 1.9.4).
Saturated fatty acids {e.g. palmitate) foimed by FAS aie converted to triglycerides for export
12
or storage by the estérification of glycerol 3-phosphate, catalysed by glycerol 3-phosphate 
acyltransferase (GPAT) (EC 2.3.1.15).
Altliough hepatic lipogenesis conti'ibutes less than 5-7% of all fatty acids present in VLDL in 
the fed state for healtliy individuals on a western (high fat) diet, the contiibution fr om DNL 
can increase to 30% in the fed state following the feeding of high carbohydrate diets 
(Hellerstein et a l, 1996). Increased DNL has been shown to be present in metabolic states 
associated with the metabolic syndiome (Section 1.2.3): First, DNL contributes to 
carbohydrate-induced hypertriacylglycerolaemia, in which the liver overproduces VLDL 
following chronic consumption of diets rich in carbohydrates (Parks and Hellerstein, 2000). 
Second, hepatic lipogenesis is increased in human obesity (Diraison et a l, 2002). Increased 
lipogenesis is also evident in non-alcoholic fatty liver disease (NAFLD) (Section 1.2.3) 
(Diraison et a l, 2003; Donnelly et a l, 2005; Fabbrini et a l, 2008). Changes in lipogenic 
gene expression are likely to contribute to the increased DNL observed in humans, as 
induction of lipogenic enzyme expression is seen in animal models of obesity and fr uctose- 
feeding (Lopez-Casillas et a l, 1991; Fiebig e ta l,  1998).
1.3.4 Lipoprotein metabolism
Lipids are transported in the circulation as complex particles known as lipoproteins, 
composed of fr ee cholesterol, phospholipid, cholesteryl ester, triacylglycerol and proteins. 
The protein components of lipoproteins, le . apolipoproteins, are produced by both the liver 
and intestine (apo referring to protein component before the formation of a lipid complex), 
with different lipoproteins containing different constituent apolipoproteins (Figure 1.4).
Dietary fatty acids and cholesterol absorbed in the intestine are packaged into chylomicrons, 
whilst endogenous lipids and those derived frrom hepatic DNL (Section 1.2.3) aie exported 
fr om tlie liver as VLDL. Botli chylomicrons and VLDL contain apoB (in the foiin apoB-48 
and apoB-100, respectively) and both aie referred to as tiiacylglycerol-rich lipoproteins 
(TRLs) due to the high percentage of esterfied fatty acids (90% in the case of chylomicrons, 
65% for VLDL) (Frayn, 2003). Following lipolysis of chylomicrons and VLDL by 
lipoprotein lipase (LPL) in the peripheral tissues, the size of TRLs is reduced to intermediate 
density lipoproteins (IDL). Fmther hydrolysis of fatty acids results in the formation of low 
density lipoprotems (LDL) with a high percentage of bound cholesterol (45%) (Frayn, 2003),
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receptor-BI; TG, triglyceride; VLDL, VLDL receptor. Diagram from review by 
Dimington (2003).
Small dense LDL is a form of LDL which has become depleted of most of its bound lipid and 
high levels carry an increased risk of developing of CHD (Griffin et a l, 1994; Lamarche et 
a l, 1997). Increased levels of small dense LDL arise due to overproduction or insufficient 
catabolism of very low density lipoprotein (VLDL) (Adiels ei a l , 2006). Small dense LDL is 
particulaiiy susceptible to oxidation and is hence considered particularly atherogenic (Frayn, 
2003). Oxidised LDL is taken up by macrophages by scavenger receptor-A (SR-A), leading 
to the formation of foam cells and the development of an atherosclerotic plaque in the vessel 
walls of major blood vessels (Figui e 1.4) (Boyle, 2005).
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The smallest of the lipoproteins, high density lipoproteins (HDL), ai e produced by the liver 
with constituent apoAI and apoAII and perform the role of tiansporting excess cholesterol 
from the periphery to the liver (reverse cholesterol transport) for excretion as bile acids. 
Cholesterol is removed from cells in the periphery by the interaction of HDL particles with 
ATP-binding cassette protein-Al (ABCAl) (Oram, 2003). Reverse cholesterol transport also 
involves the activities of plasma enzymes, lecithin-cholesterol acyl transferase (LCAT) and 
cholesteryl ester transfer protein (CETP), which facilitate the transfer of free cholesterol to 
HDL (LCAT) and the exchange of cholesteryl ester and triacylglycerol with TRLs (CETP) 
(Figure 1.4) (Rye et a l, 1999). Since the action of HDL is antiatherogenic, low 
concentrations of HDL cholesterol (<1.0 mmol/1) are associated with obesity and the 
metabolic syndrome (Durrington, 2003).
ApoC-I, -II and -III are constituents of chylomicrons, VLDL and HDL, and aie key 
modulators of the interaction of lipoproteins with a range of lipoprotein receptors involved in 
postprandial triglyceride metabolism (Jong et al., 1999). ApoCIII is of particular relevance to 
this project as tliis gene is a well-chaiacterised target gene of HNF4a (Section 1.9.5) with an 
important role in postprandial triglyceride metabolism. ApoCIII has an inliibitory effect on 
the hydrolysis of TRLs by LPL (Jong et a l, 1999). ApoCIII also has an inhibitory action on 
hepatic lipase (HL) and on the uptake of chylomicron and VLDL remnants by the liver via 
the lipolysis-stimulated receptor (LSR) (Kinnunen and Ehnolm, 1976; Windier and Havel, 
1985; Mann et a l , 1997).
In line with these modes of action, increased apoCIII plasma concentr ation is associated with 
hypertriglyceridaemia in human studies (Carlson and Ballantyne, 1976; Schonfeld et al, 
1979; Malmendier e ta l,  1989). Transgenic mice overexpressing apoCIII exhibit 
hypertriglyceridaemia and reduced VLDL clearance (Ito et a l, 1990; de Silva et a l, 1994; 
Aalto-Setala et a l, 1996), whilst apoCIII laiockout mice are show reduced plasma 
triglyceride levels and increased clearance of postprandial TG-rich lipoproteins (Maeda et a l, 
1994). ApoCIII nrRNA expression plays an important role in determining apoCIII levels 
(discussed fruther in Section 1.9.5).
15
1A Transcriptional regulation of gene expression
Since many of the key genes in metabolic pathways are regulated at the tianscriptional level, 
the structure of genes and the role of transcription factors in their expression will be 
described below.
1.4.1 Gene transcription
The regulatory regions of genes consist of promoter and enliancer elements. Promoters are 
immediately upstream of the transcription start site and consist of core promoter elements 
such as the TATA box and binding sites for gene-specific transcription factors (Smale and 
Kadonaga, 2003; Kadonaga, 2004). Enhancer elemeirts are sequences which can entrance 
gene transcription fr om a distance of up to several kilobases (kb) away from the 
transcriptional start site. Unlike promoter sequences, enhancer elemeirts are not dependent on 
their 5’ to 3’ orientation witlr respect to the gene, aird enhaircers can be upstieam or 
downstream of the transcribed gene, or witlrin an intronic region (Latchnran, 2005).
Eukaiyotic genes are transcribed by tlrree different RNA polymerases: RNA polymerase I is 
responsible for the transcription of the precursor of the 5.8S, 18S and 28S ribosomal RNA 
(rRNA) genes, RNA polyirrerase II responsible for the transcription of nrRNA and RNA 
polymerase III transcribes the 5.8S rRNA, transfer-RNAs (tRNAs) and non-coding RNAs 
such as nricroRNAs (Latchman, 2005; Dieci et al., 2007). Trairscription is initiated at an 
RNA polymerase II promoter by the sequential binding of general transcription factors 
(TFIIA-H) which form a multi-protein complex with RNA polymerase (the holoenzynre). 
Initially, TFIID binds the TATA element present at -30 bp to the transcriptional start site in 
the majority of promoters, together witlr TFIIA. TFIID consists of multiple proteins, one of 
which is TATA-binding protein (TBP), as well as TBP-associated factors (TAFs). TFIID 
recruits TFIIB wlrich can recruit RNA polymerase II. Subsequently, TFIIF, TFII and TFIIH 
bind to the RNA polymerase II complex, leading to the activation of RNA polymerase II 
(Latclrman, 2005).
1.4.2 Transcription factors
Transcription factors are DNA-binding proteins, composed of different functional domains 
wlrich serve to bind DNA, facilitate dimerization with the same or different transcription 
factors (homo- or heterodimerization), aird activate trairscription (Table 1.3). DNA-binding
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domains (DBDs) include the homeobox domain, consisting of a helix-tum-helix motif 
characterised by two a-helical regions separated by a p-sheet. This domain is present in 
many genes which are important in embryonic development (Latclrman, 2005). The zinc 
finger DBD consists of a zinc atom coordirrated by two cysteine aird two histidine residues, iir 
tire case of tire ubiquitous ti anscriptiorr factor, Spl. Alteiiratively, a zinc atom is in a 
teti’ahedr al conformation with four cysteine residues, as obseiwed in members of the NR 
family (Section 1.4.5) (Latclrman, 2005). The forldread box is another example of a DNA- 
binding domain which consists of a conserved 110 amino acid motif, also knowrr as a winged 
helix, with tlrree a-helices, tlrree p-sheets and two loop structures (Burgering arrd Mederna,
2003).
Table 1.3: Transcription factor domains.
Domain Role Examples
Homeobox DNA-binding Drosophila homeotic genes
Cysteine-histidine zinc finger DNA-binding Sp1
Cysteine-cysteine zinc fingers DNA-binding Nuclear receptor family
Forkhead box DNA-binding Fox01
Basic element DNA-binding c-jun, SREBP, ChREBP
Leucine zipper Protein dimerization c-jun, SREBP, ChREBP
Helix-loop-helix Protein dimerization Myogenin, SREBP, ChREBP
Acidic region Gene activation Nuclear receptor family
Glutamine-rich region Gene activation Sp1
Proline-rich region Gene activation c-jun
Abbreviations: CliREBP, carbohydrate response element binding protein; NFl, nuclear factor 
1; Spl, specificity protein 1; SREBP, sterol regulatory element-binding protein. Adapted 
from Latclrman (2005).
The basic element DBD is often associated with the leucine zipper (ZIP) or helix-loop-helix 
(HLH) motifs which are required for the correct positioning of the the DBD (Latchman,
2005). In class III HLH transcription factors, such as SREBP (Section 1.4.3) and CliREBP 
(Section 1.4.4), the HLH motif is adjacent to a ZIP motif (Massari aird Murr e, 2000), The 
domains of transcription factors involved in transcriptional activation often include regions 
rich in acidic amino acids, resulting in a negatively-charged region. Alternatively, glutamine- 
rich and proline- rich regions are fomrd in the trairscriptional activation domains of Spl arrd 
the proto-oncogene, (Latchman, 2005).
1.4.3 Sterol regulatory element-binding proteins (SREBPs)
SREBPs are tr anscriptioir factors of the bHLH-ZIP farrrily with a centr al role in both fatty 
acid and cholesterol synthesis (Yokoyanra et a l, 1993), arrd were originally identified as the 
protein responsible for mediating the effect of sterol depletion on LDL receptor gene 
expression (Briggs et a l, 1993; Wang et a l, 1993). SREBPs are synthesised as membrane-
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bound proteins and consist of a N-terminal transcription factor domain, a central region 
coding for two transmembrane domains and a regulatory C-terminal domain. The 
transmembrane domains anchor SREBPs in the endoplasmic reticulum membrane, in a 
complex with SREBP cleavage activating protein (SCAP) and Insig (Yang et a l, 2002). 
Dissociation of SREBP-SCAP from hisig results in their translocation to the Golgi apparatus, 
followed by proteolytic processing of SREBP by site 1 and site 2 proteases (SIP and S2P), 
releasing the mature N-terminal SREBP transcription factor so that it can translocate to the 
nucleus and activate gene expression (Brown and Goldstein, 1997; Brown and Goldstein, 
1999).
SREBP 1- and -2 aie encoded by two genes in humans, located on clnomosomes 17 and 22 
(Hua et a l, 1995). SREBP-la and -Ic aie derived by alternate promoter usage, generating 
proteins with alternative first exons. Although SREBP-la is the stronger transactivator of 
gene expression, the SREBP-lc isoform is nine-fold more abimdant than SREBP-la in 
human liver (Shimomma et a l, 1997; Shimmio et a l, 1997). SREBP-lc is also known as 
adipocyte determination differentiation dependent factor-1 (ADD-1), due to its role in 
promoting adipose differentiation and the expression of FAS and lipoprotein lipase in 
adipocytes (Kim and Spiegelman, 1996). SREBP-2 primaiily regulates the expression of 
genes involved in cholesterol biosynthesis, whilst SREBP-lc regulates genes of the lipogenic 
pathway (Figuie 1.5) (Horton et a l, 1998b; Horton et a l, 2002).
SREBP-1 has been proposed to be a key regulatory gene in disorders of lipid metabolism and 
the metabolic syndrome (Muller-Wieland and Kotzka, 2002). In agreement with this 
hypothesis, up-regulation of hepatic SREBP-lc has been shown in mouse models of obesity, 
insulin resistance and T2DM (Shimomuia et a l, 1999a; Shimomuia et a l, 2000; Kalaima et 
al, 2000; Tobe et a l, 2001). Genetic evidence in humans also points to a role for SREBP-lc 
in the development of metabolic disorders: Firstly, association of the SREBP-lc 
cliromosomal locus with metabolic syndrome, obesity and T2DM has been revealed by 
genome wide scans (Kissebah et a l, 2000; Wu et a l, 2002; Demenais et a l, 2003).
Secondly, single nucleotide polymoiphisms (SNPs) in the SREBP-lc gene are linlced to 
insulin resistance and T2DM (Laudes et a l, 2004; Haiding et a l, 2006). Whilst the activity 
of SREBP-la and SREBP-2 are primarily regulated by sterol depletion at the level of their 
proteolytic processing, SREBP-lc is also regulated at the level of its gene expression (Sheng 
et a l, 1995) (discussed fruther in Section 1.9.4).
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Diagram from Horton et al. (2002).
1.4.4 Carbohydrate response element-binding protein (ChREBP)
The transcription of numerous genes in the pathways of glycolysis and lipogenesis (Sections 
1.3.2 and 1.3.3 respectively), including L-PK and FAS (Sections 1.9.2 and 1.9.4. 
respectively), are induced by feeding of a high carbohydrate diet via a carbohydrate response 
element (ChRE) in the gene promoters consisting of two E-box elements (Uyeda et al.,
2002). These effects of excess carbohydrate were found to be dependent on the intracellular 
metabolism of glucose through the pentose phosphate pathway (Doiron et al., 1994; Doiron 
et al., 1996). The protein isolated as binding these elements in a glucose-responsive manner, 
designated ChREBP, is a member of the basic helix-loop-helix leucine zipper (bHLH-ZIP) 
family of transcription factors, which binds DNA as a heterodimer with Max-like factor 
(Mix) (Yamashita et al., 2001 ; Stoeckman et al., 2004). The intracellular localisation of 
ChREBP is determined by its phosphorylation status, with phosphorylation by PKA bringing 
about its nuclear exclusion, and dephosphorylation by a xylulose 5-phosphate-activated 
protein phosphatase (Kawaguchi et al., 2001; Kabashima et a l, 2003). ChREBP DNA-
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binding is also negatively regulated by phosphorylation by PKA or AMPK (Kawaguchi et al, 
2001; Kawaguchi et a l, 2002).
1.4.5 Nuclear receptors
The NR superfaniily comprises over 48 different members in humans, wliich have been 
classified into six groups based on evolutionary conservation (Table 1.4) (Laudet, 1997; 
Zhang et a l, 2004). NR nomenclature is based on the subfamily and group, e.g. the thyroid 
receptor-a (TRa) is classified as sub-family 1, group A, member 1 with the symbol NRlAl 
(Laudet et al., 1997). NRs play important roles in many physiological functions, with 
mutations and changes in the expression of NRs being implicated in the pathogenesis of 
many diseases, including PPARs in atherosclerosis and diabetes, the oestrogen receptor (ER) 
in breast cancer and tlie androgen receptor (AR) in prostate cancer (Kersten et a l, 2000; 
Nilsson et al., 2004; Gottlieb et a l , 2004).
Table 1.4: Classification of nuclear receptors.
Nuclear receptor 
subfamily
Example members (NR symbol) Features
1 TRaand|3(NR1A1,2)
RAR-a, -p and -y (NR1B1,2,3) 
PPAR-a, -p and -y (NR1C1,2,3) 
Rev-erba, Rev-erbp (NR1D1,2) 
ROR-a, -p and -y (NR1F1,2,3) 
FXR (NR1H4)
VDR (NR1I1)
PXR (NR1I2)
CARa and p (NR1I3,4)
NRs binding metabolites (RARs, 
PPARs. FXR, PXR), vitamin D (VDR) 
and 3,6,3'-trliodo-L -thyronine (TR). 
RORs and rev-erba/p are orphan 
NRs. CAR and PXR activity is also 
modulated by xenobiotics (Timsit and 
Negishi, 2007).
2 HNF4a, p and y (NR2A1,2,3) 
RXRa, RXRp (NR2B1,2) 
COUP-TFI, COUP-TFII (NR2F1.2)
RXRs bind aW-trans retinoic acid. 
COUP-TFs are orphan NRs. HNF4 
binds fatty acids (discussed further in 
Section 1.4)
3 ERa, ERp (NR3A1.2) 
ERR-a, pandy(NR3B1,2,3) 
GR (NR3C1)
MR (NR3C2)
PR (NR3C3)
AR (NR3C4)
Steroid hormone receptors (with the 
exception of ERRot/p which are 
orphan NRs)
4 NURR1 (NR4A2) Orphan receptors
5 LRH1 (NR5A2) Orphan receptors
6 GCNF1 (NR6A1) Orphan receptors
0 DAX1 (NR0B1) 
SHP (NR0B2)
Orphan NRs lacking DBD (DAX1, 
SHP) or LBD
NRs classified Into subfamilies based on Laudet (1997). NRs defined as orphan NRs based on Benoit et al. (2006). Abbreviations: TR, thyroid receptor; RAR, retinoic acid receptor; PPAR, peroxisome 
proliferator-activated receptor; Rev-erb, reverse-Erb; ROR, RAR-related orphan receptor; FXR, 
farnesoid X receptor; VDR, vitamin D receptor; FXR, pregnane X receptor; CAR, constitutive 
androstane receptor; RXR, retinoid X receptor; COUP-TF, chicken ovalbumin upstream promoter- 
transcription factor; ER, estrogen receptor; ERR, ER-related receptor; GR, glucocorticoid receptor; 
MR, mineralocorticoid receptor; PR, progesterone receptor; AR, androgen receptor; NURR1, Nur- 
related factor 1; LRH1, liver receptor homolog-1; GCNF1, germ cell nuclear factor 1.
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Ill the classical paradigm of steroid hormone receptor action, such as that of the GR, ligand 
binding results in a conformational change wliich activates the nuclear receptor and allows its 
translocation to the nucleus and binding to a hormone response element (HRE) in the target 
gene promoter (LaMarco and Vivanco, 1996).
NRs have a conserved domain structure (Figme 1.6) (Aranda and Pascual, 2001). The N- 
terminal A/B region varies in length in different NRs and contains a ligand-independent 
activation flmction-1 (AF-1) domain. The most conserved region of the NR protein is the 
DNA-binding domain (DBD) which contains two ‘zinc finger’ motifs (Section 1.4.2) (Kumai' 
et a l, 2004). NRs bind DNA as homodimers, heterodimers or monomers (Figuie 1.7): 
steroid hormone receptors such as the AR, ER and GR bind palindromic repeats as 
homodimers, whilst NRs which form heterodimers with RXR such as PPAR and TR bind 
direct repeat (DR) sequences. There can be a variable number of bases inbetween the half­
site sequences, with 1 bp spacing between two direct repeat sequences referred to as DR-1. 
Some orphan NRs (Section 1.4.7.) such as RORs, ERRs and NURR bind half-site sequences 
preceded by A/T as monomers (Benoit et al., 2006). The amino acid sequence of the zinc 
finger domain determines the binding affinity of the NR for different hormone response 
elements (HREs) (Figure 1.7), with the first zinc finger determining tlie sequence specificity 
and the second zinc finger determining the spacing between the half-sites of the HRE 
(Latclnnan, 2005).
Region D is refeited to as the hinge region connecting the DBD and ligand-binding domain 
(LBD) and contains the nuclear localisation signal (NLS). The LBD (region E) is composed 
of twelve a-helices (named HI-FI 12) which aie arranged in a globular' structuie, forming a 
ligand-binding pocket (LBP) (Aranda and Pascual, 2001). Other LBD functions include 
dimerization and transcriptional activation via a second AF domain (AF-2), which contains a 
conserved hydrophobic motif in HI 2 which interacts with a conserved leucine motif 
(LXXLL, L=leucine, X=any amino acid) present in co-activators. According to tlie ‘mouse 
trap’ model of nuclear receptor activation, conformational changes in the LBD upon ligand 
binding result in displacement of HI 2 and greater accessibility of AF-2 to coactivator binding 
(Moras and Gronemeyer, 1998). The F-doniain is a variable region in nuclear* receptors, 
however this region is loiown to be involved in the action of antagonists and transcriptional 
cofactors in the cases of the PR and ER (Xu et a l, 1996; Skafar and Zhao, 2008).
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Figure 1.6: Domain structure of nuclear receptors. NRs have a conserved domain 
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Diagram from Aranda and Pascual (2001).
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Figure 1.7: Nuclear receptor binding configurations. NRs bind as homodimers or 
heterodimers with RXR to hormone response elements (HREs). For dimeric NRs, each 
nuclear receptor binds to a half-site of the HRE. The half sites can be arranged as a 
palindrome (Pal) (also known as an inverted repeat), a direct repeat (DR) or an inverted 
palindrome (IP). Diagram from Aranda and Pascual (2001).
1.4.6 Peroxisome prollferator-actlvated receptors (PPARs)
PPARs were identified as NRs with a role in proliferation of peroxisomes in rat liver in 
response to hepatocarcinogens (Issemann and Green, 1990), with three PPAR isoforms 
encoded by separate genes being characterised: PPARa (NRICI), PPARô (NR1C2, also 
known as PPARp) and PPARy (NR1C3) (Dreyer et a i, 1992). PPARa is most highly 
expressed in the liver, heart, intestine and kidney, while PPARP shows a ubiquitous pattern of
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expression and PPARy is most highly expressed in adipose tissue, with smaller amounts in 
heart, liver and skeletal muscle (Muldieijee et a l, 1997). PPARs form heterodimers with 
RXR (NR2B) and bind DR-1 elements (Kliewer et ah, 1992).
Endogenous PPARa ligands include long-chain unsaturated fatty acids {e.g, linoleic acid) 
and metabolites of arachidonic acid via the lipoxygenase pathway {e.g. leukotrienes), whilst 
the fîbrate class of drugs {e.g. clofibrate, fenofibrate, Wy-14,643) are pliaimacological 
activators (Desvergne and Wahli, 1999). PPARa is a key regulator of fatty acid catabolism, 
with target genes including enzymes of mitochondrial fatty acid oxidation and ketogenesis, 
e.g. medium chain acyl CoA dehydi'ogenase and HMG CoA synthase (Desvergne and Wahli, 
1999). In the fasting state, PPARa is activated by fatty acids liberated from adipose tissue, 
leading to the stimulation of hepatic gluconeogenesis and fatty acid oxidation in the liver and 
cardiac muscle (Desvergne and Wahli, 1999; Barger and Kelly, 2000). The role of PPARa in 
the fasting state is demonstiated in PPARa-null mice which fail to utilise fatty acids as an 
energy source under fasting conditions and exhibit hypoglycaemia, hypoketonemia and the 
accumulation of intracellulai' lipid in the liver (Leone et a l , 1999; Kersten et a l , 1999). 
Fibrates exert a hypolipidaemic effect via PPARa activation of genes involved in reverse 
cholesterol transport (apoAI, apoAII), as well as inhibition of apoCIII expression (through 
competition with HNF4a) (Staels et a l, 1995; Peters et a l, 1997; Staels et a l, 1998).
PPARÔ binds both saturated and unsaturated fatty acids including arachidonic acid and 
eicosapentaenoic acid, as well as amclridonic acid derivatives via the cyclooxygenase 
pathway), prostaglandins (Willson et al., 2000). PPARô has been shown to have a role in 
promoting hepatic glucose disposal and muscle fatty acid oxidation, with PPARô agonists 
increasing insulin sensitivity in animal models of diabetes (Lee et al., 2006). PPARô 
suppresses the expression of inflammatory mediators involved in macrophage activation and 
the potential for PPARô agonists in the modulation of atherosclerosis progression is currently 
the subject of resear ch (Barish et al., 2006).
Endogenous PPARy ligands also include prostaglandin derivatives, whilst the anti-diabetic 
drugs TZDs {e.g. troglitazone, pioglitazone and rosiglitazone) are selective agonists for 
PPARy (Desvergne and Walili, 1999). PPARy is a key regulator of adipogenesis and 
stimulates the expression of SREBP-lc (Section 1.3.3) (Tontonoz et ah, 1994; Khn and
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Spiegelman, 1996). PPARy expression is up-regulated by feeding a liigh-fat diet and in 
obesity, and decreased dining fasting (Vidal-Puig et a l, 1996; Vidal-Puig et a l, 1997). In 
the fed state, PPARy promotes the uptake and utilisation of fatty acids in adipose tissue by 
stimulating the expression of LPL, fatty acid transport proteins (FATP and CD36), adipocyte 
specific fatty acid binding protein (aP2), long chain acyl CoA synthase and PEPCK, which 
generates glycerol required for tiiglyceride synthesis (Walczak and Tontonoz, 2002; 
Chakravarty et ah, 2005). PPARy is also important in macrophage biology and 
atherosclerosis (Section 1.3.4), playing a role in both lipid uptake via CD36 and efflux via its 
tai'get gene, LXRa (Walczak and Tontonoz, 2002).
1.4.7 Orphan nuclear receptors
Orphan NRs are those for which no ligand has been identified or the physiological relevance 
of the ligand is unclear (Benoit et ah, 2006). Orphan NRs are present in all six sub-families 
of nuclear receptors, as well as orphan NRs lacldng a DBD or LBD which form a separate 
sub-family (group 0) (Table 1.4). In some cases, orphan NRs lack a LBP due to bulky amino 
acids side chains filling this space (for example, NURRl) or display constitutive activity with 
an empty LBP (for example, ERRy) (Greschik et a l, 2002; Wang et a l, 2003). Alternatively, 
ligands have been identified for orphan NRs which have a structural role in the activity of the 
NR. Fatty acids have been shown to play a role in the structural stability of HNF4 (Section
1.7.2), whilst the Drosophila homologues of RXR and Rev-erb, USP (NR2B4) and E75 
(NR1D3), bind phospholipid or heme moieties respectively as ‘structural ligands' (Benoit et 
ah, 2006).
1.4.8 Chromatin structure and modification
The organisation of DNA into chromatm in the nucleus of eukaiyotic cells is one reason for 
the complexity of transcriptional regulation in higher organisms. The DNA double-helix is 
coiled around histone proteins which form an octamer consisting of core histoires H2A, H2B, 
H3, and H4. Histone HI binds to the DNA linking the nucleosomes and is involved in the 
formation of higher order clnomatin structure (Berg et ah, 2006). Promoters and regulatory 
regions of actively ti anscribed genes differ fiom inactive chromosome regions in that the 
former are less tightly complexed with histones and more accessible to RNA Polymerase II 
and the basal transcription factors necessary for the initiation of üanscription (Berg et ah,
2006).
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The reversible acétylation of lysine residues in the N- and C-terminal tails of histones H3 and 
H4 is an important mechanism of regulating the accessibility of the basal transcriptional 
machinery to DNA (Figure 1.8). Acétylation disrupts ionic interactions of DNA with the 
highly charged tails of histone molecules, leading to a more open nucleosomal structure 
(Spencer and Davie, 1999).
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Figure 1.8: Influence of histone acétylation and DNA méthylation on chromatin 
structure and transcription. In regions of actively transcribed DNA, DNA is 
unmethylated and histones are acetylated (pink circles). The latter weakens the 
interaction between the negatively charged DNA and positively charged histones and 
allowing binding of TFs to promoter sequences. Deacetylation of histones and 
méthylation of DNA (green circles) results in transcriptional repression via the 
recruitment of methyl-CpG-binding proteins (MeCP2) and HDACs. Diagram from 
Schrem et al. (2002).
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Some NR co-activators have intrinsic histone acetyltransferase (HAT) activity, for example, 
steroid receptor co-activator-1 (SRC-1), cAMP response element binding protein- binding 
protein (GBP) and p300 (further discussed in Section 1.8.4) (Spencer et ah, 1997; Kalkhoven,
2004). The reverse process catalyzed by histone deacetylases (HDACs) leads to a more 
restricted nucleosomal sti'ucture. Co-repressors of NRs, for example, silencing mediator for 
retinoid and thyroid receptors (SMRT), recruit HDACs as a mechanism of gene silencing 
(Moeluen et a l, 2004). It should be noted that NR co-activators catalyze other covalent 
histone modifications, including méthylation, phosphorylation and ubiquitination, all of 
which play roles in the structure of clnomatin (Hermanson et al., 2002). Nuclear receptor 
co-activators also include ATP-dependent clnomatin remodelling complexes (CRCs), which 
alter nucleosome positioning in a non-covalent manner. For example, a requirement for the 
ATPase BRG-1 (a constituent of the SWI/SNF class of CRCs) has been shown in GR- 
mediated transcriptional activation (Trotter and Archer, 2007).
DNA méthylation of cytosine nucleotides also plays an important role in determining whether 
a gene is in an active or inactive state (Figure 1.8). Promoter regions often contain a high 
percentage of cytosine and guanine nucleotides (genomic regions loiown as CpG islands) 
(Gardiner-Garden and Frommer, 1987). Methylated CpG bases are recognised by methyl 
CpG binding proteins, which exert a repressive effect tluough interaction with HDAC- 
containing complexes (Figure 1.8) (Nan et a l, 1998). DNA méthylation can also have a 
direct repressive effect on gene transcription by preventing transcription factor binding to 
DNA (Bird and Wolffe, 1999).
As will be discussed in the following sections, recruitment of co-factors with histone- 
modifying capabilities is liighly relevant to the tr anscriptional factor at the heart of this 
project, HNF4a. Differerrt aspects of HNF4a biology including genetics, structrue and 
modulation of transcription activity will be described in detail in the following four sections.
1.5 HNF4a: an overview
HNF4 was identified in rat liver cell extracts and was initially designated as an orphan 
member of the nuclear' receptor family due to the lack of an endogenous ligand being 
identified (Sladek et al., 1990). Hepatocyte nuclear factors (HNFs) are a group of 
transcription factors from different tr anscription factor families, whose expression is emiched 
in the liver and is required for liver development and function (Scluem et al., 2002).
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Tlu’ee genes for HNF4 exist: HNF4a (NR2A1), the originally identified isoform and two 
firrther HNF4 genes, HNF4p and HNF4y (Sladek et ah, 1990; Holewa et aL, 1997; Drewes et 
aL, 1996). HNF4a is expressed in mammals, including humans, rat and mouse (Chartier et 
ah, 1994; Sladek et aL, 1990; Hata et al, 1995). The HNF4p was identified mXenopus laevis 
(NR2A3) gene, however it is absent in mammalian genomes (Holewa et aL, 1997). The 
HNF4y gene is expressed in manmials and located on human chromosome 8 and on mouse 
chromosome 3 (Drewes et aL, 1996; Taraviras et aL, 2000).
HNF4a is expressed predominantly in the liver, the kidney, small intestine, colon and 
pancreas, with small amounts also present in the testis (Sladek et a l, 1990; Miquerol et a l, 
1994; Drewes et a l, 1996). HNF4y is expressed in the pancreas, kidney, small intestine and 
testis, but is absent fi'om the liver (Drewes et a l, 1996). In comparison with other nuclear* 
receptors such as PPARs which heterodimerize with RXRs, HNF4a imdergoes exclusive 
homodhnerization and is foimd to reside primarily in the nucleus (Jiang et a l, 1995).
HNF4a dimers binds direct repeat-1 (DR-1) elements which consist of two half-sites of six 
bases separated by a single nucleotide (Sladek and Seidel, 2001).
1.5.1 HNF4a target genes
HNF4a regulates a wide variety of tar get genes involved in nutr ient transport and the 
metabolism of lipids, sterols and glucose and amino acids (Figure 1.9). In addition, HNF4a 
regulates genes involved in many other aspects of liver function, including blood coagulation 
and immunity (Figirr e 1.9) (Sladek and Seidel, 2001). Of particular* interest in tire study of 
metabolic diseases is the role of HNF4a in tire regulation of genes involved in metabolic 
patlrways which are active under* opposing conditions: For* example, HNF4a target genes 
include key regulatory genes in both gluconeogenesis, e.g. PEPCK, and glycolysis, e.g. L- 
PK, (Hall et aL, 1995; Diaz Guena et aL, 1993). In addition, HNF4a tar get genes include 
both apolipoprotein B (apoB), a constituent of LDL, and apolipoprotein AI (apoAI), a 
constituent of HDL (Chan et a l, 1993; Metzger et a l, 1993).
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Figure 1.9: Roles of HNF4a target genes. HNF4a target genes are involved in a wide 
range of physiological processes. Diagram based on a listing of HNF4a target genes in 
Sladek and Seidel (2001), with the addition of some more recently identified target genes: 
ATP-dependent potassium channel subunit Kir6.2 (Gupta et aL, 2005); glucose-6 - 
phosphatase (G-6 -Pase) (Rajas et aL, 2002); insulin gene (Bartoov-Shifman et aL, 2002); 
liver-type carnitine palmitoyltransferase I (L-CPT-I) (Louet et aL, 2002); microsomal 
triglyceride transfer protein (MTP) (Sheena et aL, 2005); peroxisome proliferator- 
activated receptor-a (PPARa) (Pineda Torra et aL, 2002); scavenger receptor-B1 
(Malerod et al., 2003) and sterol regulatory element-binding protein Ic (SREBP-lc) 
(Tarling et a i, 2004).
1.6 Genetic evidence for the role of HNF4a in metabolic disorders
1.6.1 Maturity Onset Diabetes of the Young
Maturity-onset diabetes of the young (MODY) is defined as an early-onset form of Type 2 
diabetes which is inherited in an autosomal dominant pattern (Hattersley, 1998). Patients 
characteristically develop symptoms of hyperglycaemia and show impaired insulin secretion 
before the age of 25, without the prior development of insulin resistance or obesity (Fajans et 
al., 2001). The early-onset and monogenic nature of MODY makes it ideal for genetic 
analysis, compared to late-onset Type 2 diabetes where multi-generation pedigrees are 
difficult to obtain (Hattersley, 1998). To date six genes have been identified as causing 
MODY types 1 -6  which are typically diagnosed at different ages and vary in the severity of 
symptoms and complications (Table 1.5).
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Table 1.5: Comparison of different types of MODY.
MODY Type Gene Age of onset Most common 
treatm ent
Frequency of 
complications
M0DY1 HNF4a Postpubertal Oral hypoglycemicagent,
insulin
Frequent
MODY 2 Glucokinase Childhood Diet and 
exercise
Rare
MODY 3 HNF1a Postpubertal Oral hypoglycemicagent,
insulin
Frequent
MODY 4 IPF-1
(PDX-1)
Early adulthood Oral hypoglycemic 
agent, insulin
Rare
MODY 5 HNFIP Postpubertal Insulin Non-diabetic renal 
dysfunction present
MODY 6 NeuroDI
(BETA2)
Early adulthood to 
middle age
Insulin Unknown
Table adapted from Hattersley (1998) and Fajans et al. (2001) with additional information on 
MODY5 and M0DY6 (Lindner et ah, 1999; Malecki et a l, 1999)
With the exception of the MODY 2 gene which codes for glucoldnase, the other five 
identified MODY genes code for transcription factors (Table 1.5). Whilst glucoldnase 
mutations directly affect the metabolism of glucose to glucose-6 -phosphate, MODY-linlced 
transcription factors regulate the expression of several genes involved in glucose-stimulated 
insulin secretion (GSIS), including glycolysis, mitochondrial ATP generation, ion channels 
and insulin gene transcription (Figure 1.10) (Fajans et a l, 2001).
Linlcage studies localised the gene responsible for MODY 1 to the long aim of chromosome 
20 (Bell et a l, 1991), with the HNF4a gene subsequently being identified as the MODY 1 
gene (Yamagata et a l, 1996). As with other MODY types, MODY 1 is chaiacterised by 
deficient pancreatic insulin secretion, rather than insulm resistance (Herman et a l, 1994). 
Even in tlie prediabetic state, HNF4a mutation-carriers show an inability of pancreatic p-cells 
to increase insulin secretion when blood glucose concentrations rise above 7 imnol/1 (Byrne 
et a l, 1995). In contrast to normal individuals or other types of MODY, where insulin 
secretory response by (3-cells is primed by prior infusion of glucose or aiginine, HNF4a 
mutation-carriers lack this priming response (Byrne et a l, 1995; Herman et a l, 1997). The 
molecular* basis for pancreatic dysfunction in MODY 1 is likely to reside in deficient 
transcription of HNF4a downstream genes involved in glucose-stimulated insulin secretion 
(Figure 1.10). HNF4a has been shown to regulate several genes in glucose tr ansport and 
metabolism, subimits of the ATP-dependent chamiel, as well as the expression of another
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Figure 1.10: Role of MODY genes in pancreatic P-cell function. The M0DY2 gene, 
glucokinase, catalyses the conversion of glucose to glucose-6 -phosphate, thereby acting the 
pancreatic glucose sensor. The metabolism of glucose via the glycolytic pathway and Krebs 
cycle leads to the generation of ATP. Raised ATP levels trigger the closure of ATP- 
sensitive K  ^channels, resulting in membrane depolarisation and opening of voltage- 
dependent Ca^  ^channels. Ca^  ^influx and release from intracellular stores leads to the fusion 
of insulin-containing granules with the plasma membrane. MODY genes coding for 
transcription factors (HNF4a, HNFla, IPF-1, HNFlp and NeuroDI) code for transcription 
factors which regulate the expression of insulin, and other genes involved in GSIS.
Diagram from review by Fajans et al. (2001).
MODY gene, HNFla (Stoffel and Duncan, 1997; Wang et a l, 2000; Wang et a l, 2002; 
Gupta et a l, 2005; Miura et a l, 2006).
Interestingly, patients with MODYl also show decreased plasma triglyceride and lipoprotein 
levels, suggesting that hepatic lipid metabolism is also affected by HNF4a haploinsufficiency
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(Lehto et a l, 1999; Shih et a l, 2000). Neonatal hypoglycaemia and macrosomia due to 
foetal hyperinsulinaemia have been also observed in heterozygous caii'iers of HNF4a 
mutations, suggesting tliat over-secretion of insulin may precede the decline in insulin 
secretion observed later in life for MODY patients, reminiscent of the development of T2DM 
(Section 1.2.1) (Pearson e ta l,  2007; Fajans and Bell, 2007; Kapoor et a l, 2008).
1.6.2 Late-onset Type 2 Diabetes Meliftus
Unlike MODY, late-onset T2DM is a polygenic disorder, with nevertheless a substantial 
genetic component as demonstrated by studies with identical twins: if one identical twin has 
T2DM, the other twin has a 90% chance of developing the condition (Holt and Hanley,
2007). However, a genetic predisposition to develop T2DM can be modulated by 
environmental factors such as diet and physical activity (McCarthy and Merizel, 2001). It is 
hypothesised that genes which conferred a selective advantage during periods of starvation 
tlu'oughout human evolution have become detrimental in westernised society where calorie- 
rich food is in excess (Neel, 1962).
The HNF4a gene is located on chromosome 20q, a region which was associated with T2DM 
in several studies (Bowden et a l, 1997; Ji et a l, 1997). Single nucleotide polymorphisms 
(SNPs) in the HNF4a P2-promoter region were initially identified as being associated with 
T2DM in Fimiish and Ashkenazi Jewish populations, with odds ratios of 1.33 and 1.45 
respectively {le. there is a 33% or 45% greater likelihood of suffering fiorn T2DM in caniers 
of the HNF4a SNP compared to non-carriers) (Silander et a l, 2004; Love-Gregory et a l,
2004). Several subsequent studies found a more modest association of HNF4a P2 SNPs with 
T2DM in Caucasian populations (Damcott et a l, 2004; Hansen et a l, 2005; Bonnycastle et 
a l, 2006), Pima Indians (Muller et a l, 2005), Americans of Mexican descent (Lehman et a l, 
2007) and Japanese (Hara et a l, 2006). However, HNF4a P2-promoter SNPs were not 
associated with an increased risk of T2DM in other studies (Vaxillaire et a l, 2005; Winckler 
et a l, 2005; Yokoi et al, 2006). The association of PI promoter and intragenic SNPs with 
T2DM differed between the studies of Silander et a l (2004) and Love-Gregory et al. (2004), 
whilst PI promoter variants were shown to cany a more significant risk of T2DM than P2 
promoter variants in the Amish (Damcott et a l, 2004). hi a longitudinal study investigating 
progression fi om impaired glucose tolerance to T2DM (Section 1.1.2), female carriers of a 
minor P2 promoter SNP allele had an odds ratio of 1.7 of developing T2DM compared to
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noii-caiTiers, whilst no association was foimd in men (Andrulionyte et a l, 2006). Differences 
in the individual SNPs carrying the greatest risk observed between studies could be due to 
interactions between genotype and environmental factors such nutrition (Love-Gregory and 
Permutt, 2007).
1.6.3 Dyslipidaemia and the Metabolic Syndrome
Recent studies have shown association of HNF4a gene variants with types of dyslipidaemia 
and traits which fall under tlie classification of metabolic syndrome (Section 1.2.3). HNF4a 
SNPs have recently been associated witli familial combined hyperlipidaemia (FHCL) where 
serum cholesterol and/or triglycerides are raised, in Finnish and Mexican cohorts (Weissglas- 
Volkov et a l, 2006). Two of the individual SNPs identified in this study, located 
downstream of the P2 promoter (rs2144908) and in the PI promoter region (rs2425640) were 
also associated with T2DM, suggesting genetic and phenotypic overlap between 
dyslipidaemia and T2DM (Silander et a l, 2004; Love-Gregory et a l, 2004; Damcott et a l,
2004). The rs2425640 SNP and haplotypes composed of multiple SNPs were also associated 
with par ameters of glucose tolerance and insulin sensitivity in Finnish FHCL families. In the 
same report, different HNF4a haplotype variants were associated with raised total cholesterol 
levels in Finnish low-HDL cholesterol families, providing evidence for association of 
HNF4a variants with a different trait of the metabolic syndrome (Weissglas-Volkov et a l, 
2006). Classification of Fimiish FHCL and low-HDL cholesterol families for features of the 
metabolic syndrome also found association of distinct HNF4a haplotypes with the metabolic 
syndrome (Weissglas-Volkov et aL, 2006).
1.6.4 HNF4a knockout models
Further evidence for tlie role of HNF4a in the pathogenesis of diabetes and dyslipidaemia 
conies from targeted disruption of the HNF4a gene in mouse models. HNF4a null animals 
die during gestation due to impaired gastrulation (Chen et a l, 1994b). An alternative strategy 
to investigate HNF4a function was to disrupt the HNF4a gene in embryonic stem cells 
(Stoffel and Duncan, 1997). The latter were induced to form visceral endoderm, which 
displays properties of both the liver and endocrine pancreas (Stoffel and Duncan, 1997). 
HNF4a‘^“ stem cells showed decreased niRNA expression of several genes involved in 
glucose metabolism and GSIS including liver-pyruvate kinase (L-PK), aldolase B, GLUT2 
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Stoffel and Duncan, 1997).
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A conditional laiockout of the HNF4a gene in P-cells resulted in mice with fasting 
hypoglycaemia and hyperinsulinaemia (Gupta et a l, 2005). These findings in relatively 
young animals (five-month old) are in agr eement with recent results showing the same 
symptoms in human neonates witlr a HNF4a mutation (Pearson et aL, 2007; Fajans and Bell, 
2007; Kapoor et aL, 2008) (Section 1.6.1), However a separate p-cell HNF4a laiockout 
model did not replicate these findings (Miura et a l, 2006). Both p-cell laiockout mouse 
models showed impaired glucose tolerance due to defective insulin secretion, with both first 
and second phase insulin response being diminished (Section 1.1.1) (Gupta et a l, 2005, 
Miura et aL, 2006). Both studies pointed to K a t p  channel dysfunction contributing to the 
impaired insulin secretion, with Gupta et aL (2005) finding reduced K a t p  subimit (Kir6.2) 
niRNA expression responsible, whilst Miura et aL (2006) observed increased conductivity of 
the K a t p  channels in knockout vs. control animals.
Conditional gene laiockout of HNF4a in the liver resulted in mice with an ‘atheroprotective 
serum lipid profile’ of decreased serum triglyceride and cholesterol concentrations (Hayhurst 
et aL, 2001). However, the conditional hepatic HNF4a null mice also exhibited hepatic 
accumulation of lipid and increased sermii bile acids (Hayhiu'st et a l, 2001). Genes involved 
hi VLDL secretion (apolipoprotein B and microsomal triglyceride transfer protein) showed 
reduced expression in hepatic HNF4a knockout mice. LDL and HDL concentrations were 
lower in HNF4a laiockout animals compared to controls, which were proposed to be due to 
increased scavenger receptor B1 expression, facilitating increased HDL uptake (Hayhurst et 
aL, 2001). Genes involved in hepatic glucose metabolism were affected in another liver- 
specific laiockout of the HNF4a gene, with decreased expression of glycogen synthase and 
gluconeogenic enzymes (PEPCK and glucose-6 -phosphatase) (Paiviz et a l, 2003).
1.7 HNF4a structure and function
1.7.1 HNF4a functional domains
The classical nuclear receptor domains A-F containing DNA-binding, dinierization, ligand- 
binding and activation fmiction motifs has been mapped in the HNF4a protein sequence 
(Figure 1.11) (Fladzopoulou-Cladaias et a l, 1997). AF-1 encompasses the first N-terminal 
24 amino acids, whilst amino acids 128 to 366 are required for AF-2 (Hadzopoulou-Cladaras 
et aL, 1997). The F-domain in HNF4a is relatively large (90 amino acids) compared to that
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of other NRs and shares a proline-rich repressor region with similarity to the PR (lyemere et 
al, 1998). The presence of the F-domain inhibits HNF4a-dependent transcriptional activity 
and plays a role in the interaction of HNF4a with the co-repressor, SMRT (Sladek et a l , 
1999; Ruse et a l, 2002).
AF-1 AF-2 NRD
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Figure 1.11: HNF4a structural domains. The HNF4a F-domain inhibits transcriptional 
activity and hence was termed the negative regulatory domain (NRD). Diagram from 
Hadzopoulou-Cladaras et al. (1997).
1.7.2 Fatty acids and HNF4a
Despite initially being classified as an ‘orphan’ nuclear receptor, fatty acids have 
subsequently been shown to have a role in HNF4a ligand binding and activity. Fatty acyl 
coenzyme A (CoA) thioesters have been proposed to be the proximate ligand for HNF4a 
based on in vitro binding assays and cotransfection experiments (Hertz et a l, 1998). These 
experiments also suggested that CoA thioesters of polyunsaturated fatty acids (PUFA) have 
an inhibitory effect of HNF4a activity whilst maximal transactivation is achieved in the 
presence of the saturated palmitoyl-CoA (Hertz et al., 1998). However, X-ray 
crystallographical studies found that the HNF4a LBD contained a non-esterified fatty acid 
(Wiseley et al., 2002). The bound fatty acid moiety was found to be a saturated or 
monounsaturated fatty acid of lengths between C16 to C18, however the bound fatty acid was 
not exchangeable with '^C-labelled palmitic acid, suggesting that fatty acids form a 
permanent cofactor in the HNF4a molecule as opposed to an exchangeable ligand (Wisely et 
a l, 2002; Dhe-Paganon et a l, 2002).
Recently, it has been proposed that there is cross-talk between the regions of HNF4a 
involved in binding of free fatty acid and acyl CoA (Hertz et a l, 2005). In line with X- 
crystallographic studies, the central region of HNF4a from amino acids 133-382 was found 
to be involved in the binding of free fatty acids, whilst the C-terminal region (amino acids 
370 -  455) was found to be required for binding and hydrolysis of acyl CoAs (Hertz et al.,
2005). However, in contrast to the findings of X-ray crystallographical studies, the products
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of acyl CoA hydrolysis were able to exchange with the free fatty acid bound in the free fatty 
acid pocket and modulate HNF4a transcriptional activity (Hertz et aL, 2005).
The suppression of HNF4a activity by polyunsaturated fatty acyl-CoA (Hertz et aL, 1998) 
has been proposed be one mechanism by which PUFAs exert a hypolipidaemic effect on 
hepatic lipid metabolism (Davidson, 2006). For example, the inliibitory effect of PUFAs on 
the transcription of tlie glycolytic gene, L-PK, is mediated by the HNF4a binding site in the 
L-PK promoter (Section 1.9.2) and polyunsatiuated fatty acyl CoA was found to inliibit 
HNF4a binding to the G-6 -Pase promoter (Pan et aL, 2000; Rajas et a l, 2002). HNF4a has 
been proposed to be an alternative target for hypolipidaemic drugs, such as clofibrate (in the 
form of their CoA-conjugates), which aie traditionally thought to work as PPARa agonists 
(Bar-Taiia, 2004).
1.7.3 Splice variants of HNF4a
The HNF4a gene contains ten exons which undergo alternative splicing to yield nine 
theoretical splice variants, six of which (HNF4al, HNF4a2, HNF4a3, HNF4a4, HNF4a7 
and HNF4a8) have been identified in vivo (Figiue 1.5) (Sladek and Seidel, 2001). Splice 
variants ai e also generated through alternative promoter usage, with usage of proximal 
promoter PI to yield transcripts containing exon 1A (HNF4al-6) or usage of the distant 
upstream promoter P2 to generate tianscripts containing exon ID (HNF4a7-9) (Figure 1.12).
HNF4al was the first splice variant to be isolated in rat liver nuclear extiacts (Sladek et aL, 
1990), with a second isoform, HNF4a2 (previously referred to as HNF4B), being identified 
in rat, human and mouse liver (Hata et aL, 1992; Chaitier et a l, 1994; Hata et a l, 1995). 
HNF4a2 contains an extra 10 amino acid peptide in the C-terminal F domain, which was 
reported to be less inliibitory on co-activator binding than the HNF4al F-domain (Sladek et 
aL, 1999). The tliird splice variant of HNF4a, HNF4a3 (previously referred to as HNF4C), 
is formed by use of an alternative stop codon in exon 8 , resulting in a shorter F domain of 
only 40 amino acids (Kritis et a l, 1996). The shorter F domain may be less inhibitory in its 
interaction with the AF-2 region than the longer F domain of HNF4al and HNF4a2 (Suaud 
et aL, 1999). HNF4a4 was cloned from a human Iddney cDNA library and contains an 
addition exon, IB, coding for an additional 30 amino acids in tlie N-terminal A/B domain 
(Figure 1.12) (Drewes e ta l,  1996).
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Figure 1.12; Gene structure and splice variants of HNF4a. Exons are indicated by 
shaded boxes and additional sequences generated by alternative splice donor sites in 
exons 8 and 9 indicated by striped boxes. The number of amino acids (aa) in the 
additional coding sequences are indicated below the respective exon. Numbers indicate 
amino acid sequence of the primary peptide. The diagram is adapted from Sladek and 
Seidel (2001).
According to published sequences for HNF4a4 (or HNF4a5 based on the nomenclature of 
Sladek and Seidel (2001), Figure 1.12), the cloned splice variant contained the 10 amino acid 
peptide in the C-terminal region common with HNF4a2 (Drewes et al., 1996). Transient 
transfection experiments indicated that HNF4a4 had a much lower transactivation potential 
compared to HNF4a2 (Drewes et al., 1996). HNF4a4 has been found to be expressed in 
enterocyte cell lines, with high expression of the HNF4a4 variant being associated with a less 
differentiated status (Suaud et a l, 1997).
The HNF4a7 and HNF4a8 splice variants are associated with decreased differentiation of 
hepatic cells: HNF4a7 was initially identified in an undifferentiated murine hepatocyte cell 
line and both the HNF4a7 and HNF4a8 variants are expressed in murine foetal-like 
hepatoma cells (Nakhei et a l, 1998; Torres-Padilla et a l, 2001). HNF4a7 and HNF4a8 
originate from an alternative promoter (P2), situated -46 kb upstream of the PI promoter in 
the human genome, and contain an alternative first exon, exon ID (Thomas et al., 2001).
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HNF4al (PI promoter) and HNF4a7 (P2 promoter) splice variants undergo a difFerential 
pattern of expression in mouse liver development with HNF4a7 being expressed prenatally, 
whilst the expression of HNF4al is increased shortly before birth and postnatal ly (Torres- 
Padilla et aL, 2001). In line with these findings, the two promoters are regulated by different 
transcription factors, with the P2 promoter being subject to negative regulation by HNF4al 
(Figure 1.13) (Briancon et al., 2004). Compared to their expression in the adult liver, P2 
promoter splice variants (HNF4a7, HNF4a8 and HNF4a9) are expressed relatively highly in 
the islets of Langerhans in the pancreas (Thomas et a l, 2001; Boj et a l, 2001; Briancon and 
Weiss, 2006).
As well as their different roles in development, HNF4a PI - and P2-promoter variants 
(referred to as HNF4al and HNF4a7 for simplicity) possibly have different metabolic 
functions, as shown by knock-in mice, expressing only HNF4al or HNF4a7 (Briancon and 
Weiss, 2006). HNF4a7-only mice display dyslipidaemia, with reduced serum cholesterol 
and triglycerides and mild hepatosteatosis, whilst HNF4al-only mice were found to have 
impaired glucose tolerance (Briancon and Weiss, 2006). Dyslipidaemia observed in the 
HNF4a7-only mice may result from the inability of HNF4a to stimulate expression of genes 
involved in VLDL secretion (apoB and MTP) and catabolism (apoCII) (Briancon and Weiss,
2006).
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Figure 1.13: Regulation of HNF4a expression from its PI and P2 promoters. The
HNF4a splice variants HNF4al-5 are transcribed by the PI promoter whilst HNF4a7-9 
are transcribed by the P2 promoter. The alternative promoters are under the control of 
different liver-enriched transcription factors (HNFs). The glucocorticoid receptor (GR) 
binds the enhancer element (ENH) upstream of promoter PI. HNF4al/2 also negatively 
regulates transcription from the P2 promoter. Diagram from Briancon et al. (2004).
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As this project focuses on the regulation of HNF4a transcriptional activity by metabolic 
stimuli such as insulin and glucagon (Section 1.1.1), the different regulatory mechanisms 
through which metabolic stimuli could influence HNF4a activity, such as post-translational 
modification, interactions with co-factors and changes in HNF4a mRNA expression, will be 
discussed in the following section.
1.8 Metabolic regulation of HNF4a activity
1.8.1 Regulation of HNF4a activity by post-translational modification
One mechanism by which metabolic stimuli influence HNF4a transcriptional activity is 
through post-translational modification of the HNF4a protein by phosphorylation or 
acétylation. There are several potential sites for serine (S) and threonine (T) phosphorylation 
within the HNF4a protein (Figure 1.14) (Jiang et aL, 1997). HNF4a is phosphorylated by 
PKA within the DBD at SI34, leading to reduced DNA-binding activity (Viollet et aL, 1997). 
Phosphorylation of S304 by AMPK within the LBD inhibits FlNF4a dimerization and brings 
about a reduction in HNF4a protein levels (Leclerc et aL, 2001 ; Hong et a i, 2003).
PKC PKA p38MAPK AMPK
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Figure 1.14: HNF4a serine/threonine phosphorylation sites. Phosphorylation sites are 
shown as identified by phosphopeptide mapping (Jiang et aL, 1997), from which this 
diagram is taken. Positions are given in the rat HNF4a protein sequence and putative 
phosphorylation sites indicated by the symbols indicated below. Arrows refer to studies 
confirming HNF4a being a target for intracellular protein kinases: PKC at S78 (Sun et a l,
2007), PKA at SI34 (Viollet et aL, 1997), p38 MAPK at S I58 (Guo et aL, 2006) and by 
AMPK at S304 (Leclerc et aL, 2001).
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Recent reports demonsti*ate that SI58 is a target of p38 MAPK, wliich has a positive effect on 
HNF4a DNA-binding and transcriptional activity, and protein stability (Guo et a l, 2006; Xu 
Qt a l, 2007). Finally, phosphorylation of FINF4a at S78, which is located between the two 
zinc fingers of the DBD, by protein kinase C (PKC) disrupts its DNA-binding activity, 
protein stability and nuclear* localisation (Sim et a l, 2007). In addition, HNF4a is subject to 
phosphorylation at tyrosine residues, which also play a role in its DNA-binding activity and 
subnuclear localisation, although the specific residues involved were not characterised 
(Ktistaki et a l, 1995). HNF4a transcriptional activation and nuclear retention is promoted 
by acétylation of lysine residues within the NLS by the co-activator CBP (Soutoglou et al, 
2000).
1.8.2 Regulation of HNF4a activity through interaction with co-factors
From a structural point of view, the interaction of HNF4a with co-factors is key to its 
adopting an active conformation. In the case of ligand-activated NRs, ligand binding triggers 
a conformation change and repositioning of the AF-2 domain in the twelfth a-helix (HI2) of 
the LBD, whereas H I2 of HNF4a remains in an open position even with a fatty acid in the 
ligand binding pocket (Figure 1.15) (Duda et al., 2004). The crystal structure of fatty acid- 
bound FINF4a with a co-activator peptide (SRC-1) showed HI2 to be in a closed, active 
conformation, suggesting that co-factor binding could be a decisive event in HNF4a 
activation (Figure 1.15) (Duda etal., 2004).
Both HNF4a AF-1 and AF-2 domains have been shown to mediate the interaction of HNF4a 
with co-factors (Wang et a l, 1998; Green et a l, 1998). Variation of these regions in HNF4a 
splice variants could be one mechanism facilitating differential interactions with co-activators 
and hence differential tar get gene expression. Differences in the F domain of HNF4al, 
HNF4a2 and HNF4a3 influenced their interactions with cofactors (Sladek et a l, 1999;
Suaud et a l, 1999). Fiu’thermore, HNF4a variants transcribed from the PI promoter 
(HNF4al-5) contain the activation module AF-1 in the A/B region whereas those transcribed 
from the P2 promoter (FINF4a7-9) do not. The weaker transactivation potential of HNF4a8 
compared to HNF4a2 was attributed to its lack of interaction with co-factors which bind to 
the AF-1 region, such p300 (Eecldioute et al., 2003). The interaction of co-factors with 
HNF4a can be modulated by promoter context: For example, tr ansactivation of the apoB
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Figure 1.15: Structure of HNF4a LBD in the presence and absence of a co-activator 
peptide. Ribbon diagram illustrates the structure of HNF4a LBD homodimers in a binary 
complex (turquoise) with a non-esterified fatty acid superimposed upon the structure of 
FTNF4a LBD homodimers in a ternary complex (magenta) with a non-esterfied fatty acid 
and a SRC-1 peptide (blue). In the binary complex, the alO and a l2  helices are in an 
extended position in the left-hand HNF4a molecule of the homodimer, whereas in the 
ternary complex, helix a l  2 (HI 2) is in a closed conformation against the body of the 
LBD. Diagram from Duda et al. (2004).
promoter by HNF4a was found to be independent of the co-activator GRIP-1, whilst 
expression of an apoAI reporter plasmid (Section 1.11) showed synergism in the interaction 
of HNF4a, p300 and GRIP-1 (Torres-Padilla and Weiss, 2003).
The interaction of HNF4a with co-factors may be governed by metabolic stimuli, as co­
activators are themselves phosphoproteins and targets of protein kinase cascades (Wu et a l,
2005), Two HNF4a co-activators of importance in this project, PGC-la and p300, will be 
described in greater detail below.
1.8.3 Peroxisome proliferator-activated receptor-y coactivator-a (PGC- 
1 a)
PGC-la is a 798 amino acid protein that functions as a ‘bridging’ co-activator, acting as a 
molecular scaffold to facilitate interactions between a transcriptional activator and the RNA 
polymerase holoenzyme (Section 1.4.1) (Acevedo and Kraus, 2004). PGC-la facilitates the
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recruitment of further co-activators tlirough different protein domains: Through its N- 
terminal activation domain, PGC-la mteracts with coactivators that display HAT activity 
such as p300 and SRC (Section 1.4.8), whilst the PGC-la C-terminus interacts with thyroid 
hormone receptor-associated protein/vitamin D receptor-interacting protein complex 
(TRAP/DRIP, or Mediator), which interacts directly with RNA Polymerase (Figure 1.16A) 
(Puigseiver, 1999; Wallberg et a l, 2003). PGC-la is also involved in splicing of pre- 
mRNAs via its C-terminus (Finck and Kelly, 2006),
PGC-la was discovered as a cold-inducible co-activator of PPARy in the process 
thermogenesis in brown adipose tissue (Puigserver, 1998). In addition to brown adipose 
tissue, PGC-la is expressed in other tissues with a high oxidative capacity such as heart, 
slow-twitch skeletal muscle and liver (Finck and Kelly, 2006). PGC-la interacts with a wide 
range of NRs, transcription factors involved in mitochondrial biogenesis (nuclear respiratory 
factors (NRFs)) and muscle-specific gene expression (myocyte enhancing factor-2 (MEF2)) 
(Figure 1.16 A) (Finck and Kelly, 2006). Expression of tlie PGC-la gene is induced in the 
liver in response to fasting stimuli (glucagon and glucocorticoids), leading to activation of 
gluconeogenic gene expression (Yoon et a l, 2001). The interaction of HNF4a and PGC-la 
is crucial to the PGC-la-dependent stimulation of PEPCK and G-6 -Pase expression (Rhee et 
al, 2003). The PGC-la LXXLL motif interacts with the HNF4a AF-2 domain (Yoon et al., 
2001). PGC-la is also known to interact wdth other transcription factors in the regulation of 
PEPCK including CREB and Foxol (Herzig et a l, 2001; Puigserver et a l, 2003). PGC-la is 
activated by p38 MAPK phosphorylation downsti eam of cytokine stimulation in muscle cells 
(Puigserver et a l, 2001).
1.8.4 p300
p300 is a ti'ansciiptional co-activator with intrinsic HAT activity. p300 shares regions of high 
homology with CBP and often the two co-activators are referred to interchangeably in the 
literature, however CBP contains a unique polyglutamine str etch towards the C-terminus 
which is linked to neurogenerative diseases (Kalldioven, 2004). p300 is a large protein of 
over 2400 amino acids with regions which facilitate its interactions with otlier proteins (CHI, 
CH3, KIX domains) and with acetylated residues (bromodomain), and contain its HAT 
domain (Figure 1.16B) (Chan and La Thangue, 2001). p300 can interact with basal 
transcription factors, TBP and TFIIB, and RNA Polymerase II tlirough its N- and C-termini,
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Figure 1.16: Domain structure of HNF4a coactivators (A) PGC-la and (B) p300. (A)
Key functional domains of PGC-la and their interaction with NRs, nuclear respiratory 
factor-1 (NRF-1), MEF-2, and FOXOl. MAPK phosphorylation (P) sites are also indicated. 
Diagram from Finck and Kelly (2006). (B) Key functional domains of p300: 
cysteine/histidine-rich domains CHI, CH2 and CH3 (red), the KIX domain (green), the 
bromodomain (Br) (blue) and the ADA2 homology region (black). Diagram from Chan and 
Thangue (2001).
thereby acting as a molecular scaffold to stabilize the basal transcription complex 
(Kalkhoven, 2004).
HNF4a interacts with p300 through the HNF4a AF-1 and AF-2 domains and impaired 
recruitment of p300 is a possible mechanism for the reduced activity of HNF4a mutations 
found in MODY (Eeckhoute et a i, 2001 ; Eeckhoute et al., 2003). S I834 of p300 is a target 
for phosphorylation by PKB; a mechanism which plays a role in the stimulation of 
glucokinase gene expression by insulin (Roth et a i, 2004). On the other hand, 
phosphorylation of S89 by AMPK blocks the interaction of p300 with nuclear receptors 
(Yang et a i, 2001).
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1.8.5 Regulation of HNF4a gene expression
Alterations in HNF4a gene expression levels may be one mechanism which leads to changes 
in expression of HNF4a target genes. HNF4a mRNA expression has been shown to be up- 
regulated in the fasting state in vivo (Yoon et aL, 2001). Expression of the HNF4a gene in 
primary rat liver hepatocytes was also found to be stimulated by glucagon and 
dexamethasone, a synthetic glucocorticoid (Oyadomari et al., 2000). A glucocorticoid 
response element in an enhancer region ~ 6  kb upstream of the PI-promoter is responsible for 
induction by glucocorticoids (Figure 1.13) (Bailly et a l, 2001). Oyadomari and coworkers 
(2 0 0 0 ) also foimd that insulin antagonized the effects of glucagon and dexamethasone and 
reduced HNF4a mRNA levels. In line with this finding, in streptozotocin-induced diabetic 
rats that caimot produce insulin, levels of HNF4a mRNA are elevated and can be normalised 
by insulin treatment (Oyadomari et a l, 2000).
PEPCK, L-PK, SREBP-lc, FAS, apoCIII and PPARa are HNF4a target genes in 
differentially regulated metabolic and transcriptional pathways (Section 1.3). As the 
expression of these HNF4a target genes were studied in this project, the factors influencing 
their mRNA expression will be discussed in the following section.
1.9 Transcriptional regulation of HNF4a target gene expression
1.9.1 PEPCK
PEPCK is a key regulatory gene in the gluconeogenic pathway (Section 1.3.1). The 
transcription of PEPCK is tightly regulated according the fasting-fed cycle: glucagon/cAMP 
and glucocorticoids up-regulate its transcription wliilst insulin acts as a dominant inhibitory 
stimulus (Earners et a l, 1982; Gramier et a l, 1983; Sasald et a l, 1984). The PEPCK 
promoter has been described as consisting of tlnee regulatory regions (Figure 1.17) (Hanson,
2005). Region 1 contains a cAMP response element (CRE), which binds CRE-binding 
protein (CREB) amongst other members of the leucine zipper family of transcription factors 
(Chakravarty et a l, 2005). Region 2 is also important in the up-regulation of PEPCK 
expression in response to glucagon/cAMP and contains a binding site for CAAT/enliancer- 
binding protein (C/EBP) (Liu et a l, 1991). Region 3 is required for the induction of PEPCK 
expression by glucocorticoids and contains a proximal and distal glucocorticoid regulatory 
unit (GRU), each consisting of a glucocorticoid regulatory element and accessory factor
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(AF)-binding sites, which bind transcription factors other than the GR and are necessary for 
the transcriptional response to glucocorticoids (Imai et a l, 1990). The -90 bp CRE also 
interacts with the proximal GRU in the induction of PEPCK expression by glucocorticoids 
(Imai et a l, 1993). There are two sterol regulatory elements (SREs) in the PEPCK promoter 
(at positions -322 to -313 and -590 to -581 bp), and SREBP-lc has been implicated in the 
insulin inhibition of PEPCK expression (Chakravarty et a l, 2004).
HNF4a was initially identified as binding to the accessory factor site 1 (AFl) of the proximal 
GRU and has subsequently been shown to play a role in stimulation of PEPCK expression via 
the AFl site in distal GRU (Hall et a l, 1995; Cassuto et a l, 2005). The interaction of 
HNF4a with the fasting-induced co-activator, PGC-la (Section 1.8.3), is important in the 
fasting-induced expression of PEPCK (Yoon et al., 2001; Rhee et al., 2003).
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Figure 1.17: Regulatory elements of the PEPCK gene promoter. Diagram showing 
regulatory elements in the PEPCK promoter and the transcription factors and co-factors 
which bind to them. Abbreviations used: ATF-3: activating transcription factor 3, CRE: 
cAMP regulatory element, CREB: CRE-binding protein, COUP-TF, Chicken Ovalbumin 
Upstream Promoter-Transcription factor, PPARy2: Peroxisome Profilerator-Activated 
Receptor-y2, SREBP-1: Sterol Regulatory Element Binding Protein-1, GRU: 
Glucocorticoid Regulatory Unit, T3R: Thyroid Hormone Receptor, Pol II, RNA 
Polymerase II, NFkB: Nuclear Factor kB. Diagram adapted from Hanson (2005) with 
notation of HNF4a binding to dAFl element (Cassuto et a l, 2005).
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1.9.2 L-PK
L-PK is a key regulatory gene in the glycolytic pathway (Section 1.3.2). L-PK gene 
transcription is regulated in an opposite manner to that of PEPCK: L-PK mRNA expression 
is induced by glucose and insulin following feeding of car bohydrates, and repressed by 
glucagon (Raymondjean et at., 1991). The differential regulation of L-PK mRNA exprssion 
facilitates the utilisation of diets rich in carbohydrates, wliilst in tlie fasted state, the 
gluconeogenic pathway is active and fatty acids are the primary source of energy production 
in the liver (Salway, 2004). Thyroid and glucocorticoid hoiinones play a permissive role in 
the hepatic expression of L-PK (Mumiich et a l, 1984; Vaulont et a l, 1986). As the 
glycolytic pathway generates substrates for the TCA cycle and lipogenic pathways (Sections
1.2 and 1.3), n-3 PUFA and PPARa agonist Wy14,643 which have hypolipidaemic effects on 
hepatic lipogeriesis (Section 1,7.3 and 1.7.4) also suppress L-PK mRNA expression (Jump et 
aL, 1994; Pan et a l, 2000). The aiiti-hyperglycaernic drug, metformin, stimulates L-PK 
mRNA expression, thereby both promoting hepatic glucose utilisation and suppressing 
hepatic gluconeogenesis (Fulgencio etal., 2001).
The -200 bp region of the L-PK proximal promoter contains key elements in the regulation of 
L-PK gene expression by glucose, insulin and glucagon (Thompson and Towle, 1991; Bergot 
et a l, 1992) (Figure 1.18). This regions contains binding sites (named LI to L4) for four 
transcription factors (in order of proximity to the transcriptional start site): HNFl, Nucleai' 
Factor-1 (NF-1), HNF4 and CIiREBP (Vaulont et a l, 1986; Yamashita et a l, 2001).
ChREBP (Section 1.4.4) is activated by intracellulai' glucose metabolism and stimulates L- 
PK mRNA expression by binding to the L4 element (also known as tlie carbohydrate 
response element, ChORE or ChRE) (Yamashita et al., 2001). FlNF4a binds to the adjacent 
L3 element and cooperates with CliREBP in tlie induction of L-PK gene expression by 
glucose (Diaz Guerra et al., 1993; Liu et a l, 1993). Both ChREBP and HNF4a mediate the 
negative effects of glucagon (and its second messenger, cAMP) on L-PK transcription 
(Goui'don et al., 1999; Kawaguchi et al., 2001). The inhibition of L-PK expression by n-3 
PUFA is mediated via the L3 element, with n-3 PUFA being foimd to transiently suppress the 
binding of HNF4a to the L-PK promoter (Liimatta et a l, 1994; Xu et a l, 2006).
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Figure 1.18: L-PK promoter elements and factors affecting L-PK gene 
transcription. L-PK promoter elements aie identified as sequence motifs boimd by 
CliREBP-Mlx (ChORE composed of two E boxes, HNF4a (DR-1 element), NF-1 and 
HNFl. Promoter elements are also labelled LI to L4 in line with nomenclature used by 
Vaulont et al. (1986). Factors inducing L-PK expression are indicated in the upper part 
of the diagram, whilst factors repressing L-PK gene expression aie indicated in the 
lower part of the diagiam, with aiTows reflecting the promoter elements tluough which 
these factors act. Diagram adapted from Xu et al. (2006).
1.9.3 SREBP-lc
Of the tlu'ee isoforms of SREBP (Section 1.4.3), only SREBP-lc gene expression is subject 
to regulation by nutritional status, with decreased expression in the fasting state and increased 
transcription upon refeeding, an effect which is common to adipose tissue, liver and muscle 
(Kim et a l, 1998; Horton et a l, 1998a; Bizeau et a l, 2003). The transcription of SREBP-lc 
in hepatocytes is induced by insulin and glucose, and inhibited by glucagon and PUFAs (Kim 
et a l, 1999; Foretz et a l, 1999b; Shimomura et a l, 1999b; Hasty et a l, 2000; Matsuzaka et 
al, 2004). The induction of SREBP-lc in the fed state stimulates the expression of 
downstream lipogenic genes such as ACC and FAS (Horton et a l, 1998a; Foretz et al,
1999b), The hmnan SREBP-lc promoter shares only 42% identity with that of the mouse, 
with novel binding sites being identified for HNF4a and PDX-1, the gene responsible for 
MODY4 (Section 1.6.1) (Tailing et al., 2004). Overexpression of HNF4a or PDX-1 
stimulated expression from the human SREBP-lc promoter, raising the possibility that these
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ti’anscription factors aie involved in the regulation of SREBP-lc gene expression in human 
tissues (Tarling et al., 2004).
1.9.4 FAS
The activity of FAS is regulated at the level of its gene expression, as FAS is not modulated 
allosterically or by covalent modification. Expression of the FAS gene is activated in the fed 
state, with insulin, glucocorticoids and glucose contributing to its induction (Paulauskis and 
Sul, 1989; Rufo et a l, 1999). In common with L-PK and SREBP-lc, FAS gene transcription 
is suppressed by cAMP and PUFAs (Paulauskis and Sul, 1989; Blalce and Clarke, 1990).
Insulin Response Elements at -65 and -332 bp bound by upstream stimulatoiy factors (USFs) 
are important in mediating the effect of insulin on FAS gene transcription (Moustaid et a l, 
1994; Wang and Sul, 1995; Moon et a l, 2000). The binding of SREBP-1 to a SRE at -150 
bp in the FAS promoter is also regulated by nutritional state (Latasa et a l, 2000; Latasa et a l, 
2003). Transgenic mice overexpressing SREBP-1 showed increased FAS niRNA expression 
(Shimano et a l, 1996; Shimano et a l, 1997; Horton et a l, 1998a), whereas SREBP-1 
knockout animals show an impaired response of FAS to refeeding (Shimano et a l, 1999).
The SREPB-lc isoform has been identified as the major mediator of insulin action on FAS 
expression (Foretz et a l, 1999a). In addition, CliREBP is a key mediator of the effect of 
glucose on FAS expression (Dentin et a l, 2004; Isliii et a l, 2004; lizuka et a l, 2004). A 
ChoRE has been identified in an enliancer region -  7 kb upstieam of the FAS gene 
transcriptional stai't site (Rufo et a l, 2001). As in the case of the L-PK gene (Section 1.9.2), 
the FAS ChoRE is adjacent to a HNF4a DR-1 site, witli both factors cooperating in the 
caibohydrate induction of the FAS gene (Adamson et a l, 2006).
1.9.5 apoClil
In view of the physiological role of apoCIII in inhibiting LPL activity (Section 1.3.4), the 
expression of apoCIII inRNA is suppressed by insulin, thus facilitating die hydrolysis of 
chylomicrons in the fed state (Chen et a l, 1994a). However in a state of insulin resistance, as 
occurs in T2DM, raised apoCIII plasma concentrations are observed in hiunans, with 
increased apoCIII mRNA expression also observed in the db/db diabetic mouse model 
(Gervaise et a l, 2000; Altomonte et a l, 2004). The transcription factor, forkliead box 01 
(Foxol), is a key mediator of the inliibitoiy action of insulin on apoCIII gene transcription.
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acting via insulin response element (IRE) -470/-453 bp upstream of the tr anscriptional start 
site (Altomonte et a l, 2004).
HNF4a is a transcriptional activator of apoCIII expression (Taylor et a l, 1996), witli HNF4a 
binding sites being present in the proximal promoter (-67/-S7 bp) and two enhancer elements 
(-734/-716 bp and -2880/-2929 bp) (Sladek et a l, 1990; Kardassis et a l, 1997; Vergnes et a l, 
1997). Acute-phase response cytokines {e.g. tumor necrosis factor-a (TNFa) and interleukin 
1 (IL-1)) decrease HNF4a activity at the apoCIII promoter (Nikolaidou-Neokosrnidou et a l,
2006). The latter is mediated by the nuclear* factor-icB (NF-icB) pathway, a key pathway in 
immune and irrflammator*y processes, activation of which results in translocation of the 
transcription factor NF-icB from the cytoplasm to the nucleus (Perkins and Gilmore, 2006). 
The MAPK signalling pathway (Section 1.1.1) has also been shown to inliibit HNF4a- 
dependent transcriptional activation of apoCIII gene expression (Reddy et a l, 1999).
1,9.6 PPARa
In line with its role in the fasting state (Section 1.4.5), PPARa mRNA expression is induced 
by glucocorticoids and inliibited by insulin (Steineger et a l, 1994; Lemberger et a l, 1994). 
HNF4a is a positive regulator of PPARa transcription, as shown by decreased PPARa 
mRNA expression in HNF4a conditional Icnockout models (Hayhurst et a l, 2001; Gupta et 
ah, 2005, Mima et ah, 2006), and a functional response element for FINF4a has been 
identified in the human PPARa promoter (Pineda Torra et a l, 2002).
As described in the above section, HNF4a regulates a range of hepatic tai get genes whose 
expression is alternately controlled by metabolic stimuli. Genetic evidence (Section 1.6 ) also 
points to HNF4a playing a role in the development of T2DM and dyslipidaemia. Since 
hepatic HNF4a target genes such as PEPCK, L-PK and SREBP-lc contribute to 
oveiproduction of glucose and triglycerides by the liver in these metabolic disorders, HNF4a 
fimction in the liver was investigated in the course of this research. The choice of model and 
different tecliniques used to study the mipact of HNF4a activity on hepatic gene expression 
are therefore discussed in the following two sections.
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f . 10 Modefs of liver metabolism
In vivo models present the most physiological setting in which to study liver metabolism, 
however investigation of human liver metabolism in vivo is prevented by the dangers 
associated witli liver biopsy. Studies in animals provide an alternative approach, however 
this approach is costly and genetic manipulation is a more lengthy process compared to the 
use of in vitro models. In vitro models for the study of hepatic metabolism include primary 
hepatocytes and cultuied cells derived from hepatomas. There are advantages and 
disadvantages to both primary and cultured cells: First, human hepatocytes have limited 
availability and display phenotypic instability (Castell et a l, 2006). Differences between 
human and rat liver may malce primary rat hepatocytes less than ideal as a model; for 
example, differences exist between human and rat liver in the expression levels of PPARa 
and the action of peroxisome proliferators (Palmer et a l, 1998). Human hepatoma cell lines 
offer the advantage of being of human origin and ease of manipulation for repeated 
experiments and procedures such as tr ansient transfection (Castell et a l, 2006). Tlrree 
commonly used human hepatoma cell lines are described in greater detail below.
The HuH-7 cell line originated from well-differentiated hepatocellular* carcinoma tissue 
excised from a 57-year* old Japanese male (Nakabayashi et al, 1982). The HuH7 cell line was 
fomrd to secrete a range of liver-specific mar kers, including plasma proteins (including 
albumin, a  1-antitrypsin, transferrin and LDL) and low activities of glucose-6 -phosphatase 
and fructose-1,6-bisphosphatase. However HuH7 cells were not foimd to express liver-type 
pyruvate kinase or glucokinase, suggesting that whereas they have a liver-like phenotype, it is 
not complete (Nalcabayashi et a l, 1982).
The HepG2 cell line was established ffom a liver biopsy of a male Caucasian aged 15 years, 
with a well differentiated hepatocellular carcinoma (hepatoblastoma type) (Aden et al,
1979). HepG2 cells also secrete most of the major plasma proteins including albumin, a2- 
macroglobulin, a  1-antitrypsin, transferrin and plasminogen, as well as LDL and HDL and the 
major apolipoproteins (Knowles et a l, 1980; Thrift et a l, 1986). HepG2 cells are able to 
metabolise chylomicrons, VLDL, LDL and HDL and are able to produce bile acids fr om 
cholesterol, making the cell line a useful model for the study of lipid metabolism (Javitt, 
1990).
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The Hep3B cell line was established from a liver biopsy of a African American male aged 8 
years (Aden et al., 1979). Like tire HepG2 cell line, Hep3B cells secrete a wide range of 
plasma proteins. Unlike the HuH7 and HepG2 cell lines, the Hep3B cell line expresses two 
polypeptides of the Hepatitis B Surface Antigen and contain an integrated copy of the 
Hepatitis B genome (Knowles et a l, 1980).
1.11 Approaches to studying transcriptions! regulation
Changes in gene expression can occur* at the transcriptional, post-transcriptional, translational 
or post-translational levels. Whilst studying changes at the mRNA level does not talce 
accoimt of changes affecting protein expression or stability, transcriptional networks ar e 
undoubtedly important in the pathogenesis of T2DM: For example, five of the six genes 
responsible for MOD Y (Section 1.6.1) code for transcription factors. Since HNF4a is a 
transcription factor, it is appropriate to study changes in transcription of its target genes, as 
changes in the expression or activity of HNF4a will take effect at this level. Therefore two 
approaches for studying changes in mRNA expression and gene transcription are described 
below.
1.11.1 Reverse Transcriptase Polymerase Chain Reaction
Reverse tr anscriptase polymerase chain reaction (RT-PCR) enables the study of mRNA 
expression levels in cell extracts and tissue samples under different experimental conditions, 
with detection of low abundance transcripts possible. RT-PCR consists of two steps: the 
reverse transcription of RNA into complementary DNA (cDNA) and the amplification of the 
cDNA by PGR. RNA is reverse transcribed by an RNA-dependent DNA polymerase usually 
derived fr om a retrovirus such as Moloney Mmine Leukaemia Virus (M-MuLV), which also 
possesses exoribonuclease activity and therefore degrades the RNA template following 
cDNA synthesis, resulting in single-stranded (ss) cDNA (Figure 1.19A). Primers for first- 
strand synthesis include poly-dT, which binds the RNA polyA 3’-tail, random hexamer and 
gene-specific oligonucleotides. The subsequent PCR reaction amplifies the gene of interest 
using gene-specific primers, which bind to both the sense (5’^ 3 ’) and antisense (3’—>5’) 
DNA strands. During each cycle of PCR, double-stranded DNA is denatm ed to facilitate 
primer binding, which is followed with primer extension by thermostable Tag polymerase 
which originates from the bacteriimi Thermus aqiiaticus, in the presence of 
deoxyribonucleotide triphosphates (dNTPs). With the exception of the first cycle of PCR 
where single-stranded cDNA is converted to double-stianded DNA, each PCR cycle results
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Figure 1.19: (A) Reverse Transcription (RT) reaction (B) Polymerase Chain 
Reaction (PCR). (A) RNA templates are reverse transcribed into cDNA and 
subsequently digested by the RNA-dependent DNA polymerase and ribonuclease (RNase) 
activities of the reverse transcriptase enzyme. (B) cDNA is converted into dsDNA and 
undergoes logarithmic amplification following each PCR cycle of dsDNA dénaturation, 
primer annealing and primer extension by Tag DNA polymerase. Diagram based on Voet 
and Voet (1995).
in a doubling of the number of double-stranded DNA molecules, hence providing a 
logarithmic amplification of the targeted DNA region (Figure 1.19B).
The amplified DNA can be detected by gel electrophoresis (Section 2.2.5.5) or in real-time 
by using fluorescence-based probes (Section 2.2.8). The RT-PCR steps can take place in the
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same tube (one-step RT-PCR) using gene-specific primers for both steps, or in separate 
reaction tubes (two-step RT-PCR), whereby cDNA is usually generated from all RNA 
templates present in the extract using poly-dT or random primers, followed by separate PCR 
reactions using gene-specific primers.
1.11.2 Reporter genes
Reporter genes consist of a plasmid with a reporter gene, expression of which can be 
controlled by the promoter or enliancer regions of interest. The promoter or enhancer region 
of interest is cloned and inserted into a plasmid containing a reporter protein, Wlien the 
reporter plasmid is tiansfected into a cell line with the necessaiy tianscription factors and co­
factors to stimulate expression from the cloned promoter, RNA Polymerase II stimulates 
transcription of the reporter gene, followed by the production of the protein by the host cell 
tianslational macliinery. Reporter proteins must be distinguishable from the endogenous 
proteins produced by the cell system being employed (Schenborn and Groskreutz, 1999). 
Detection methods include both enzyme-based assays such as luciferase, which is able to 
produce luminescence in the presence of its substrate, luciferin (Section 2.2.7.4), and the 
fluorescent properties of the reporter protein, such as green fluorescent protein (Schenborn 
and Grosla'eutz, 1999). Reporter gene constructs enable the dissection of gene promoters in 
terms of the DNA elements which mediate the effects of stimuli on expression of the gene of 
interest (e.g. cAMP, PUFAs) and the transcription factors which bind to the DNA elements.
1.12 Hypothesis, Aims and Objectives
HNF4a promotes the transcription of genes which are oppositely regulated by metabolic 
stimuli. Whilst some HNF4a taiget genes, e.g. PEPCK, aie induced by glucagon, otliers, e.g. 
L-PK, aie transcriptionally repressed by the same stimulus. Conversely, whilst PEPCK 
expression is inliibited by insulin, L-PK expression is activated by insulin. The cuiTent 
research therefore focussed on the question: How does HNF4a participate in both gene 
activation and repression imder a same metabolic condition?
Hypothesis: Glucagon and insulin have opposite effects on HNF4a activity in terms of the 
regulation of gluconeogenic genes compared to those of glycolytic and lipogenic genes, i.e. 
glucagon stimulates HNF4a to promote gluconeogenesis, whilst insulin stimulates HNF4a- 
regulated glycolytic and lipogenic gene expression.
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HNF4a has been shown to be a target for insulin signalling via its interaction with Foxol, 
with the latter acting as a co-repressor of HNF4a activity (Hirota et al., 2003). Insulin 
relieves Foxol-mediated repression of HNF4a by causing phosphorylation of Foxol and its 
exclusion from the nucleus (Hirota et al., 2003). These findings suggest that this or other 
interactions of HNF4a may play a role in its regulation taiget gene promoters. Since the 
transcription of HNF4a target genes, L-PK, SREBP-lc and FAS, is activated by insulin 
(Paulauskis and Sul, 1989; Rayniondjean e ta l,  1991; Shimomuia et a l, 1999b), it is 
hypothesized that insulin has a stimulatory effect on HNF4a activity at these gene promoters.
Contrasting effects of glucagon on HNF4a activity are reported in the literature. IiNF4a is 
crucial to the action of PGC-la in the activation of gluconeogenic gene expression in 
response to glucagon (Rliee et a l, 2003). The latter report conflicts with die finding that 
glucagon has an inliibitory effect on HNF4a DNA-binding capacity (Viollet et a l, 1997). It 
is tiierefore hypothesized that HNF4a activity is modulated by promoter context, such that 
glucagon activates HNF4a when boimd to the promoters of gluconeogenic genes such as 
PEPCK.
To address the above hypothesis, the project aims were as follows:
Aim 1: To char acterise the hmnan hepatoma cell lines, HuH7, HepG2 and Hep3B, for the 
expression of FINF4a and its splice variants, and HNF4a target genes.
Objectives:
• To profile the expression of HNF4a splice variants in the HepG2, Hep3B and HuH7
cell lines using RT-PCR with splice-var iant specific primers.
• To compare the expression profile of HNF4a splice variants in the human hepatoma
cell lines with those of adult and foetal human liver.
• To study the expression of HNF4a and its hepatic target genes in a hepatoma cell
cultur e system, using serni-quantitative RT-PCR under different conditions of glucose 
and insulin concentration.
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Aim 2: To investigate the effects of feeding and fasting stimuli on HNF4a transcriptional 
activity by studying downstream effects on HNF4a tar get genes in the pathways of 
glycolysis, gluconeogenesis and lipogenesis.
Objectives:
® To investigate the effects of different metabolic stimuli on HNF4a reporter gene
expression utilising reporter plasmids containing promoter sequences of key HNF4a 
tar get genes in the metabolic pathways of glycolysis, gluconeogenesis and lipogenesis 
together with HNF4a over-expression.
® To investigate the effect of insulin on the mRNA expression of lipogenic (SREBP-lc, 
SREBP-2, ACC, FAS) and glycolytic (L-PK) genes in HepG2 cells, and the role of 
HNF4a in these effects by HNF4a overexpression.
® To char acterize the effects of a range of feeding and fasting stimuli on the mRNA 
expression of HNF4a target genes in oppositely regulated pathways in HepG2 cells, 
and to investigate the role of HNF4a in these effects by overexpression of dominant- 
negative HNF4a .
Aim 3: To investigate the mechanisms by which HNF4a differentially regulates its target 
genes under fasting vs. feeding conditions.
Objectives
® To ascertain the role of HNF4a co-activators, PGC-la and p300, in the regulation of 
HNF4a-dependent reporter gene expression for genes from opposing metabolic 
pathways .
® To investigate the role of HNF4a and its co-activators, p300 and PGC-la, in the 
regulation of HNF4a target genes by metabolic stimuli by overexpression of co­
activators, individually and in combination with HNF4a overexpression.
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Chapter 2 
Materials and Methods
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Chapter 2:
2.1 Materials
Dulbecco’s Modified Eagle Medium (DMEM) (1000 mg/1 D-glucose, 110 mg/1 sodium 
pyruvate), Dulbecco’s Modified Eagle Medium without phenol red (1000 mg/L D-glucose, 
110 mg/1 sodimn pyruvate), Dulbecco’s Modified Eagle Medium without glucose and sodium 
pyruvate (DMEM G“), Medium 199 with Earle’s Salts, Foetal Bovine Serum (FBS), Non- 
essential amino acids (NEAA), Trypsin-EDTA (0.25% Trypsin 1 niM EDTA), Trypan Blue, 
Penicillin (10,000 units/ml) -  Streptomycin (10 mg/ml) solution, Trizol Reagent and 
UltraPure^^ DNase/RNase-fiee water were obtained fr om Invitrogen (Paisley, U.K.).
Small (culture area 25 cnf), medium (culture area 80 cm^) and large cell cultine flasks 
(culture area 175 cnf), multiwell tissue culture plates and cryovials were obtained from 
Nunclon (Roskilde, Denmark).
Sigma-Aldrich (Gillingham, U.K.) supplied 5-aminoimidazole-4-cai*boxamide 1-p-D- 
ribofuranoside (AICAR), 8-bromoadenosine 3',5'-cyclic monophosphate sodium salt (8-Br- 
cAMP), dexamethasone, diethyl pyrocarbonate (DEPC), D-Glucose solution, 3-isobutyl-1- 
methylxanthine (IBMX), human recombinant insulin solution, (10 mg/ml), L-glutamine (200 
mM) - penicillin (10,000 U/ml) - streptomycin (10 mg/ml) solution, phosphate buffered 
saline tablets (PBS), sodium pyruvate solution and triiodo-L-thyronine. D-Glucose 
(anliydrous) was obtained from Fisher Scientific (Loughborough, U.K.).
Gel and PCR Clean-up System, Wizard Plus Miniprep DNA Pmification System, agarose, 
restriction endonucleases, restriction endonucleases reaction buffers, 100 bp DNA maikers, 1 
kb DNA markers, RQl RNase-Free DNase and Bright-Glo® and Steady-Glo® Luciferase 
Assay Systems were supplied by Promega (Southampton, U.K.),
Amersham Biosciences (Little Chalfont, U.K.) Ready-to-Go RT-PCR Beads were used for 
RT-PCR. PCR Primers for semi-quantitative PCR were supplied as unmodified 
oligonucleotides by MWG Biotech (Ebersberg, Germany).
Fugene-6 Transfection Reagent was purchased from Roche Diagnostics (Indianapolis, IN, 
U.S.A.). Phospha-Light™ SEAP Reporter Gene Assay System, Applied Biosystems 
(Bedford, MA, U.S.A.) was used for quantification of SEAP activity.
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Sterile white opaque 96-well microplates for luciferase assays, non-sterile white opaque 96- 
well opti-plates for SEAP assays and cleai* adhesive top-seals for microplates were obtained 
from Perldn Elmer (Zaventem, Belgium). Abgene (Epsom, U.K.) provided Thermo-Fast® 96 
non-sldrted, opaque white PCR plates and Absolute™ QPCR seals.
Qiagen (Hilden, Germany) supplied RNeasy Mini Kit for RNA purification, QuantiTect 
Reverse Transcription Kit, QuantiTect SYBR Green PCR Kit and target gene-specific 
QuantiTect Primer Assays. Homo sapiens housekeeping gene detection kits for use with 
SYBR Green chemistry from Primer Design (Southampton, U.K.) were used for reference 
gene quantification by real-time PCR.
Cambrex (Rockland, ME, U.S.A.) low-melting point NuSieve GTG Agarose and 20 bp DNA 
ladder were used for gel analysis of real-time PCR products.
The RNA 6000 Nano Chip and RNA 6000 Nano Kit from Agilent Technologies (Waldbronn, 
Germany) were used for analysis of RNA integrity.
2.2 Methods
2.2.1 Cell culture
2.2.1.1 HuH7, HepG2 and Hep3B human hepatoma cell lines
Three human hepatoma cell lines were cultured in the course of the project:
• HuH7 (Cell Line No. JCRB0403, Japanese Collection of Reseaich Bioresources - Cell 
Bank, Osaka, Japan)
• HepG2 (Cell Line No. 85011430, ECACC, Salisbury, U.K.)
• Hep3B (Cell Line No. 86062703 ECACC, Salisbury, U.K.)
The standard cell cultuie medium (SCM) for all tlnee cell lines was Dulbecco’s Modified 
Eagle Medium (DMEM) supplemented with 10% FBS, 1% non-essential amino acids 
(NEAA) and 1% L-glutamine (200 mM) - Penicillin (10,000 U/ml) - Streptomycin (10 
mg/ml) solution (PSG). Cells were incubated in a hmnidified incubator at 37°C, 5% CO2.
2.2.1.2 Passage of cells
Cells were grown in mediiun cell culture flasks (culture area 80 cnf) mitil approximately 
80% confluent. Medium was removed by aspiration. Cells were washed twice with 10 ml 
sterile PBS before addition of 4 ml 0.25% Trypsin-1 mM EDTA (approximately 1 ml per 25 
cnf culture area). The flask was gently rocked to ensure even coverage of the cells with the
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protease and incubated at 37°C for 3 - 5  minutes until the cells had detached, as checked by 
microscopy. An equal volume of SCM : trypsin was added to the flask to neutralise tiypsin 
activity, and the cells mixed by pipetting. Cells were passaged 1:4 to 1:6 by dividing the cell 
suspension between 4 - 6  new flasks (of equal culture area) and then incubated at 37°C, 5 % 
CO2. The cell culture medium was refreshed every 2-3 days with 10 -  15 ml of SCM per 
flask.
2.2.1.3 Preparation of frozen stocks
Cells were grown in large cell culture flasks (culture ar ea 175 cm^) witli 25 ml standard cell 
culture medium imtil 90% confluent. Cells were passaged as described above with 7 ml 
Trypsin-EDTA per flask. After cells had detached, 7 ml SCM was added and 10 pi sample of 
the suspension removed for counting of cells using a haemocytorneter (see Section 2.2.1.5). 
The cell suspension was centrifuged at 900 x g  (2000 rprn, Sigma 6IC10 centrifiige) for 5 
minutes at room temperature. The cell pellet was resuspended in freezing rnediimi containing 
90% FBS, 10% DMSO (v/v) to a concentration =4 x 10^  cells/ml. Aliquots of the cell 
suspension were placed in an alcohol bath at -80°C to enable cooling at a rate of l-3°C/rnin 
before being transferTcd to liquid nitrogen storage (ECACC Procedwe for Freezing Cells).
2.2.1.4 Plating of frozen stocks
An ampoule containing 1 ml frozen cells in freezing medium was thawed rapidly in a 37°C 
water bath. The cell suspension was transferred to 10 ml SCM (37°C) and centrifuged at 900 
X g  (2000 rpm, Sigma 6K10 centrifiige) for 5 minutes at room temperature. The cell pellet 
was resuspended in 5 ml SCM and tr*ansferred to a small cell culture flask (culture area 25 
cni^), and cultured under standard conditions.
2.2.1.5 Estimation of ceil number using a haemocytorneter
Cell number was estimated using a haemocytorneter; the central region of haemocytometer 
contains two etched counting grids which can be viewed by light microscopy (Figure 2.1). A 
cover slip is attached to the haemocytometer by breathing on the cover slip and pressing it 
gently onto the central part of the haemocytometer. On the sides of the coverslip small 
rainbow-lilce rmgs can be seen - these are an indication of a proper fit, and are laiown as 
Newton's Rings.
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BCover glass 
Cover glass support
Counting chamber 
0.1mm depthZ
Figure 2.1: Use of haemocytometer. (A) Side view of a haemocytometer showing depth 
of counting chamber and position of coverslip. (B) Counting ^rid of haemocytometer.
The region highlighted in red corresponds to an area of 1 mm" and a volume of 10“* ml.
For calculations of cell number, a 10 pi sample was removed from a suspension of cells and 
mixed with 90 pi Trypan Blue solution. Trypan Blue is excluded from live cells therefore 
only cells which appear white/yellow on the grid are counted, whilst cells which appeared 
blue are excluded. The Trypan Blue suspension was pipetted at the edge of the coverslip 
either side of each counting grid and allowed to fill the haemocytometer chamber by capillary 
action. The number of cells was counted in all 4 regions of the grid, each corresponding to 1 
mm^ (Figure 2.1), utilising both sides of the haemocytometer, and a mean no. of cells 
calculated. The concentration of cells in the original suspension was then calculated using 
Equation 2.1 (Freshney, 1994).
Concentration of 
cells in original 
suspension (/ml)
Mean cell count Dilution factor to 
original sample 
(10)Volume of grid section (10  ^ml)
Equation 2.1: Calculation of cell concentration. The estimated concentration of cells in 
the original suspension is based on the mean cell count in a grid section of 1 mm  ^with 
depth 0.1 mm from a 10 pi sample diluted to a volume of 100 pi with Trypan Blue 
(dilution factor of 10).
2.2.1.6 Preparation of hormone stock solutions
Hormone stock solutions were prepared according to manufacturer’s product information 
(Sigma):
• The solubility of 5-aminoimidazole-4-carboxamide 1-p-D-ribofuranoside (AICAR, 
Formula Weight (FW) 258.23 g/mol) is > 10 mg/ml in water. 5 mg AICAR was
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dissolved in 5 ml of serum-free DMEM (containing antibiotics and NEAA) to a 
concentration of 1 mg/ml.
• 8-bromoadenosine 3%5'-cyclic monophosphate sodium salt (8-Br-cAMP, FW 430.08 
g/mol) is very soluble in aqueous solutions. 25 mg 8-Br-cAMP was dissolved in 10 
ml seriun-fiee DMEM (containing antibiotics and non-essential amino acids) to 
prepare a stock solution of 2.5 g/1.
• Dexamethasone (FW 392.5 g/mol) stock solution (1 mg/ml) was prepared by 
dissolving 25 mg dexamethasone in 25 ml filter-sterilised ethanol.
• Glucagon (FW 3482.75 g/mol) stock solution (0.1 mg/ml) was prepared by dissolving 
1 mg glucagon in 10 ml 0.05 M acetic acid.
• 3-isobutyl-1-inethylxanthine (IBMX, FW 222.24 g/mol) was dissolved in DMSO to a 
concentration of 100 g/1 by warming at 37°C.
• 3,3',5-triiodo-L-thyronine (Tg) (FW 673.0 g/mol) stock solution was prepared by 
dissolving triiodothyronine in sterile 1 M NaOH to a concentration of 1 g/1.
Hormone stock solutions were mixed by pipetting and were frozen in aliquots -20°C.
Insulin (10 rng/rnl) and glucose (450 g/1) were supplied as stock solutions. In the case of 
insulin, a final concentration of 100 riM was required, thus the supplied insulin solution (10 
mg/ml) was diluted 1:100 in sterile water or experimental cell culture mediiun to a 
concentration of 0.1 rng/ml, before a second dilution was made to acliieve the final 
concentration. Other stock solutions of hormones and protein kinase activators were diluted 
in cell culture medium to acliieve the required final concentration and mixed by pipetting 
several times (Table 2.1). In the case of media containing dexamethasone, Tg or IBMX, the 
appropriate volume of solvent (sterile ethanol, 1 M NaOH or DMSO respectively), was added 
to the standar d medimn to act as the vehicle control.
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2.2.2 Isolation of total RNA from cell culture samples
2.2.2.1 Trizol method
In experiments where gene expression was analysed by semi-quantitative RT-PCR, total 
RNA was purified using Trizol reagent (Invitrogen). Trizol reagent is a mono-phasic solution 
of phenol and guanidine isothiocyanate, which disrupts cell membranes and nucleoprotein 
complexes, whilst maintaining RNA integrity by inhibiting endogenous ribonucleases 
(RNases).
Cells were grown in six-well plates prior to RNA isolation. Cell culture media was removed 
and the cells washed twice witli PBS (1 ml). Cells were lysed witli 1 ml Trizol per 10 cm  ^
culture ar ea (1 ml per well) and lysate mixed thoroughly by pipetting. All stages were 
performed in a sterile laminar* flow hood. RNase-free water was prepared by adding 0.1 % 
diethyl pyrocarboriate to deionised water and leaving overnight prior to autoclaving.
Total RNA was extracted according to Trizol product information (Invitrogen). Samples 
were incubated at room temperature for* 5 mmutes to permit the complete dissociation of 
nucleoprotein complexes. 0.2 ml of chloroform was added per 1 ml Trizol and the tubes 
shaken vigorously by hand for 15 seconds. Samples were incubated at room temperature for 
2 to 3 mmutes and centrifiiged for* 15 minutes at 2 -  8°C at 12,000 x g (11,400 rpm, 
Eppendorf microcentrifuge model 5415D) in order to separate the total RNA in the aqueous 
phase fiom the organic phenol/chloroform phase. The upper aqueous phase was then 
transferred to a fiesh microcentrifuge tube and RNA precipitated with 0.5 ml isopropanol per 
1 ml Trizol reagent, facilitated by incubation at room temperature for* 10 minutes. The 
samples were then centrifuged at 12,000 x g ( l l  ,400 rpm) for 10 minutes at 2 -  8°C. 
Following centrifiigation, the supernatant was removed and 1 ml of 75 % ethanol (in 0.1 % 
DEPC-tr eated water) was added per* 1 ml of Trizol reagent to wash the RNA pellet and 
remove residual isopropanol. The sample was mixed by vortexing and centrifuged at 7,500 x 
g (8,900 rpm) for 4 minutes at 2 -  8°C. The supernatant was removed and the RNA pellet 
air-dried for 5 minutes. Traces of 75% ethanol were removed by blotting with tissue at the 
edge of the tube. RNA samples were normally dissolved in 50 pi RNase-free water. RNA 
samples were then kept on ice or frozen at -80“C.
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2.2.2 2 RNA purification using microspin coiumn chromatography
In experiments where gene expression was analysed by real-time quantitative PCR, total 
RNA was purified using RNeasy® Mini microspin colimins (Qiagen), which contain a silica- 
based membrane that specifically bmds RNA. Like Trizol reagent, this method uses a buffer 
containing the chaotropic agent guanidine isothiocyanate to lyse cells and disrupt the nucleic 
acid -  protein interactions. However, this method of RNA purification is performed without 
phenol/chloroform, which has the advantage of avoiding caiTy-over of phenol that can affect 
the highly sensitive detection of gene tr anscript levels by real-time RT-PCR.
RNA was isolated from cultrues of HepG2 cells seeded at 5 x 10^  cells/well in 24-well plates 
according to the ‘Protocol: Purification of Total RNA from Animal Cells using Spin 
Technology’ (RNeasy Mini Handbook, 2006). Initial optimization experiments were 
performed to ensure that the total number of cells did not exceed the recommended maximum 
of 5 X 10  ^cells per 350 pi lysis buffer. In addition to presence of guanidine isothiocyanate in 
the lysis buffer (RLT), (3-mercaptoethanol (10 pi per 1 ml) was added to inhibit RNase 
activity. At the endpoint of the experiment, cells were washed once with 1 ml PBS to remove 
traces of the cell cultur e medimn and lysed with 350 pi Buffer RLT. The sample was mixed 
by pipetting and transferred to an RNase-fr ee microcentrifuge tube. The lysate was 
homogenized by passing through a sterile 21-gauge needle attached to a 1 ml syringe at least 
5 times. The homogenized lysate was normally fr ozen at -80°C and thawed at 37°C when 
required.
After thawing, one volume of 70% ethanol was mixed with the homogenized lysate for 
optimal binding of the RNA to the spin column matrix. The sample was transferred to an 
RNeasy spin column, centrifuged for 15 s at 8,000 x g  (9,300 rpm, Eppendorf 
Microcentrifuge Model 5415D) and the flow-through discarded. The colmnn was then 
washed tlnee times with the supplied buffers RWl (700 pi) and RPE (with the appropriate 
volume of ethanol added) (500 pi), each followed by centrifugation for 15 s (or 2 minutes for 
the final wash with buffer RPE) at 8,000 x g. The RNeasy column was then placed in a new 
collection tube and centrifiiged at full-speed (14,000 x g) for 1 minute to allow complete 
evaporation of residual ethanol fr om the wash buffers. The RNA was eluted fr om the silica 
membrane by placing the column in 1.5 ml microcentrifuge tube and adding 50 pi RNase-
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free water directly to the column membrane, followed by centrifugation for 1 minute at 8,000 
X g. After elution, RNA samples were kept on ice or frozen at -80°C for long-term storage.
2.2.3 Measurement of nucleic acid concentration and quality
2.2.3.1 Measurement of nucleic concentration and purity by UV spectroscopy
Nucleic acid concentration was measured using a Nanodrop ND-1000 Spectrophotometer 
(Nanodrop Technologies, Montchanin, U.S.A.). Nuclease-free water was used to initialize 
and blank the spectrophotometer. Sample type was selected as DNA or RNA, as appropriate, 
and 1 pi of DNA or RNA sample was loaded.
X A in  I0 S I7
Figure 2.2: An example of Nanodrop ND-1000 Spectrophotometer output for the 
measurement of DNA concentration and purity. A spectroscopic scan is performed for 
wavelength range from 230 -  350 nm. The Nanodrop software displays absorbance at 
260 and 280 nm (normalised to a 10 mm path length), concentration (ng/pl) and ratios of 
absorbances at 260/280 nm and 260/230 nm as measures of nucleic acid purity.
A spectroscopic scan of wavelengths from 230-350 nm is made automatically and displayed 
together with calculations of nucleic acid concentration and purity (Figure 2.2). The 
measurement of concentration (ng/pl) is based on the absorbance at 260 nm, using a modified 
form of the Beer-Lambert equation with the wavelength-dependent extinction coefficients of 
50 ng.cm/pl for dsDNA and 40 ng.cm/pl for RNA. The ratio of absorbances at 260/280 nm 
was used as the primary measure of nucleic acid purity. A ratio 260/280 > 1.8 indicated 
acceptably pure DNA solutions and a 260/280 ratio of ~2.0 as acceptably pure for RNA 
solutions. The ratio of absorbances at 260/230 nm provides a secondary indication of nucleic 
acid purity with a 260/230 ratio between 1.8 and 2.2. considered acceptable (Nanodrop ND- 
1000 Spectrophotometer V3.0.1 Users Manual (2004), Nanodrop Technologies). Increased
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absorbance aroimd either the 280 nm or 230 nm regions may suggest tlie presence of 
contaminating protein (280 mn) or phenol (230 mn).
2.2.3 2 Measurement of RNA integrity
RNA purity and integrity was also assessed in selected RNA samples, prior to their use in 
quantitative PCR analysis of gene expression, with a 2100 Bioanalyzer and RNA 6000 Nano 
Chip (Agilent Teclmologies, Waldbromi, Germany). This system consists of a microfluidic 
chip with 12 wells connected to a microcapillary gel system. An intercalating dye enables 
RNA to be detected by laser-induced fluorescence and migration time through the gel 
channel is indicative of the size of the RNA molecules (Mueller et a l, 2000). The 2100 
Bioanalyzer softwar e displays an electropherogram of fluorescence against migration time 
alongside a densitometry simulation (gel view), together with measurements of RNA 
concentration (based on area imder the tr ace), ratio of the 28S/18S ribosomal RNA (rRNA) 
and RNA Integrity Number (RIN). Traditionally, a ratio of the peak densities of 28S to 18S 
rRNA bands was considered the main determinant of RNA integrity, witli a ratio of 2.0 
indicating high quality RNA. However, other factors such as the presence of RNA 
degradation products or shear ed genomic DNA also contribute to the performance of the 
RNA in downstream reactions (Imbeaud et a l, 2005). The RIN method utilizes an algoritlim 
which detects the presence of these factors in the electropherogram and assigns a RIN fr om 1 
-  10, with 1 indicating a completely degraded sample and 10 indicating fully intact RNA 
(Schi’oeder et a l, 2006).
The RNA 6000 Nano Chip was prepared according to manufacturer’s instructions (Agilent 
Technologies, 2006). A gel matrix was spin-filtered at 1500 x g for 10 minutes at room 
temperature (Eppendorf Microcentrifuge Model 5415D) and 65 pi aliquot used to prepare 
gel-dye mix: A dye-concentrate was equilibrated to room temperature and vortexed for 10 
seconds before 1 pi of the dye concentr ate added to 65 pi filtered gel. After vortexing, the 
gel-dye mix was centrifuged at 13,000 x g for 10 minutes at room temperature. The RNA 
6000 Chip was primed with 9.0 pi gel-dye matrix, which was distributed tlrroughout the chip 
with the aid of a syringe attached to the Agilent Chip Priming Station, A further 9.0 pi gel- 
dye mix was loaded into a second well of the chip. All twelve sarnple-wells of the chip, in 
addition to the well used for the RNA molecular size ladder, were loaded with 5.0 pi RNA 
6000 Nano marker per well, used as an internal standard to correct for drift in migration time 
(Mueller et a l, 2000). RNA samples were diluted with RNase-free water to the
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concentration range 25 -  500 ng/p.1. Aliquots (1.5 fil) of the RNA samples and RNA ladder 
were heated for 4 minutes at 65°C and then kept on ice; this process causes the dénaturation 
of heterogeneous RNA secondary structures and the formation of the most energetically 
favourable secondary structure, hence reducing variability in the migration pattern of the 
different RNA molecules (Frequently Asked Questions: Lab-on-a-Chip RNA Assay, Agilent 
Technologies). 1.0 pi RNA ladder or 1.0 pi RNA sample was loaded into each of the sample 
wells. The chip contents were mixed by vortexing at 2400 rpm for 1 minute and the chip run 
on the 2100 Bioanalyzer within 5 minutes.
In total, the RNA integrity of 20 different RNA samples, purified using RNeasy® Mini spin 
columns (Section 2.2.2.2), were analyzed using the 2100 Bioanalyzer. In all cases, RIN 
values of > 9.4 were calculated, indicative of high quality RNA.
[FU]
Sample 1
6 0 -
4 0 -
2 0 - —
0 -
1 1 1 ■ I ' r  ■ r *1 1 1 1
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Overall Results for sample 1 : Sample 1
RNA Area: 25C.4 
RNA Co-'ce't atiD": 193 ng.'pl 
Ratio [2Ss / ISsj 1.9 
RNA Integi ry SwTOti (RIN): 9.7 (B.02.02)
Fraoment table for samule 1 : Samule 1
Name Start Time [s] End Time [s] Area *Vb of total Area
18Szas 43.93 :3.24 62.3 24.9 47. r  51.:2 '18 2 -7.2
Figure 2.3: Typical Electropherogram for an RNA sample analysed using a 2100 
Bioanalyzer (Agilent). Fluorescence (FU) is plotted against migration time (s) and peaks 
corresponding to the 18S and 28S rRNA bands are indicated. Alongside the graphical 
output, the 2100 Bioanalyzer software produces a densitometry simulation. RNA 
concentration is determined based on the area under the trace.
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2.2.4 Agarose gel electrophoresis of DNA
2.2 4.1 Standard agarose gel electrophoresis
Agarose gel electrophoresis facilitates the size separ ation of DNA (or RNA) molecules by 
virtue of their differing speed of migration through an agar ose gel when an electrical voltage 
is applied across the gel. Agarose is an unbranched polysaccharide purified from seaweed, 
which dissolves upon boiling and sets to form a gel. Due to their overall negative charge, 
nucleic acids migrate towards the anode of a gel electrophoresis tank; DNA molecules of 
greater length will migrate more slowly thr ough the pores of an agarose gel than smaller 
fragments. DNA conformation (e.g. supercoiled or linearised plasmid DNA) also influences 
the migration of DNA. The position of the migr ated DNA is visualised by the presence of an 
intercalating agent, such as ethidiimi bromide which fluoresces under UV illumination (Sharp 
etal^ 1973).
Tris-Borate-EDTA (TBE) was used as the buffer for preparing and running agarose gels.
TBE was prepared as a 5x stock solution (0.45 M Tris, 0.45 M boric acid, 0.01 M EDTA, 
adjusted to pH 8.0 with HCl). Agarose gels were produced by dissolving agarose in Ix TBE 
buffer by microwave heating. The percentage of agarose in the gel was chosen according to 
the resolving power for DNA molecules of different lengths (Sambrook et a l, 1989). For tlie 
analysis of PCR products (size range 150 -  600 bp), 2% (w/v) gels were prepared by 
dissolving 2 g agarose in 100 ml TBE. For the analysis of plasmid DNA, 0.9 % gels were 
prepared. Ethidium bromide was added to the agarose solution to a final concentration of 0.2 
pg/nil in order visualise DNA imder UV illumination. Once set, the agarose gel was placed in 
a gel tank containing Ix TBE. For the analysis of PCR products, 10 pi samples were loaded 
with 2 pi loading dye (Orange G) along with 100 bp DNA markers. Gels were am at 4-5 
V/cm imtil the Orange G dye fr ont had migrated thr ee-quarters to full length of the gel. Gels 
were photographed using a Genesnap camera and software (Syngene, Frederick, Maryland, 
U.S.A.).
2.2 4.2 Low melting point agarose gel electrophoresis
In order to confirm the size of smaller amplicons (<150 bp) from real-time PCR reactions, 
high concentration gels were prepared using low-melting point agarose. 3.5% NuSieve GTG 
Agarose (Cambrex Bioscience, Rockland, U.S.A.) gels were prepared according to the 
manufacturer’s instructions. Agarose powder was added to chilled Ix TBE with stirring and
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soaked in the buffer for 15 minutes at room temperature prior to heating in a microwave oven 
for 2 minutes at medium power, followed by bringing the solution to boiling point for 1 
minute at full power. The solution was cooled to 50-60°C before pouring the gel. 10-15 pi 
real-time PCR product was mixed with 6x loading dye and loaded on the gel, alongside 20 bp 
DNA markers.
2.2.5 Measurement of gene expression by semi-quantitative reverse 
transcriptase polymerase chain reaction (RT-PCR)
2.2.5.1 Cell culture conditions
2.2.5.1.1 Incubation of cell lines for the detection of HNF4a spiice variants
HuH7, HepG2 and Hep3B cell lines were cultured under standard conditions (Section 
2.2.1.1) until 90% confluence and then lysed with the appropriate volume of Trizol reagent 
(Section 2.2.2.1).
2.2.5.1.2 incubation of HuH7 celis with different concentrations of glucose
Medium containing 0.2 mM (low glucose), 5.5 mM (standard glucose) or 25.0 mM glucose 
(liigh glucose) was prepared usmg standard DMEM or DMEM G", containing 10% FBS, 1% 
PSG and 1% NEAA witii the additional supplements (Table 2.2).
Table 2.2: Preparation of low, standard and high glucose cell culture media.
Medium type Basal medium Supplem ents
Low glucose (0.2 mM)* DMEM G” 1 % sodium pyruvate
Standard glucose (5.5 mM) DMEM None
High glucose (25.0 mM) DMEM Anhydrous D-glucose
High glucose (25.0 mM) medium was prepared by adding anliydrous D-glucose to standard 
cell culture medimn and filter-sterilising. * Concentr ation of glucose due to glucose present 
in FBS used (10%).
HuH7 cells were grown mider standard conditions (Section 2.2.1.1) in medium cell culture 
flasks (culture area 80 cm^) until 90% confluent and the medium refreshed one day prior to 
the start of the experiment. The cells were passaged as per standar d method and the number 
of cells in the resulting suspension counted using a haemocytometer (Sections 2.2.1.2 and 
2.2.1.5). The cell suspension was centrifiiged at 900 x g (2000 rpm, Sigma 6K10 centrifuge) 
for 5 minutes, the supernatant removed and the cell pellet resuspended in either low, standard 
or high glucose medium. HuH7 cells were plated at a density of 1 x 10^  cells/well in six-well
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plates with 5 ml medium per well (n = 3 for each media type and time point). RNA extracts 
in Trizol were prepared after 0, 24, 48, 72 and 96 h incubation (Section 2.2.2.1).
2.2.5.1.3 Incubation of HuH7 and HepG2 ceiis with glucose and insulin
Media containing different concentrations of glucose and insulin were prepared (Table 2.3). 
All media consisted of DMEM with 5% FBS, 1% NEAA acids and 1% PSG. D-Glucose 
solution and human insulin solution (10 mg/ml) were diluted (Section 2.2.1.6) to achieve the 
final concentrations shown in Table 2.3. HuH7 and HepG2 cells were passaged and seeded 
in six-well plates as previously (Section 2.2.5.1.2), with the cell pellet resuspended in one of 
the four types of media (Table 2.3). Cells were plated at a density of 1 x 10^  cells/well in six- 
well plates and incubated for 48 horns at 37°C, 5% CO2, after which cells were washed with 
1 ml PBS per well and lysed with 1 ml Trizol per well.
Table 2.3: Composition of cell culture media for incubation of HuH7 and HepG2 cells 
with glucose and/or insulin.
Medium No. Basai medium Glucose 
Concentration (mM)
Insulin concentration 
(nM)
1 DMEM 5.5 0
2 DMEM 20.0 0
3 DMEM 5.5 100
4 DMEM 20.0 100
2.2.5.2 Semi-quantitative one-step RT-PCR
For the semi-quantitative measurement of gene expression, one-step RT-PCR was performed 
using Ready-to-Go RT-PCR Beads contain M-MuLV Reverse Transcriptase, Taq DNA 
polymerase, 200 p,M of each dNTP, RNAguard™ Ribonuclease Inhibitor, stabilisers and 10 
mM Tris-HCl, 60 niM KCl, 1.5 niM MgClz when reconstituted to a final volume of 50 pi 
(Amersham Biosciences, Little Chalfont, U.K.). Oligonucleotide primers were supplied by 
MWG Biotech (Ebersberg, Germany) in lyophilized fonn and resuspended in nuclease-free 
water to a concentration of 100 pM.
RT-PCR reactions were prepared on ice prior to initiation of the reverse transcription phase 
of the reaction. The appropriate amount of room temperature DEPC-treated water (as per 
Table 2.4) was added to the side of each tube to dissolve the RT-PCR bead and the tube 
tapped or pipetted gently in order to mix. RT-PCR tubes were incubated on ice for 
approximately 5 minutes imtil the bead was dissolved. 1 pi fbrwaid and 1 pi reverse primers
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were added to each tube (Table 2.4) to a final concentration of 2 pM. Finally RNA was 
added to a final volmne of 50 pi and the reaction contents mixed by pipetting. The tubes 
were transferred to a pre-warmed thermal cycler (Hybaid Model Omn-E). A program for 
one-step RT-PCR was run as outlined in Table 2.5, with an annealing temperatur e (T) of 
approximately 5°C less that tlie lowest melting temperature (Tm) of a primer pair, based on 
the Tm values supplied by MWG Biotech. After completion of the RT-PCR, tubes were 
placed on ice until use or stored at -20°C.
Table 2.4; Contents of each RT-PCR reaction (whole-bead).
Material Volume
DEPC-treated water Zpl
Forward primer (100 pmol/gl) n i l
Reverse primer (100 pmol/pl) 1 pi
RNA template Y pi
Total volume 50 pi
DEPC-treated water was added to a RT-PCR bead. Once the bead was dissolved, other 
contents were added
Table 2.5: RT-PCR cycling conditions.
RT-PCR Temperature (°C) Duration (mln) No. of Stage of RT-PCR reaction
Stage Cycles
No.
1 42 30 1 Reverse Transcription
95 5 Reverse Transcriptase 
dénaturation
2 95 1 25 Dénaturation
T 1 Annealing of primers
72 2 Extension
3 72 10 1 Final extension
N/A 25 N/A Holding Temperature
RT-PCR reactions consisted of cDNA synthesis with subsequent denatiuation of the reverse 
transcriptase, followed by PCR cyclmg with an amiealing temperature (T) of approximately 
5°C less than the lowest calculated melting temperatur e (Tm) of the pair of primers. The 
annealing temperature (T) used for pairs of primers are specified in Table 2.6 and Table 2.7.
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2.2.5.3 Detection of HNF4a splice variant mRNA expression in HuH7, HepG2 
and HepSB cell lines
Primers were used for RT-PCR which bound to sequences unique to each splice variant of 
HNF4a (Figure 2.4, Table 2.6). RT-PCR was performed using 400 -  2000 ng RNA per 50 pi 
reaction under standard cycling conditions (Table 2.4, Table 2.5) with annealing temperatures 
(T) as per Table 2.6. As a control for the amount of RNA present, RT-PCR with p-actin 
primers (Table 2.7) was also performed. 10 pi of the RT-PCR product were separated on a 
2% agarose gel and photographed (Section 2.2.4).
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Figure 2.4: Position of primers to HNF4a splice variants. The structure of the HNF4a 
gene is shown above together with the mRNA structure of the splice variants HNF4-al, 
-a2, -a3, -a4, -a l  and -a8 below together the position of primer binding. The primer 
pair FI and R1 amplify a fragment of the HNF4a transcript common to all splice variants. 
Splice variant specific primers bind to exons or exon boundaries (in the case of primer 
R9) unique to the specific splice variant. Diagram adapted from Sladek and Seidel (2001)
2.2.5.4 RT-PCR of HNF4a and target gene expression
For the analysis of the expression of HNF4a, apoCIII and FAS under conditions of variable 
glucose and insulin levels, RT-PCR beads (Table 2.4) were split into five aliquots after the 
addition of DEPC-treated water and primers (final concentration 2 pM) to make a final 
reaction volume of 10 pi after the addition of RNA. HNF4a, apoCIII and FAS mRNA 
expression was detected using gene-specific primers for HNF4a (all splice variants. Table
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2.6) or target genes (Table 2.7), and normalised to p-actin expression. Approximately 100 ng 
RNA was used in each 10 pi reaction. RT-PCR products (10 pi) were electiophoresed on a 
2% agarose gel and the relative amount of each product quantified, as described below 
(Section 2.2.5.5).
Table 2.6: PCR primers used for detection of HNF4a splice variants.
HNF4a
sp lice
varian t
Prim er
nam e
P rim er se q u e n c e  (5’->3’) Tm
(“C)
T
rc)
P roduct 
s ize  (bp)
Ref.
HNF4a
(all)T
F1
R1
CTGCTCGGAGCCACCAAGAGATCCATG
ATCATCTGCCAGGTGATGCTCTGCA
69.5
64.6
60 370 1
1
HNF4a1 F1
R9
As above
GGTCTCAGGGGTGGACATCTGTCCGTTG
69.5
71.0
65 581 1
HNF4a2 F1
R4C
As above
CTGTCCCCTGGGTCGGGGCCACTCAC
69.5
74.3
65 593 1
1
HNF4a3 F6
R6
CCTGGCAGATGATCGAGCAGATC
AAACTGAGGCACAGACAGGTTAAGCAACTTGC
64.2
68.2
60 230 1
1
HNF4a4 F7
R7
CATGGACATGGCCGACTACAGTGCT 
CTGTCC CCTGGTCGGGGCCACTCAC
63.2
72.2
60 248 1
1
HNF4-
a7/8
F8
R3
CTTGGCCATGGTCAGCGTGAACG
CGAATGTCGCCGTTGATC
66.0
56.0
60 529 3
3
F  refers to forwaix 
of HNF4a connnoi 
with some modifi 
Primer R9 was des 
Eeckhoute et al. (2
primer, R refers to reverse primer. Primers FI and R1 amplify a section 
1 to all splice variants. References: (1) primers used by Suaud et al. (1997) 
cations to match sequences as published by Chaitier et al. (1994); (2) 
igned to span the splice site between exons 9 and 10; (3) primers used by 
003).
Tab)e 2.7: PCR primers used to detect HNF4 a target gene expression.
Na
me
G ene Prim er se q u e n c e  (5’->3’) P osition  in 
g en e
Produ 
c t s ize  
(bp)
Tm
(°C)
Ref. G enbank
A ccession
Ref.
FI
R1
3-actin ATCATGTTTGAGACCTTCAA 
CAT CTC TTG CTC GAA GTCCA
404-424
702-722
318 51.2
57.3
1 X00351
FI
R1
ApoCIII CCG AGGATGCCTC CCTTCTC 
CAGGCATGAGGTGGGGTAGG
98-117
444-463
365 63.5
63.5
2 M28614
F2
R2
FAS GAAACTGCAGGAGCTGTC
CACGGAGTTGAGGCGCAT
6672-6689
6811-6828
156 56.0
58.2
3 NM_004104
F  refers to forward primer, R refers to reverse primer. The annealing temperature (T) used 
for PCR cycling was 46°C for p-actin, 57°C for apoCIII and FAS primers. References: (1) 
Eecldioute et al. (2003); (2) Hsu et al. (2001); (3) Yang et al. (2003).
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2.2.S.5 Measurement of gene expression by gel image digitization and 
quantification
Relative gene expression was measured using Scion Image software (Scion Corporation, 
Frederick, Maryland, U.S.A.) to digitize agarose gels and measiu'e the relative intensity of the 
RT-PCR product of the gene of interest relative to that a housekeeping gene ((3-actin).
2.2.5.5.1 Preparation and photography of agarose gels
RT-PCR products were rmi in lanes next to that of the housekeeping gene (P-actin) on a 2% 
agarose gel containing 0.2 pg/ml ethidium bromide, prepared as described in Section 2.2.4. 
Gels were photographed using a Genesnap camera and software (Syngene, Frederick, 
Maryland, U.S.A.). An umnodified digital image was saved in the TIFF file format.
2.2.5.5.2 Digitization and quantification of gel images
After loading Scion Image softwar e, macros were activated luider the Special > Load Macros 
menu and the option Gel plot 2 selected. The gel image was loaded under Menu, and the 
lanes containing the gene of interest and p-actin highlighted. The two lanes were plotted and 
the line tool was used to draw a base line from the left hand side of the peak in question to the 
right hand side in order to create a baseline of background emission due to etliidium bromide 
in the gel. A tangent was drawn to the main peak in the case of there being an extra peak or 
blurring before or after the main peak (Figure 2.5). The area between the peak and the 
baseline was selected and the number of square pixels was calculated for both the 
housekeeping and target gene peaks, and the process repeated three times. The mean ratio 
Area under Target Gene peak (square pixels) / Area under housekeeping gene peak (square 
pixels) was used to calculate the relative expression of the gene in question.
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Figure 2.5: Quantification of gel bands using Scion Image software. (A) A gel
photograph with bands corresponding to the RT-PCR products for the housekeeping and 
target genes is digitized in Scion Image and (B) the relative intensity of the area plotted. 
The background intensity is estimated by drawing a line at the bottom of the peak and 
then the area between the peak and the background measured in square pixels. In some 
cases, where there was blurring after the main gel peak, this was deducted by means of a 
tangent drawn from the main peak (example shown as diagonally striped area).
2.2.6 Plasmid DNA
2.2.6.1 Plasmid DNA information
2.2.6.1.1 Reporter gene information
L-PK reporter plasmids containing elements from the L-PK proximal promoter inserted into 
luciferase reporter plasmid pGL3-Basic (Promega) (Figure 2.6) were a gift from B. Viollet 
(INSERM, Paris, France).
The PEPCK reporter plasmid pPL32.Luc, containing the rat PEPCK proximal promoter 
(-467/+65) inserted into the luciferase plasmid pGL3 (Figure 2.6A) was a gift from D. K. 
Granner (Vanderbilt University Medical School, Tennessee, U.S.A.).
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Figure 2.6: (A) Luciferase reporter plasmid pGL3 (B) L-PK promoter elements.
(A) pGL3-Basic vector (Promega). L-PK promoter constructs are ligated at the multiple 
cloning site upstream of the luc+ luciferase reporter gene. (B) L-PK promoter contracts 
containing oligomeric repeats of the ChREBP (L4) and / or HNF4a (L3) binding sites 
upstream of the 54 bp proximal promoter sequence.
The pGL4 843 SREBP-lc reporter plasmid contains the -780/+62 promoter region to the 
human SREBP-lc gene (GenBank accession no.: NT 010718), driving the expression of the 
firefly luciferase luc2 gene in the pGL4.10(luc2) reporter plasmid (Promega) (Figure 2.7A). 
This reporter plasmid was a gift from E. Tarling (University of Nottingham, U.K.).
pSEAP-3’Rep was a gift from K. Plant (FHMS, University of Surrey, U.K.) and contains the 
secretory alkaline phosphatase (SEAP) reporter gene under control of the cytomegalovirus 
(CMV) promoter (Figure 2.7B). It was generated by replacing the green fluorescent protein 
(GFP) coding region from pEGFP C2 (Clontech, Mountain View, CA, U.S.A.) with the 
SEAP coding region from pSEAP2 basic (Clontech) (K. Plant, personal communication). 
pSEAP-3’rep was co-transfected with luciferase reporter plasmids as a control for 
transfection efficiency.
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Figure 2.7: Vector maps of (A) pGL4 843 SREBP-lc and (B) pSEAP-3’Rep reporter 
plasmids. (A) pGL4.10(luc2) vector (Promega) containing the human SREBP-lc 
proximal promoter region (-760/+42). Vector map provided by E. Tarling (University of 
Nottingham, U.K.). (B) pSEAP-3'rep is used as a control for transfection efficiency. The 
expression of the SEAP reporter plasmid is under control of the CMV promoter. Vector 
map provided by K. Plant (FHMS, University of Surrey, U.K.).
2.2.6.1.2 Expression vector information
An expression vector containing the rat HNF4al cDNA sequence with the CMV promoter 
region (PCR3.HNF4) was obtained from B. Viollet (INSERM, Paris, France) (Viollet et al.,
1997). An expression vector for haemagglutinin-tagged human HNF4a2 
(pcDNA3.HA.hHNF4a2) was gifted by A. Fukamizu (University of Tsukuba, Japan) (Hirota 
et a l, 2003).
Vectors for wild-type human HNF4aI (pDGT26.I) and dominant negative-HNF4a2 (DN- 
HNF4a) (pDGT23.I) were gifts from T. Leff (Wayne State University School of Medicine, 
Detroit, U.S.A.). The DN-HNF4a differs from wild-type in that it contains a point mutation 
at position 316, resulting in the replacement of a cysteine residue with arginine in the DNA 
binding domain, rendering one of the zinc finger motifs non-functional. DN-HNF4a retains 
its dimerization ability and forms defective heterodimers with wild-type HNF4a, interfering 
with transcriptional activity (Taylor et al., 1996).
An expression vector containing the human coding sequence of the co-activator p300 
(pVR1012 p300) was donated by G. Nabel (NIH Vaccine Center, Maryland, U.S.A.) (Figure 
2.8). J. K. Kemper (University of Illinois, U.S.A.) supplied an expression vector coding for
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mouse PGC-la (pcDNA3.PGCl) (Bhalla ei al., 2004). Basic expression plasmids lacking 
inserted DNA, pSG5 (Stratagene) or pcDNA3.1 (Invitrogen), were used as controls for the 
amount of DNA in cases where cells were transfected with variable amounts of expression 
vectors for HNF4a, p300 or PGC-la (Figure 2.9).
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Figure 2.8: Vector map of p300 expression vector (pVR1012 p300). Vector map 
provided by G. Nabel (NIH Vaccine Center, Maryland, U.S.A.).
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Figure 2.9: Vector maps of basic expression plasmids (A) pSG5 and (B) pcDNA3.1.
(pSG5 Vector Instruction Manual, 2000; pcDNA3.I Vector Instruction Manual, 2001).
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2.2.6.2 Preparation of competent Escherichia coii DHSa
Escherichia coli (E.coli ) strain DH5a were made chemically competent based on the 
calcium-chloride method of Inoue et al, (1990). Luiia-Bertani (LB) medium was prepared 
with 1% (w/v) bactotryptone, 0.5% (w/v) yeast extract and 1% (w/v) NaCl. Super Optimal 
Broth (SOB) was prepared witli 2% (w/v) bactotryptone, 0.5% (w/v) yeast extract, 10 mM 
NaCl, 2.5 mM KCl, 10 mM MgCli and 10 niM MgS0 4 , and adjusted to pH 6.1-1.0 with HCl. 
Bacterial growth media were sterilised by autoclaving. Transformation Buffer (TB) was 
prepared to contain 10 mM Pipes, 55 mM MnClz, 15 mM CaClz, 250 mM KCl, adjusted to 
pH 6.7 with KOH, and filter-sterilised.
A starter culture of K coli DH5a in LB was inoculated 1:1000 into 100 ml SOB medium and 
grown at 20°C until the culture had reached ODeoo “  0.6 (-20 hours). The bacterial culture 
was centrifuged at 1000 x g (2100 r*pm, Sigma 6K10 centrifuge) for 10 minutes at 4°C. The 
cell pellet was resuspended in 32 ml ice-cold TB solution by gentle pipetting and incubated 
on ice for 10 minutes. The cell suspension was centrifuged 1000 x g as above for 10 minutes 
at 4°C and the cell pellet resuspended in 8 ml of ice-cold TB. DMSO was added to a final 
concentration of 7% (v/v). Aliquots of 100 pi were prepared on ice and frozen at -80°C.
2.2.5.3 Transformation of bacteria with plasmid DNA
Competent E.coli DH5a (Section 2.2.6.2) were thawed on ice and 1 -  5 pi plasmid DNA was 
added to 50 pi of competent bacteria, and incubated on ice for 30 minutes. The bacteria were 
heat-shocked for 45 seconds at 42°C and returned to ice for 5 minutes. 250 pi LB medium 
was added to each tube followed by incubation for-1 hour at 37®C with shaking (this is an 
optional stage in the case of plasmids coding for ampicillin resistance, but required for 
kanamycin resistance plasmids). Bacteria were plated on LB-agar plates containing 1.5% 
agar and the selective antibiotic (50 pg/ml ampicillin or 50 pg/ml kanamycin) and incubated 
overnight at 37°C.
2.2.G.4 Preparation of plasmid DNA
Endotoxin-free, transfection grade DNA was prepared using Qiagen Plasmid Midi Kits, 
which utilise alkaline lysis of the bacterial culture followed by binding of plasmid DNA to an 
anion-exchange resin. Endotoxins such as lipopolysaccharide are present in the outer 
membrane of gram-negative bacteria, such as E.colU which can lead to decreased transfection
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efficiency in human cell lines. Therefore an additional endotoxin removal step was included 
in the plasmid purification, after which only endotoxin-free buffers were used.
Plasmid DNA for transfection purposes was prepared according to the Qiagen Supplementary 
Protocol: ‘Isolation of endotoxin-free plasmid DNA using the QIAGEN® Plasmid Midi Kit’ 
(2001). A starter culture containing 2 -  5 ml LB containing the selective antibiotic (50 pg/ml 
ampicillin or 50 pg/ml kanamycin) was inoculated from a single colony of E.coli transformed 
with the plasmid of interest and incubated for ~8 hours at 37°C with shaking. The starter 
culture was diluted 1/1000 into 50 ml selective LB and grown for a further 12 -  16 hours at 
37°C with shaldng. The bacteria were harvested by centrifugation at 6000 x g  (6500 rpm, 
Beclanan J2-21 centrifrige) for 15 minutes at 4°C and the cell pellet resuspended in 4 ml 
supplied Buffer PI by vortexing. Bacteria were lysed by addition of 4 ml Buffer P2, which 
contains sodium hydr oxide and sodium dodecyl sulphate (SDS), thus causing disruption of 
cellular membranes and dénatur ation of DNA. The lysis reaction was not allowed to proceed 
for more than 5 minutes in order to prevent permanent dénaturation of the plasmid DNA. 
After 5 minutes, 4 ml drilled Buffer P3 was added and mixed gently by inversion. The 
presence of acetic acid in Buffer P3 allows the renaturation of plasmid, however genomic 
DNA and cellular* debris are precipitated in the presence of high salt. The lysate is then 
poured into a QIAfilter Cartridge, incubated for 10 minutes and filtered into a endotoxin-free 
tube. 1 ml endotoxin removal Buffer ER was added to the filtered lysate, mixed by inversion 
10 times and incubated on ice for 10 minutes.
After endotoxin removal, the lysate was applied to a Qiagen-tip 100 chromatography column, 
previously equilibrated with Buffer QBT. RNA and low molecular weight impurities were 
then removed from the column with two washes with a medium salt Buffer QC (10 ml) and 
the column allowed to empty by gravity flow. DNA was eluted with a high salt buffer QN (5 
ml) into a fresh endotoxin-ftee tube. The eluted DNA was precipitated with 3.5 ml room- 
temperatuie isopropanol and centriftiged at 15,000 x g for 30 minutes (4°C), in order to 
remove residual liigh salt buffer. The supernatant was removed and the DNA pellet washed 
with 2 ml of 70% ethanol and centiifuged at 15,000 x g for 10 minutes (4°C). After the 
supernatant was removed, the DNA pellet was air-dried for 5-10 minutes and redissolved in 
100 pi endotoxin-free TE buffer. The concentration and purity of the prepared DNA was
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measured using a Nanodrop Specti'ophotometer (Section 2.2.3.). The DNA was diluted to a 
concentiation of 100 ng/pl in endotoxin-free TE buffer prior to transfection experiments.
2.2.6.5 Restriction endonuclease digestion of plasmid DNA
The plasmids were subjected to restriction endonuclease (RE) digestion with a RE whose 
cutting site was present in its multiple cloning site (MCS) (and, if known, at other positions 
in the plasmid) in order to linearize the DNA and confirm the size of the prepared DNA 
(Table 2.8). Reagents were added to a sterile microcentrifuge tube (Table 2.9), mixed by 
pipetting and incubated at 37°C for 1-2 hours. 3 pi of gel loading buffer was then added and 
the digested DNA run on a 0.9% agarose gel (Section 2.2.4), alongside 1 kb DNA markers 
and samples of the imcut plasmids.
Table 2.8: List of restriction endonucleases used for diagnostic digestion of plasmid 
DNA.
Plasmid name Restriction Endonuclease (s) Product size(s) (bp)
pSG5 Bam HI, Eco RI 4100
pcDNA3.1 Xba 1 5428
pcDNA3.1 Nog I 735, 1351, 3342
(L3)3-54.PK Hind III -5000
(L4L3)4-54PK Hind III -5000
pPL32 (PEPCK) Bam HI 5318
pGL4 843 SREBP-1C Kpn 1 (Acc 65 1) 5040
pGL4 843 SREBP-lc Xho 1 5040
pSEAPI-3'rep Bam HI 1432, 4150
pDGT26.1 (human HNF4a1) Bam HI -8000
pDGT26.1 (human HNF4a1) Hind 111 -8000
pDGT23.1 (DN-HNF4a) Xho I -6500, -1200
PDGT23.1 (DN-HNF4a) Hind III -6000, -1700
PCDNA3.PGC1 Bam HI -5500, -2500
pcDNA3.PGC1 Hind III -5500, -2500
pVR1012p300 Xho 1 12100
pVR1012 p300 Hind III 9436 bp, 2748 bp
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Table 2.9; Restriction digestion of plasmid DNA.
Reagent Volume (gl)
Sterile water 3.0
Buffer (10x) 1.5
Plasmid DNA 10.0
Restriction Endonuclease (10 units/gl) 0.5 (5 U)
Final volume 15.0
Restriction digests were performed with 5 units o: 
250 ng of plasmid DNA and the appropriate buffer
' the restriction enzyme and a minimum of 
in a reaction volume of 15 pi.
2.2.7 Study of HNF4a reporter gene activity in HepG2 ceils
2.2.7.1 Culture of HepG2 cells for reporter gene experiments
The standard transfection medium (STM) used for transfection experiments with L-PK 
reporter genes consisted of 199 medium with 3% FBS and 1% penicillin-streptomycin 
solution. 199 medium was chosen as this type of medimn was used by Gourdon and co­
workers in their original study of L-PK reporter genes in primar y hepatocytes (Gour don et 
a l, 1999). The proportion of FBS in the cell culture medium was restricted to 3% to limit the 
concentration of hormones in tlie final medium. In addition, the same batch of FBS was used 
throughout the tr ansfection experiments in order to avoid variation in the concentration of 
hormones or growth factors in the control medium.
Following optimisation of factors contributing to the efficiency of the luciferase assay 
(Section 2.2.7.4), the basal medium was changed to DMEM without phenol red (containing 
3% FBS and 1% penicillin-streptomycin solution, as described above), as the presence of 20 
mg/1 phenol red in 199 medium can reduce relative luminescence output by 50% (Technical 
Manual: Bright-Glo Luciferase Assay System (2006), Promega). As phenol red in cell 
cultiue media serves as a pH indicator, opened bottles of DMEM without phenol red were 
discarded one month after opening to prevent changes in pH. STM containing DMEM 
without phenol red was used in experiments with the PEPCK and SREBP-lc reporter 
plasmids.
The typical protocol for culture of HepG2 cells for transfection was as follows (Bombail, 
2003, with some modifications). HepG2 cells were grown to 90% confluence in SCM. On 
Day 1, the cells were trypsinized as per Section 2.2.1.2. The cell suspension was then
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centrifuged at 230 x g  (1000 rprn. Sigma 6K10 centrifuge) for 5 minutes at room temperature 
and the cell pellet resuspended in 5 ml STM, and the number of cells/ml counted using a 
haernocytometer (Section 2.2.1.5). The cell suspension was diluted to a concentration of 5 x 
10^  cells/ml. The cells were seeded in a 96-well plate at a concentration of 5 x lO'^  cells/well, 
with 100 pi medimn per well. The 96-well plate was incubated in a himiidifred container 
within the incubator (to avoid changes in cell culture medium volmne caused by evaporation) 
for 24 hours mider standard conditions (37°C, 5% CO2).
On Day 2, 10 pi transfection mix (prepared as described below, Section 2.2.7.2) was added to 
each well of the 96-well plate. After 16 hours incubation (Day 3), the transfection medium 
was removed and replaced with STM supplemented with the metabolites/hormones under 
investigation. The cells were incubated for a fmther 24 horns before the luciferase and SEAP 
assays were performed (Day 4).
2.2.7.2 Preparation of transfection complexes
HepG2 cells were transfected with relevant plasmids, using Fugene-6 reagent (Roche 
Molecular Biochemicals). Fugene-6 is a lipid-based transfection agent which forms a 
complex with plasmid DNA and enables fusion with the cytoplasmic membrane and 
endosomal uptalce into the cell (Fugene-6 Transfection Reagent Instruction Manual, 2000). 
Fugene-6 has been shown to have 6-fold higher transfection efficiency in HepG2 cells in 
comparison to a calcium-phosphate-based method (ICurachi et a l, 1998).
For each assay, cells were tr ansfected with 100 ng/well of the luciferase reporter plasmid, 25 
ng/well SEAP-3’rep reporter plasmid as a control for transfection efficiency, along with 
expression vector(s) for HNF4a, p300 or PGC-la (dependent on experiment). The basic 
expression vector pSG5 was used as a control for the amomit of DNA so that all cultme wells 
were transfected with the same quantity of DNA. Fugene-6 transfection reagent was used in 
a 3:1 ratio of volume of reagent (pi) to DNA (pg). The transfection mix was prepared as per 
manufacturer’s instructions (Fugene-6 Transfection Reagent Instruction Manual, 2000) by 
adding the required volume of Fugene-6 transfection reagent to additive-free basal medium 
(199 or DMEM without phenol red) to a volume of 100 pi, mixing by tapping the tube and 
incubated for 5 minutes at room temperature. The Fugene-6 transfection complex was then 
added to the plasmid DNA, mixed by tapping, and incubated for 30 minutes at room
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temperature. The volume of tiausfectiou mixture was then made up to the appropriate 
volume with additive-free basal medium and 10 pi of the transfection was added directly to 
each well of the 96-well plate.
2.2.7 3 Secretory alkaline phosphatase (SEAP) assay
Prior to the luciferase assay, media samples (normally 20 pi) were removed from culture 
wells (96-well plate) and the medium replaced with the same volume of STM. Media 
samples were assayed for SEAP activity according to the manufacturer’s instructions 
(modified from the Phospha-Light System Teclmical Manual (2000)). 6.25 pi of the media 
was transferred to a white optiplate, 19 pi of Ix dilution buffer added per optiplate well and a 
thermal seal applied to the plate to prevent evaporation. The plate was centrifiiged at 1000 
rpm for 1 minute to mix (193 x g , Eppendorf Centrifuge 5810) and then incubated at 65°C 
for 30 minutes to destroy endogenous alkaline phosphatase activity. The optiplate was 
removed from the oven and placed on ice for 2 minutes. 25 pi of assay buffer was added per 
well and the optiplate incubated for 5 minutes at room temperatur e. 25 pi of reaction buffer 
was added per well and the optiplate incubated for a further 15-20 minutes at room 
temperatiu'e followed by measurement of luminescence. Luminescence was measured using 
a Packard Lumicount 11 plate reader with a read length of 1.0 s, with the detector gain being 
set automatically based on the well with the highest luminescence.
2.2.7.4 Luciferase assay
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Figure 2.10: Reaction catalysed by firefly luciferase enzyme. Firefly luciferase 
catalyses the oxygenation of beetle luciferin in tlie presence of ATP, Mg^ "^  and O2 to form 
oxyluciferin, AMP and CO2 with the concomitant emission of light which is measured 
with a luminometer. (Bright-Glo Luciferase Assay System Technical Manual, 2006).
The luciferase gene was originally cloned from the bioluminescent firefly Photinus pyralis 
(de Wet et a l, 1987) and catalyses tlie oxygenation of luciferin with the concomitant 
production of light (Figure 2.10). Unlike SEAP, luciferase is not secreted into the cell culture 
medium, therefore cell lysis is required in order for the reaction to proceed. Luciferase 
reporter gene activity in HepG2 cells was assayed with the homogenous Steady-Glo or
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Bright-Glo Luciferase Systems (Promega) which contain both cell lysis reagents and 
luciferase assay substrates. The Steady-Glo reagent was used in initial experiments using L- 
PK reporter genes, however tlie Bright-Glo reagent was used for the majority of reporter gene 
experiments as it achieves higher sensitivity compared to the Steady-Glo reagent (Bright-Glo 
Luciferase Assay System Technical Manual, 2006).
To perform the luciferase assay, the cell culture plate was equilibrated to room temperature 
and 100 pi of luciferase reagent added to each well (containing 100 pi of medimn). The cells 
and luciferase reagent were mixed using the mix function of the luminometer. In tlie case of 
the Steady-Glo reagent which has a longer signal half-life (~ 5 horns) compaied to the 
Bright-Glo reagent (signal half life ~ 25 minutes), the plate was incubated for at least 5 
minutes at room temperatme to allow cell lysis to occur. For the Bright-Glo reagent, cell 
lysis was achieved after an incubation time of 2 minutes. After cell lysis, luminescence was 
measmed using a Packard Lmnicount II plate reader, with a read length of 6.0 s and detector 
gain being set automatically depending on the well with the highest Imninescence.
2.2.7 5 Calculation of induction
Equations 2.2; Calculation of (A) Corrected luciferase gene reading and (B) 
Induction. (A) Luciferase output fi*om each well of a 96-well plate was conected for 
transfection efficiency by dividing by tlie SEAP reading. (B) The effect of a hormone or 
metabolite on reporter gene expression was calculated by dividing the mean corrected 
luciferase reading for the condition with the hormone / metabolite by that for STM or 
vehicle control medium (VCM).
Corrected luciferase reading
Luciferase output
SEAP output
B
Mean corrected luciferase reading (Condition: + Hormone)
Induction
Mean corrected luciferase reading (Condition: STM or VCM)
Luciferase reporter gene expression was corrected for transfection efficiency by normalising 
each luciferase assay reading by the SEAP assay reading (Equations 2.2A). Fold-induction in 
reporter gene expression was calculated as the ratio of reporter gene expression in the
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presence of the hormone or metabolite under investigation to that under the control condition 
(Equations 2.2B).
2.2.8 Study of HNF4a target gene expression using real-time PCR
2.2.8.1 Principles of real-time PCR
Real-time PCR provides a highly accurate and sensitive method for the quantification of gene 
transcripts, as the progress of the PCR reaction can be monitored in real-time and the amount 
of PCR product which has accumulated can be measured during the log-linear phase of the 
reaction (Figure 2.11 A).
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Figure 2.11: Principles of (A) Real-time methods for detection of PCR reaction (B) 
SYBR-Green biochemistry. (A) Real-time PCR cyclers detect the amount of PCR 
product which has accumulated after each PCR cycle and enable the linear phase of the 
PCR reaction to be accurately defined. (B) SYBR-Green fluoresecent dye intercalates 
into double-stranded DNA and can be detected in this state by its specific excitation / 
emission spectra. (Qiagen, Critical Factors for Successful Real-time PCR, 2004).
The progress of the PCR reaction can be monitored using sequence-specific probes labelled 
with a fluorophore or a fluorescent dye that intercalates with double-stranded DNA. The 
latter approach was used in this project and the fluorescent dye, SYBR-Green I, used to 
monitor the accumulation of PCR product. The intercalation of SYBR-Green I dye with 
double-stranded DNA is proportional to the amount of double-stranded DNA and this 
interaction can be detected by virtue of the specific excitation / emission spectra of the 
SYBR-Green:DNA complex (excitation maximum X = 494 nm, emission maximum k= 521
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lira) (Figure 2.1 IB). SYBR-Green enables a range of gene targets to be detected using 
standard oligonucleotide primers, however as SYBR-Green also binds to primer-dimers and 
non-specific PCR products, melting cur ve analysis needs to be performed for each PCR run, 
to the fluorescence reporter signal corresponds to only the PCR product of interest (Section
2.2.8.7.2). In addition, real-time PCR products were analysed by agarose gel electrophoresis 
(Section 2.2.4.2), to validate that real-time PCR products of the correct size were present.
2.2.8 2 Culture of HepG2 cells for analysis of gene expression (Q-PGR)
A typical timeline for the analysis of gene expression in HepG2 cells by real-time 
quantitative PCR (Q-PCR) is outlined in Figure 2.12.
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Figure 2.12: Experimental timeline for the incubation of HepG2 cells for the analysis 
of gene expression by Q-PCR.
HepG2 cells were grown in SCM until 90% confluent and trypsinized (Section 2.2.1.2), 
followed by centiifugation at 230 x g  (1000 rpm. Sigma 6K10 centrifuge). The cell pellet 
was resuspended in 5 ml SCM and a 10 pi aliquot removed for counting (Section 2.2.1.5).
The cell suspension was then diluted to a concentration of 5x10^ cells/ml and seeded in 24- 
well plates in a volume of 1 ml cell suspension/well. Following 24 hours incubation under 
standard conditions (37°C, 5% CO2), cells were transfected with plasmid DNA (Day 2), in 
the case of experiments involving the over-expression of HNF4a, p300 or PGC-la (Section 
2.2.8.3), and incubated for a further 16 hours. On Day 3, tlie culture medium was removed 
and the cells washed twice with 1 ml PBS and the medium replaced with serum-ffee medium 
(SFM) (DMEM with 1% NEAA and 1% PSG). Following 24 hours serum-star vation, tlie 
medium was removed and the cells washed once with 1 ml PBS. The medium was replaced 
with SFM containing the hormones, metabolites or kinase activators under investigation 
(Section 2.2.1.6.). Following an experimental incubation (typically 6 hoius), the medium was 
removed and cells washed once with 1 ml PBS prior to the addition of lysis buffer and RNA 
isolation (Section 2.2.2.2).
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2.2.8.3 Overexpression of HNF4a, p300 and PGC-1a
Based on the results of transcription factor overexpression in reporter gene experiments, 
HepG2 cells were transfected with Fugene-6;DNA complexes using a 3:1 ratio of Fugene-6 
transfection reagent (pi) to DNA (pg) (Section 2.2.7.2). The following small changes were 
applied in order to take into account the larger cell culture area of 24-well plates (1.9 cm^) 
compared to 96-well plates (0.4 cm^): Fugene-6 was initially diluted in additive-ffee DMEM 
to a volume ten times that of the Fugene-6 reagent (rather than 100 pi as previously. Section
2.2.7.2). The Fugene-6 complex was then divided between tubes containing the different 
plasmid DNAs being used in the experiment, plus sufficient additive free DMEM such that 
the volume of DNA-Fugene 6 transfection mix added to each well of the 24-well plate was 50 
pi. A typical calculation including 10% excesses is shown in Table 2.10. Cells were 
transfected with between 125 -  500 ng/well DNA per expression plasmid. Control culture 
wells were transfected with an equal amount of the basic expression vector, pcDNA3.1 
(Invitrogen), which lacks an inserted coding sequence (Section 2.2.6.1.2).
Table 2.10: Example calculation: Fugene-6:DNA transfection mix.
Transfection No.: 1 2 Total TransfectionMix*
Content
Control
plasmid
Expression
plasmid
No. of wells (n) 10 10 20No. of wells including excess 
(n+10%) 11 11 22
DNA (ug per well) 0.5 0.5
Fugene (ul) :DNA (ug) ratio 3 3
Control plasmid (pcDNA3.1) (100 ng/ul) (pi) 55.0 55.0
Expression plasmid (100 ng/ul) (pi) 55.0 55.0
Absolute volume Fugene-6 (pi) 16.5 16.5 33.0 36.3
Final volume Fugene-6 mix (pi) 165 165 330 363
Final vol. (pi) 550 550
Volume additive-free DMEM (pi) 330 330 660 327
A transfection mix (right-hand column) of Fugene-6 was prepared in additive-free DMEM 
(*including 10% excess). Appropriate volumes of the transfection mix were added to 
tubes containing control plasmid, pcDNA3.1, or expression plasmid, plus additional 
DMEM to allow 50 pi Fugene-DNA complex to be added to each well of a 24-well plate.
2.2.8.4 RNA purification and DNase treatment of RNA
RNA was purified from HepG2 cells using Qiagen RNeasy Mini columns (Section 2.2.2.2). 
RNA concentration and purity were measured using a Nanodrop Spectrophotometer and. in 
the case of selected samples, RNA integrity was assessed using an Agilent 2100 Bioanalyzer
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(Section 2.2.3). The purified RNA was diluted to a final concentration of 100 ng/pl with 
RNase-ffee water.
DNase tieatnient of RNA was performed on all samples to ensure the removal plasmid DNA 
(in the case of over-expression experiments) and residual genomic DNA. The amount of 
RNA used in the DNase treatment and subsequent cDNA synthesis stages was optimised to 
ensure that the presence of plasmid DNA was not detected by Q-PCR in the RT- (RT minus) 
conti'ol. 500 ng RNA was DNase-treated using RQl DNase-fiee RNase (Promega) according 
to the manufacturer’s protocol (Table 2.11). Reagents were pulse-centrifuged to mix and 
incubated at 37°C for 30 minutes. The DNase enzyme was inactivated by the addition of 1 pi 
DNase stop solution and a further incubation at 65^C for 10 minutes. 2 pi DNase-treated 
RNA (-100 ng) was used for cDNA synthesis.
Table 2.11: Reaction composition of DNase treatment of RNA.
Component Volume (gl)
RNA (100 ng/gl) 5
RNase-free water 3
Reaction Buffer ( l O x ) 1
RQl RNase-free DNase (1 unit/gl) 1
Volume (DNase reaction) 10
500 ng RNA was treated using in a reaction volume of 10 pi, containing 1 p i reaction buffer 
and 1 pi DNase.
2.2.8 5 cDNA synthesis
In contrast to semi-quantitative analysis of gene expression, where the RT reaction was 
performed using gene-specific primers as part of a one-step RT-PCR reaction (Section
2.2.5.2), cDNA was synthesized from RNA using an oligonucleotide primer mix consisting 
of oligo-dT and random nonamers, supplied as part of the QuantiTect Reverse Transcription 
kit (Qiagen). This mix of primers for first-stiand syntliesis is designed to amplify all regions 
of the RNA template. The QuantiTect Reverse Transcription kit also included a genomic 
DNA (gDNA) treatment stage, providing a second DNase treatment in addition to that 
described above (Section 2.2.8.4), which ensured that all plasmid and genomic DNA was 
removed.
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cDNA was prepared according to the manufactiu'er’s protocol for tlie QuantiTect Reverse 
Transcription kit (Qiagen), using 100 ng DNase-treated RNA (QuantiTect Reverse 
Transcription Handbook, 2005). All reagents were thawed at room temperature, briefly 
centrifuged to pool contents and kept on ice. All reactions were prepared on ice. For the first 
gDNA elimination stage (Table 2.12A), a mastermix of gDNA Wipeout Buffer and RNase- 
free water was prepared for the number of reactions («) with an excess of 10% and divided 
between reaction tubes (12 pi per tube). Template RNA (2 pi DNase-treated RNA, -100 ng) 
was then added to make a reaction volume of 14 pi, pulse-centrifuged to mix and incubated at 
42°C for 2 minutes, and then retuiiied to ice.
Table 2.12 A: Reaction composition of gDNA elimination reaction.
Component Volume (gl)
DNase-treated RNA solution (-100 ng) 2
gDNA Wipeout Buffer (7x) 2
RNase-free water 10
Total volume (gDNA elimination step) 14
Table 2.12B; Reaction composition of RT reaction.
Component Volume (gl)
Template RNA (gDNA elimination reaction) 14
Quantiscript Reverse Transcriptase 1
Quantlscript RT Buffer (5x) 4
RT Primer Mix 1
Total volume (RT step) 20
100 ng DNase-treated RNA underwent an additional gDh 
cDNA synthesis (B) using QuantiTect Reverse Transcription
A treatment stage (A) prior to 
kit (Qiagen).
An RT masteimix consisting of Reverse Transcriptase, RT Buffer and RT Primer Mix (Table 
2.12B) was prepared and 6 pi added to each tube containing tlie gDNA treatment reaction.
An RT- reaction was performed with reverse fr anscriptase replaced by 1 pi RNase-fr ee 
water, in order to serve as a control for the presence of contaminating plasmid DNA or 
gDNA. The RT reaction tubes were incubated for 15 minutes at 42°C, followed by 3 minutes 
incubation at 95 °C in order to denature the reverse transcriptase. Each 20 pi RT reaction was 
diluted to a volume of 100 pi with PCR-grade water to a concentiation equivalent to 1 ng/pl 
RNA, mixed by tapping the tube and pulse-centrifrigation and then stored at -20°C until 
required.
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2.2.8 6 Quantitative real-time PCR using SYBR-Green I
2.2.8.6.1 Real-time PCR primer sets
PCR primers for detection of housekeeping genes (Primer Design) and target genes (Qiagen 
QuantiTect Primer Assays) were supplied as lyophilised oligonucleotides consisting of both 
forward and reverse primers, with the exception of SREBP-lc primers (Table 2.13). PCR 
primer sets were resuspended according to the manufactui'er’s instructions in nuclease-free 
water (housekeeping gene primer sets) or molecular’ biology grade TE (10 rnM Tris-HCl, 1 
mM EDTA, pH 8.0) (QuantiTect Primer Assays) and vortexed.
SREBP-lc primers were supplied as HPLC-pui’ified forward and reverse primers (MWG 
Biotech). The separate SREBP-lc forward and reverse primers were initially reconstitirted in 
nuclease-ffee water to a concentration of 100 pmol/pl concentration and a primer mix of 
forward and reverse primers prepared in nuclease-fr ee water (concentration of each primer: 8 
pmol/pl). Reconstituted primer mixes were stored at -20°C in aliquots.
2.2.8.6.2 Preparation of real-time PCR reactions
Real-time PCR reactions were performed using QuantiTect SYBR Green PCR kit (Qiagen), 
which contains HotStar (heat-activated) Taq polymerase, PCR buffer, SYBR-Green I dye and 
ROX dye, the latter acting as an internal reference for normalisation of the SYBR-Green 
signal. Mastermixes were prepared using the manufactmers’ recommended volumes of each 
reconstituted primer mix, SYBR Green Mix and PCR-grade water and 20 pi mastermix 
added to each well of a 96-well PCR plate (Table 2.14). 5 pi of each cDNA sample was then 
added per well. In addition, a ‘no template control’ (NTC) containing 5 pi PCR-grade water 
instead of cDNA was included as an indicator of contamination and a 5 pi RT- sample was 
included to ensure the efficacy of the DNase treatment of the RNA prior to cDNA synthesis 
{le. an indicator of genomic or plasmid DNA contamination). A thermal seal was applied to 
the top of the PCR plate (to avoid evaporation during the thermal cycling process) and the 
plate centrifiiged for 1 minute at 1000 rpm (193 x g , Eppendorf Centrifuge 5810) in order to 
mix the primer-PCR masteimix and cDNA sample.
90
Table 2.13: Real-time PCR primers.
Gene (symbol*) Genbank Accession No. Source (Reference)
Ampllcon 
length (bp)
18 S rRNA(ieS) Ml 0098 Primer Design Not supplied
p-2-microglobulin (B2M) NM_004048 Primer Design Not supplied
Cytochrome c-1 (CYC1) NM_001916 Primer Design Not supplied
Eukaryotic translation initiation 
factor 4A (EIF4A2)
NM_001967 Primer Design Not supplied
Topoisomerase 1 (T0P1) NM_003286 Primer Design Not supplied
Ubiquitin C (UBC) NM_021009 Primer Design 137
Acetyl CoA carboxylase (ACACA) NM_000664 NM_198835 Qiagen (QT00033761) 116
Apolipoprotein Gill (ApoCIII) NM_000040 Qiagen (QT00012537) 78
Fatty acid synthase (FASN) NM_004104 Qiagen (QT00014588) 71
Hepatocyte Nuclear Factor (HNF4A) NM_178849. NM_000457 Qiagen (QT00019411) 90
Liver-type pyruvate kinase (PKLR) NM_000298NMJ81871 Qiagen (QT00016156) 169
Phosphoenol pyruvate 
carboxykinase (cytosolic) (PCK1) NM_002591 Qiagen (QT00001197) 97
Peroxisome proliferator-activated 
receptor-a (PPARA) NM_001001928 Qiagen (QT00017451) 109
E1A binding protein p300 (EP300) NM_001429 Qiagen (QT00094500) 72
Mus musculus Peroxisome 
proliferator-activated receptor-y 
coactivator 1-a (PPARGCIa)
NM_008904 Qiagen (QT00156303) 63
Homo sapiens Peroxisome 
proliferator-activated receptor-y 
coactivator 1-a (PPARGCIa)
NM_013261 Qiagen (QT00095578) 134
Sterol regulatory element binding 
protein-1 c (SREBP-lc) NM_004176 (Oberkofler et al., 2004) 80
Sterol regulatory element binding 
protein-2 (SREBF2) NM_004599 Qiagen (QT00052052) 145
Housekeeping gene primer sets were supplied by Primer Design. The majority of target gene 
primer sets used were obtained as QuantiTect Primer Assays (Qiagen). All primer sets are 
designed to detect the human transcript unless stated otherwise below. *The gene symbol 
used by the manufacturer is given in parenthesis.
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Table 2.14A: Composition of real-time PCR reactions using housekeeping gene or 
SREBP-lc primers.
Component Volume / reaction (pi) Final concentration
Reconstituted primer mix 1.25 400 nM
QuantiTect SYBR Green Mix (2x) 12.5 1 X
PCR-grade water 6.25
cDNA (1 ng/pl RNA equivalent) 5.0 0.2 ng/pl RNA equivalent
Final volume 25
Table 2.14B: Composition of real-time PCR reactions using QuantiTect Primer Assays.
Component Volume / reaction (pi) Final concentration
QuantiTect Primer Assay (10x) 2.5 1 X
QuantiTect SYBR Green Mix (2x) 12.5 1 X
PCR-grade water 7.5
cDNA (1 ng/pl RNA equivalent) 5.0 0.2 ng/pl RNA equivalent
Final volume 25
2.2.8.6.3 Real-time PCR cycling conditions
Real-time PCR reactions were performed using an ABI PRISM 7000 Sequence Detection 
System cycler and associated software (Applied Biosystems, Foster City, U.S.A.). The 
cycling conditions were based on parameters outlined for the use of QuantiTect SYBR Green 
PCR mix and Primer Assays (Qiagen) with this real-time PCR cycler (Table 2.15) 
(QuantiTect SYBR Green PCR Handbook (2005), Qiagen; QuantiTect Primer Assay 
Handbook (2006), Qiagen). Following PCR cycling, a dissociation protocol with a starting 
temperature of 55°C was programmed (Section 2.2.8.7.2).
Table 2.15: Real-time PCR cycler conditions.
Step Time Temperature Comment
Initial activation step 15 min 95°C
1
Activation of HotStar Taq DNA 
polymerase
Dénaturation 15s 94°C 1 Dénaturation double-strand DNA
Annealing 30 s 55°C Primer binding
Extension 30 s 72°C Synthesis of second strand DNA 
Fluorescence data acquisition
PCR reactions were performed with the following cycling steps using an ABI PRISM 7000 
real-time PCR cycler. Taq DNA polymerase was activated by 15 minutes activation at 95°C 
followed by 45 cycles consisting of dénaturation, annealing and extension steps.
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2.2.8.7 Analysis of real-time PCR data
2.2.8.7.1 Acquisition of real-time PCR data
The reporter signal generated by SYBR Green fluorescence was automatically corrected for 
the signal from the passive reference dye (ROX) to generate the normalised reporter signal 
(delta Rn) which reflects the progress of the PCR reaction. An amplification plot of delta Rn 
after each PCR cycle was produced using the ABI PRISM 7000 software (Figure 2.13). A 
baseline level, corresponding to background fluorescence separate from the progress of the 
PCR reaction, was set between 6 and 15 cycles. The threshold level, corresponding to the 
level of reporter signal at which relative abundance of transcripts was quantified, was 
adjusted manually to a region of the plot within the log-linear region of the reaction curves 
for all wells of the PCR plate. The threshold cycle (Ct) number at which the fluorescence 
reporter signal for each PCR reaction exceeded the threshold was then calculated and 
exported in the form of a Results Export File from the ABI PRISM 7000 program.
Delta Rn vs Cvcle
Cycle Number
Threshold
Baseline
Figure 2.13: Annotated amplification plot of delta Rn against cycle number. Typical 
amplification plot of normalised fluorescence intensity (delta Rn) against cycle number 
produced for each PCR reaction (coloured lines) by ABI PRISM 7000 software. The 
baseline level corresponding to background fluorescence was set between 6 and 15 cycles 
and the threshold level (thick black line) set manually to a level corresponding to the 
exponential phase of the PCR reaction throughout all wells of the PCR plate. The 
threshold cycle (CJ corresponds to the fractional cycle number at which the fluorescence 
reporter signal for a particular well crosses the threshold.
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2.2.8.7.2 Interpretation of melting curve analysis
Following PCR cycling, a melting curve analysis of each sample was performed by 
measuring the fluorescence in each well over a temperature gradient (55°C - 85°C). The 
resulting dissociation plot of the first derivative of fluorescence reporter signal against 
temperature indicates the gradient of the melting curve at each temperature, i.e. a steep 
decrease in fluorescence reporter signal indicates increased dénaturation of double-stranded 
DNA at that temperature. A single peak observed in the dissociation curve (Figure 2,14) 
corresponds to single PCR product (Nolan, 2004). The absence of multiple PCR products 
was also confirmed by gel electrophoresis (Section 2.2.4.2).
Dissociation Curve
60 65 70 75
Temperature (°C)
80 85 90 95
PCR product
Figure 2.14: Annotated dissociation curve analysis. Typical dissociation curve of first 
derivative (of the fluorescence reporter signal) against temperature. Peaks attributable to 
primer-dimer and PCR product melting are indicated.
2.2.8.7.3 Calculation of PCR efficiency
A PCR efficiency of 100% assumes that there is a doubling of the number of PCR products 
following each cycle of PCR. However, PCR efficiency can vary with different primer sets 
due to different GC content of primers, efficiency of primer annealing or other experimental 
factors, leading to a PCR efficiency of less than 100%. It was necessary to calculate PCR 
efficiency for each primer set in order to quantify gene expression data without the use of a 
standard curve (Section 2.2.8.7.4). This was achieved by performing PCR reactions with 
several dilutions of a single cDNA sample (in PCR-grade water) for each gene-specific
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primer set. The resulting Ct values were plotted against the logarithm of the amount of RNA 
(ng) used in the cDNA synthesis reaction and a trendline fitted to the data points (Figure 
2.15). The slope (S) of the trendline was used to calculate PCR efficiency (E) using 
Equations 2.3A. The average PCR efficiency was calculated based on the results of slope 
values generated from two PCR experiments using dilutions of two different cDNA samples.
33.5
32.5
c5 31.5
30.5
-3 .477X  + 3 1 .9  
R2 = 0 .9 7
29.5
29
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Figure 2.15: Plot of Ct against log RNA (ng) for the calculation of PCR efficiency (E).
PCR efficiency (E) was determined from the slope of trendline relating Ct values to 
logio[RNA].
2.2.8.7A Relative quantification of gene expression
Gene expression data for target genes was normalised to the expression of an endogenous 
reference gene (housekeeping gene) based on the ACt method (Pfaffi, 2001). The relative 
expression of a particular gene within a biological repeat experiment was compared by 
subtracting the Ct value of the sample from the minimum Ct value (i.e. sample with the 
highest expression of the gene in question) in order to derive the ACt value for each sample 
(Equations 2.3B). The ACt value was then used to derive the relative expression level of a 
gene based on Equations 2.3C, which takes into account the PCR efficiency of the gene- 
specific primer set. For example, a ACt value o f -1.0 would equate to a 2-fold reduction in 
the abundance of the transcript in the sample in question compared to the sample with the 
highest expression (in the case of a PCR efficiency of 100%). The relative gene expression
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quantities were tlien normalised to the expression of an endogenous reference gene, (3-2- 
microglobulin (B2M), by a ratio-based method (Equations 2.3D). Tills is a similar- approach 
as the A ACt method (Livak and Schmittgen, 2001), however in this case it is possible to take 
into accoimt different PCR amplification efficiencies (Pfaffi, 2001).
Equations 2.3: Formulae used in analysis of real-time PCR data. (A) PCR efficiency 
E was calculated from the slope S  of the plot of Ct vs logio(RNA(ng)). (B) ACt for each 
sample is calculated by substracting the Ct value for the sample from the minimum Ct 
values for all samples for a pai'ticulai* gene. (C) Calculation of the quantity of each sample 
(relative to the sample with the highest expression of the gene) using the values for PCR 
efficiency E  and ACt for each sample. (D) The relative quantity of each tar get gene was 
normalised by dividing by the quantity of a housekeeping gene.
(A ) PCR Efficiency (E) = -1
(B ) àC^ = minimum (all values) -  (sample)
(C ) Quantity = (1 + E)^ ^^ *
Quantity: target gene
(D ) Normalised gene expression level = -------------------------------------------------
Quantity: housekeeping gene
2 2.8.8 Selection of most stable housekeeping gene (GeNorm method)
The choice of housekeeping gene to use as an endogenous reference for relative 
quantification of gene expression was made using the geNorm method and associated Visual 
Basic Application for Microsoft Excel (http://medgen.ugent.be/~jvdesornp/genorm/), which 
calculates housekeeping gene stability and the optimum number of housekeeping genes to use 
for normalisation (Vandesompele et al, 2002). The method uses the assumption that for two 
stably expressed housekeeping genes, tlie ratio between the two genes should be the same 
under each set of experimental conditions. The method outlined by Vandesompele and 
colleagues calculates the average pair wise var iation in the expression of each housekeeping 
gene compar ed with other housekeeping genes within a set to define the average internal 
control gene stability measure M. Stepwise omission of the housekeeping gene with the 
highest {le. least stable) M value results in the two housekeeping genes with the most stable 
expression under the tested experimental conditions (Figure 2.16). (3-2-microglobulin (B2M) 
was selected as the most stable HKG based on being within the two most stable HKGs in two
96
geNorm analysis using samples from separate biological experiments investigating the effect 
of HNF4a over-expression on SREBP-lc gene expression in HepG2 cells (Chapter 5).
Average expression stability values of remaining control genes
S  0 55
w 0.45
EIF4A2
Least stable genes Most s ta tile genes ::::>
Figure 2.16: Plot of average expression stability for a set of housekeeping genes. The
analysis of average expression stability (Af) of remaining housekeeping genes following 
stepwise exclusion of the least stable housekeeping gene was generated using the geNorm 
application for Microsoft Excel (Vandesompele et al, 2002).
2.2.9 Sequencing of DNA
2.2.9.1 Purification of HNF4a RT-PCR products
Briefly, 25 pi of RT-PCR or PGR product was separated on a 1.5% agarose gel for 
approximately 1 hour. The gel was visualized using a UV lamp and the band corresponding 
to the PGR product excised using a sterile razor blade and transferred to a sterile 
microcentrifuge tube with sterile forceps. The gel slice was then treated according to the 
manufacturer’s instructions for gel purification using the Wizard® SV Gel and PGR Glean-up 
System (Wizard SV Gel and PGR Glean-Up System Technical Bulletin, 2004). The weight 
of the gel slice was established using an empty microcentrifuge tube as a blank. The gel slice 
was dissolved in 10 pi Gel Binding Solution per 10 mg gel slice at 50-65°G for 10 minutes 
with regular vortexing. The dissolved gel slice was added to a SV Minicolumn, incubated for
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1 minute at room temperature and cenfrifliged at 16,000 x g  for 1 minute (14,000 rpm, 
Eppendorf Microcentriflige Model 5415D). The column was then washed with 700 pi 
Membrane Wash Solution (diluted with 95% ethanol) for 1 minute at 16,000 x g, followed by 
a second wash with 500 pi Membrane Wash Solution for 5 minutes at 16,000 x g. The 
column was then placed in an empty collection tube and centrifuged for a further 1 minute to 
allow complete evaporation of ethanol. The minicolumn was then placed in a fresh 1.5 ml 
microcentiifiTge tube and the DNA eluted with 50 pi nuclease-free water. DNA 
concenfration and puiity were determined using a Nanodrop ND-1000 Spectrophotometer 
(Section 2.2.3.1).
2.2.9.2 DNA sequencing and analysis
HNF4al, HNF4a2 and HNF4a3 RT-PCR products were sequenced by the Functional 
Genomics Centre (FHMS, University of SuiTey, U.K.) using a CEQ 2000XL DNA Analysis 
System (Bedanan Coulter, Fullerton, U.S.A.). The sequencing of the HNF4a7/8 RT-PCR 
product was performed externally by Cogenics (Lark Technologies, Hope End, Takeley, 
U.K.),
Table 2.16: Primers for sequencing of HNF4-al, -a2 and -a7/8 RT-PCR products.
HNF4a splice 
variant
Primer name Sequence (5’->3’) Tm (°C) Position*
a1/a2 seqprimerFI TCCAGTTCATCAAGCTCTTC 55.5 1153-1172
a1/a2 seqprimerF2 AGCTTGGAGGACTACATCAA 54.9 1100-1120
a7/a8 a7primerR1 TGTCCTCATAGCTTGACCTT 54.9 354-373
Sequencing primers were designed with a T ^ of ~55°C and a GC content o f-50% using 
Primer3 primer design software. ^Position of the primers in the Genbanlc nucleotide 
sequences for HNF4al (NM_178849) and HNF4a7/8 (AY680696).
In the case of the HNF4a3 RT-PCR product, primer R6 (Table 2.6) was used for primer 
extension. In the case of the HNF4-al, HNF4a2 and HNF4a7/8 RT-PCR products, internal 
oligonucleotides were designed to achieve sequencing of tire region to unique to the 
particular splice variant usmg Primer3 primer design software (http://fr odo.wi.mit.edu/cgi- 
bin/primer3/prinier3_www.cgi) (Table 2.16). For example, the positions of the primers for 
sequencing the HNF4al and HNF4a2 splice variants were chosen so that the sequencing 
product would include the 3’ end of the RT-PCR product which differs between tire HNF4al 
and -a2 splice variants (Figure 2.4). The sequencing results were compared to the published
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sequences for human HNF4a transcript variants using ClustalW sequence analysis progiam 
(http://www.ebi.ac.ulc/clustalw/).
2.2.10 Statistical analysis
2.2.10.1 Descriptive statistics
In order to express differences in gene expression or repoiter gene expression under different 
incubation conditions, the mean expression levels were calculated. The standar d error of the 
mean (SEM) for each condition was calculated by dividing the standard deviation by the 
squar e route of nimiber of data points per condition (n) (Watt, 1993).
Relative gene or reporter gene expression levels were expressed as a percentage of the control 
condition by division of each datapoint, already normalised to housekeeping gene expression 
for PCR analysis (Equations 2.3D), or SEAP expression for reporter gene analysis (Equations 
2.2A), by the mean normalised value for the control condition (Equation 2.4). In this way, 
the mean relative expression level of the control condition is set as 100%, with all values 
being expressed as a percentage of the gene or reporter gene expression in the control 
condition.
Equation 2.4: Calculation of relative gene expression or reporter expression.
Normalised gene expression level
Relative gene expression level (%) =
Mean normalised gene expression 
level (control condition)
2.2.10.2 Comparison of group means
The statistical significance of differences between means of different experimental groups 
was assessed with SPSS for Windows (Version 13.0). The differences between two 
conditions was analysed by paired Mest, by pairing of the data points for each condition 
vrithin a biological repeat. The statistical significance of differences between more than two 
different groups was calculated using a one-way analysis of vaiiance (ANOVA). The 
dependent variable was selected as the relative gene expression value (for RT-PCR data) or 
corrected luciferase reading (for reporter gene data) and the independent variable was the 
incubation and/or hansfection condition. One-way ANOVA compares tlie vaiiance between
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the different groups (due to the independent variable) with the variance within each group 
(due to chance) (Pallant, 2005). The F-statistic and its associated significance value (p) were 
calculated. If the ANOVA showed overall statistical significance between gimips (p < 0.05), 
Tukey’s post-hoc test was used to analyse differences between two gioups.
The data was also subject to Levene’s test for homogeneity of variance which tests the 
assumption that the variance in data is the same in each of the groups. If the result of this 
was a significance value (p) of greater than 0.05, then this assumption is correct. However, if 
p  < 0.05, then the variance of the groups is not the same, and in this case, the Welch and 
Brown-Forsytlie tests were used as robust tests of equality of means instead of one-way 
ANOVA (Pallant, 2005). The Games-Howell post-hoc test was used to identify significant 
differences between groups in this case, as this test does not assume equality of variances.
For data involving two independent variables, both of which were discrete (such as 
transfection condition and incubation condition), two-way ANOVA was perfoimed in 
GraphPad Prism for Windows (Version 5). In the case of thnecouise experiments, the effects 
of incubation condition and period of incubation were analysed by a repeated measures 
ANOVA with SPSS for Windows (Version 13.0).
2.2.10.3 Bivariate correlations
Coirelations between pairs of continuous variables were performed by a two-tailed Pear son 
correlation test, with degree of correlation between the variables and its statistical 
significance being assessed from the resulting coiTelation coefficient (R) and p-value. 
Correlation analysis was performed using SPSS for Wmdows (Version 13.0) or linear 
regression analysis in GraphPad Prism for Wmdows (Version 5).
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Chapter 3
Characterisation of human hepatoma 
cell lines for the expression of 
HNF4a and its target genes
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Chapter 3:
3.1 Introduction
HNF4a splice valiants have been shown to have different properties in terms of their 
recruitment of co-factors and of their transactivation of different gene regulatory elements 
(Sladek et al, 1999; Torres-Padilla et al,  2002; Eecldioute et al, 2003; Torres-Padilla and 
Weiss, 2003). Therefore, the expression of HNF4a tai'get genes in hrmian hepatoma cell 
lines could be influenced by the profile of the HNF4a splice variants which are expressed. 
The HNF4 isoform expression profile of colonic enterocyte cell lines has been associated 
with their phenotype: the more differentiated phenotype shown by Caco-2 cells is associated 
with a wider range of expressed HNF4 isofoims (HNF4a2, HNF4a4 and HNF4y), whereas 
less differentiated HT-29 G- cells predominantly express the HNF4a4 splice variant (Suaud 
et al, 1997). In hepatocytes, changes the expression and phosphorylation state of HNF4al 
and HNF4a2 are associated with changes in differentiation state (Runge et al, 1999).
Aim: To characterise the human hepatoma cell lines, HuH7, HepG2 and Hep3B, for the 
expression of HNF4a and its splice variants, and HNF4a tai'get genes.
Objective 1: To profile the expression of HNF4a splice variants in the HepG2, Hep3B and 
HuH7 cell lines using RT-PCR with splice-variant specific primers, and compare tlie 
expression profile of HNF4a splice variants with those of adult and foetal human liver.
HepG2 cells have been previously reported to express HNF4al and HNF4a2 (Chartier et al, 
1994), HNF4a3 (Kiitis et al,  1996) plus splice variants derived from the P2 promoter 
(HNF4a7/8) (Thomas et al,  2001). However, the Hep3B and HuH7 cell lines have not been 
characterised for the profile of HNF4a splice variants expressed, wliich is important to 
detemiine how they compare to both the HepG2 cell line and in vivo situation. Comparison 
of HNF4a splice variant expression in the three human hepatoma cell lines with human liver 
samples will provide an indication of wliich cell line is the most ideal model for studying 
HNF4a function.
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Objective 2: To study tlie expression of HNF4a and its hepatic tai’get genes in a hepatoma 
cell cultui’e system, using semi-quantitative RT-PCR under different conditions of glucose 
and insulin concentration.
Splice variants of HNF4a function differently at different target gene promoters (Torres- 
Padilla and Weiss, 2003), therefore cell lines with different expression patterns of HNF4a 
splice valiants could show different patterns of HNF4a target gene expression. In addition, 
the differential interactions of HNF4a variants with co-factors (Eeckhoute et al, 2003; 
Eeckhoute et al, 2006; Pascussi et al, 2007) could entail differential modulation of target 
gene expression in response to metabolic stimuli such as glucose concentration and insulin, as 
HNF4a co-factors such as SRC-1 and p300/CBP aie known to be targets of different signal 
transduction pathways (Ait-Si-Ali et al, 1999; Yang et al, 2001; Wu et al,  2005).
3.2 Expression of HNF4a and its spiice variants in human 
hepatoma ceii tines and human iiver
3.2.1 Rationale
Three human hepatoma cell lines, HuH7, HepG2 and Hep3B, were investigated for the 
expression of total HNF4a and its splice variants HNF4al, HNF4a2, HNF4a3, HNF4a4 
(splice valiants tianscribed from promoter PI) and HNF4a7/8 (referring to all P2 promoter 
splice variants) (Introduction, Figure 1.12). In order to compare the profile of expressed 
splice valiants in human liver cell lines with those expressed in the hmnan liver, RT-PCR 
reactions for HNF4a and its splice valiants were also performed on total RNA fr om human 
foetal and adult male and female liver samples. An RT-PCR reaction using primers for P- 
actin was also included, as a control for amount and quality of the mRNA in the sample.
3.2.2 Results
As previously reported, HepG2 cells were shown to express a wide range of HNF4a splice 
valiants, including HNF4al, HNF4a2, HNF4a3 and HNF4a7/8, however HNF4a4 was not 
detected (Figure 3.1). Sequencing of gel-puiified HNF4al and HNF4a2 RT-PCR products 
confirmed that the C-terminal 30 bp insert unique to HNF4a2 was present in this RT-PCR 
product (Appendix 1, Box 8.2), whilst the 30 bp insert was found to be absent in the HNF4al
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RT-PCR product (Appendix 1, Box 8.1). An RT-PCR product of the predicted size for 
HNF4a7/8 was also detected (Figure 3.1) and sequencing revealed the presence of exon ID, 
the alternate first exon present in HNF4a7/8, compared to exon 1A present in HNF4al-6 
(Appendix 1, Box 8.4).
HNF4a sp lice variant
300 bp
200 bp
700 bp 
600 bp 
500 bp 
400 bp
HNF4a1 / HNF4a2 
HNF4a7/8
HNF4a3
Figure 3.1: Expression of HNF4a splice variants in the HepG2 cell line. RT-PCR was 
performed with 2 pg total RNA from HepG2 cells cultured under standard conditions 
(Section 2.2.1) with primers to P-actin and HNF4a (all splice variants) and to the 
individual HNF4a splice variants (Section 2.2.5). Figure is representative of RT-PCR 
performed with two different samples of HepG2 RNA.
HNF4a splice variant
s 2SCN CO h-a a a a a a'«ru_ LL Li. Li. Li. Li.z Z z z Z zI I I I X X
 <------  HNF4a1 / HNF4a2
 <------  HNF4a7/8
HNF4a3
Figure 3.2: Expression of HNF4a splice variants in the Hep3B cell line. RT-PCR was 
performed with 400 ng total RNA from Hep3B cells cultured under standard conditions 
(Section 2.2.1) with primers to P-actin, HNF4a (all splice variants) and to the individual 
HNF4a splice variants (Section 2.2.5).
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The Hep3B cell line also expressed HNF4a and showed the same profile of expressed 
HNF4a splice variants as the HepG2 cell line with HNF4al, HNF4a2, HNF4a3 and 
FTNF4a7/8 being detected by RT-PCR (Figure 3.2).
HNF4a was found to be expressed in HuH7 cells (Figure 3.3A); importantly, only the 
HNF4a3 splice variant was detected by RT-PCR using primers specific to different HNF4a 
splice variants (Figure 3.3B). This result suggests that HuH7 cells do not express HNF4al, 
HNF4a2, HNF4a4 or HNF4a7/8 at a level detectable by RT-PCR. Sequencing of the 
HNF4a3 RT-PCR product showed sequence identity with the published HNF4a3 sequence 
(Appendix 1, Box 8.3).
HNF4a was expressed in all human liver samples (Figure 3.4). Bands corresponding to 
HNF4al, HNF4a2 and HNF4a3 and a faint band for the HNF4a7/8 RT-PCR product were 
present following gel electrophoresis of the RT-PCR products of the adult male and female 
liver RNA samples (Figure 3.4A-B). RT-PCR products for the HNF4al, HNF4a2 and 
HNF4a3 splice variants could also be identified in the human foetal liver RNA sample, 
however the HNF4a7/8 variant was not detectable (Figure 3.4C).
B  HNF4a splice variant
700 bp
600 bp
500 bp
400 bp
300 bp
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HNF4a3
Figure 3.3: Expression of (A) HNF4a and (B) HNF4a splice variants in the HuH7 cell 
line. HuH7 cells were cultured under standard conditions (Section 2.2.1) and total RNA 
isolated. RT-PCR was performed with 2 pg total RNA from HuH7 cells with primers to p- 
actin and (A) HNF4a (all splice variants) or (B) primers to specific HNF4a splice variants 
(Section 2.2.5). Gels are representative of RT-PCR performed with two different samples of 
HuH7 RNA.
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Figure 3.4: Expression of HNF4a splice variants in human (A) adult male (B) adult 
female and (C) foetal liver total RNA samples. 400 ng human liver total RNA was 
subject to RT-PCR with primers for P-actin, HNF4a and its individual splice variants 
(Section 2.2.5).
3.3 Regulation of HNF4a and downstream gene expression in 
HuH7 and HepG2 ceiis by glucose and insulin concentration
3.3.1 Rationale
The liver is exposed to a wide range of blood glucose and insulin concentrations compared to 
peripheral tissues due to the transport of digested carbohydrate from the small intestine and 
insulin secreted by the pancreas direct to the liver via the hepatic portal vein (Frayn, 2003). 
The expression of HNF4a has been shown to be regulated by insulin in vivo (Oyadomari et 
ai,  2000) and HNF4a regulates its own expression from both the PI and P2 promoters 
(Bailly et al,  2001; Briancon et al, 2004; Magenheim et al, 2005). Given the involvement 
of HNF4a in the regulation of its target genes by high glucose concentration (Diaz Guerra et 
al,  1993; Adamson et al, 2006), the role of both glucose concentration and insulin in the 
expression of the HNF4a gene was investigated in HuH7 and HepG2 cells.
ApoCIII and FAS are HNF4a target genes (Sladek et al, 1990; Kardassis et al, 1997; 
Vergnes et al, 1997; Adamson et al, 2006) which are oppositely regulated by feeding 
stimuli. The expression of apoCIII is inhibited by insulin (Chen et al,  1994a), whilst FAS 
expression is stimulated by high glucose concentration and insulin (Paulauskis and Sul, 1989; 
Prip-Buus et al, 1995). Therefore the regulation of apoCIII and FAS mRNA expression by
106
insulin and glucose concentration was studied in human hepatoma cells. As HuH7 and 
HepG2 cells show different HNF4a splice variant expression patterns (Figures 3.1 and 3.2), 
it was hypotliesised this could lead to differences in the regulation of apoCIII and FAS by 
insulin and glucose concentration, therefore these aspects were compaied between the two 
cell lines.
3.3.2 Results
The effect of glucose on the overall expression of HNF4a was investigated by incubating 
HuH7 cells witli glucose-containing media of different concentrations over a period of 96 
hours and measuring the expression of HNF4a relative to the housekeeping gene p-actin by 
semi-quantitative RT-PCR (Figure 3.5). The effects of incubation time and glucose 
concentration on HNF4a expression were analysed by two-way ANOVA. Levels of HNF4a 
showed a tendency to increase over time under all tliree conditions, although tliis came short 
of significance {p = 0.06). Glucose concentration had a significant effect on the expression of 
HNF4a ip < 0.05). AMiough post-hoc tests did not identify significant differences between 
pairs of incubation conditions, HNF4a expression appear ed to be lower under conditions of 
low glucose concentration (Figme 3.5A).
The expression of HNF4a and its tar get genes, apoCIII and FAS, in HuH7 cells and HepG2 
cells was measured following an incubation period of 48 hours with medium of standard (5.5 
mM) or high (20 niM) glucose concentration in the presence or absence of 100 riM insulin 
(Figure 3.6A and B), and the effects of glucose concentration and insulin on gene expression 
analysed by two-way ANOVA. The expression of HNF4a, apoCIII and FAS was not 
significantly modulated by glucose concentration or insulin in HuH7 cells (Figure 3.6A). On 
the other hand, glucose concentration had a significant effect on HNF4a expression in 
HepG2 cells ip < 0.05) (Figure 3.6B). Post-hoc tests did not show significant differences 
between two individual incubation conditions; however the difference in HNF4a expression 
between 5.5 rnM and 20 mM glucose was greatest in the presence of insulin, with FINF4a 
expression 115% greater in the higher glucose concentration (Figure 3.6B). Due to high 
variability of data withm each incubation condition, no significant differences between 
incubation conditions were foimd in apoCIII and FAS expression in HepG2 cells (Figure 
3.6B). A non-significant 75% decrease in apoCIII riiRNA levels was observed in HepG2
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Figure 3.5: Expression of HNF4a under conditions of (A) low (B) standard and (C) 
high glucose concentration over a period of 96 hours in HuH7 cells. HuH7 cells were 
incubated in media containing low (0.2 mM), standard (5.5 mM) or high (25.0 mM) 
glucose concentration for 0, 24, 48, 72 and 96 hours after which RNA was isolated. RT- 
PCR was performed with 100 ng RNA with primers to p-actin and HNF4a and the RT- 
PCR products quantified by gel digitization. Expression of HNF4a was normalised to the 
expression of a housekeeping gene, P-actin, and expressed as a percentage. Values shown 
as mean ± SEM (n = 3) or as individual data points in the case, n = 1 or n = 2.
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Figure 3.6: Effect of glucose concentration and insulin on the expression of HNF4a, 
apoCIII and FAS in (A) HuH7 cells and (B) HepG2 cells. Ceils were incubated for 48 
hours in media containing 5.5 mM or 20 mM glucose ± 100 nM insulin. RNA was isolated 
and RT-PCR performed with 100 ng RNA with primers to HNF4a, apoCIII and FAS. The 
RT-PCR products were quantified by gel digitization and the expression of each gene 
normalized to P-actin levels. Values shown as mean ± SEM (n = 3). Two-way ANOVA 
analysis of the effects of glucose concentration and insulin on the expression of each gene 
showed glucose concentration significantly altered HNF4a expression in HepG2 cells {p < 
0.05).
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cells incubated with 100 nM insulin (under 5.5 mM glucose conditions) compared insulin- 
free medium (Figure 3.6B). Mean FAS mRNA levels were 50% higher in HepG2 cells under 
conditions of 20 mM glucose in the presence of insulin compaied to standard 5.5 mM glucose 
insulin-fr ee conditions although the lar ge variance of data within each incubation condition 
meant this effect was not statistically significant (Figure 3.6B).
As a large degree of variability was noted in the results of the above gene expression analyses 
(Figures 3.5 and 3.6), the accuracy of the one-step RT-PCR method used in the above 
experiments was investigated. The effects of cycle number and RNA concentration on the 
accumulation of RT-PCR product DNA were investigated for a highly expressed gene (p- 
actin) and a less abundant gene (apoCIII). Firstly, the linearity of the accumulated PCR 
product as measured by gel digitization (Section 2.2.5.5) with respect to cycle number was 
investigated (Figure 3.7). Accumulation of RT-PCR product was linear with respect to cycle 
number within the range 10 to 25 cycles for p-actin (Figure 3.7A) and within the range 15 to 
30 cycles for apoCIII (Figure 3.7B).
Secondly, the relationship between the abundance of mRNA transcripts and resulting levels 
of RT-PCR products was investigated by quantifying RT-PCR product DNA for a range of 
dilutions of a single RNA sample (Figure 3.8). A range of PCR cycles were also investigated 
to assess whether this factor had any bearing on the relationship between these two factors. 
Accumulation of P-actin RT-PCR product was linear with respect to RNA concentration 
within the range 2.5 to 20 ng/pl when a PCR cycle number of 25 was used (Figure 3.8A). 
However, when a similar RT-PCR experiment was performed for apoCIII detection, a linear* 
relationship between RNA concentration and RT-PCR product levels was not observed over 
any part of the concentration range, or for any of the PCR cycle numbers employed (Figure 
3.8B).
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3.4 Discussion
Three human hepatoma cell lines, HepG2, Hep3B and HuH7, were characterised for the 
expression of HNF4a and the expression of selected HNF4a tai'get genes. Firstly, the 
expression of HNF4a at the mRNA level was confirmed in all thiee cell lines and the profile 
of expressed HNF4a splice variants was studied in each of the cell lines.
HepG2 cells were found to express HNF4a (Figure 3.1), in agreement with published results 
which suggest HNF4a mRNA expression is high in HepG2 cells and even exceeds that of 
cultiued hepatocytes (Castell et a l, 2006). HNF4a expression is also evident at the protein 
level in HepG2 cells (Naiki et a l, 2004). Endogenous HNF4a activity in HepG2 cells is also 
suggested by the utilisation of the cell Ime to char acterize the binding sites and interactions of 
HNF4a in reporter gene studies: for example, for the human sterol 27-hydroxylase (Garuti et 
a l, 2002) and apoAI genes (Hai'iiish et a l, 1996).
HepG2 cells were found to express promoter PI-derived splice variants, HNF4al, HNF4a2, 
HNF4a3, as well as low levels of transcripts from the P2-promoter (denoted HNF4a7/8) 
(Figure 3.1). HepG2 cells are documented to express HNF4al, HNF4a2, HNF4a3 and 
HNF4a7/8 (Chartier et a l, 1994; Kiitis et a l, 1996; Thomas et a l, 2001; Castell et al,
2006), which validates this RT-PCR assay for the detection of HNF4a splice variants in the 
HuH7 and Hep3B cell lines, which had not been previously been investigated for this aspect.
Like HepG2 cells, Hep3B cells were found to express HNF4a and the HNF4al, HNF4a2, 
HNF4a3 and HNF4a7/8 splice variants were detected (Figure 3.2). HuH7 cells were found 
to express HNF4a, however only the HNF4a3 splice variant was detected with the splice 
variant-specific primers (Figure 3.3). HNF4a expression has been detected at the protein 
level in HuH7 cells, although HNF4a mRNA levels were barely detectable by northern 
blotting (Naiki et a l, 2002; Naiki et a l, 2004). Altliough HNF4a3 was foimd to be an 
equally effective transactivator as HNF4al or HNF4a2 in one report (Kritis et a l, 1996), 
another report suggested that HNF4a3 is a weaker transactivator at certain promoters (Suaud 
et a l, 1999), which could be a reason for tlie lack of expression of the EtNF4a target gene, L- 
PK, in HuH7 cells (Nakabayashi et a l, 1982).
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HNF4a splice variants HNF4al, HNF4a2 and HNF4a3 were detected in adult human liver 
(Figure 3.4), in agreement with published works (Chartier et a l, 1994; Kiitis et a l, 1996). 
HNF4a4 was not detected by RT-PCR imder the conditions used in any of the human 
hepatoma cell lines or liver samples (Figures 3.1 to 3.4), whereas the HNF4a4-specific exon 
IB was previously detected in human liver (Fmuta et al., 1997). It is possible that HNF4a4 
is more highly expressed in HNF4a-expressing tissues other the liver, as this splice variant 
was cloned from a kidney cDNA library and also detected in the enterocytic Caco2 cell line.
The HNF4a7/8 splice variant was detected in human adult liver samples (Figure 3.4A and 
3.4B), suggesting that P2-promoter transcripts are present in adult human liver, as are found 
in adult mouse liver (Naldiei et al., 1998). The low levels of RT-PCR product observed 
(Figure 3.4A and 3.4B) suggest that HNF4a transcripts derived from the P2 promoter are less 
abundant in adult liver than PI-promoter derived transcripts (HNF4al-5) (Tones-Padilla et 
al, 2001). However, HNF4a7/8 was not detected in human foetal liver RNA (Figure 3.4C), 
whilst the expression of HNF4al, HNF4a2 and HN4a3 appeared to be at similar' levels to 
those in adult liver samples (Figure 3.4), in disagreement with findings that HNF4a7/8 
expression is higher during embryogenesis (Torres-Padilla et a l, 2001). It is possible that the 
expression of HNF4a7/8 is different in human foetal development compared to that of mouse 
(Torres-Padilla et a l, 2001), or tliat the foetal sample used here is relatively late in foetal 
development when PI prornoter-transcripts have already been up-regulated relative to tliose 
originating from tire P2 promoter.
The impact of the different HNF4a splice variant expression profiles in HuH7 and HepG2 
cells was investigated by studying the expression of HNF4a and its target genes, apoCIII and 
FAS, imder different metabolic conditions. A timecourse study of HNF4a expression 
revealed differences in HNF4a expression under conditions of variable glucose 
concentration, as well as a tendency for HNF4a expression to increase with length of cultur e 
period (Figure 3.5). Increased confluence in HuH7 cells may be associated with increased 
HNF4a expression, as another hepatoma cell line, HepG2 cells, have been shown to adopt a 
more differentiated phenotype with increased confluence, exhibiting higher expression of 
HNF4a target genes, L-PK and aldolase B (Kelly and Darlington, 1989). A more than 60% 
reduction in HNF4a expression was observed under low glucose concentration (0.2 mM)
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compared to standard conditions (5.5 mM glucose) at tire 48, 72 and 96 hour time points 
(Figure 3.5). This effect may be due to an indirect effect of low glucose concentration on 
HNF4a mRNA expression. A possible mechanism may be via activation of AMPK brought 
about by decreased glycolytic flux and ATP concentration. HNF4a activity is suppressed by 
AMPK and negative feedback on HNF4a mRNA expression may be exerted via HNF-1, 
wliich forms a regulatory circuit with HNF4a (Hatzis and Talianidis, 2001; Leclerc et a t, 
2001; Hong et a t, 2003).
In a separate experiment, HNF4a expression in HuH7 cells was also not modulated by 
standard (5.5 mM) vs. high (20 mM) glucose concentration or the presence of insulin (Figure 
3.6A). On the other hand, a non-significant two-fold increase in HNF4a expression in 
HepG2 cells under conditions mimicking the fed state (20 mM glucose +100 nM insulin) 
compared to standard conditions (5.5 mM glucose) was observed (Figure 3.6B). The latter 
result does not agree with other results which point to HNF4a expression being up-regulated 
under fasting conditions (Yoon et a i, 2001). However, insulin was shown to antagonise the 
stimulatory effect of glucagon on HNF4a expression in the livers of streptozotocin-induced 
diabetic rats and in rat hepatocytes (Oyadomari et a l, 2000), while HuH7 and HepG2 cells 
were incubated with insulin m the absence of glucagon (Figure 3.6), which may be a reason 
for insulin not having an inliibitory effect on HNF4a expression.
Different trends in the regulation of HNF4a target genes by glucose concentration and insulin 
were observed in HuH7 and HepG2 cells, although a high degree of var iability meant tliat tlie 
trends were not significant at the 5% level. Whilst apoCIII expression in HuH7 cells was not 
modulated by glucose concentr ation or insulin, a 75% decrease in apoCIII levels in HepG2 
cells incubated with 100 nM insulin compared to standard conditions, indicating that insulin 
had an inliibitory effect on the tr anscription of this HNF4a target gene in HepG2 cells,
(Figure 3.6). ApoCIII has been shown to be down-regulated by insulin at the transcriptional 
level in vivo (Chen et a l, 1994a). In HepG2 cells, mean FAS mRNA levels were also 50% 
liigher under conditions of high glucose concentration in the presence of insulin compar ed to 
standard conditions (Figure 3.6B), agreeing witli results obtained in vivo and in primary rat 
hepatocytes, showing that insulin and high glucose concentration induce expression of the 
FAS gene (Paulauskis and Sul, 1989; Prip-Buus et al, 1995). Together, the results of 
studying HNF4a tar get gene expression in HuH7 and HepG2 cells suggest tliat the apoCIII
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and FAS genes are modulated to a greater extent by metabolic stimuli in the latter cell line. 
The differences in expression of HNF4a splice variants in the two cell lines may contribute 
to the differences observed in HNF4a target gene expression. Overexpression of HNF4a2 in 
pancreatic INS-1 cells brought about changes in a great number of downstream genes than 
overexpression of HNF4a8 (Erdmann et a l, 2007), therefore the targets of HNF4a3, the 
dominant splice variant in HuH7 cells, may be more limited than those of the additional 
HNF4a splice variants expressed in HepG2 cells.
The high degree of variability in the RT-PCR results (Figure 3.5 and 3.6) suggests that the 
one-step RT-PCR method employed was not sufficiently quantitative for the purpose of 
measuring gene expression changes in HNF4a and its target gene mRNA levels under 
different incubation conditions. The linearity of the RT-PCR reaction with respect to cycle 
number and RNA concentration was further investigated (Figures 3.7 and 3.8 respectively).
It was confirmed that the PCR reaction was in tlie linear' phase of the reaction for both the 
housekeeping and target genes at a PCR cycle number of 25 (Figure 3.7), which was used for 
the gene expression analyses (Figures 3.5 and 3.6). Therefore it was concluded that PCR 
cycle number was not responsible for the variability in the results.
Investigation of the relationship between RNA concentration and PCR product (Figure 3.8), 
revealed that p-actin RT-PCR product abmidance reflected starting transcript levels at die 
RNA concentration of 10 ng/pl used in the previous gene expression analyses (Figures 3.5 
and 3.6), however the level of apoCIII RT-PCR product did not correlate witli star ting 
amounts of transcript (Figure 3.8B). As the PCR reaction was within its linear phase for both 
genes investigated (Figme 3.7), these experiments suggest that the RT stage of the RT-PCR 
reaction could be responsible for the problems in using this method to quantify transcripts of 
lower abundance such as apoCIII (Figme 3.8B) and that variation in the efficiency of the RT 
reaction could be one reason for the high variability of results. More reproducible results 
may have been obtained by using a two-step RT-PCR method, where tlie primers for cDNA 
synthesis are the same for all targets, as opposed to tlie use of gene-specific primers for 
cDNA synthesis in one-step RT-PCR (Pfafff, 2001).
Ariotlier factor wliich may have contr ibuted to the lack of significance in the results obtained 
was the choice of housekeeping gene (P-actm). Although p-actin has been shown to be a
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stable housekeeping gene in some studies investigating the action of msulin on gene 
expression (Sutherland et a l, 1995; Twisk et a l, 1995), other reports indicate that its 
transcription is up-regulated by insulin (Buchou et a l, 1991; Messina, 1992).
In conclusion, the profile of expressed HNF4a splice variants was established for the cell 
lines, HuH7, HepG2 and Hep3B. The HepG2 and Hep3B cell lines were shown to be closest 
to adult human liver in their expression of all HNF4a splice variants except HNF4a4, 
suggesting that these two cell lines are a closer model to human liver for the study of HNF4a 
action. The results of studying the expression of apoCIII and FAS in HuH7 and HepG2 cells 
also suggest that these genes are regulated in a more physiological maimer in HepG2 cells 
than in HuH7 cells. As the Hep3B cell line contains an integrated hepatitis B viral genome, 
the expression of wliich is influenced by insulin and glucocorticoids (Chou et a l, 1992; Chen 
et a l, 1997), it is considered that the HepG2 cell line is the best model for studying HNF4a- 
mediated gene expression. As a semi-quantitative RT-PCR approach produced a high level 
of variability in the results, reporter gene assays and real-time PCR analysis were considered 
be potentially more accmate methods for subsequent studies of HNF4a-mediated gene 
expression.
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Chapter 4
Regulation of HNF4a-dependent 
reporter gene expression by 
metaboiic stimuli
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Chapter 4:
4.1 Introduction
Reporter gene analysis enables the study of a gene promoter by delineating tlie roles of 
upstream DNA promoter elements and transcription factors which bind to them (Alani and 
Cook, 1990). Previously reporter gene constructs have been used to eludicate the role of 
HNF4a in the regulation of downstream genes in response to metabolic stimuli including 
hormones and metabolites, such fatty acids and glucose (Gourdon et a l, 1999; De Fabiani et 
a l, 2000; Massillon et a l, 2003; Roth et a l, 2004; Adamson et a l, 2006; Song and Chiang, 
2006; Hamiiman et a l, 2006).
The regulation of HNF4a transcriptional activity by metabolic signals is lilcely to be 
modulated by the promoter context and the other transcription factors and co-factors. The L- 
PK, PEPCK and SREBP-lc genes are important examples of oppositely-regulated HNF4a 
target genes in that each is key regulatory gene in controlling the rates of glycolysis, 
gluconeogenesis and lipogenesis in the liver (Section 1.3). L-PK and SREBP-lc are induced 
in response to the feeding signals of insulin and glucose, whilst PEPCK gene expression is 
activated by the fasting signals of glucagon and glucocorticoids (Section 1.9) (Girard et a l, 
1997; Hanson and Reshef, 1997; Kim et a l, 1998). Therefore reporter genes containing 
cognate HNF4a binding sites within proximal promoter elements from the L-PK, PEPCK 
and SREBP-lc genes were utilised in tins study to investigate the influence of hormones and 
metabolites on HNF4a-dependent tr anscriptional regulation. The influence of hormones and 
metabolites on HNF4a tr anscriptional activity should be reflected by increases or decreases 
in the level of luciferase reporter gene expression (Alarn and Cook, 1990).
Aim:
• To investigate the effects of feeding and fasting stimuli on HNF4a transcriptional 
activity in activating or inliibiting expression of reporter constructs of HNF4a target 
genes involved in tlie pathways of glycolysis (L-PK), gluconeogenesis (PEPCK) and 
lipogenesis (SREBP-lc).
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Objective 1: To investigate the effects of glucose concentration and hormones (insulin, 
triiodo-L-thyronine and dexamethasone) on L-PK reporter gene expression in HepG2 cells.
Objective 2: To study the effect of metabolic stimuli (glucose concentrations, insulm, 
glucagon and dexamethasone) on HNF4a activity at the L-PK promoter using different 
reporter gene constmcts together with HNF4a overexpression.
Objective 3: To study the regulation of PEPCK reporter gene expression by HNF4a, the 
effects of key hormones (insulin, dexamethasone) and the nuclear* receptor co-activator PGC- 
la .
Objective 4: To study the regulation of SREBP-lc reporter gene expression by HNF4a and 
the influence of metabolic stimuli (insulin and glucose concentration) and HNF4a co­
activators (PGC-la and p300),
4.2 Régulation of L-PK reporter gene expression by giucose 
concentration and hormones in HepG2 ceiis
4,2,1 Rationale
L-PK is a key regulatory gene in tlie glycolytic pathway, which is induced by the feeding 
stimuli of dietary carbohydrate and insulin, and repressed during fasting by glucagon and its 
downstream effector cAMP (Vaulont et al., 1986; Decaux et a l, 1989). The -183/+11 
proximal promoter region of the L-PK gene, which was previously found to confer 
responsiveness to dietary and hormonal factors in transgenic mice, consists of four 
transcription factor binding sites, named LI -  L4 (in order of proximity to the L-PK 
transcriptional start site) (Vaulont et a l, 1989). The LI site binds hepatocyte nuclear* factor 1 
(HNFl) and L2 binds the ubiquitous nuclear factor 1 (NFl). HNF4a binds to tlie L3 site in 
the L-PK promoter which is contiguous to the ChREBP-binding site (L4) (Vaulont et al, 
1989; Diaz Guerra et a l, 1993; Yaniashita et a l, 2001).
The initial objective in using L-PK reporter constructs to study HNF4a-mediated gene 
expression was to reproduce tlie effect of induction by high glucose concentrations, as 
demonstrated by the original investigators in primai'y rat hepatocytes (Gour don et al., 1999),
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in the hmnan hepatoma cell line HepG2, and confirm that the promoter functioned 
physiologically in response to high glucose concentiation (25 mM). In addition to studying 
the effect of glucose concentration on L-PK reporter gene expression, the influence of 
hormones previously suggested to be important in permitting glucose-induced gene 
expression, namely insulin or tlie combination of insulin, triiodo-L-thyronine and the 
synthetic glucocorticoid, dexamethasone, was also investigated (Munnich et a l, 1984; Doiron 
e ta l, 1994).
Transfections were performed in HepG2 cells with the L-PK reporter constructs (L4L3)4- 
54PK, which contains four oligomeric repeats of adjacent ChREBP- and HNF4a-binding 
sites and shows maximal induction by glucose, and (L3)3-54PK, which contains three 
oligomeric repeats of the HNF4a bmding site L3 ((Gourdon et a l, 1999), reproduced in 
Materials and Methods, Figure 2.7).
4.2.2 Results
The (L4L3)4-54PK reporter construct was induced more than five-fold by an increase from 
5.5 mM to 25 mM glucose under all conditions used (Figure 4.1). The expression of 
(L4L3)4-54PK reporter gene did not differ between 25 mM glucose medium and medium 
containing 25 niM glucose and 100 iiM insulin. The level of reporter gene expression after 
incubation with 25 niM glucose HSM was lower than that following incubation with 25 mM 
glucose medium with the addition of only insulin. Thus, insulin, triiodo-L-thyronine and 
dexamethasone do not potentiate the induction of (L4L3)4-54PK reporter gene by 25 mM 
glucose. The presence or absence of added hormones did not modify the expression of the 
(L4L3)4-54PK reporter plasmid under conditions of low glucose concentration (5.5 mM).
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Figure 4.1: Effect of glucose concentration and hormones on L-PK reporter gene 
expression in HepG2 cells. HepG2 cells were transfected with the luciferase reporter genes 
(L4L3)4-54PK and (L3)3-54PK along with pSEAPI-3’rep under control of the CMV 
promoter as a control for transfection efficiency. 16 h post-transfection, the media was 
changed and the cells incubated in media containing either 5.5 mM or 25 mM glucose ± 100 
nM insulin, or hormone-supplemented medium (HSM) containing 100 nM insulin, 1 pM 
triiodo-L-thyronine and 1 pM dexamethasone for 24 hours. Luciferase readings were 
corrected for transfection efficiency based on SEAP expression levels. Values are shown as 
mean ± SEM (n = 4). Reporter gene expression between incubation conditions and reporter 
plasmids was compared by two-way ANOVA, followed by Bonferroni post-hoc tests.
Results of selected post-hoc tests (where only one factor changed between the two groups 
analysed) are displayed: * p<  0.05; ***/?< 0.001. A full summary of the post-hoc analysis 
is shown in Appendix Section 8.2.
The reporter expression of the (L3)3-54PK reporter plasmid was significantly lower than that 
of the (L4L3)4-54PK plasmid under all conditions containing 25 mM glucose, whilst the 
level of expression between the two reporter plasmids did not differ under 5.5 mM conditions 
(Figure 4.1). The expression of the (L3)3-54PK reporter gene was not inducible by high 
glucose concentration and was not altered by incubation with insulin or a combination of 
insulin, dexamethasone and triiodo-L-thyronine (HSM) under conditions of either low (5.5 
mM) or high (25 mM) glucose concentration.
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4.3 Regulation of L-PK reporter gene expression by HNF4a and 
metaboiic stimuii
4.3.1 Rationale
The role of HNF4a in tlie modulation of L-PK reporter gene activity by hormones and 
metabolites was investigated using the (L4L3)4-54PK and (L3)3-54PK repoiter plasmids in 
combination with overexpression of HNF4a.
4.3.2 Results
The role of FINF4a in the response of L-PK reporter genes containing both CliREBP and 
HNF4a binding sites ((L4L3)4-54PK) or only HNF4a binding sites ((L3)3-54PK) to 25 mM 
glucose and insulin was further investigated by human HNF4a2 overexpression (Figure 4.2). 
Incubation with insulin or 25 niM glucose and insulin resulted in liigher reporter gene 
expression compared to standard medium (5.5 mM glucose). Incubation with 25 mM glucose 
medium without insulin did produce an induction of (L4L3)4-54PK reporter gene expression 
over expression levels at 5.5 mM glucose. Increased glucose concentration had an inhibitory 
effect on the expression of tlie (L3)3-54PK reporter plasmid when cells were incubated in the 
presence of insulin, while different glucose concentrations did not modulate expression of the 
reporter gene in the absence of insulin.
The effects of fasting hormones (glucagon and dexamethasone) compar ed to the feeding 
hormone (insulin) on the activity of HNF4a were investigated by transfecting HepG2 cells 
with the (L3)3-54PK reporter plasmid in the presence or absence of a human HNF4a2 
expression vector (Figure 4.3). The reporter gene expression of the (L3)3-54PK plasmid was 
increased over 35-fold by co-transfection with a human HNF4a2 expression vector under all 
incubation conditions (Figure 4.3 A). In the case of HNF4a2 overexpression, incubation of 
HepG2 cells with dexamethasone or glucagon, alone or in combination, did not alter (L3)3- 
54PK reporter gene expression, whilst incubation witli insulin produced a significant 38% 
decrease in reporter gene expression relative to the control medium (Figure 4,3 A). The 
combination of glucagon and insulin in the medium produced a significant 59% decrease 
relative to the control medium (Figure 4.3 A). In the absence of the human HNF4a2 
expression vector, no significant differences between the incubation conditions were 
observed (Figure 4.3B).
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Figure 4.2: Effect of human HNF4a2 overexpression on the regulation on (L4L3)4- 
54PK and (L3)3-54PK reporter gene expression by glucose concentration and insulin.
HepG2 cells were transfected with the luciferase reporter plasmids (L4L3)4-54PK or (L3)3- 
54PK and an expression vector for human HNF4a2 (3.3 ng/well). pSEAPI-3’rep was co­
transfected as a control for transfection efficiency. 16 hours post-transfection, the media was 
changed and the cells incubated in media containing 5.5 mM or 25 mM glucose ± 100 nM 
insulin. Luciferase readings were corrected for transfection efficiency based on SEAP 
expression levels. Values are shown as mean ± SEM (n = 4). The effects of incubation 
condition and reporter plasmid were analysed by two-way ANOVA with Bonferroni post-hoc 
tests; * p<  0.05.
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4.4 Regulation of PEPCK reporter gene expression by HNF4a, 
PGC-1 a and hormones
4.4.1 Rationale
HepG2 cells were transfected with a luciferase reporter gene containing the PEPCK proximal 
promoter region (-467Z+65 relative to the transcription start site), wliich includes the proximal 
GRU and cAMP regulatory element (CRE) (Quimi et al.  ^ 1988). The PEPCK reporter gene 
was transfected with an expression vector coding for rat HNF4al, in order to confirm 
activation of PEPCK reporter expression by HNF4a and assess the contribution of HNF4a to 
the regulation of PEPCK gene expression by fasting and feeding hormones (dexamethasone 
and insulin respectively). In order to investigate the role of PGC-1 a  in co-activation of 
HNF4a, the effect of co-transfection with PGC-1 a  and HNF4a expression vectors on 
PEPCK reporter plasmid expression was also investigated.
The HNF4a expression vector was changed fi'om one coding for human HNF4a2 
(pcDNA3.HA.liHNF4a2), used in experiments with L-PK reporter plasmids (Section 4.3), to 
a rat HNF4al expression vector (PCR3.HNF4), as it was noted that the latter activated 
SREBP-lc reporter gene expression more effectively than the hirrnan HNF4a2 vector (data 
not shown).
4.4.2 Results
Overexpression of rat HNF4al produced a 50-fold increase in PEPCK reporter gene 
expression over basal levels, confirming HNF4a as a positive regulator of PEPCK expression 
(Figure 4.4). Incubation of the transfected cells with 1 pM insulin for 24 hours did not alter 
the level of HNF4a-stirnulated PEPCK reporter gene expression, whilst incubation with 1 
pM dexamethasone produced a 40% decrease in expression. Co-transfection witli the co­
activator PGC-1 a  halved the HNF4a-stimulated induction of PEPCK reporter gene 
expression, suggesting that PGC-1 a  represses HNF4a under control incubation conditions 
(i.e. the absence of external metabolic stimuli).
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Figure 4.4: Regulation of PEPCK reporter by rat HNF4al, insulin, dexamethasone and 
PGC-la. HepG2 cells were transfected with a luciferase reporter gene containing the PEPCK 
proximal promoter (-467/+65), pSEAPI-3’rep as an internal transfection control, together with 
expression vectors for rat HNF4al (25 ng/well), PGC-la (25 ng/well) or control pSG5 as 
indicated. After transfection, cells were incubated with the standard transfection medium or 
media containing 1 pM insulin or 1 pM dexamethasone (Dex.). Data is expressed as mean 
values ± SEM (n = 4), relative to the condition: + HNF4a. Differences between conditions 
were analysed by one-way ANOVA with Tukey’s post-hoc test: *** p < 0.001.
4.5 Regulation of SREBP-1c reporter gene expression by HNF4a, 
metaboiic stimuii and co-activators
4.5.1 Rationale
The regulation of SREBP-lc gene expression by HNF4a was studied in HepG2 cells using a 
reporter plasmid containing the human SREBP-lc proximal promoter region (-780/+62 
relative to the transcription start site). This region contains a putative binding site for HNF4a 
(Tarling et a i, 2004). HNF4a overexpression was utilised to confirm HNF4a as a positive 
regulator of SREBP-lc expression and to assess the factors important in HNF4a-dependent 
activation of SREBP-lc expression. As feeding stimuli are important inducers of SREBP-lc 
expression in vivo (Kim et a l, 1998), the influence of insulin and glucose concentration in the 
cell culture medium were investigated. The interaction of HNF4a with co-factors in
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transcriptional regulation of SREBP-lc expression was studied by co-expression of PGC-la 
or p300.
4.5.2 Results
4.5.2.1 Regulation of SREBP-lc reporter gene expression by HNF4a,
insulin, glucose and PGC-la
The modulation of SREBP-lc reporter gene expression by HNF4a, insulin, glucose and 
PGC-la was studied in HepG2 cells (Figure 4.5). Two different expression vectors were 
used for HNF4a overexpression: one expressing the rat HNF4al coding sequence (Figure 
4.5A) and anotlier expressing tlie human HNF4al coding sequence (Figure 4.5B), enabling 
the comparison of species differences between rat and human HNF4a in human hepatoma 
cells.
Basal SREBP-lc reporter gene expression in the absence of exogenously expressed HNF4a 
was relatively low and a stimulatory effect of insulin could not be detected. Overexpression 
of rat TINF4al resulted in a mean 42-fold increase in reporter gene expression (Figure 4.5 A) 
and overexpression of human HNF4al led to a mean 18-fold increase in reporter gene 
expression (Figure 4.5B). Incubation with 1 pM insulin increased the level of HNF4a-driven 
reporter gene expression a further 41% in tlie case of tlie rat HNF4al vector and 76% in the 
case of the human HNF4al vector under 5.5 mM glucose conditions (Figuie 4.5A and B 
respectively). Incubation under high glucose (25 iiiM) conditions did not alter the level of 
HNF4a-stiniulated reporter gene expression relative to standard glucose conditions (5.5 
niM). The induction of HNF4a-driven reporter gene expression by insulin was similai' under 
25 mM glucose conditions as under standard glucose levels (5.5 mM), with a 60% increase 
observed for botli rat and liimian HNF4a vectors (Figure 4.5A and B).
Overexpression of both HNF4a and PGC-la produced a decrease in SREBP-lc reporter 
gene expression compared to HNF4a alone, with a significant reduction of 60% being 
obseiwed for the rat HNF4al vector and a non-specific decrease of 44% for the human 
HNF4al vector (Figure 4.5A and B).
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SREBP-lc reporter expression following incubation witli insulin-containing medium was 
also suppressed by co-transfection of PGC-la, with a reduction of 63% relative to HNF4a 
overexpression alone for both rat and human HNF4al vectors (Figure 4.5 A and B).
4 5.2.2 Effect of HNF4a levels on SREBP-lc reporter gene expression
In order to confirm that HNF4a positively regulates SREBP-lc reporter gene expression in a 
concentiation-dependent manner, HepG2 cells were tiansfected with the SREBP-lc reporter 
gene and a range of HNF4a vector concentrations (Figure 4.6). The concentiation of rat 
HNF4al expression vector showed a good correlation with the level of SREBP-lc reporter
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Figure 4,6: Concentration-dependent regulation of SREBP-lc reporter gene expression 
by HNF4a. HepG2 cells were transfected with a SREBP-lc promoter (-780/+62) reporter 
gene, pSEAPI-3’rep as an internal transfection control, together with variable amounts of rat 
or human HNF4al vector as indicated. After transfection, cells were incubated with the 
standai'd transfection medium containing 1 pM insulin. Corrected luciferase readings are 
expressed relative to the condition: + 25 ng/well rat HNF4al vector and as mean values ± 
SEM (n = 4). Correlation analysis is indicated by dashed lines and the Pearson correlation 
coefficient (R^) and associated significance levels (p) are indicated.
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gene expression witliin the range 0 -1 0 0  ng/well expression vector (R  ^= 0.98, p  < 0.01) 
(Figui’e 4.6). The concentration of the human HNF4al expression vector also positively 
coiTelated with the expression of the SREBP-lc reporter gene in the range 0 -50  ng/well 
expression vector (R  ^= 0.83,p  < 0.01), however reporter gene expression appeared to 
approach a plateau at a concentration of greater than 50 ng/well.
4.5.2.3 Effect of HNF4a co-activators PGC-la and p300 on SREBP-lc 
reporter gene expression
In initial experiments investigating HNF4a-dependent regulation of SREBP-lc reporter 
plasmid expression (Section 4.5.2.1), PGC-la overexpression was shown to reduce SREBP- 
lc reporter gene transcription when co-tiansfected with an expression plasmid for rat 
HNF4al under both standard incubation conditions and in the presence of 1 pM insulin 
(Figure 4.5A) and with an expression plasmid for human HNF4al under in the presence of 1 
pM insulin (Figure 4.5B). To investigate whether this effect occurred in a concentiation- 
dependent manner, SREBP-lc reporter expression was studied over a range of PGC-la 
concentrations with a constant amount of either rat or human HNF4al expression vector 
(Figuie 4.7A and B). Incubation conditions containing 1 pM insulin were chosen as these 
produced maximum HNF4a-activated reporter gene expression in initial experiments (Figure
4.5).
SREBP-lc reporter gene expression showed inverse correlation with increasing levels of 
PGC-la. When rat HNF4al was overexpressed, a dose-dependent decrease was observed in 
the range 1 - 3 0  ng/well PGC-la expression vector, however this fell short of statistical 
significance (R  ^= 0.24, jo = 0.05) (Figure 4.7A). When human HNF4al was overexpressed, 
SREBP-lc reporter gene expression showed inverse correlation with PGC-la expression 
vector levels in the range 10-100 ng/well expression vector (Figure 4.7B).
The effect of p300 on HNF4a-activated SREBP-lc reporter gene expression was tested over 
a range of p300 vector concentrations (Figure 4.8). When rat HNF4al was overexpressed, 
p300 overexpression produced inverse correlation with SREBP-lc reporter gene levels across 
the tested range (0 -3 0  ng/well expression vector). In the case of human HNF4al 
overexpression, an diverse correlation of SREBP-lc reporter gene levels and p300 expression
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vector concentration was obseiwed between 0 and 20 ng/well, with reporter gene expression 
approaching a plateau level at 30 ng/well expression vector.
140%
120%
I -
»  100% 1
80%
a  60%
g 40%
20%
0%
i - . .
R® = 0.24 (p = 0.05)
SREBP-lc reporter 
plasmid + rat HNF4al 
expression vector
"I
10 20 30 40 50 60 70 80
PGC-la expression vector (ng/well)
90 100
B 140%
120%
100%
80% -
jg 60% -
© 40% -
20%
0%
SREBP-lc reporter 
plasmid + human 
HNF4al expression 
  vector
R* = 0.86
(p < 0.01)
Ü
10 20 30 40 50 60 70 80
PGC-la expression vector (ng/well)
90 100
Figure 4.7; Effect of PG C -la concentration on HNF4a-stiraulated SREBP-lc reporter 
gene expression. HepG2 cells were transfected with a SREBP-lc reporter plasmid and (A) 
rat or (B) human HNF4al expression vectors (25 ng/well) and a range of concentrations of 
PGC-la expression vector as indicated. After transfection, cells were incubated in STM 
containing 1 pM insulin for 24 horns. Corrected luciferase readings are expressed relative to 
the condition: 0 ng/well PGCl-a for each HNF4a expression vector. Mean values ± SEM (n 
= 4) are displayed alongside correlation analyses (dashed lines) with the Pearson correlation 
coefficient (R^) and associated significance levels (p).
132
120%
100%
80%
g, 60%I
S ’ 40%
œ 20%
0%
SREBP-lc reporter 
plasmid + rat HNF4al 
expression vector
R^=0.80
(p<0.01)
10 15 20
p3O0 exp ress ion  vector (n g/w ell)
25 30
B 120%
100%
I  80%
S' 60%
g  40%
20%
0%
SREBP-lc reporter 
plasmid + human 
HNF4al expression 
vector
I  'A
R^  = 0.88
(p<0.01)
10 15 20
p300 exp ression  vector (ng/w ell)
25 30
Figure 4.8; Effect of p300 concentration on HNF4a-stimuIated SREBP-lc reporter gene 
expression. HepG2 ceils were transfected with a SREBP-lc reporter gene and (A) rat or (B) 
human I-INF4al expression vectors (25 ng/well) and a range of concentrations of p300 
expression vector as indicated. After transfection, cells were incubated in STM containing 1 
pM insulin for 24 hours. Corrected luciferase readings are expressed relative to the condition: 
0 ng/well p300 for each HNF4a expression vector. Mean values ± SEM (n = 4) are displayed 
alongside correlation analyses (dashed lines) with the Peaison conelation coefficient (R^) and 
associated significance levels (p).
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4.S.2.4 Effect of insulin concentration on SREBP-lc reporter gene 
expression
In order to investigate the effect of insulin concentration on SREBP-lc reporter expression 
and the role of HNF4a in the effect of insulin, HepG2 cells were transfected with the 
SREBP-lc reporter plasmid with control, rat HNF4al or human HNF4al expression vectors 
(Figure 4.9A, B and C respectively), and then incubated with a range of insulin 
concentrations for 24 hours.
The insulin concentration of FBS measured using an ELISA assay was found to be 9.7 pM. 
Therefore, the insulin concentration of standard transfection medimn (STM) due to the 
presence of 3% FBS was calculated to be 0.3 pM, corresponding to the lowest point of the 
range displayed as log[Insulin(M)] = -12.5 (Figure 4.9). It was important to establish the 
insulin concentiation of FBS as insulin has been shown to have effects on gene expression at 
the levels found in FBS (Hasty et a l, 2000).
SREBP-lc reporter gene expression in the absence of FINF4a overexpression (Figure 4.9A) 
resulted in approximately 100-fold lower reporter gene expression relative to the level of 
reporter gene expression in the presence of rat HNF4al overexpression (Figuie 4.9B), 
therefore the inset to Figure 4.9A shows SREBP-lc reporter gene expression on a lai'ger scale 
(0-2.2%, as opposed to 0-220%). In tlie absence of HNF4a overexpression, no correlation of 
SREBP-lc reporter gene expression with insulin concentration in the medium was observed 
(Figure 4.9A inset).
SREBP-lc reporter gene expression showed a positive correlation with insulin concentration 
in the presence of both rat and hmnan HNF4al overexpression, with greatest correlation 
between 0.3 pM and 100 nM insulin (Figiae 4.9B and C). Maximimi SREBP-lc reporter 
gene expression was observed at 100 nM insulin, with 20-40% higher expression observed 
compared to 1 pM insulin, the concentration tested in initial experiments with the SREBP-lc 
reporter plasmid (Figiue 4.5).
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Figure 4.9: Insulin-dependeiice of SREBP-lc reporter gene expression in the presence 
of (A) control (B) rat or (C) human HNF4al expression vectors. HepG2 cells were 
transfected with a SREBP-lc promoter reporter plasmid with the indicated control (pSG5) 
(A) or HNF4a expression vectors as previously (B,C) (Figure 4.5). After transfection, cells 
were incubated in STM containing a range of insulin concentrations. Corrected luciferase 
readings are expressed relative to the condition: + rat HNF4al (STM without added insulin). 
Mean values are plotted ± SEM (n = 4). Correlation analyses are indicated by dashed lines 
witli the Pearson correlation coefficient (R^) and associated significance levels (p).
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4.6 Discussion
In tliis chapter, the overall aim of studying the impact of fasting and feeding stimuli on 
HNF4a activity was investigated using reporter gene constructs containing sequences from 
the L-PK, PEPCK and SREBP-lc, representing key genes in the metabolic control of 
glycolysis, gluconeogenesis and lipogenesis.
In respect to the initial objective of comparing the effects of liigh glucose, insulin and other 
hormones on L-PK reporter gene expression in HepG2 cells with results in primary 
hepatocytes, it was foimd that the expression of an L-PK reporter gene construct containing 
both ChREBP (L4) and HNF4a (L3) binding sites was inducible by high glucose 
concentiation (Figui e 4.1), in agreement with the behavioui' of the reporter constmct in 
primary hepatocytes (Gourdon et a l, 1999). The level of induction differed between HepG2 
cells and primary rat hepatocytes, ivith 25 mM glucose inducing a five-fold increase in 
(L4L3)4-54PK reporter gene expression in HepG2 cells (Figure 4.1) compared to a 51-fold 
increase in primary rat hepatocytes (Gourdon et a l, 1999). The level of induction by high 
glucose in HepG2 cells could be lower due to a number of reasons. Firstly, species 
differences could mean that the rat L-PK promoter is less responsive to glucose in hmnan 
liver cells than in rat hepatocytes. Secondly, hepatoma cell lines are likely to be less sensitive 
to glucose levels than primaiy hepatocytes (Meienhofer et a l, 1987), The (L3)3-54PK 
reporter plasmid containing only HNF4a binding sites (L3) and the 54 bp proximal promoter 
region, was not inducible by 25 mM glucose-containing medium (Figine 4.1), which is also 
in line with previous results (Gomdon et ah, 1999).
The (L4L3)4-54PK reporter plasmid was induced by 25 mM glucose in the absence of added 
hormones (Figme 4.1), suggesting that the concentration of insulin, tiiiodo-L-thyronine and 
glucocorticoid hormones in the serum component of the medium (3%) is sufficient. 
Alternatively, the tliree hormones are not required for the observed effect of high glucose in 
HepG2 cells. The combination of insulin, triiodo-L-thyronine and glucocorticoids was shown 
to be required for the induction of L-PK in the refed state in vivo (Munnich et a l, 1984). Ex 
vivo studies of (L4L3)4-54PK reporter gene expression in primary rat hepatocytes were also 
conducted in the presence of 100 nM insulin, 1 pM ti iiodo-L-thyronine and 1 pM 
dexamethasone (Gomdon et a l, 1999).
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HNF4a positively regulated the expression of the (L3)3-54PK reporter gene in HepG2 cells, 
as demonstiated by the substantial increases in reporter gene expression activity observed 
upon HNF4a overexpression (Figure 4.2). HNF4a overexpression also increased the 
expression of the (L3)3-54PK reporter gene in primary rat hepatocytes (Gourdon et al,
1999), although the fold-change (less tlian two-fold) was not as maiked as that in HepG2 
cells (over 35-fold), suggesting lower endogenous HNF4a activity in HepG2 cells compared 
to primaiy liver cells.
Insulin did not have a consistent effect on the expression of the (L3)3-54PK reporter gene in 
presence of HNF4a overexpression: a reduction of (L3)3-54PK reporter gene expression was 
observed in one experiment (Figuie 4.3), whilst insulin had no effect in a subsequent 
experiment (Figure 4.2). On the other hand, insulin increased the expression of the (L4L3)4- 
54PK reporter gene under conditions of both standai'd and high glucose concentrations 
(Figure 4.2). These results suggest that insulin activates HNF4a via its interaction with 
ChREBP at the L-PK promoter; indeed, the functional cooperation and contiguity of the L4 
(ChREBP) and L3 (HNF4a) elements has been foimd to be important in mediating the 
transcriptional response of tlie L-PK gene to feeding stimuli (Bergot et a l, 1992; Diaz Guerra 
et a l, 1993; Liu and Towle, 1995).
High glucose did not sthmilate the expression of the (L4L3)3-54PK reporter gene when 
HNF4a was overexpressed (Figure 4.2), in contrast to results in the absence of HNF4a 
overexpression (Figure 4.1). Possibly, CliREBP levels become limiting in the presence of 
HNF4a overexpression and prevent significant induction of the (L4L3)4-54PK reporter 
plasmid by high glucose concentration.
Incubation of HepG2 cells with glucagon, or glucagon and dexamethasone, did not change 
the expression of the (L3)3-54PK reporter gene compared to control conditions (Figure 4.3). 
In contrast, the activity of (L3)3-54PK reporter was strongly repressed by cAMP, a second 
messenger of glucagon, in primaiy rat hepatocytes (Gourdon et a l, 1999). HNF4a DNA- 
binding activity was previously shown to be reduced in nucleai' extiacts from the livers of 
fasted rats or following treatment of nuclear extracts with glucagon (Viollet et a l, 1997), 
however the lack of inliibition of (L3)3-54PK reporter gene expression by glucagon in
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HepG2 cells suggests that glucagon does not modulate HNF4a activity in a similar maimer in 
this cell line.
Dexamethasone did not alter (L3)3-54PK reporter plasmid activity (Figure 4.2), suggesting 
that this fasting stimulus does not alter HNF4a activity at the L-PK promoter, and that an 
interaction between HNF4a and GR is not relevant to the modulation of HNF4a activity in 
the context of the L-PK promoter. This result is in keeping with published results showing 
that glucocorticoids exert their effects of L-PK mRNA expression at a post-transcriptional, 
rather than at a transcriptional level (Vaulont et a l, 1986).
HNF4a overexpression stimulated PEPCK reporter gene expression, confirming HNF4a as a 
positive regulator of PEPCK reporter gene expression, in agreement with published work 
(Yamamoto et a l, 2004). Incubation with 1 pM insulin did not alter the level of HNF4a- 
stimulated PEPCK reporter gene expression (Figuie 4.4). In vivo, insulin inhibits both basal 
and cAMP and/or dexamethasone stimulated PEPCK expression (O'Brien and Granner,
1996), however the inliibitory effect of insulin was not apparent on basal PEPCK reporter 
gene expression performed in HepG2 or rat hepatoma H4IIE cells, with insulin exerting an 
inhibitory effect on cAMP- and dexamethasone-stimulated PEPCK reporter gene expression 
(Xing and Quimi, 1993; Rucktaeschel et a l, 2000). This result indicates that insulin does not 
activate or repress HNF4a when boimd to the PEPCK promoter. This result also provides 
confirmation that the stimulatory effect of insulin on HNF4a-driven L-PK and SREBP-lc 
reporter gene expression is promoter-specific (Figuies 4.3 and 4.5).
Incubation of HepG2 cells with dexamethasone reduced HNF4a-dependent PEPCK reporter 
gene levels by 40% (Figure 4.4). This is in contrast to the stimulatory action of 
dexamethasone on PEPCK niRNA expression in rat liver in vivo and on PEPCK reporter 
gene expression in H4IIE cells (Earners et a l, 1982; Xing and Quinn, 1993). However, 
dexamethasone has previously been shown to have a negative action on PEPCK reporter gene 
expression in HepG2 cells: When PEPCK reporter plasmid activity was stimulated by 
overexpression of PKA, incubation with dexamethasone brought about a 40% reduction in 
expression levels (Xing and Quinn, 1993). Furthermore, it was demonstiated that 
dexamethasone induces proteasomal degradation of the GR in HepG2 cells, resulting in 
decreased PEPCK mRNA expression (Sengupta and Wasylyk, 2001). In this manner, the
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reduction in GR protein levels brought about by dexamethasone in HepG2 cells could limit 
HNF4a-dependent PEPCK reporter expression, as HNF4a is known to interact 
synergistically with the GR in activating PEPCK gene expression (Hall et a l, 1995; Wang et 
a l, 1999; Stafford et a l, 2001).
PGC-la has previously been shown to stimulate hepatic gluconeogenic gene expression and 
its interaction with HNF4a is essential in mediating this effect (Yoon et a l, 2001; Rliee et 
a l, 2003). In light of this, the reduction in PEPCK reporter gene expression by co­
transfection of HNF4a and PGC-la compared to HNF4a alone is surprising (Figure 4.4), 
however it possible that additional stimuli such as glucocorticoids and/or glucagon are 
required to mediate die synergistic interaction of HNF4a and PGC-la. PGC-la is known to 
be activated through phosphorylation by p38 MAPK downstream of glucagon signalling 
(Puigserver et a l, 2001; Fan et a l, 2004; Cao et a l, 2005), therefore potentially the 
phosphorylation state of PGC-la under the basal incubation conditions does not permit its 
co-activation of HNF4a (Figiue 4.4).
Overexpression of eitlier rat or human HNF4al increased SREBP-lc reporter gene 
expression in HepG2 cells (Figure 4.5), in agreement with experiments employing the same 
reporter gene and HNF4a overexpression in rat hepatoma McA-RH7777 cells (Tarling et a l, 
2004). The fold-change upon HNF4a overexpression differed somewhat between the studies 
in HepG2 and McA-RH7777 cells, with HNF4al overexpression producing 42- and 18-fold 
increases in reporter gene levels over basal expression levels for the rat and human HNF4al 
expression vectors respectively (Figure 4.5A and B), wliilst FINF4al and HNF4a2 
overexpression resulted in 0.5- and 3-fold increases respectively in McA-RH7777 cells 
(Tarling et a l, 2004). Differences in the experimental parameters in terms of cell nmnbers or 
transfection efficiency of the two cell lines could explain the low basal SREBP-lc reporter 
gene expression in HepG2 cells. Alternatively, higher endogenous HNF4a activity in McA- 
RH7777 cells could be responsible for the smaller fold-changes observed upon HNF4a 
overexpression compared to HepG2 cells. The large increases in SREBP-lc reporter gene 
expression upon HNF4a overexpression suggest that HNF4a activity could be one of the 
factors limiting SREBP-lc expression in HepG2 cells.
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Overexpression of rat HNF4al produced greater induction of SREBP-lc reporter gene 
expression over basal levels (42-fold) compared to human HNF4al (18-fold) (Figure 4.5A 
and B). The observed disparity could stem from differences in the efficiency of the 
promoters driving their expression, or alternatively the rat and human proteins could be 
metabolised differently within human HepG2 cells, for example, in their rates of degradation. 
The relationship between HNF4a expression vector concentration and SREBP-lc reporter 
gene levels also differs between the two HNF4a vectors, with SREBP-lc reporter gene 
expression approaching a plateau in the range 50-100 ng/well in the case of the human 
HNF4a expression vector, whilst rat HNF4a expression vector concentration positively 
correlated with SREBP-lc reporter gene expression throughout the tested range (0 -100  
ng/well) (Figure 4.6). These results also suggest that human HNF4al protein is metabolised 
differently to rat HNF4al in HepG2 cells.
The influences of insulin and glucose concentration on FINF4a-dependent activation of 
SREBP-lc reporter gene expression were also investigated. When HNF4a was 
overexpressed, SREBP-lc reporter gene expression was enhanced a further 40-80% in 
response to incubation with 1 pM insulin compared to STM (Figure 4.5). Insulin had a 
concentration-dependent effect on the SREBP-lc reporter gene, with maximal expression at 
100 iiM insulin (Figure 4.9). A decrease in SREBP-lc reporter gene expression was 
observed at 1 pM compared to 100 nM insulin, suggests a blimting of the cellular response to 
insulin at the higher concentration (Figrue 4.9). This could be due to increased down- 
regulation of the insulin receptor and downstream pathways at the higher concentration 
(Frittitta et a l, 2000).
Conditions of high glucose concentration (25 mM), on the other hand, did not significantly 
alter HNF4a-dependent SREBP-lc expression in the presence or absence of insulin (Figure
4.5). This agi’ees with other studies using a reporter gene approach that showed insulin 
stimulated SREBP-lc reporter gene expression, whilst high glucose had no effect (Deng et 
al, 2002; Dif et a l, 2006). Overall, the induction of HNF4a-dependent SREBP-lc reporter 
gene expression by insulin suggests that insulin increases HNF4a transcriptional activity 
when bound to this promoter. Insulin could promote the formation of a transcriptionally 
active complex via changes in phosphorylation or nuclear abundance of HNF4a and other 
transcription factors involved (Mournier and Posner, 2006).
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Other transcription factors which bind to downstieani sites in the SREBP-lc promoter 
(Figuie 4.10) have been shown to contiibute to the mechanism by which insulin up-regulates 
SREBP-lc expression. Reporter gene constructs containing the -571/+90 and -257/+90 bp 
regions from the human SREBP-lc promoter aie also stimulated in response to insulin in 
HEK-293 cells (Dif et a l, 2006). The -571/+90 region of the human SREBP-lc promoter 
contains two liver X receptor elements (LXREs) and two downstream sterol response 
elements (SREs), which ai e one of the consensus binding motifs for SREBPs. Both LXR and 
SREBPs have been proposed to play a role in the induction of SREBP-lc expression by 
insulin, hi hepatocytes, LXR was shown to play a central role in the induction of mouse 
SREBP-lc reporter gene expression by insulin (Chen et a l, 2004), whilst the combinatorial 
action of SREBP, Spl, nucleai* factor Y (NF-Y) and LXR were foimd to contribute to the 
effect of insulin on tlie rat SREBP-lc reporter gene (Cageii et a l, 2005). These findings 
suggest that interactions of HNF4a with one or more the aforementioned transcription factors 
could be important in mediating the stimulatoiy effect of insulin.
The presence of a putative HNF4a binding site in the human SREBP-lc promoter suggests 
that HNF4a could have a role in the tissue-specific expression of SREBP-lc in the liver and 
otlier organs which express HNF4a, such the pancreas and small intestine. Compaied to 
adipose tissue and muscle, where SREBP-lc iiiRNA levels return to the levels of control 
animals upon refeeding after a period of fasting, SREBP-lc gene expression in liver is 
induced ~ 5-fold above control values upon refeeding (Gosniain et a l , 2005). The induction 
of SREBP-lc in the liver in the absorptive state could be related to its exposuie to higher 
levels of insulin than peripheral tissues (Frayn, 2003) and suggests that specific mechanisms 
in hepatocytes, which transmit signals downstream of insulin, facilitate the expression of
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Figure 4.10: In silico analysis of the mouse and human SREBP-lc promoter regions.
Mouse and human SREBP-lc proximal promoter regions were analysed in silico for 
transcription factor binding sites (Tarling et a l, 2004).
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SREBP-lc, enabling utilisation of dietaiy carbohydrate in the synüiesis of fatty acids.
HNF4a could serve to amplify the stimulatory effects of insulin on SREBP, LXR or other 
transcription factors involved to induce SREBP-lc gene expression in the liver. Interestingly, 
a binding site for PDX-1 is present upstream of the HNF4a binding site within the human 
SREBP-lc promoter region (Figure 4.10). PDX-1 is a key transcription factor in the glucose- 
sensitive transcription of the insulin gene (Melloul et a l, 1993), therefore the proximity of 
the PDX-1 and HNF4a binding sites suggests that their interaction could be important in the 
nutritional regulation of the SREBP-lc gene in the pancreas.
HNF4a-dependent transactivation of SREBP-lc reporter expression was repressed by PGC- 
la , when co-transfected in both equal amounts as HNF4a and across a range of 
concentrations, up to a four-fold ratio of PGC-1 a:HNF4a expression vector DNA (Figure 4.5 
and Figuie 4.7). Tliis suggests that PGC-la does not co-activate HNF4a in promoting 
SREBP-lc gene expression and potentially represses HNF4a activity or disrupts HNF4a 
interactions with otlier proteins in the SREBP-lc promoter. PGC-la overexpression reduces 
the induction of SREBP-lc reporter gene expression by insulin from 41% to 29% in the case 
of rat HNF4a and from 76% to 14% in the case of human HNF4a overexpression (Figure 
4.5 A and B respectively). This suggests that repressive effect of PGC-la on HNF4a activity 
is greater in the presence of insulin. As PGC-la has been shown to be activated by 
phosphorylation downstream of glucagon and cAMP (Cao et a l, 2005), insulin signalling 
could potentially reduce PGC-la phosphorylation and activation via stimulation of cAMP 
phosphodiesterases (PDEs) which reduce intracellular cAMP levels (Houslay and Kilgoui*, 
1990). Dephosphorylated PGC-la shows enhanced interaction with co-repressors, such as 
plbo^BP 2001 ; Fan et a l, 2004), therefore PGC-la could potentially recruit
co-repressors to the SREBP-lc promoter under fed conditions corresponding to raised insulin 
concentration.
Alternatively, PGC-la-mediated disruption of HNF4a-dependent SREBP-lc expression 
could act via the adjacent LXRE in the SREBP-lc promoter. PGC-la has been shown to co- 
activate LXRiRXR heterodimers in the activation of himian SREBP-lc reporter gene 
expression by oxysterols and 9-cis retinoic acid in HepG2 cells (Oberkofler et a l, 2004). 
Possibly LXR activation by PGC-la prevents HNF4a binding to its cognate site in the
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SREBP-lc promoter, in a similar manner to the LXR-mediated displacement of HNF4a at 
the apoAI promoter in response to LXR ligands (Huuskonen et a l, 2006).
}
Overexpression of the co-activator p300 also led to a dose-dependent decrease in HNF4a- 
dependent SREBP-lc expression in the presence of insulin (Figuie 4.8), likewise suggesting 
that p300 could be disrupting the interaction(s) of HNF4a with other transcription factors or 
co-factors. p300 and closely related co-activator CBP have been shown to potentiate HNF4a 
transcriptional activity and promote nuclear retention by acétylation of HNF4a (Yoshida et 
al, 1997; Dell and Hadzopoulou-Cladaras, 1999; Soutoglou et a l, 2000; Eeckhoute et a l,
2001). However the magnitude of enhancement of HNF4a activity by co-expression of p300 
was found to be promoter-specific using reporter constructs of different apolipoprotein gene 
promoters (Torres-Padilla and Weiss, 2003). p300 has been shown to be a substrate for 
protein kinase B (PKB/Alct) downstream of insulin and, whilst phosphoiylation of p300 has 
been linlced to insulin-stimulated expression of glucoldnase by a complex including HNF4a 
and hypoxia inducible factor-1 (HIF-1), phosphorylation of p300 on Ser-1834 also disrupts 
its interaction with CAAT/enhancer-bindiiig protein-a (C/EBPa) (Guo et a l, 2001; Roth et 
a l, 2004). The latter scenario could occur in the interaction of p300 with HNF4a in the 
context of the SREBP-lc promoter, as the effect of p300 co-transfection was not tested in the 
absence of insulin.
In summaiy, the combination of raised glucose concentration and insulin stimulated L-PK 
reporter gene expression for constructs containing both HNF4a and ChREBP binding sites, 
but not those containing only HNF4a binding sites. HNF4a overexpression increased the 
expression of L-PK reporter genes, with an additive effect of insulin for the construct 
containing HNF4a and CliREBP binding sites, whilst none of the metabolic stimuli tested 
modulated L-PK reporter gene expression for the construct containing only HNF4a-binding 
sites. HNF4a overexpression also stimulated PEPCK reporter gene expression, with 
incubation with dexamethasone or co-transfection of PGC-1 a  leading to reduced reporter 
gene levels. Insulin did not modulate PEPCK reporter gene expression. Lastly, HNF4a- 
activated SREBP-lc expression was stimulated by incubation of HepG2 cells with insulin, 
but not high glucose concentration. PGC-la and p300 repressed SREBP-lc reporter gene
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expression when co-ti'ansfected with HNF4a, indicating that these co-factors compete with 
other HNF4a partners when bound to the SREBP-lc promoter.
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Chapter 5
Regulation of lipogenic and glycolytic 
mRNA expression in HepG2 cells by 
HNF4a and insulin
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Chapter 5:
5.1 Introduction
The expression of SREBP-lc and L-PK reporter plasmids was found to be positively 
regulated by HNF4a overexpression and incubation of HepG2 cells witli insulin (Chapter 4). 
In order to investigate whether HNF4a target genes in their endogenous chiomatin-bound 
form were regulated in the same manner by HNF4a overexpression and insulin, the mRNA 
expression of SREBP-lc, L-PK and other target genes was studied in FIepG2 cells using a 
quantitative real-time (Q-PCR) approach. Overexpression of HNF4a has previously been 
shown to increase the expression of a range of HNF4a tar get genes in HepG2 cells and to 
activate functions associated with the hepatic phenotype such as brealcdown of ammonia 
(Naiki et al., 2004).
Hypothesis
FINF4a, in the presence of insulin, up-regulates lipid synthesis by regulating the expression 
of genes involved in glycolysis and lipogenesis.
Aims:
• To demonstiate, using real-time Q-PCR, that HepG2 cells increase the expression of 
SREBP-lc and SREBP-lc tai’get genes (ACC, FAS) when tiansfected with a human 
HNF4a expression plasmid.
• To investigate up-regulation of other HNF4a target genes in the glycolytic (L-PK) and 
lipogenic (FAS) pathways by insulin.
Objective 1: To identify stable housekeeping genes in HepG2 cells under conditions of 
HNF4a overexpression and incubation with insulin, for the purpose of relative quantification 
of tai'get gene expression.
Objective 2: To detennine the relative mRNA expression levels of lipogenic (SREBP-lc,
SREBP-2, ACC, FAS) and glycolytic (L-PK) genes in HepG2 cells following HNF4a 
overexpression and incubation with insulin-containing vs. control medium (STM).
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Objective 3: To assess the time- and concentration-dependence of insulin action on SREBP- 
Ic mRNA expression in HepG2 cells.
5.2 Identification of stabie housekeeping genes in HepG2 ceiis
5.2.1 Rationale
The choice of housekeeping gene (also known as reference gene) used for relative 
quantification of gene expression is an important factor in the accurate quantification of 
tai'get gene expression under different experimental conditions (Thellin et al., 1999). 
Therefore the most stably expressed housekeeping genes under the experimental conditions 
to be used in investigating the impact of HNF4a overexpression on SREBP-lc mRNA 
expression (Objective 2) were analysed using the GeNorm approach (Vandesompele et al.,
2002) (see Section 2.2.8.8). The relative stability of six different housekeeping genes was 
analysed: 18S rRNA, (3-2-microglobulin (B2M), cytoclirome c-1 (CYCl), eukaryotic 
tianslation initiation factor 4A (EIF4A2), topoisomerase 1 (TOPI) and ubiquitin C (UBC).
Both rat and human HNF4al expression vectors were utilised previously in analysing the 
regulation of SREBP-lc reporter plasmid expression by HNF4a (Section 4.5). The human 
HNF4al expression vector was chosen for further experiments to eliminate any possible 
species-specific effects of rat HNF4al in a human cell line (discussed in Section 4.6). As 
only a single HNF4a expression vector was used for this and subsequent experiments, 
overexpression of human HNF4al will be referred to as HNF4a overexpression hereafter.
5.2.2 Results
The stability of expression of six housekeepmg genes following transfection with human 
HNF4al or control expression vectors and incubation in the presence or absence of insulin 
was assessed using the GeNorm method (Figure 5.1). Two independent expermients were 
performed in order to confirm that the ranking of housekeeping gene stability did not differ 
significantly due to valuation between biological repeats (Figui’e 5.1A and B). 18S and 
EIF4A2 were ranlced as the least stable genes in both experiments; in compaiison, B2M was 
ranked in the two most stably expressed genes in both analyses and was therefore chosen as 
die housekeeping gene for relative quantification of target gene expression.
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Figure 5.1: GeNorm analysis of most stable housekeeping genes in HepG2 cells. HepG2 
cells were ti'ansfected with a human HNF4al expression vector (125 ng/well) or control DNA 
(pcDNA3). 16 houi's after transfection, cells were incubated with STM ± 1 pM insulin for a 
fmther 24 hours, after which RNA was isolated and cDNA prepared. The expression of 18S, 
B2M, CYCl, EIF4A2, TOPI and UBC mRNA in samples ftom two independent experiments 
(A and B) was calculated using ACt values (Equation 2.3). The relative stability of the 
expression of the six housekeeping genes was analysed using tlie Genorm application for 
Microsoft Excel (Section 2.2.8.8).
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5.3 Effect of HNF4a overexpression and insulin on the regulation 
of lipogenic and giycoiytic gene expression in HepG2 ceiis
5.3.1 Rationale
The rcgulation of SREBP-lc mRNA expression by HNF4a and insulin in HepG2 cells was 
investigated by transfecting UepG2 cells with a HNF4a expression vector, followed by 
incubating the cells in the presence or absence of insulin for 24 houi's. The incubation time of 
24 hours was initially chosen because a 24 houi* incubation with insulin-containing medium 
was previously shown to increase HNF4a-dependent SREBP-lc reporter gene expression 
(Section 4.5). Likewise, the amount of HNF4a expression vector DNA (125 ng/well) was 
based on the amoimt of expression vector DNA used in experiments with the SREBP-lc 
reporter plasmid (25 ng/well) (Section 4,4), scaled up to reflect the larger well size of a 24- 
well plate compaied to a 96-well plate.
It was reasoned that if SREBP-lc expression were up-regulated following HNF4a 
overexpression, tlie expression of SREBP-lc target genes, ACC and FAS, would also 
increase (Oberkofler et al., 2004). The impact of HNF4a overexpression on the glycolytic 
gene (L-PK), also a target gene of HNF4a, was also assessed. The mRNA expression of 
HNF4a was measured in order assess efficiency of HNF4a overexpression. As two different 
genes for SREBP exist in the human genome (Yokoyama et a l, 1993; Hua et a l, 1993), 
SREBP-2 mRNA levels were also quantified in order to assess effects on SREBP-target 
genes not attributable to changes in SREBP-lc expression.
In order to investigate whether HNF4a overexpression led to changes in downstream target 
gene expression following incubation times of greater than 24 hours, timecour se experiments 
were also performed. It was reasoned that changes in HNF4a mRNA levels upon HNF4ot 
overexpr ession may take effect at tire protein level at a later time point than 24 hours 
(corresponding to 40 hours post-transfection). In turn, changes in SREBP-lc mRNA levels 
may also talce a longer time period to be revealed at the level of SREBP-lc downstream 
genes (ACC and FAS).
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5.3.2 Results
Figures 5.2 to 5.7 show the effects of HNF4a overexpressioii vs. control transfection on 
HNF4a and target gene expression prior to (0 h time point) and after incubation times of 24, 
48, 72, 96 or 144 hours with (a) control rnediimi (STM) or (b) STM containing 1 pM insulin. 
For the control incubation condition and for certain time points (72 and 144 horns) in the 
insulin-containing incubation condition, only a single biological replicate was performed. 
Statistical analysis by repeated measures ANOVA was performed with data ftom time points 
where a biological replicate was available.
HNF4a mRNA levels were significantly higher in HNF4a transfection condition compared 
to control vector (pcDNA3) after 24 and 48 hours incubation with insulin, while a difference 
in HNF4a expression levels between transfection conditions was not evident at the 0 h time 
point (Figure 5.2B). In the HNF4a transfection condition, HNF4a mRNA levels rose over 
200% after 24 and 48 hours incubation compared to levels at tlie 0 h time point (p < 0.01), 
with a drop in expression levels evident after 72 and 96 hours incubation (Figure 5.2B). On 
the other hand, a non-significant 50% decrease in endogenous HNF4a mRNA levels (control 
transfection) was observed after 48 hours incubation with insulin-containing medium (Figure 
5.2B). Under control incubation conditions (n =1), HNF4a mRNA levels were also higher 
following transfection with the HNF4a expression vector compared to control vector at tlie 
24 and 48 hours time points (Figure 5.2A).
After 24 hours incubation with insulin, SREBP-lc mRNA expression showed a modest 
increase (50%) under control transfection conditions (Figure 5.3B), although a 35% increase 
in SREBP-lc was also observed following 24 hours control incubation (Figure 5.3A). A 
64% rise in SREBP-lc expression was observed after 96 hours incubation with hisulin under 
conditions of HNF4a overexpressiori (Figure 5.3B). Maximal SREBP-lc expression was 
observed after 144 hours incubation with insulin, with rises of 290% and 100% observed for 
the control and HNF4a transfection conditions respectively (Figure 5.3B).
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Figure 5.2: Effect on HNF4a overexpression on HNF4a mRNA expression in 
HepG2 cells under (A) control and (B) 1 pM insulin incubation conditions. HepG2 
were transfected with a HNF4a expression vector (125 ng/well) or contr ol DNA 
(pcDNAS. 1). 16 hours after transfection (0 h time point), cells were incubated with STM 
± 1 pM insulin for 24-144 hours as indicated, after wliich RNA was isolated and cDNA 
prepar ed. The expression of HNF4a was quantified by Q-PCR and normalised to the 
expression of a housekeeping gene, B2M, and expressed relative to mean expression level 
of the contr ol transfection at the 0 h time point. Results are expressed as individual 
datapoints with 0 h time point data shown on both plots for purpose of comparison. The 
effects of HNF4a overexpression and incubation time on gene expression were analysed 
by repeated measures ANOVA where n > 1, with the results of Bonferroni post-hoc tests 
as indicated in the Key.
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Figure 5.3: Effect on HNF4a overexpression on SREBP-lc mRNA expression in 
HepG2 cells under (A) control and (B) 1 pM insulin incubation conditions.
Experiment and data analysis performed as detailed in Figure 5.2. Results are expressed 
as individual datapoints with 0 h time point data shown on botli plots for purpose of 
comparison. The effects of HNF4a overexpression and incubation time on gene 
expression were analysed by repeated measures ANOVA where n > 1, with the results of 
Bonferroni post-hoc tests as indicated in the Key.
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In the absence of insulin, little variation was apparent m ACC expression after different 
incubation time points or between transfection conditions (Figure 5.4A). In cells transfected 
with the control expression vector, ACC expression decreased with time following incubation 
with insulin-containing medium, with expression after 48 hours incubation 36% lower tlian at 
tire 0 h time point (p < 0.05), and after 96 hours incubation 48% lower than levels at the 0 h 
time point {p < 0.05) (Figure 5.4B). For cells transfected with a HNF4a expression vector 
and incubated with insulin, ACC expression rose 93% between the 24 and 96 hour time 
points (p < 0.01) and 87% between the 48 and 96 hours time points (p < 0.01) (Figure 5.4B). 
However, post-hoc tests did not identify direct differences in the expression of ACC between 
the control and HNF4a transfection conditions at any time pomt (Figure 5.4B). For both 
transfection conditions, maximal ACC expression was observed after 144 hours incubation 
with insulin (Figure 5.4B).
FAS expression did not show significant alterations following different incubation times or 
between transfection conditions (Figure 5.5). For the control transfection, FAS expression 
after incubation with insulin remained within a similar* range (65% -103%) to that imder 
control incubation conditions (89% -  119%) (Figure 5.5). In the case of HNF4a 
overexpression, FAS expression was within the range 53% -128% following incubation with 
insulin and in the range 32% - 106% under control incubation conditions (Figure 5.5).
Although statistical comparison was not possible due to data only being available ftom single 
experiments, L-PK showed a drop in expression at the 24 hoiu time point, with a gr eater than 
70% decrease observed for the HNF4a overexpression condition under both the control and 
insulin incubation conditions, and for the control transfection followed by incubation with 
insulin (Figure 5.6). L-PK levels after 48 hoius incubation with insulin were also 70% lower 
than those prior to the incubation (0 h time point) for both control and HNF4a transfection 
conditions (Figure 5.6B).
SREBP-2 expression did not appear to vary considerably with incubation time or between 
transfection conditions, although statistical comparison was again not possible due data only 
being available from a single experiment (Figiue 5.7).
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Figure 5.4: Effect on HNF4a overexpression on ACC mRNA expression in HepG2 
cells under (A) control and (B) 1 pM insulin incubation conditions. Experiment and 
data analysis performed as detailed in Figure 5.2. Results are expressed as individual 
datapoints with 0 h time point data shown on both plots for purpose of comparison. The 
effects of HNF4a overexpression and incubation time on gene expression were analysed 
by repeated measures ANOVA where n > 1, with the results of Bonferroni post-hoc tests 
as indicated in the Key.
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Figure 5.5: Effect on HNF4a overexpression on F AS mRNA expression in HepG2 
cells under (A) control and (B) 1 pM insulin incubation conditions. Experiment and 
data analysis performed as detailed in Figine 5.2. Results are expressed as individual 
datapoints with 0 h time point data shown on both plots for purpose of comparison. The 
effects of HNF4a overexpression and incubation time on gene expression were analysed 
by repeated measures ANOVA where n > 1, with no significant differences observed 
between conditions.
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Figure 5.6: Effect on HNF4a overexpression on L-PK mRNA expression in HepG2 
cells under (A) control and (B) 1 pM insulin incubation conditions. Experiment and 
data analysis performed as detailed in Figine 5.2. Results are expressed as individual 
datapoints with 0 h time point data shown on both plots for purpose of comparison. The 
effects of HNF4a overexpression and incubation time on gene expression were analysed 
by repeated measures ANOVA where n > 1, with no significant differences observed 
between conditions.
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Figure 5.7; Effect on HNF4a overexpression on SREBP-2 mRNA expression in 
HepG2 cells under (A) control and (B) 1 pM insulin incubation conditions.
Experiment and data analysis performed as detailed in Figure 5.2, Results are expressed 
as individual datapoints with 0 h time point data shown on both plots for puipose of 
compaiison. The effects of FINF4a overexpression and incubation time on gene 
expression were analysed by repeated measuies ANOVA where n > 1, with no 
significant differences observed between conditions.
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5.4 Time- and concentration- dependence of insulin action on 
SREBP-lc mRNA expression in HepG2 ceiis
5.4.1 Rationale
The possibility that short-term induction of SREBP-lc by insulin occurred over a shorter 
timescale than incubation periods of 24 horns or greater (Figuies 5.2 to 5.7) was investigated 
by comparing SREBP-lc mRNA levels after 6 hours vs. 24 horns incubation with insulin- 
containing medium. In order to ascertain whether endogenous SREBP-lc mRNA expression 
in HepG2 cells was responsive to insulin concentration in the cell culture medium, different 
concentrations of insulin were compared.
Previously, a decrease in endogenous HNF4a mRNA expression was observed after 24 and 
48 hours incubation with insulin-containing medium (Figure 5.2A(ii)), therefore the time- 
and concentration-dependence of this effect was followed up by measuring HNF4a mRNA 
expression after 6 and 24 houis across a range of insulin concentrations.
It was also considered that hormones present in the 3% serum component of STM used in the 
previous experiment (Figuies 5.2 to 5.7) could affect endogenous SREBP-lc expression in 
HepG2 cells. It was noted that HepG2 cells were serum-stai'ved in published studies 
investigating insulin effects on gene expression in this cell line (Xu et oA, 1999; Hafiier et a l, 
2006; Infantino et a l, 2007). Therefore, a 24 hour serum starvation period was introduced 
prior to incubation with insulin, and serum-hee medium (SFM) was used as the control 
medium (see Experimental outline. Figure 2.12).
5.4.2 Results
The mRNA expression of HNF4a and SREBP-lc in HepG2 cells was measured following 6 
or 24 hours incubation with SFM medium containing 0, 1, 10 or 100 nM insulin (Figure 5.8). 
Based on linear regression analysis, HNF4a mRNA expression differed between the two 
incubation periods (p < 0.05), however a concentmtion-dependent effect of insulm on 
HNF4a mRNA expression was not evident after either 6 or 24 horns incubation (Figuie 
5.8A). SREBP-lc expression did not correlate with insulin concentration within the range 0 
to 100 iiM after either 6 or 24 hours incubation, and no significant differences between the 
two incubation periods was noted (Figure 5.8B).
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Figure 5.8: Insulin-dependence of (A) HNF4a and (B) SREBP-lc mRNA expression 
in HepG2 cells after 6 and 24 hours incubation. HepG2 cells were seeded in 24-well 
plates and incubated in standai'd cell medium (SCM) for 40 houis, serum-starved for 24 
houi's and incubated with SFM containing a range of insulin concentiation for 6 (A) or 24 
(A) hours as indicated. Following RNA isolation and cDNA synthesis, the expression of 
(A) HNF4a and (B) SREBP-lc was quantified by Q-PCR and normalised to the expression 
of a housekeeping gene, B2M, and expressed relative to expression level of the control 
incubation (0 nM insulin) at the 6 h time point. Results are expressed as individual 
datapoints. The effect of insulin concentiation on HNF4a or SREBP-lc expression were 
analysed by linear regression analysis, with R2 and p-values for each mcubation time as 
indicated. The slopes and intercepts of the analyses for the different incubation times was 
compared (double-headed arrow). {N.S., not significant).
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5.5 Discussion
Previously, SREBP-lc reporter gene expression in HepG2 cells was shown to be positively 
regulated by HNF4a and insulin (Section 4.5), therefore the regulation of endogenous 
SREBP-lc mRNA expression in HepG2 cells by HNF4a and insulin was investigated.
Insulin did not positively regulate SREBP-lc mRNA levels in HepG2 cells. Although 
SREBP-lc mRNA expression increased by 50% following 24 hours incubation with insulin 
(Figure 5.3B, pcDNA3 transfection), a 35% increase in SREBP-lc expression was also 
observed after the first 24 hours of the control incubation (Figure 5.3 A, pcDNAS 
tiansfection), suggesting that this rise in SREBP-lc expression was not insulin-dependent. In 
a subsequent experiment (Figuie 5.8B), SREBP-lc mRNA levels did not show dose- 
dependency over a range of insulin concentrations (0 to 100 nM), which was previously 
shown to induce SREBP-lc expression in primaiy rat hepatocytes after both 6 and 24 hour 
incubation time points (Foretz et al., 1999b). Induction of SREBP-lc by 100 iiM was also 
evident in primary rat hepatocytes after 6 or 24 hours incubation time (Foretz et a l, 1999; 
Shimomuia et a l, 2000). Tliis leads to the conclusion that SREBP-lc expression in HepG2 
cells is not regulated by insulm as occurs in vivo (Shimomura et a l, 1999b).
The lack of insulin responsiveness in SREBP-lc expression in HepG2 cells could be linked 
to changes in tlie expression of SREBP-la and -Ic splice variants in this cell line compared to 
their tissue of origin. Whilst human adult liver expresses six-fold higher SREBP-lc than 
SREBP-la, HepG2 express SREBP-la as the dominant vai'iant, with SREBP-lc mRNA 
levels half those of SREBP-la (Sliimomura et a l, 1997). SREBP-la has been shown to be a 
stronger transactivator of gene transcription compaied to the -Ic isoform (Shimano et a l, 
1997) and cancer cells require increased SREBP-1 activity in order to meet the requirement 
for fatty acid synthesis associated with rapid growth (Pizer et a l, 1997; Li et a l, 2000). 
HepG2 cells also show a lack of insulin responsiveness in the regulation of PEPCK gene 
expression and have been shown to lack a factor which is present in the insulin-responsive 
H4IIE cell line (Quinn and Yeagley, 2005). Therefore HepG2 cells may be deficient in a 
transcription factor or co-factor required for the response of SREBP-lc expression to insulin.
Fuithermore, the lack of activation of SREBP-lc expression upon HNF4a overexpression 
(Figure 5.3), despite a tlnee-fold increase in HNF4a expression levels (Figure 5,2), could be
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due to inaccessibility of the SREBP-lc promoter to HNF4a binding due to altered chromatin 
in the transformed cell line compared to in vivo. While a number of HNF4a target genes 
such as PEPCK and apoCIII were activated upon HNF4a overexpression in the human 
hepatoma cell lines, HepG2 and HuH7, the expression of the transthyi etin gene was 
unaltered, which is unexpected (Naiki et a l, 2002; Naiki et a l, 2004). However, when 
primary hepatocytes were transfected with an adenovhal HNF4a vector, transthyretin mRNA 
expression increased, leading the authors to suggest that epigenetic alterations between 
primaiy cells and cell lines limited transthyretin expression in the latter (Naiki et a l, 2005). 
Certain genes, which failed to be activated by ectopic HNF4a expression in the 
dedifferentiated rat hepatoma H5 cell line, were found to re-expressed upon treatment with 
the demethylating agent, 5-azacytidine (Spath and Weiss, 1997).
In conclusion, HNF4a overexpression did not activate SREBP-lc mRNA expression in 
HepG2 cells compared control transfection conditions, in contrast to the results of HNF4a 
overexpression on SREBP-lc reporter gene expression (Chapter 4). A stimulatory effect of 
insulin on SREBP-lc expression was also not observed, which in combination with published 
results, leads to the conclusion that further validation of human SREBP-lc as a target gene of 
HNF4a is not possible in the HepG2 cell line. Prolonged incubation with insulin led to 
changes in SREBP-lc, ACC and L-PK, which could be associated with the development of 
insulin resistance in HepG2 cells. FAS and L-PK were also not up-regulated by HNF4a and 
/ or insulin (Figuies 5.5 and 5.6), suggesting that further investigation of the incubation 
conditions and incubation time effecting the transcription of FAS and L-PK is required.
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Chapter 6
Role of HNF4a in the differential 
regulation of its target genes in HepG2
cells
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Chapter 6:
6.1 Introduction
HNF4a regulates the ti'anscription of a wide range of tai'get genes, occupying some 40% of 
all gene promoters in the liver (Odom et a l, 2004). Its target genes form key regulatory 
points in opposingly regulated metabolic patliways (Sladek and Seidel, 2001), such as 
gluconeogenesis va', glycolysis, and de novo lipogenesis vj. lipid transport. Fuithermore, 
HNF4a regulates the transcription of other ti'anscription factors, forming part of complex 
cross-regulatory networks (Kuo et a l, 1992; Odom et a l, 2004; Kyrmizi et a l, 2006). 
Building on results studying regulation of HNF4a-dependent reporter gene expression by 
metabolic stimuli (Chapter 4), the differential regulation of HNF4a target genes in their 
chromosomal context was studied in HepG2 cells at the mRNA level by a quantitative real­
time RT-PCR (Q-PCR) approach.
Hypothesis:
HNF4a differentially regulates its tai'get genes by forming alternate complexes with co­
activators in response to fasting vs. feeding stimuli.
Aim;
To investigate the mechanisms by which HNF4a differentially regulates its tai'get genes 
under fasting vs. feeding stimuli.
Objective 1: To characterize the effects of metabolic stimuli on HNF4a tai'get genes in 
HepG2 cells.
Objective 2: To investigate the timecourse of changes in target gene expression in response 
to metabolic stimuli.
Objective 3; To characterise the effects of overexpression of DN-HNF4a on target gene 
expression in HepG2 cells under standard incubation conditions.
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Objective 4: To determine the role of HNF4a in the regulation of its tai'get genes by 
metabolic stimuli by overexpression of DN-HNF4a.
Objective 5: To investigate the role of HNF4a co-activators, p300 and PGC-la, in the 
regulation of HNF4a tai'get genes by metabolic stimuli by overexpression of individual co­
activators in HepG2 cells.
Objective 6: To investigate the role of HNF4a-coactivator complexes in the regulation of 
HNF4a target genes by metabolic stimuli by compaiing target gene expression when HNF4a 
and co-activators are overexpressed V5'. control transfection conditions.
6.2 Characterisation of the effects of metaboiic stimuli on HNF4a 
target gene expression in HepG2 cells
6.2.1 Rationale
The transcriptional regulation of a range of HNF4a target genes by metabolic stimulation 
were studied in HepG2 cells. Tai'get genes under investigation were chosen to include key 
regulatory genes in the metabolic pathways of gluconeogenesis (PEPCK), glycolysis (L-PK), 
lipogenesis (FAS), lipoprotein metabolism (apoCIII) as well as transcription factors, SREBP- 
lc and PPARa. Since SREBP-lc mRNA expression in HepG2 cells was observed to be 
umesponsive to insulin and HNF4a overexpression in Chapter 5, SREBP-lc was included 
here in order to confirm that SREBP-lc gene transcription was not modulated by any other 
metabolic stimuli. HNF4a mRNA expression was also quantified in order to relate possible 
changes in target gene expression due to changes in HNF4a expression levels.
Metabolic stimuli exammed were those contained within the fasting vs. feeding cycle, by 
incubating HepG2 cells with the hormones dexamethasone, glucagon or insulm, or cell- 
permeable activators of downstieam pathways. 8-Br-cAMP acts downstream of glucagon 
and activates protein kinase (PKA) by direct activation in the case of 8-Br-cAMP (Meyer and 
Miller, 1974). IBMX also mimicks the effect of glucagon by raising intracellulai' cAMP 
levels via inliibition of cAMP PDE activity (IBMX) (Houslay and Kilgour, 1990). In 
addition to the actions of hormones and their downstream mediators on HNF4a tar get gene 
expression, the influence of AMPK was also studied. AMPK is activated physiologically by
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low intracellulai* energy status reflected in an increased ratio of AMP/ATP (Winder and 
Hai'die, 1999). The hifluence of AMPK activation on tai'get gene expression was studied by 
incubating HepG2 cells with the synthetic AMPK activator, AIC AR.
6.2.2 Results
HNF4a mRNA levels were not significantly affected by the presence of hormones and 
protein kinase activators compar ed to control serum-fiee medium conditions (Figiu'e 6.1 A). 
The fasting hormones, dexamethasone and glucagon, did not alter L-PK or PEPCK mRNA 
expression: However, 8-Br-cAMP, wliich acts downstr eam of glucagon, produced a 220% 
increase in PEPCK expression and a non-significant 48% inliibition in L-PK expression 
(Figures 6.IB and 6.2A). The PKA activator, IBMX, also stimulated PEPCK expression 
(100% increase) and produced a non-significant 38% decrease in L-PK expression (Figures 
6.IB and 6.2A). Incubation with dexamethasone, AICAR or insulin did not lead to any 
significant changes in PEPCK or L-PK mRNA expression (Figures 6.IB and 6.2A).
The expression of apoCIII and FAS was not significantly affected by any of the incubation 
conditions, although apoCIII expression showed a non-significant decrease of 42% in the 
presence of insulin, while FAS expression showed a non-significant increase of 88% in the 
presence of insulin, compared to the control incubation (Figur e 6.2B and C).
The expression of the transcription factors, PPARa and SREBP-lc, were not affected by 
incubation with any of the hormones or protein Idnase activators (Figure 6.3 A and B).
6,3 Timecourse of effects of metaboiic stimuli on gene expression
6.3.1 Rationale
In published work, maximal PEPCK niRNA levels were observed two hour s after exposure to 
glucagon in primary rat hepatocytes (Koo et ah, 2005). Therefore, the possibility tliat 
maximal induction of PEPCK by 8-Br-cAMP in HepG2 cells occuned at an earlier time point 
than the 6 hour incubation period used in the previous experiment (Figure 6.IB) was 
investigated by means of a timecour se experiment. Likewise, changes in L-PK expression 
were obser*ved over the same timecourse, in order to ascertain the timecourse of the inliibitory 
eflfect of 8-Br-cAMP on L-PK expression (Figure 6.2A). In addition, a timecourse 
experiment of changes in FAS and apoCIII mRNA expression was observed in order to
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Figure 6.1: Effects of metabolic stimuli on (A) HNF4a and (B) PEPCK mRNA 
expression in HepG2 cells. HepG2 cells were serum-starved for 24 hours and incubated 
in SFM with the addition of 1 pM dexamethasone (Dex.), 100 nM glucagon, 1 mM 8-Br- 
cAMP, 0.5 mM IBMX, 0.2 mM AICAR or 100 nM insulin as indicated for 6 hours, after 
which RNA was isolated and cDNA prepared. The relative expression level of each gene 
was quantified by real-time PCR, normalised to the expression of B2M and expressed 
relative to the control incubation condition (SFM). Data is expressed as mean values ± 
SEM from a minimum of three independent experiments. Differences between multiple 
incubation conditions were analysed by one-way ANOVA followed by Tukey’s post-hoc 
test {* p<  0.05; *** p < 0.001).
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Figure 6.2: Effects of metabolic stimuli on (A) L-PK, (B) apoCIII and (C) FAS 
mRNA expression in HepG2 cells. Experiment and data analysis performed as detailed 
in Figure 6.1.
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Figure 6.3: Effects of metabolic stimuli on (A) PPARa and (B) SREBP-lc mRNA 
expression in HepG2 cells. Experiment and data analysis performed as detailed in Figure 
6.1.
confirm that the previously used 6 hour time point (Figure 6.2B-C) was optimal for further 
experiments investigating the action of insulin on these genes.
6.3.2 Results
The expression of PEPCK and L-PK was measured following incubation lengths of between 
0.5 and 6 hours and the fold induction between 8-Br-cAMP-containing and control medium 
calculated at each time point (Figure 6.4). Changes in PEPCK expression with respect to 
incubation time followed a sigmoidal pattern, with maximum PEPCK mRNA levels observed 
after 6 hours incubation with 8-Br-cAMP (Figure 6.4A). Changes in L-PK expression, on the 
other hand, did not show a consistent pattern with respect to incubation time, with inhibition
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of L-PK expression by 8-Br-cAMP only observed at the 0.5 and 2 horn* time points (Figure 
6.4B).
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Figure 6.4: Timecourse of 8-Br-cAMP action on (A) PEPCK and (B) L-PK gene 
expression. HepG2 cells were semm-staived for 24 hours and lysed (0 h time point) or 
incubated with SFM ± 1 mM 8-Br-cAMP for 0.5-6 houis as indicated, after which RNA 
was isolated and cDNA prepared. The relative expression level of PEPCK and L-PK was 
quantified by real-time PCR, normalised to the expression of B2M. The fold difference in 
expression at each time point between 8-Br-cAMP and control medium are shown as 
individual datapoints (n =1).
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Figure 6.5: Timecourse of insulin action on (A) apoCIII and (B) F AS gene 
expression. HepG2 cells were serum-starved for 24 hour s and lysed (0 h time point) or 
incubated with SFM ±100 nM insulin for 1-24 hours as indicated, after which RNA was 
isolated and cDNA prepar ed. The relative expression level of apoCIII and FAS was 
quantified by real-time PCR, normalised to the expression of B2M. The fold difference in 
expression at each time point between insulin and control medium are shown as 
individual datapoints (n = 1).
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The timescale of potential actions of insulin on apoCIII and FAS expression was also 
investigated (Figure 6.5), Insulin produced a gradual decrease in apoCIII expression over an 
incubation period of 24 hours, with apoCIII at 67% of their star ting levels after 24 hours 
(Figure 6.5 A). Like PEPCK expression (Figure 6.4A), the graph of FAS expression followed 
a sigmoidal shape with respect to incubation time with a sharp increase in FAS mRNA levels 
after 4 hours and a plateau bemg approached after 24 hours (Figrrr e 6.5B).
Talcen together with the results of previous experiments (Figures 6.1-6.2), it was concluded 
from the timecourse experiments that changes brought about by 8-Br-cAMP and insulin on 
target gene expression were reflected in mRNA expression at the 6 hour time point (Figures
6.4 and 6.5). Therefore, this incubation time was used for furtlrer experiments.
6.4 Characterisation of effects of dominant-negative HNF4a (DN- 
HNF4a) on target gene expression
6.4.1 Rationale
An expression vector coding for human HNF4a2 with a dominant-negative mutation in its 
DNA-binding domain (DN-HNF4a) (Taylor et ah, 1996) was utilised to investigate the role 
of HNF4a in the regulation of its tar get genes in HepG2 cells. The DN-HNF4a protein 
contains a functional dimérisation domain that has been shown to disrupt the binding of wild- 
type HNF4a to DNA by producing defective heterodimers, leading to a reduction in HNF4a- 
mediated reporter gene expression (Taylor et a l, 1996; Gourdon et a l, 1999; Jahan and 
Chiang, 2005). Initially, different amounts of DN-HNF4a expression vector DNA were 
compared with control expression vector (pcDNAS) in order to ascertain the optimum dose 
for subsequent experiments (Section 6.5).
6.4.2 Results
HepG2 cells were transfected witli vaiymg amounts of a DN-HNF4a expression vector or 
conti'ol expression vector DNA (pcDNAS) and the expression of HNF4a target genes, 
PEPCK and L-PK (Figure 6.6), apoCIII and FAS (Figiue 6.7), measiued 46 hours after 
transfection (Experimental timeline, Figure 2.12). Cells were incirbated in SFM for the final 
six hour's of the experiment, in order to match the incubation time which was used when 
incubating HepG2 cells with metabolic stimuli (Section 6.2). A decrease in PEPCK mRNA
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levels with increasing DN-HNF4a expression vector concentration was observed (R“ = 0.48, 
/? < 0.01), however no significant differences were established when comparing the linear 
regression analyses of the control and DN-HNF4a expression vectors (Figure 6.6A). The 
expression of the other HNF4a target genes investigated (L-PK, apoCIII and FAS) was not 
modulated by DN-HNF4a expression vector concentration and did not show any differences 
in expression pattern compared to cells transfected with equal amounts of contr ol expression 
vector (Figures 6.6B and Figure 6.7).
This DN-HNF4a expression vector has not previously been used to investigate effects on 
endogenous cellular mRNA expression, whilst its mechanism of action has been extensively 
characterised using reporter gene studies (Taylor et a l, 1996; Gouidon et a l, 1999; Jalian and 
Cliiang, 2005). Therefore, the ability of DN-HNF4a to disrupt HNF4a-stimulated reporter 
gene expression was confirmed using L-PK (L3)3-54PK and SREBP-lc reporter genes 
(Chapter 4) (Figure 6,8).
In line with previous results (Chapter 4), the expression of (L3)3-54PK and SREBP-lc 
reporter genes was induced upon overexpression of wild-type human HNF4a2, with 14- and 
33-fold increases over basal expression observed respectively (Figure 6.8). The repressive 
action of DN-HNF4a was investigated by co-transfection of a constant dose of wild-type 
HNF4a (25 ng/well) with increasing amounts of DN-HNF4a expression vector (Figure 6.8). 
(L3)3-54PK reporter gene expression was repressed by co-expression of DN-HNF4a, with a 
30% inliibition of reporter gene expression obseiwed with 25 ng/well DN-HNF4a compar ed 
to wild-type vector alone (Figure 6.8A). DN-HNF4a concentration and (L3)3-54PK reporter 
gene expression exhibited negative correlation within the range 0 -2 5  ng/well DN-HNF4a 
expression vector (R  ^= 0.78, p  < 0.001), with reporter gene expression reaching a plateau 
corresponding to -25% inliibition at 50 and 100 ng/well DN-HNF4a (Figine 6.8A). SREBP- 
lc reporter gene expression also displayed negative correlation with DN-HNF4a 
concentration throughout the tested range (0 -1 0 0  ng/well) (R  ^= 0.55,/? < 0.001) (Figure 
6.8B). The maximum inhibition of HNF4a-activated SREBP-lc reporter gene expression 
occurred with 100 ng/well DN-HNF4a, with a 25% reduction in reporter gene activity 
observed.
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Figure 6.6: Effect of DN-HNF4a expression vector concentration on (A) PEPCK and 
(B) L-PK mRNA expression in HepG2 cells. HepG2 cells were transfected with 10, 
125, 250 or 500 ng/well control (pcDNA3) or DN-HNF4a expression vector DNA. 16 
hours after transfection, cells were serum-starved for 24 hours then incubated for a further 
6 hours in SFM, after which RNA was isolated and cDNA prepared. The expression of 
PEPCK and L-PK was normalised to B2M and expressed relative to the lowest 
concentration of pcDNA3 (10 ng/well). Results are plotted as individual datapoints. The 
effect of expression vector concentration on gene expression was analysed by linear 
regression analysis, as indicated by dashed lines, with goodness of fit (R^) and statistical 
significance (p) indicated on each plot. Differences between control and DN-HNF4a 
expression vectors were analysed by comparing the slopes and intercepts of the linear* 
regression analyses, with no significant differences in PEPCK or L-PK mRNA expression 
being observed between control and expression vectors.
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Figure 6.7: Effect of DN-HNF4a expression vector concentration on (A) apoCIII and
(B) FAS mRNA expression in HepG2 cells. HepG2 cells were transfected with 10, 125, 
250 or 500 ng/well control (pcDNA3) or DN-HNF4a expression vector DNA. 16 hours 
after transfection, cells were serum-starved for 24 hour's then incubated for a further 6 
hour's in SFM, after wliicli RNA was isolated and cDNA prepared. The expression of 
apoCIII and FAS was normalised to B2M and expressed relative to the lowest 
concentration of pcDNA3 (10 ng/well). Results are plotted as individual datapoints. The 
effect of expression vector concentration on gene expression was analysed by linear 
regr ession analysis, as indicated by dashed lines, witii goodness of fit (R^) and statistical 
significance (p) indicated on each plot. Differences between control and DN-HNF4a 
expression vectors were analysed by comparing the slopes and intercepts of the linear 
regression analyses, with no significant differences in apoCIII or FAS mRNA expression 
being observed between control and expression vectors.
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Figure 6.8: Dose-dependence of DN-HNF4a effects on HNF4a-stimuJated expression 
of (A) L-PK (L3)3-54PK and (B) SREBP-lc reporter plasmids. HepG2 cells were 
seeded in STM in 96-well plates and transfected with luciferase reporter plasmids (L3)3- 
54PK or SREBP-lc (-780/+62) (100 ng/well), with expression vector for human HNF4al 
(25 ng/well) and DN-HNF4a expression vector (0 -1 0 0  ng/well) as indicated (symbol: 
♦). Basal reporter gene expression in the absence of HNF4a overexpression was also 
measirred (symbol: O). pSEAPI-3’rep was co-transfected as a control for transfection 
efficiency. Luciferase readings were corrected for transfection efficiency based on SEAP 
expression levels. Values are shown as mean ± SEM (n = 4), relative to reporter gene 
expression in the presence of wild-type HNF4a expression vector alone. The relationship 
between DN-HNF4oi expression vector concentration and reporter gene expression was 
analysed by Pearson’s correlation, as indicated by a dashed line along with R  ^andp- 
values.
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In addition to validation of the DN-HNF4a mechanism of action by reporter plasmid 
experiments, the wild-type and DN-HNF4a expression vectors were sequenced, confirming 
the presence of a point mutation (T -> C) at position 316 in DN-HNF4a (Taylor et a l, 1996) 
(Appendix Section 8.3, Box 8.5).
6.5 Effects of dominant-negative HNF4a on tiie reguiation of gene 
expression by metabolic stimuli
6.5.1 Rationale
The DN-HNF4a expression vector has previously been utilised to investigate the role of 
HNF4a in regulation of its target genes by metabolic stimuli: for example, in the stimulation 
of G-6-Pase expression by SCFAs and PKA (Massillon et al, 2003; Gautier-Stein et a l, 
2005), and in the stimulation of L-CPTI expression by cAMP (Louet et a l , 2002). In the 
latter case, expression of DN-HNF4a prevented induction of L-CPTI reporter gene 
expression by cAMP, but did not change basal L-CPTI expression, indicating a role of 
HNF4a in the regulation of L-CPTI by cAMP (Louet et a l, 2002).
As the expression of PEPCK and L-PK was found to be modulated by cAMP (Figures 6. IB 
and 6.2A), the role of HNF4a in these effects was investigated by overexpression of DN- 
HNF4a. In addition, apoCIII and FAS expression showed some evidence of regulation by 
insulin (although these effects were not significant) (Figure 6.2B-C), therefore the effect of 
the DN-HNF4a expression vector on apoCIII and FAS expression under conditions of insulin 
w. control medium (SFM) was also measured. Since DN-HNF4a differs from wild-type 
HNF4a in the alteration of only a single base (Taylor et a l, 1996), it is likely that RT-PCR 
analysis with primers to wild-type HNF4a would also detect DN-HNF4a transcripts and 
therefore HNF4a mRNA expression was measured in order to an indication of the expression 
level of DN-HNF4a in the experiment.
6.5.2 Results
Overexpression of DN-HNF4a resulted in increases in HNF4a mRNA levels, however it is 
not possible to determine whether this increase reflects both endogenous (wild-type) and DN- 
HNF4a mRNA expression (Figure 6.9). Transfection with DN-HNF4a expression vector 
resulted in a 6.9-fold increase over the control transfection following incubation with
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8-Br-cAMP ip < 0.01). Non-significant 2.3- and 3.4-fold increases over control HNF4a 
levels were also observed in DN-HNF4a-transfected cells incubated with control and insulin- 
containing medium respectively (Figure 6.9).
The role of HNF4a in the effects of 8-Br-cAMP on PEPCK and L-PK expression was 
investigated by comparing cells transfected with the DN-HNF4a vs. control expression 
vectors (Figure 6.10). Under control transfection conditions, PEPCK mRNA levels were 3.5- 
fold higher following incubation with 8-Br-cAMP. A mean 5.5-fold increase in PEPCK 
mRNA expression over control levels was observed in cells transfected with DN-HNF4a, 
however the difference between pcDNA vs. DN-HNF4a was not found to be significant in 
post-hoc tests (Figure 6.10A).
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Figure 6.9: Effect of DN-HNF4a expression on the mRNA expression of HNF4a in 
HepG2 cells under different incubation conditions. HepG2 cells were transfected with 
500 ng/well DN-HNF4a or control (pcDNA3) expression vector. 16 hours after 
transfection, cells were serum-starved for 24 hours, followed by a 6 hour incubation 
period with control medium (SFM) or medium containing 1 mM 8-Br-cAMP or 100 nM 
insulin as indicated. Total RNA was then isolated, cDNA prepared and gene expression 
measured by real-time PCR. The expression of FTNF4a was normalised to B2M and 
expressed relative to the control transfection and incubation condition. Results are 
expressed as mean values ± SEM (n = 4). The effects of expression vector (pcDNA3 vs. 
DN-HNF4a) and incubation conditions on gene expression were analysed by two-way 
ANOVA with Bonferroni post-hoc tests (** p<  0.01).
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Incubation of HepG2 cells with 8-Br-cAMP did not inhibit L-PK expression in control- 
transfected cells, whilst a 29% drop in L-PK expression was observed in DN-HNF4a- 
transfected cells {p < 0.05), although direct differences between pcDNAS vs. DN-HNF4a 
were not revealed in post-hoc tests (Figure 6.1 OB).
In order to establish whether PEPCK or L-PK expression correlated with changes in HNF4a 
mRNA expression, linear regression analyses were performed relating HNF4a and target 
gene mRNA levels (Figure 6.11). This revealed that PEPCK expression positively correlated 
with HNF4a expression in the presence of 8-Br-cAMP (R  ^= 0.82,/? < 0.01) (Figure 6.11 A). 
A positive, though non-significant, correlation of L-PK with HNF4a mRNA levels under 8- 
Br-cAMP conditions was also observed (R  ^= 0.41,p  = 0.09) (Figure 6.1 IB).
The role of HNF4a in the regulation of target genes whose expression is modified by insulin 
(apoCIII and FAS) was also investigated, however insulin did not significantly modulate the 
expression of either gene in cells transfected with either control or DN-HNF4a expression 
vectors (Figure 6.12). In addition, DN-HNF4a expression did not alter apoCIII or FAS 
expression compared to control vector (Figure 6.12). Linear regression analysis of the 
relationsliip between apoCIII or FAS and HNF4a mRNA levels also indicated that 
expression of DN-FINF4a did not significantly alter the expression of these tar get genes 
under either incubation condition (Appendix Section 8.4, Figure 8.1).
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Figure 6.10: Effect of DN-HNF4a on the regulation of (A) PEPCK and (B) L-PK 
mRNA expression by cAMP. HepG2 cells were transfected with 500 ng/well DN- 
HNF4a or control (pcDNA3) expression vector. 16 hours after transfection, cells were 
serum-starved for 24 hours, followed by a 6 hour incubation period with control medium 
(SFM) or medium containing 1 mM 8-Br-cAMP as indicated. Total RNA was then 
isolated, cDNA prepared and gene expression measured by real-time PCR. The 
expression of PEPCK and L-PK was normalised to B2M and expressed relative to the 
control transfection and incubation condition. Results are expressed as mean values ± 
SEM (n = 4). The effects of expression vector (pcDNA3 vs. DN-HNF4a) and incubation 
conditions on gene expression were analysed by two-way ANOVA with Bonferroni post- 
hoc tests {* p<  0.05, *** p<  0.001).
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Figure 6.11: Effect of DN-HNF4a on the regulation of (A) PEPCK and (B) L-PK 
inRNA expression by cAMP: Linear regression analysis. Analyses of correlation 
between (A) PEPCK or (B) L-PK and HNF4a mRNA expression levels were performed 
with data from conti'ol (closed triangles A )  and 8-Br-cAMP (open triangles A) 
incubation conditions (from both pcDNAS- and DN-HNF4a-transfection conditions), 
from experiment as described in Figure 6.10. Results are presented as individual 
datapoints with correlation analyses indicated by a dashed line with adjacent R  ^andp- 
values. Differences between control and 8-Br-cAMP incubation conditions were analysed 
by comparing the slopes and intercepts of the linear regression analyses and a significant 
difference between the two lines is indicated by a double-arrow and adjacent/?-value 
{N.S., not significant).
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Figure 6.12: Effect of DN-HNF4a on the regulation of (A) apoCIII and (B) FAS 
mRNA expression by insulin. HepG2 cells were transfected with 500 ng/well DN- 
HNF4a or control (pcDNAS) expression vector. 16 hours after transfection, cells were 
serum-starved for 24 hours, followed by a 6 hour incubation period with control medium 
(SFM) or medium containing 100 nM insulin as indicated. Total RNA was then isolated, 
cDNA prepared and gene expression measured by real-time PCR. The expression of 
apoCIII and FAS was normalised to B2M and expressed relative to the control 
transfection and incubation condition. Results are expressed as mean values ± SEM (n = 
4). The effects of expression vector (pcDNA3 vs. DN-HNF4a) and incubation conditions 
on gene expression were analysed by two-way ANOVA.
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6.6 Effects of HNF4a co-activators p300 and PGC-1 a  on the
regulation of PEPCK and L-PK expression
6.6.1 Rationale
The results of overexpressioti of DN-HNF4a suggested a role for HNF4a in the stimulation 
of PEPCK expression by cAMP (Figure 6.11 A). The expression of L-PK in the presence of 
8-Br-cAMP also appeared to be related to the expression of HNF4a (Figures 6.1 OB and
6.1 IB). Therefore, the role of HNF4a co-activators, p300 and PGC-la, in these effects was 
fluther investigated by studying the impact of overexpressing each co-activator in HepG2 
cells.
6.6.2 Results
HepG2 cells were transfected with expression vectors coding for p300, PGC-la or control, 
and the expression of HNF4a, PEPCK and L-PK measured following a six horn incubation 
with 8-Br-cAMP-containing or control medium (Figure 6.13). HNF4a mRNA levels did not 
vary significantly between transfection or incubation conditions (Figure 6.13A). Incubation 
of HepG2 cells with 8-Br-cAMP resulted in induction of PEPCK expression in the contr ol 
and PGC-la transfection conditions respectively, with 2.7-fold and 2.9-fold increases in 
PEPCK mRNA levels obsei'ved respectively (Figure 6.13B). On other hand, the level of 
induction of PEPCK expression following incubation with 8-Br-cAMP in the p300 
transfection condition was attenuated, with the 2.0-fold increase obsei'ved not reachhig the 
level of significance (Figur e 6.13B). In contrast, L-PK expression only showed inliibition by 
8-Br-cAMP when p300 was overexpressed, but not in the control or PGC-la transfection 
conditions (Figure 6.12C).
Although not found to be significant following a two-way ANOVA analysis, mean HNF4a 
levels were below the level of the contr ol transfection and incubation condition (set as 
100%), when PGC-la was overexpressed (in both incubation conditions) and when p300 was 
overexpressed (in the presence of 8-Br-cAMP) (Figure 6.13 A). Alterations in HNF4a 
expression were further investigated by studying the relationship between tar get gene and 
HNF4a expression levels under each incubation condition by correlation analysis (Figures 
6.14 and 6.15).
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Under the control incubation condition, a highly significant relationship between PEPCK and 
HNF4a inRNA levels was evident (R  ^= 0.84, j; < 0.001) (Figure 6.14). In the presence of 8- 
Br-cAMP, the correlation between PEPCK and HNF4a mRNA levels fell short of 
significance (R  ^= 0.40, p  = 0.07) (Figure 6.14). Compar ison of the intercepts of the linear* 
regression analyses for the control and 8-Br-cAMP incubation conditions mdicated that 8-Br- 
cAMP had a highly significant effect on PEPCK expression (p < 0.0001), when PEPCK 
mRNA levels were expressed as a function of HNF4a mRNA levels (Figure 6.14). This 
result suggests that HNF4a abundance could be a limiting factor in determining PEPCK 
expression.
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Figure 6.14: Effects of p300 and PGC-la overexpression: Relationship between 
HNF4a and PEPCK mRNA expression under control and 8-Br-cAMP incubation 
conditions. Analysis of correlation between HNF4a and PEPCK mRNA expression was 
performed with results presented in Figure 6.13 by combining data from all tliree 
transfection conditions (pcDNAB, p300 and PGC-la). Results are presented as individual 
datapoints with the combined linear regression analysis for each incubation condition 
indicated by a dashed line with adjacent R  ^andp-value. Differences between control and 
8-Br-cAMP incubation conditions were analysed by comparing the linear regression 
analyses and a significant difference between the intercepts of the two lines is indicated 
by a double-aiTow and adjacent /7-value.
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L-PK expression positively correlated witli HNF4a mRNA levels under both the control 
incubation condition (R  ^= 0.47,/? < 0.05) and in the presence of 8-Br-cAMP (R  ^= 0.91,/? < 
0.001) (Figure 6.15). Compaiison of the intercepts of the linear regression analyses for the 
control and 8-Br-cAMP incubation conditions indicated tliat 8-Br-cAMP also had a highly 
significant effect on L-PK expression ip < 0.001), when L-PK mRNA levels were expressed 
as a fimction of HNF4a mRNA levels (Figure 6.15). This result suggests that HNF4a 
abimdance was modulated by the overexpression of PGC-la or p300 and this had an impact 
on L-PK expression.
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Figure 6.15; Effects of p300 and PGC-la over expression; Relationship between 
HNF4a and L-PK mRNA expression under control and 8-Br-cAMP incubation 
conditions. Analysis of correlation between HNF4a and L-PK mRNA expression was 
performed with results presented in Figure 6.13 by combining data from all tlnee 
transfection conditions (pcDNA3, p300 and PGC-la). Results are presented as individual 
datapoints with the combined linear regression analysis for each incubation condition 
indicated by a dashed line with adjacent R  ^and/?-value. Differences between control and 
8-Br-cAMP incubation conditions were analysed by comparing the linear regression 
analyses and a significant difference between the intercepts of the two lines is indicated 
by a double-arrow and adjacent /?-value.
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6.7 Role of HNF4a-co-actlvator complex in the differential
regulation of PEPCK and L~PK expression
6.7.1 Rationale
Overexpression of eitlier p300 or PGC-la resulted in changes to PEPCK and L-PK 
expression which were related to endogenous HNF4a mRNA levels (Figures 6.14 and 6.15), 
suggesting that HNF4a quantity could be a limiting factor in the regulation downstream 
genes by either co-activator. Furthermore, nuclear receptors require the presence of co­
activators with both bridging- and HAT-capabilities in order to activate transcription 
(Acevedo and ICiaus, 2004). Activation of gene expression by PGC-la involves the 
recruitment of HAT-type co-activators, p300 or CBP, owing to PGC-la lacldng HAT 
activity (Puigserver, 1999). Therefore, HNF4a and both co-activators (p300 and PGC-la) 
were overexpressed in order to test the hypothesis that a complex of HNF4a, p300 and PGC- 
l a  differentially regulates downstieam genes, PEPCK and L-PK, under opposing metabolic 
conditions.
6.7.2 Results
HepG2 cells were transfected with expression vectors for HNF4a, p300 and PGC-la or 
control DNA (pcDNA3) followed by incubation of the cells with 8-Br-cAMP and/or 
dexamethasone (fasting conditions), or insulin and/or liigh glucose concentration (25 mM) 
(feeding conditions). The mRNA levels of the overexpressed factors were measui ed (Figures 
6.16 and 6.17), as well as those of tar get genes, PEPCK and L-PK (Figure 6.18 and Figure 
6.23 respectively). For conditions containing dexamethasone, an additional incubation with 
vehicle control medium (0.04% ethanol) was performed in order to ensure dexamethasone- 
specifrc effects were attributable to the action of the glucocorticoid, not the vehicle (ethanol) 
(Appendix Section 8.4, Figures 8.2 and 8.3).
HNF4a mRNA expression was not modulated by incubation with any of the metabolic 
stimuli under control transfection conditions (Figure 6.15 A). In the HNF4a-p300-PGC-1 a  
transfection condition, HNF4a mRNA levels were between 35% and 146% greater than 
under the control transfection condition, however post-hoc tests only identified a significant 
difference in HNF4a expression between active vs. control transfection in the case of cells 
incubated with 8-Br-cAMP (p < 0.01) (Figure 6.16A).
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In the control transfection condition, p300 expression was 72% greater when cells were 
incubated with 25 mM glucose medium compared to control medium (p < 0.05) (Figure 
6.16B). A significant difference between 25 mM glucose- vs. dexamethasone-containing 
conditions was also identified (p < 0.05) (Figure 6.16B). p300 expression did not increase 
significantly upon transfection of HepG2 cells with a p300 expression vector under any of the 
incubation conditions, with the maximum percentage-change of 38% observed in the 
dexamethasone incubation condition not reaching the level of significance (Figure 6.16B).
As the PGC-la expression vector used encoded mouse PGC-la cDNA, it was possible to 
differentiate between the expression of endogenous PGC-la gene in hmnan HepG2 cells and 
expression vector-derived murine PGC-la transcripts (Figure 6.17). Endogenous PGC-la 
expression was significantly induced by 8-Br-cAMP and dexamethasone in both control (p < 
0.05) and active (p < 0.001) transfection conditions (Figure 6.16A). Human PGC-la was 
also greater in the presence of 8-Br-cAMP alone compared to the 25 mM glucose and insulin 
incubation condition under control transfection conditions (p < 0.05), but not in the active 
transfection condition (Figure 6.16A).
No differences in human PGC-la expression between control and exogenous PGC-la 
transfection conditions were obser*ved, suggesting that the PCR reporter signal using human 
PGC-la primers does not reflect expression-vector derived transcripts (Figure 6.17A).
Mouse PGC-la primers were also species-specific, with no signal being detectable in the 
majority of cases for samples from the control transfection condition (Figure 6.17B).
Expression of the PGC-la expression vector was increased 3.9-fold by 8-Br-cAMP over 
control incubation conditions (p < 0.001) (Figure 6.17B). The combination of 8-Br-cAMP 
and dexamethasone almost doubled expression vector-derived PGC-la transcript levels 
compared to 8-Br-cAMP alone (p < 0.001), suggesting the two compounds synergise to 
promote expression of the transfected DNA (Figure 6.17B).
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Figure 6.16: Expression of (A) HNF4a and (B) p300 under different metabolic 
conditions. HepG2 cells were transfected with 125 ng HNF4a, p300 and PGC-la 
expression vectors per well or control (375 ng/well pcDNA3). 16 hours after transfection, 
cells were serum-starved for 24 hours, followed by a 6 hour incubation period with 
control medium (SFM) or medium containing 1 mM 8-Br-cAMP, 1 pM dexamethasone, 
100 nM insulin or 25 mM glucose as indicated. Total RNA was isolated, cDNA prepared 
and gene expression measured by real-time PCR. Gene expression levels were normalised 
to B2M and expressed relative to the control transfection and incubation condition.
Results are expressed as mean values ± SEM (n = 4). The effects of transfection and 
incubation conditions were analysed by two-way ANOVA, with the results of Bonferroni 
post-hoc tests as indicated (* p <0.05, ** p <0.01).
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Figure 6.17: Expression of (A) endogenous and (B) ectopically expressed PGC-la 
under different metabolic conditions. HepG2 cells were transfected with control 
(pcDNA3) or HNF4a, p300 and PGC-la expression vectors and incubated under 
different conditions as described in Figure 6.15. Gene expression levels of (A) 
endogenous human PGC-la (hsPGC-la) or (B) expression vector-derived mouse PGC- 
la  (mmPGC-la) were normalised to B2M and expressed relative to (A) the control 
transfection and incubation condition or (B) the PGC-la transfection and control 
incubation condition. Results are expressed as mean values ± SEM (n = 4). The effects 
of transfection and incubation conditions were analysed by two-way ANOVA, with the 
results of Bonferroni post-hoc tests as indicated (* p  <0.05, *** p  <0.001). The absence 
of brackets indicates the incubation condition was significantly different to all other 
incubation conditions.
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The impact of overexpression of HNF4a, p300 and PGC-la on downstream genes, PEPCK 
and L-PK was analysed. PEPCK expression was significantly induced by incubation of 
HepG2 cells with 8-Br-cAMP, with a mean 3.3-fold increase in expression observed under 
control transfection conditions {p < 0.05) (Figure 6.18). 8-Br-cAMP in the presence of 
dexamethasone caused a similar increase in PEPCK expression, with a mean 3.5-fold 
increase observed V5. the control incubation condition in the pcDNA3 transfection group {p < 
0.05) (Figure 6.17). Overexpression of HNF4a, p300 and PGC-la resulted in 2.0-fold 
higher PEPCK expression in the 8-Br-cAMP incubation condition compared to the control 
transfection condition (p < 0.01) (Figure 6.18).
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Figure 6.18: Role of HNF4a-p300-PGC-la complex in the regulation of PEPCK 
mRNA expression by metabolic stimuli. HepG2 cells were transfected with control 
(pcDNA3) or HNF4a, p300 and PGC-la expression vectors and incubated under 
different conditions as described in Figure 6.16. Total RNA was isolated, cDNA prepared 
and gene expression measured by real-time PCR. PEPCK expression levels were 
normalised to B2M and expressed relative to the control transfection and incubation 
condition. Results are expressed as mean values ± SEM (n = 4). The effects of 
expression vector and incubation condition were analysed by two-way ANOVA, with the 
results of Bonferroni post-hoc tests as indicated (* p <0.05, ** p  <0.01, *** p < 0.001). 
The 8-Br-cAMP and 8-Br-cAMP + dex. incubation conditions were significantly different 
to all other incubation conditions.
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PEPCK expression following incubation with the combination of 8-Br-cAMP and 
dexamethasone was 1.4-fold higher in the HNF4a-p300-PGC-la ti*ansfection condition 
compared to control, however this was not found to be significant in post-hoc tests (Figme
6.18).
As expression levels of the transfected HNF4a- and co-activator-expression vectors vai ied 
between biological repeats (Figures 6.16 and 6.17), the influence of HNF4a, p300 and PGC- 
l a  expression levels on PEPCK expression was flnther analysed by linear regression analysis 
(Figures 6.19 to 6.22), The correlation of PEPCK expression with HNF4a, p300 and both 
endogenous (human PGC-la) and transfected (mouse PGC-la) was analysed. As PEPCK 
expression was shown to be significantly stimulated by the incubation of HepG2 cells with 8- 
Br-cAMP (alone and in combination with dexamethasone), correlation analyses of PEPCK 
expression vs. expression of HNF4a, p300 and PGC-la imder 8-Br-cAMP and 
dexamethasone incubation conditions are presented here (Figures 6.19 to 6.21), alongside 
coiTelation analyses of PEPCK expression under conditions mimicking the opposite 
metabolic scenario of the fed state (25 mM glucose and insulin) (Figure 6.22). Correlation 
analyses were also performed for the other incubation conditions investigated and are 
presented in the Appendix (Figures 8.4-8.5, Section 8.4). The linear' regression analysis for 
each incubation condition was also compared with that of the control incubation condition in 
terms of differences in intercept and slope of the two lines. A significant difference in the 
intercepts was interpreted as evidence of the incubation condition modifying the expression 
of the tar get gene (PEPCK), wliile a significant difference in the slopes of the lines suggested 
that changes in the activity of the transcription factor or co-activator in question influenced 
changes in expression of the target gene between the incubation conditions.
Differences in the intercepts of the linear regression analyses for the control and 8-Br-cAMP 
conditions indicated that 8-Br-cAMP significantly increased the expression of PEPCK 
(Figure 6.19A, B and D), in line with results of two-way ANOVA (Figme 6.18). When cells 
were incubated with control medium, PEPCK expression correlated with HNF4a mRNA 
levels (R  ^= 0.90, p  < 0.0001, with the omission of one anomalous datapoint) (Figure 6.19 A). 
In the presence of 8-Br-cAMP, PEPCK mRNA levels positively correlated with HNF4a 
mRNA levels when two anomalous values were omitted (R  ^= 0.12, p  < 0.05) (Figme 6.19A). 
p300 mRNA expression levels were not related to PEPCK expression levels under control or
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8-Br-cAMP conditions (Figure 6.19B). Endogenous PGC-la levels significantly correlated 
with PEPCK expression levels under control and 8-Br-cAMP incubation conditions (Figure 
6.19C). A steeper gradient in the relationship between endogenous PGC-la and PEPCK in 
the presence of 8-Br-cAMP compared to control medium suggests that PGC-la has greater 
activity in the presence of 8-Br-cAMP. Exogenous PGC-la transcript levels came close to a 
significant positive correlation with PEPCK expression under control (R  ^= 0,47, p  = 0.06) 
and 8-Br-cAMP incubation conditions (R  ^= 0.50, p  ~ 0.05) (Figure 6.19D).
Dexamethasone appeared to suppress PEPCK mRNA expression, based on linear regression 
analyses of HNF4a and endogenous PGC-la V5. PEPCK expression levels (Figure 6.20A 
and C). A significant decrease in the slopes of the lines relating HNF4a or human PGC-la 
mRNA levels with those of PEPCK suggested that dexamethasone suppresses the activity of 
both factors, resulting in decreased PEPCK mRNA expression (Figure 6.20A and C).
8-Br-cAMP and dexamethasone significantly stimulated PEPCK mRNA expression, based 
on differences in the intercepts of linear regression analysis for this incubation condition v^ . 
control medium (Figme 6.21 A, B and D). Unlike for 8-Br-cAMP alone (Figure 6.19A), a 
statistically significant lineai* relationsliip between HNF4a and PEPCK expression levels was 
not apparent in the presence of both 8-Br-cAMP and dexamethasone (R  ^= 0.26, p  = N.S.) 
(Figure 6.21 A). Under these incubation conditions, both endogenous PGC-la and 
ectopically expressed PGC-la mRNA levels positively correlated with PEPCK expression 
(R  ^= 0.75,p  < 0.01) (Figure 6.21C) and (R  ^= 0.69,/? < 0.05) (Figure 6.2ID) respectively.
Linear regression analysis of PEPCK expression under high glucose concentration and 
insulin conditions suggested that this incubation condition diminishes PEPCK expression 
compared to control medium, with the intercept for the 25 mM glucose and insulin line being 
significantly lower than that for contiol mediimi for the p300, human PGC-la and mouse 
PGC-la analyses (Figure 6.22B, C and D). Wlien comparing the slopes of lineai* regression 
analyses for HNF4a between 25 mM glucose and insulin with control medium, a significant 
difference in the slopes of the lines was appaient (/? < 0.001) (Figure 6.22A).
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Figure 6.19: Correlation between expression of PEPCK and (A) HNF4a, (B) p300 
(C) endogenous PGC-la and (D) exogenous PGC-la mRNA levels under 1 inM 8- 
Br-cAMP incubation conditions. Lineai* regression analysis of the relationships 
between PEPCK and HNF4a / co-activator mRNA expression levels was performed with 
data horn control (closed triangles A ) and 8-Br-cAMP (open triangles A) incubation 
conditions presented in Figures 6.16 to 6.18. Results are presented as individual 
datapoints with lineai* regression analyses indicated by a dashed line with adjacent R  ^and 
/^-values, t  Anomalous datapoints (circled) omitted fi*om analysis.
Differences between control and 8-Br-cAMP incubation conditions were analysed by 
comparing the linear regression analyses and a significant difference between the 
intercepts or* slopes of the two lines is indicated by a double-aiTow and adjacent /?-value or 
N.S. in the case of no significant differences. (If tlie difference is between the slopes, this 
is noted; no additional notation corresponds to a difference between the intercepts).
193
Ai&Q)
g
I<U>
o :
300%-,
250%-
200%.
160%-
100% -
50%-
Control:
, R2 = 0.90
/  p<  0.001 +
A'f p < 0.001 (slopes)A .A  _
 ^ Dex.:
R2 = 0.09 
p = 0.47
—I----- i----- 1----- 1----- 1----- 10% 50% 100% 150% 200% 250% 300%
Relative HNF4a expression
B
cIIiOu0)>
300%-
250%-
200%  -
150%-
50%-
0%.
.4^''
A
Control: 
R2 = 0.15 
p = 0.35
N .S .
*  ^ Dex.:
R2 = 0.28
 ^ p = 0.18
0% 50% 100% 150% 200% 250% 300%
Relative p300 expression
C
IIi0
1
300%.
250%-
200%  -
150%-
100% -
50%.
0%.
/  Control;
' R2 = 0.91
p<  0.001+
p < 0.01 (slopes)
A
Dex.:
4 ...... : R2 = 0.08 p = 0.49
0% 50% 100% 150% 200% 250% 300%
Relative hsPGC-la expression
D
250%.
W
S  200%-Ii 150%-
100%.
50%.
0%.
N .S .
A
A
Control: 
R2 = 0.47
p = 0.06
Dex.:
R2 = 0.09 
p = 0.48
0% 50% 100% 150% 200% 250% 300%
Relative mmPGC-1 a expression
Figure 6.20: Correlations between expression of PEPCK and (A) HNF4a, (B) p300 
(C) endgenous PGC-la and (D) exogenous PGC-la mRNA levels under incubation 
conditions of 1 pM dexamethasone. Linear regression analysis of the relationships 
between PEPCK and HNF4a / co-activator niRNA expression levels was performed witli 
data from control (closed triangles A) and dexamethasone (Dex.) (open triangles A) 
incubation conditions as presented in Figures 6.16 to 6.18. Results are presented as 
individual datapoints with linear* regression analyses indicated by a dashed line with 
adjacent R  ^and/?~vahies. j*Anomalous datapoints omitted from analysis (Figure 6.19). 
Differences between tlie incubation conditions were analysed by comparing the linear 
regression analyses and a significant difference between the intercepts or slopes of the two 
lines is indicated by a double-anow and adjacent /?-value or N.S. in tire case of no 
significant differences. (If tire difference relates to the slopes, this is rroted; rro additiorral 
notation corresponds to a difference between the irrtercepts).
194
AI0)>
800%-,
600%-
400%-
0%
/A
8-Br-cAMP and Dex. 
R2 = 0.26 
p = 0.20
/ AÀ Û p < 0.001
I Control;
/  R2 = 0.904^ p < 0.001+
200% 400% 600% 800% 1000% 1200%
Relative HNF4cc expression
B
,2 600%-
400%-,
ISS-Q>ia0)
irs 200%
0%
A 4
8-Br-cAMP and Dex.
R2 = 0.09
p = 0.47
t\
a4 p < 0.001
' Control:Y R2 = 0.15,ikA 
* A p = 0.35
0% 200% 400% 600% 800% 1000% 1200%
Relative p300 expression
800% -
c
■f 200%- I
600%-
400%-
0%-
8-Br-cAMP and Dex. 
R2 ^ 0.75
p < 0.01
; a  a
f A N.S.
Ai
é
Control:
R2 = 0.91
p<  0.001+
0% 200% 400% 600% 800% 1000% 1200%
Relative hsPGC-1 a expression
D
c0%£
1
i0)>
600%-
400%-
% 2 00%.
0%.
11'* A
B-Br-cAMP and Dex.: 
R2 = 0.69 
p < 0.05
A 4
4 p < 0.001
A 4
Control: 
R2 = 0.47 
p = 0.06
—I----- 1—'—I----- 1----- 1----- 10% 200% 400% 600% 800% 1000% 1200%
Relative mmPGC-la expression
Figure 6.21: Correlations between expression of PEPCK and (A) HNF4a, (B) p300 
(C) endogenous PG C -la and (D) exogenous PG C -la mRNA levels under incubation 
conditions of 1 mM 8-Br-cAMP and 1 pM dexamethasone. Linear regression analysis 
of the relationships between PEPCK and HNF4a / co-activator inRNA expression levels 
was performed with data from control (closed triangles A) and 8-Br-cAMP +Dex. (open 
triangles A ) incubation conditions as presented in Figures 6.16 to 6.18. Results are 
presented as individual datapoints with linear regression analyses indicated by a dashed 
line with adjacent R  ^and /7-values, f  Anomalous datapoints omitted from analysis (Figme 
6.19). Differences between contr ol and 8-Br-cAMP+Dex. incubation conditions were 
analysed by comparing the linear regression analyses and a significant difference between 
the intercepts or slopes of the two lines is indicated by a double-anow and adjacent p- 
value OY N.S. in the case of no significant differences. (If the difference is between the 
slopes, tills is noted; no additional notation corresponds to a difference between the 
intercepts).
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Figure 6.22: Correlations between expression of PEPCK and (A) HNF4a, (B) p300
(C) endgenous PGC-la and (D) exogenous PGC-la mRNA levels under incubation 
conditions of 25 mM glucose and 100 nM insulin. Lineai* regression analysis of the 
relationships between PEPCK and HNF4a / co-activator mRNA expression levels was 
performed with data from control (closed triangles A) and 25 mM glucose + Ins. (open 
triangles A ) incubation conditions as presented in Figures 6.16 to 6.18. Results are 
presented as individual datapoints with linear regression analyses indicated by a dashed 
line with adjacent R  ^and /7-values, f  Anomalous datapoints omitted fr om analysis (Figure
6.19).
Differences between the incubation conditions were analysed by compaiing the lineai* 
regression analyses and a significant difference between the intercepts or slopes of the two 
lines is indicated by a double-arrow and adjacent /7-value or N.S. in the case of no 
significant differences. (If the difference relates to the slopes, this is noted; no additional 
notation corresponds to a difference between the intercepts).
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Under ‘fed state’ conditions, PEPCK expression levels showed no relationship with those of 
HNF4a (R  ^= 0.00, p  = N.S.) (Figure 6.22A), suggesting decreased HNF4a activity. A 
decreased slope in the relationsliip between HNF4a and PEPCK mRNA expression levels 
was also apparent for cells incubated with insulin or 25 niM glucose individually (Appendix, 
Figure 8.4A and 8.5A). A positive linear relationship between human PGC-la and PEPCK 
expression levels was observed under for the 25 mM glucose and insulin incubation condition 
(R  ^= 0.53,p  < 0.05) (Figine 6.22C), whilst exogenous PGC-la expression did not correlate 
with PEPCK niRNA expression (Figure 6.22D). In presence of insulin only, human PGC-la 
expression levels did not con elate with those of PEPCK and a significant decrease in the 
slope of the linear regression analysis compared to conti ol also suggested that decreased 
PGC-la activity had a negative impact on PEPCK mRNA expression (Appendix, Figuie 
8.4C). Likewise, exogenously expressed PGC-la mRNA levels did not correlate with those 
of PEPCK in the presence of insulin or 25 mM glucose (Appendix, Figui es 8.4D and 8.5D).
The expression of the oppositely regulated target gene, L-PK, was also analysed under the 
same range of conditions as PEPCK by two-way ANOVA (Figure 6.23). Whilst direct 
differences between the two transfection conditions were not noted in post-hoc tests, the 
influence of incubation condition on the expression of L-PK was different between the 
control and HNF4a-p300-PGC-la transfection groups, with a significant interaction between 
ti’ansfection condition and incubation condition being shown by two-way ANOVA (p <
0.05). In the contiol transfection condition, the expression of L-PK was significantly lower 
(> 50%) when cells were incubated with 8-Br-cAMP compared to L-PK expression in the 
presence of dexamethasone, insulin, 25 niM glucose or 25 mM glucose with insulin (Figure 
6.23). L-PK expression was also at least 40% lower in the presence of 8-Br-cAMP with 
dexamethasone compared to fom* other incubation conditions (dexamethasone, insulin, 25 
mM glucose or 25 mM glucose with insulin) (Figure 6.23).
When HNF4a, p300 and PGC-la were overexpressed, L-PK expression in the presence of 8- 
Br-cAMP was no longer decreased compared to any of the other incubation conditions. In 
addition, L-PK expression under tlie ‘fed-state’ conditions of 25 mM glucose or 25 mM 
glucose with insulin was decreased relative to the dexamethasone incubation condition (p < 
0.05) (Figure 6.23). Tliis suggests that overexpression of HNF4a in combination witli p300 
and PGC-la reduces L-PK expression under conditions mimicking the fed-state (25 mM
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glucose or 25 mM glucose with insulin), whilst attentuating the inhibitory action of 8-Br- 
cAMP on L-PK expression (Figure 6.23).
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Figure 6.23: Role of HNF4a-p300-PGC-la complex in the regulation of L-PK 
mRNA expression by metabolic stimuli. HepG2 cells were transfected with control 
(pcDNA3) or HNF4a, p300 and PGC-la expression vectors and incubated under 
different conditions as described in Figure 6.15. Total RNA was isolated, cDNA prepared 
and gene expression measured by real-time PCR. L-PK expression levels were 
normalised to B2M and expressed relative to the control transfection and incubation 
condition. Results are expressed as mean values ± SEM (n = 4). The effects of 
expression vector and incubation condition were analysed by two-way ANOVA, with the 
results of Bonferroni post-hoc tests indicated with the least significant p-value (* p  <0.05).
The relationship between the expression of HNF4a, p300 and PGC-la and that of the L-PK 
gene was investigated by linear regression analysis, in order to gain insight into whether each 
transcription factor was linked to stimulation or repression of L-PK transcription under each 
set of incubation conditions. As differences in the expression of L-PK were observed 
between the two transfection groups under incubation conditions of 8-Br-cAMP, 25 mM 
glucose or 25 mM glucose with insulin (Figure 6.23), correlation analyses for these 
incubation conditions are presented here (Figures 6.24 to 6.26) with analysis of the remaining 
incubation conditions displayed in the Appendix (Section 8.4, Figures 8.6-8.8).
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8-Br-cAMP induced a significant decrease in L-PK expression compared to control 
conditions, as judged by a lower intercept of linear regression analyses of HNF4a and 
exogenous PGC-la v^ . L-PK mRNA levels (Figure 6.24A and D). Both HNF4a and 
exogenous PGC-la expression levels positively correlated with those of L-PK in the 8-Br- 
cAMP condition, (R  ^= 0.93, p  < 0.001, with omission of an anomalous value) (Figure 6.24A) 
and (R  ^= 0.62, p  < 0.05) (Figure 6.24D) respectively. L-PK mRNA expression did not show 
concentration-dependence with p300 or endogenous PGC-la expression levels (Figure 6.24B 
and C).
Based on linear' regression analysis, incubation of UepG2 cells with dexamethasone had the 
opposite effect on L-PK compared to PEPCK mRNA expression, with higher intercepts in the 
relationships between HNF4a, p300 and mouse PGC-la vs. L-PK mRNA levels in the 
dexamethasone condition compared to control (Appendix, Figure 8.6A, B and D). In 
contrast, 8-Br-cAMP combined with dexamethasone inhibited L-PK mRNA expression based 
on decreased intercepts of linear regression analyses for all four transcription (co-)factors vf. 
L-PK (Appendix, Figure 8.7A-D). Unlike in the presence of 8-Br-cAMP alone, L-PK mRNA 
expression did not significantly correlate with HNF4a or PGC-la mRNA levels in the 8-Br- 
cAMP and dexamethasone incubation condition (Appendix, Figure 8.7A and C).
Under incubation conditions corresponding to the fed state {i.e. those with the addition of 
insulin, 25 mM glucose or both to the cell culture rnediimi), no significant differences 
between these incubation conditions and the control condition were observed by linear' 
regression analysis of HNF4a or co-activator v.y. L-PK expression levels (Figures 6.25, 6.26 
and Appendix, Figure 8.8), suggesting tliese stimuli did not induce L-PK mRNA expression 
in HepG2 cells. Changes in HNF4a mRNA expression did not appear' to modulate L-PK 
expression imder these conditions, nor did those of p300 or PGC-la (Figures 6.25, 6.26 and 
Appendix, Figur e 8.8). A negative tr end in the direction of the linear regr ession plot for 
exogenous PGC-la vs. L-PK mRNA expression was obser'vable under conditions of 25 mM 
glucose and insulin, however this came short of significance (R  ^= 0.35, p  = 0.12) (Figure 
6.26D). Differences in the slopes between the analyses of PGC-la vs. L-PK mRNA 
expression for the control and 25 mM glucose and insulin incubation conditions also fell 
short of significance (p = 0.08) (Figure 6.26D).
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Figure 6.24: Correlation between expression of L-PK and (A) HNF4a, (B) p300 (C) 
endogenous PGC-la and (D) exogenous PGC-la mRNA levels under control and 1 
mM 8-Br-cAMP incubation conditions. Analysis of correlation between L-PK and 
I-INF4a / co-activator mRNA expression levels was performed with data from control 
(closed triangles A) and 8-Br-cAMP (open triangles A) incubation conditions, from 
experiment as described in Figures 6.16, 6.17 and 6.23. Results are presented as 
individual datapoints with correlation analyses indicated by a dashed line with adjacent R  ^
and p-vahies. t  Anomalous datapoint (circled) omitted from correlation analysis of 
HNF4a vs. L-PK (8-Br-cAMP incubation). Differences between the incubation conditions 
were analysed by compaiing the linear regression analyses and a significant difference 
between the intercepts or slopes of the two lines is indicated by a double-arrow and 
adjacent p-value or KS. in the case of no significant differences. (If the difference relates 
to the slopes, tliis is noted; no additional notation corresponds to a difference between the 
intercepts).
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Figure 6.25: Correlation between expression of L-PK and (A) HNF4a, (B) p300 (C) 
endogenous PGC-la and (D) exogenous PGC-la mRNA levels under incubation 
conditions of 25 mM glucose. Analysis of coiTelation between L-PK and HNF4a / co- 
activator mRNA expression levels was performed with data ftom contiol (closed triangles 
A ) and 25 mM glucose (open tiiangles A ) incubation conditions from experiment as 
described in Figures 6.16, 6.17 and 6.23. Results are presented as individual datapoints 
with correlation analyses indicated by a dashed line with adjacent R  ^and/?-values. 
Differences between the incubation conditions were analysed by compaiing the linear 
regiession analyses and a significant difference between the intercepts or slopes of the two 
lines is indicated by a double-airow and adjacent p-value or N.S. in the case of no 
significant differences. (If the difference relates to the slopes, this is noted; no additional 
notation corresponds to a difference between the intercepts).
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Figure 6.26: Correlation between expression of L-PK and (A) HNF4a, (B) p300 (C) 
endogenous PG C -la and (D) exogenous PG C -la mRNA levels under incubation 
conditions of 25 mM glucose and insulin. Analysis of correlation between L-PK and 
HNF4a / co-activator mRNA expression levels was performed with data from control 
(closed triangles A ) and 25 mM glucose and insulin (open triangles A ) incubation 
conditions from experiment as described in Figuies 6.16, 6.17 and 6.23, Results aie 
presented as individual datapoints with conelation analyses indicated by a dashed line 
with adjacent R  ^and p-values. Differences between the incubation conditions were 
analysed by comparing the linear regiession analyses and a significant difference between 
the intercepts or slopes of the two lines is indicated by a double-arrow and adjacent p- 
valiie or N.S. in the case of no significant differences. (If the difference relates to the 
slopes, this is noted; no additional notation corresponds to a difference between the 
intercepts).
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6.8 Discussion
6.8.1 Effects of metabolic stimuli in HepG2 cells
In characterising the role of HNF4a in differentially regulated targets genes, the regulation of 
multiple target genes by a range of physiological mediators was initially characterised in 
HepG2 cells, prior to studying the impact of HNF4a and co-activators on their expression. 
Metabolic stimuli investigated included endocrine mediators of tlie fasting (glucagon, 
dexamethasone) and fed (insulin) cycle, as well as compounds stimulating intracellular 
signalling downstream of glucagon (8-Br-cAMP, IBMX). Postprandial increases in glucose 
concentration were investigated by raising the glucose concentration of medium from 5.5 
mM to 25 mM. Metabolic regulation of target genes by the activation of intracellular energy­
sensor, AMPK, was also investigated by incubating HepG2 cells with AICAR.
Glucagon did not stimulate tlie expression of PEPCK in HepG2 cells, however downstream 
effectors of glucagon, 8-Br-cAMP and IBMX, produced 220% and 100% increases in 
PEPCK mRNA levels respectively (Figure 6.IB). These findings suggest glucagon 
signalling in HepG2 cells is defective at the level of the glucagon receptor. The expression of 
G-6-Pase catalytic subunit which, like PEPCK, is stimulated by glucagon in vivo, was also 
refractory to glucagon in HepG2 cells (Hombuckle et a l, 2004). Transfection of HepG2 
cells with a glucagon receptor expression vector restored glucagon sensitivity to G-6-Pase 
catalytic subunit reporter gene expression (Hornbuckle et a l, 2004). In agreement with the 
results of 8-Br-cAMP on gluconeogenic gene expression in HepG2 cells presented here 
(Figure 6.IB), cAMP analogues also stimulated PEPCK reporter gene expression 
(Ruclctaeschel et a l , 2000), and G-6-Pase mRNA expression in tliis cell line (Hornbuckle et 
a l, 2004). In a similai" manner to their effects on PEPCK mRNA expression, L-PK mRNA 
expression was not altered by glucagon itself, wliilst downstream activators, 8-Br-cAMP and 
IBMX, decreased L-PK mRNA levels, albeit non-significantly (Figure 6.2A).
Investigation of the timecomse of cAMP action on PEPCK expression suggested that PEPCK 
mRNA levels reached a maximum after 6 hours incubation with 8-Br-cAMP (Figure 6.4A), a 
similar timeframe to the induction of PEPCK gene expression observed in primary rat 
hepatocytes (maximal at 2 horns) (Koo et a l, 2005) or human hepatocytes (maximal at 3 
hours) (Song and Chiang, 2006). Measurement of L-PK mRNA levels over the same
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timeframe ( 0 -8  hours) did not reveal a consistent tiend in the inliibitory action of 8-Br- 
cAMP on L-PK gene expression (Figure 6.4B). The extent of inhibition of L-PK expression 
also varied under the contiol transfection condition in later experiments with transfected 
cells, with 8-Br-cAMP not producing a significant down-regulation in L-PK mRNA levels vs. 
control medium (Figures 6.1 OB, 6.13C and 6.23). On the other hand, a robust induction of 
PEPCK by 8-Br-cAMP was observed in FIepG2 cells transfected with control DNA (Figures 
6.1OA, 6.13B and 6.18). These results suggest that heterogeneity in the responsiveness of L- 
PK gene regulation by cAMP may exist in HepG2 cells despite limiting the passage number 
to within ten passages. Alterations in the regulation of L-PK by metabolic stimuli have also 
been obsei-ved in rat hepatoma cell lines (Meienliofer et a l, 1987; Lefrancois-Maitinez et a l, 
1994).
Dexamethasone did not stimulate PEPCK mRNA expression in HepG2 cells (Figure 6. IB), 
with linear regression analysis suggesting that dexamethasone had a repressive effect on 
PEPCK mRNA expression compared to control medium (Figure 6.20). Dexamethasone did 
not synergise with 8-Br-cAMP to increase PEPCK expression (Figure 6.18), in contrast to 
results in primary cells (Yoon et a l, 2001). The absence of dexamethasone-stimulated 
PEPCK expression in HepG2 cells in the results presented here is in agreement with a 
previous reports showing dexamethasone does not increase PEPCK reporter gene expression 
above basal levels and even reduces PKA-stiniulated PEPCK expression (Xing and Quinn, 
1993; Sengupta and Wasylyk, 2001). In contrast, the combination of dexamethasone and 8- 
Br-cAMP enhanced PGC-la mRNA expression (Figure 6.17C) and dexamethasone alone 
also had slight stimulatory effect on L-PK mRNA expression (Appendix, Figure 8.4). In 
primary hepatocytes, the combination of 8-Br-cAMP and dexamethasone is also known to 
stimulate PGC-la mRNA expression (Yoon et a l, 2001). However, expression-vector 
derived PGC-la mRNA levels were also increased by this treatment (Figure 6.17D), wliilst 
expression-vector derived-HNF4a expression was not (Figure 6.16A). Possibly 
dexamethasone acts post-transcriptionally to stabilise PGC-la and L-PK transcripts, an 
action of glucocorticoids previously reported for L-PK gene expression (Vaulont et al,
1986).
The apoCIII and FAS genes exhibited non-significant trends to be inliibited and stimulated by 
insulin respectively (Figme 6.2B-C and Figure 6.5). The degiee of inhibition of apoCIII
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niRNA expression brought about by insulin (> 40%, Figuie 6.2B) is in agreement with the 
percentage inhibition of apoCIII reporter gene expression in HepG2 cells, which ranged from 
between 30% and 50% (Li et a l, 1995; Dallinga-Thie et a l, 2001). FAS mRNA expression 
was raised only 88% by incubation of HepG2 cells with insulin. In comparison to the > 19- 
fold increase in FAS mRNA levels brought about by insulin in vivo and in primaiy rat 
hepatocytes (Paulauskis and Sul, 1989; Stoeclmian and Towle, 2002), the response in HepG2 
cells appears blunted and inconsistent.
AICAR did not produce significant effects on the expression of HNF4a mRNA or that of its 
target genes (Figuies 6.1 to 6.3), despite PEPCK, LPK, FAS and SREBP-lc being targets of 
AMPK (Foretz et a l, 1998; Lochliead et a l, 2000; Foretz et a l, 2005). These findings could 
be attributable to the AICAR concentiation used here (0.2 mM): wliilst incubation of primary 
rat hepatocytes with 0.2 mM AICAR resulted in inliibition of HNF4a taiget gene expression, 
including that of L-PK and apoCIII, AICAR concentrations of 1 mM or gieater were required 
to mai'kedly down-regulate expression of the HNF4a target gene, apoAV, in HepG2 cells 
(Prieur et a l , 2005).
PPARa gene expression was unaffected by any of the metabolic stimuli under investigation 
(Figure 6.3A), in contrast to results obtained in primary rat hepatocytes, which indicate that 
PPARa mRNA expression is stimulated by dexamethasone and inhibited by insulm 
(Steineger et a l, 1994). This could be due to differences in transcription factor binding sites 
in the human vs. rat PPARa promoters (Pineda Torra et a l, 2002).
In line with results presented in Chapter 5, SREBP-lc mRNA expression in HepG2 cells was 
not enhanced by insulin in the cell cultuie medimn (Figure 6.3B), nor by glucagon or cAMP, 
which have been shown to inhibit SREBP-lc gene expression in primaiy rat hepatocytes 
(Foretz et a l, 1999b).
6.8.2 Differential gene regulation by HNF4a
HNF4a may differentially regulate its taiget genes under different metabolic states tlnough 
changes in HNF4a abundance and through post-tianslational modifications affecting its 
interactions with target promoters and/or co-factors. The former was investigated by 
monitoring HNF4a mRNA levels in the presence of hormones and protein kinase activators.
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HNF4a mRNA expression in HepG2 cells was not modulated by fasting stimuli 
(dexamethasone, glucagon, 8-Br-cAMP or IBMX) or insulin (Figiues 6.1 A, 6.9, 6.13A and 
6.16A). In agreement with these results, HNF4a mRNA levels also remained stable in 
primary human hepatocytes when incubated with glucagon or 8-Br-cAMP (Song and Chiang, 
2006), in contrast to results in rodent models which show that HNF4a mRNA expression is 
up-regulated under fasting conditions (Oyadomari et a l, 2000; Yoon et a l, 2001). No 
changes in HNF4a expression were brought about by incubation with dexamethasone or 
insulin (Figures 6.1 A and 6.9). This contrasts with results in primary rat hepatocytes, where 
insulin was found to antagonise the stimulatory action of dexamethasone on HNF4a mRNA 
expression (Oyadomari et a l, 2000). In summary, changes in endogenous HNF4a mRNA 
abundance do not play a role in the regulation of HNF4a target genes by metabolic stimuli in 
HepG2 cells.
Changes in the interactions of HNF4a with target promoters induced by metabolic stimuli 
could also regulate HNF4a target genes in a differential manner. This aspect was 
investigated by knockdown of HNF4a function in HepG2 cells. The HNF4a knockdown 
approach was performed by expressing a DN-HNF4a, which forms non-DNA binding 
heterodimers with wild-type HNF4a (Taylor et a l, 1996). The impact of DN-HNF4a 
expression was studied on the expression of HNF4a tar get genes: PEPCK, L-PK, apoCIII 
and FAS (Figures 6.6 to 6.12). Overexpression of DN-HNF4a did not bring about any 
specific changes in the expression of any of the four target genes investigated under contr ol 
incubation conditions (Figures 6.6 and 6.7), possibly due to insufficient expression of these 
genes under the conditions employed. In support of this hypothesis, HNF4a has been shown 
to bind to the apoCIII promoter in HepG2 cells, however recruitment of RNA polymerase II 
is deficient in this cell line (Martinez-Jimenez et a l, 2006). On the other hand, expression of 
an alternative DN-HNF4a with an N-terminal truncation, lacldng a DNA-binding domain, 
did decrease expression of apoCIII at the mRNA level in another study in HepG2 cells 
(Fraser a/a/., 1997).
Overexpression of DN-HNF4a was associated with a non-significant increase in mean 
PEPCK mRNA expression fr om 350% to 550% relative to that of the control incubation and 
transfection condition (Figuie 6.10A). This increase appears counterintuitive, when
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compai'ed to the downward trend in HNF4a-dependent reporter gene expression observed in 
the presence of DN-HNF4a, as shown here (Figure 6.8) and in published studies (Taylor et 
a l, 1996; Gourdon et a l, 1999; Jahan and Chiang, 2005). HNF4a inRNA expression was 
also higher in the presence of DN-HNF4a (Figur e 6.9), although due to lack of specific 
primers, it was not possible to ascertain whether this increase conesponded to endogenous 
transcripts or DN-HNF4a mRNA. Fuilher investigation of the effect of DN-HNF4a on 
PEPCK mRNA expression revealed that PEPCK mRNA levels positively in correlated with 
those of HNF4a (Figure 6.11 A). HNF4a gene expression has been shown to be subject to 
negative autoregulation and overexpression of another DN-HNF4a lacking DNA-binding 
activity resulted in increased endogenous HNF4a mRNA expression (Magenheim et a l,
2005). Therefore, it is possible to speculate that the increase in HNF4a mRNA expression 
observed in the presence of DN-HNF4a (Figure 6.9) mcludes an increase in endogenous 
HNF4a tr anscripts, which could be responsible for the increased in PEPCK expression under 
8-Br-cAMP conditions (Figure 6.11 A). Increased endogenous HNF4a levels in the presence 
of DN-HNF4a may also explain why a four-fold excess of DN-HNF4a plasmid DNA over 
wild-type HNF4a expression vector only produced a 25% decrease in reporter gene 
expression (Figure 6.8).
Increased endogenous HNF4a mRNA expression in the presence of DN-HNF4a could also 
be responsible for the positive, though non-significant, trend in the relationship between 
HNF4a and L-PK mRNA levels in the presence of 8-Br-cAMP (Figure 6.1 IB). In the 
presence of DN-HNF4a but not control expression vector, 8-Br-cAMP also had a significant 
inhibitory effect on L-PK expression, suggesting that HNF4a has a role in mediating the 
negative effects of glucagon-cAMP on L-PK expression. HNF4a binding studies using rat 
liver extracts and reporter gene studies in rat hepatocytes also point to HNF4a being a key 
mediator of the negative effects of cAMP on L-PK expression (Viollet et a l, 1997; Gourdon 
et a l, 1999).
6.8.3 The role of co-activators In differential gene regulation by HNF4a
The mechanisms by wliich HNF4a differentially regulates transcription of PEPCK and L-PK 
were further investigated by studying the effects of co-activators, p300 and PGC-la. When 
individual co-activators were overexpressed, induction of PEPCK expression by 8-Br-cAMP
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was evident under tlie control and PGC-la overexpression conditions, but not in the p300 
overexpression condition (Figure 6.13B), suggesting that PGC-la overexpression facilitates 
PEPCK induction by 8-Br-cAMP. PEPCK expression also showed positive correlation with 
FINF4a expression levels (Figure 6.14), suggesting that co-activator effects were dependent 
upon HNF4a levels, in agreement with studies showing the partnership of HNF4a and PGC- 
l a  in PEPCK expression (Rliee et a l, 2003). For the L-PK gene, inhibition of its expression 
was evident when p300 was overexpressed, but not in the control or PGC-la conditions 
(Figure 6.13C). As with co-activator effects on PEPCK expression, HNF4a expression 
levels appeared to be a determining factor for L-PK expression (Figure 6.15).
The relationship between HNF4a and co-activators was further investigated by co-expression 
of HNF4a, p300 and PGC-la under a range of metabolic conditions (Figures 6.16 to 6.26). 
Maximal mean PEPCK mRNA expression occurred in the presence of 8-Br-cAMP and 
overexpression of HNF4a, p300 and PGC-la (Figure 6.18), which coincided with maximal 
HNF4a expression levels (Figure 6.16A).
HNF4a expression levels positively correlated with basal PEPCK expression (control 
medium) and over a limited range of HNF4a levels under incubation with 8-Br-cAMP 
(Figure 6.19 A). However, the linearity of the relationship between the two variables did not 
extend to datapoints corresponding to maximum PEPCK or maximum HNF4a expression, 
suggesting that HNF4a levels are not the limiting factor in promoting PEPCK transcription, 
once full occupancy of the PEPCK promoter by HNF4a is achieved (Figure 6.19A). Further 
induction of PEPCK expression is then dependent on the interaction of HNF4a and PGC-la, 
as illustrated by the linear relationsliip between exogenously expressed PGC-la and PEPCK 
mRNA levels in the presence of 8-Br-cAMP, either alone or in combination with 
dexamethasone (Figures 6.19D and 6.2ID). These results are in broad agreement with 
published work, which show that HNF4a expression is a requirement for the induction of 
PEPCK expression brought about by PGC-la overexpression (Rhee et at., 2003). Increased 
degradation of the GR in the presence of dexamethasone (Sengupta and Wasylyk, 2001) 
could lead to reduced activity of HNF4a and PGC-la in stimulating PEPCK expression, as 
evidenced by a lack of correlation between HNF4a and PGC-la with PEPCK mRNA
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expression levels in the presence of dexamethasone (Figure 6.20), suggesting the GR could 
be a component of the complex with HNF4a and PGC-la (Yoon et al., 2001).
Under the opposite metabolic conditions of high glucose concentration and insulin, PGC-la 
expression levels also con elated with those of PEPCK, whereas PEPCK expression was 
independent of HNF4a expression levels, in contrast to the contiol incubation condition 
(Figure 6.22). This suggests that HNF4a and PGC-la do not functionally interact under fed 
conditions at the PEPCK promoter. Indeed, decreased binding of HNF4a to the distal GRU 
upon incubation with insulin has been observed in vivo (Cassuto et a l, 2005). Possibly, 
PGC-la activates PEPCK expression via alternative protein-protein interactions mider these 
conditions, such as with the GR (Knutti et a l, 2000; Yoon et a l, 2001).
For the oppositely-regulated HNF4a target gene, L-PK, the inhibitory effects of 8-Br-cAMP 
on L-PK expression were diminished when HNF4a was overexpressed together with p300 
and PGC-la (Figuie 6.23). Fiuther analysis revealed a positive correlation between HNF4a 
mRNA levels with L-PK mRNA levels in the presence of 8-Br-cAMP (Figure 6.24A), 
suggesting that HNF4a overexpression counteracts the inhibitory effect of cAMP on L-PK 
expression, but not under other metabolic conditions (Figures 6.23-6.25). This confirms that 
HNF4a is a critical factor in the response of L-PK to fasting stimuli, in line with published 
works (Bergot et a l, 1992; Viollet et a l, 1997; Gourdon et a l, 1999). Exogenously-derived 
PGC-la expression levels also positively correlated with L-PK expression under this 
metabolic condition (Figure 6.24D), suggesting that the HNF4a-PGC-la interaction could 
also be active in permitting L-PK m the presence of 8-Br-cAMP. On the other hand, the 
decrease in L-PK expression in the presence of 25 mM glucose and insulin (Figme 6.23) 
coincided with a non-significant downward trend in tlie relationship between ectopically 
expressed PGC-la and L-PK mRNA levels (Figme 6.26D). This result suggests that PGC- 
la  does not co-activate HNF4a under these conditions and may disrupt interactions between 
HNF4a and other factors boimd to the L-PK promoter.
Unlike HNF4a and PGC-la, p300 mRNA levels were not raised by p300 overexpression 
(Figme 6.16B) which may be one reason why p300 mRNA levels did not correlate with those 
of PEPCK or L-PK under any of the incubation conditions (Figures 6.19 -  6.22, Figures 6.24-
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6.26 and Appendix, Figures 8.4-8.8). p300 mRNA levels may be tightly controlled at a post- 
transcriptional level, such that increased transcription of p300 did not impact on the p300 
mRNA pool. In addition, p300 mRNA expression may already be at a level in HepG2 cells 
which does not limit the formation of an active complex at target promoters. Indeed, p300 
was found to be expressed in HepG2 cells at levels comparable to those of primaiy human 
hepatocytes (Martinez-Jimenez et al., 2006). Wlien p300 alone was overexpressed, L-PK 
expression was inhibited by incubation of cells with 8-Br-cAMP (Figure 6.13C), which 
suggests that p300 does not compete with the factors responsible for mediating this effect. 
This finding is in agreement with those of Gourdon et al. (1999), who found that p300 
overexpression did not prevent the inhibition of L-PK reporter gene expression by cAMP.
In summary, HNF4a was found to play a role in cAMP-stimulated PEPCK expression based 
on the results of DN-HNF4a overexpression (Section 6.5). HNF4a was also a limiting factor 
in PEPCK expression when individual co-activators were overexpressed (Section 6.6). 
Overexpression of HNF4a together with p300 and PGC-la raised cAMP-stimulated PEPCK 
expression, witli PEPCK mRNA levels positively correlating with those of HNF4a and PGC- 
l a  in the presence of 8-Br-cAMP, suggesting that HNF4a and PGC-la interact to stimulate 
PEPCK expression under these conditions (Section 6.7). HNF4a mRNA expression was 
also found to be a limiting factor in L-PK expression in the presence of 8-Br-cAMP, based on 
DN-HNF4a and co-activator overexpression experiments (Sections 6.5 and 6.6). 
Overexpression of HNF4a, p300 and PGC-la relieved the inhibitory action of 8-Br-cAMP 
on L-PK expression, whilst L-PK expression in the presence of 25 mM glucose was reduced 
(Section 6.7). Taken together, the results of studying PEPCK and L-PK expression under 
fasting vj. fed conditions suggest that HNF4a positively interacts witli PGC-la under fasting 
conditions, whilst a protein complex of HNF4a and PGC-la does not activate transcription 
under fed conditions.
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Chapter 7:
7.1 Conclusion
The development of T2DM is associated with the dysregulation of metabolic pathways in 
response to endocrine stimuli which signal the nutritional status of the organism, namely 
insulin signalling the fed state and glucagon signalling the fasting state. In the state of insulin 
resistance associated with the development of T2DM, insulin fails to suppress hepatic 
gluconeogenesis. On the other hand, hepatic glycolysis and lipogenesis aie stimulated by 
hyperinsulinaemia, which results from tlie compensatory response of the p-cell to insulin 
resistance in the liver, muscle and adipose tissue (Kahn, 2003). Since HNF4a is a candidate 
gene for T2DM, its regulation of tai get genes in the above-mentioned metabolic pathways 
may play a role in the pathogenesis of the disease (Gupta and Kaestner, 2004). Therefore, 
this project focussed on the role of HNF4a in the regulation of its hepatic target genes by 
metabolic stimuli and possible mechanisms which facilitate its involvement in differentially- 
controlled processes.
In vitro hepatic cellular models are a usefril resource for the study of liver biology under 
disease states such as diet-induced obesity, or for prediction of in vivo toxicology of 
investigational new drugs (Gomez-Lechon et ah, 2007; Castell et ah, 2006). Therefore it was 
important to find a suitable model for studying HNF4a activity and the first aim of this study 
was to characterise the expression of HNF4a and its splice valiants in three in viti'o human 
liver models, the HuH7, HepG2 and Hep3B hepatoma cell lines. HepG2 and Hep3B cells 
were found to express a similar profile of HNF4a splice variants compared to human liver 
(Chapter 3), suggesting that these cell lines provide the best models for study of HNF4a 
activity. Since the HepG2 cell line displayed physiological trends in the regulation of 
apoCIII and FAS by insulin and high glucose concentration (Chapter 3), this cell line was 
thought to provide the best in vitj'o model for further exploration of the role of HNF4a in the 
metabolic regulation of its tar get genes (Chapters 4 to 6).
However, the regulation of HNF4a target genes in HepG2 cells differed in some aspects to 
results obtained in vivo and in primary hepatocyte model systems. For example, despite 
apoCIII being a well-established target gene of HNF4a (Section 1.5.4), apoCIII mRNA
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expression in HepG2 cells was not modulated by overexpression of DN-HNF4a (Figure 6.7). 
In previous studies, many target genes of HNFs were found to be down-regulated in 
hepatocellular carcinomas (Xu et a l, 2001a). ApoCIII was amongst the genes that were 
down-regulated in gene expression microar ray profiling of different hepatocellular- carcinoma 
samples, as were other HNF4a target genes, PEPCK, G-6-Pase, transthyretin, transfemn, 
GAPDH, and FAS (Xu et a l, 2001a; Xu et a l, 2001b). Overexpression of wild-type HNF4a 
was found to reactivate apoCIII expression in HepG2 cells, suggesting that apoCIII 
transcription responds to increased, rather tlian decreased, FINF4a activity (Naiki et a l, 
2004). These findings suggest that the HepG2 cell line displays lower HNF4a activity than 
primary hepatocytes, which can limit tlie expression of HNF4a target genes (Castell et al.,
2006).
The metabolic flexibility of in vitro hepatocellular models in terms of responsiveness to 
hormonal stimulation, for example, in the up-regulation of glycogen synthesis in response to 
insulin is considered a key feature of differentiated liver function (Gomez-Lechon et al., 
2001). In the current study, metabolic flexibility at the level of gene transcription in HepG2 
cells was important for studying changes in HNF4a activity due to metabolic stimuli such as 
insulin, glucagon and glucocor-ticoids. Insulin was found to stimulate HNF4a-dependent 
SREBP-lc reporter gene expression (Chapter 4), however insulin did not activate the 
transcription of endogenous SREBP-lc gene transcription (Chapter 5). A trend for insulin to 
stimulate endogenous FAS gene expression was observed, however this was inconsistent 
(Figure 6.2). An intact insulin-PI3K-PKB signalling pathway has been utilised in HepG2 
cells to study the effects of glucotoxicity on the development of insulin resistance, and 
intracellular- effects of insulin such as stimulation of glycogen synthesis are observed in 
HepG2 cells (Nalcajima et a l, 2000), suggesting that insulin signalling cascades are active in 
HepG2 cells. Insulin is able to modulate the expression of some endogenous genes m HepG2 
cells, such as the suppression of insulin-like growth factor-binding protein-1 and MTP gene 
expression by insulin (Cichy et a l, 1998; Au et a l, 2003), but not others, for example, 
PEPCK (Quinn and Yeagley, 2005). This suggests that the limited induction of SREBP-lc 
and its target gene, FAS, by insulin could be due to the expression of gene-specific factors 
being limiting in HepG2 cells (Quinn and Yeagley, 2005). The results of Chapter 5 in 
conjunction with published work suggest that SREBP-lc expression is down-regulated and
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non-inducible in HepG2 cells, hence low SREBP-lc expression could limit the stimulation of 
FAS mRNA expression by insulin (Shimoimna et a l, 1997; Foretz et a l, 1999a).
The induction of L-PK mRNA expression by high media glucose concentration was also 
limited in HepG2 cells (Figure 6.22). CliREBP is required for induction of L-PK expression 
by high glucose concentration (Yamashita et a l, 2001), however the relative expression of 
this transcription factor in HepG2 cells compared to primary hepatocytes is unknown.
Possibly low expression of ChREBP prevents an inductive effect of high glucose 
concentration on L-PK mRNA expression. Alternatively a repressor of L-PK expression in 
HepG2 cells could limit L-PK mRNA expression. An extinguisher of L-PK expression 
acting at an upstream region (between -1.2 and 2.1 kb) in tlie L-PK promoter was obseiwed in 
reporter gene experiments with HepG2 cells (Raymondjean et a l, 1991; Cognet et a l, 1991). 
The latter conclusion would explain why induction of expression of a reporter plasmid 
containing elements of the L-PK proximal promoter (-196 bp) showed induction by high 
glucose concentration in HepG2 cells (Figure 4.1), whilst endogenous L-PK mRNA 
expression was not inducible by high glucose concentration (Figure 6.22). As discussed in 
Chapters 4 and 6, lack of dexamethasone effects on PEPCK expression in HepG2 cells are 
attributable to increased turnover of the GR in response to dexamethasone in this cell line 
(Xing and Quinn, 1993; O'Brien et a l, 1995; Sengupta and Wasylyk, 2001). Overexpression 
of GR restores glucocorticoid-responsiveness to PEPCK reporter gene expression, confirming 
the expression of the GR as a key limiting factor in the effect of dexamethasone in HepG2 
cells (Cassuto et a l, 2005).
The second aim of the current study was to study the regulation of HNF4a ti anscriptional 
activity by fasting and feeding stimuli as reflected in downstream effects on target gene 
expression in order to evaluate the role of HNF4a in controlling the metabolic pathways of 
gluconeogenesis, glycolysis and lipogenesis.
As a model gene of the gluconeogenic pathway, PEPCK gene transcription is up-regulated in 
the fasting state by glucagon and glucocorticoids, hence die role of HNF4a in these effects 
was investigated. Although PEPCK reporter gene expression was not responsive to glucagon 
in HepG2 cells (Chapter 4), the downstream activator, 8-Br-cAMP, stimulated PEPCK 
mRNA expression in this cell line (Figuies 6.1). Under conditions of DN-HNF4a, HNF4a
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niRNA levels positively correlated with those in PEPCK in the presence of 8-Br-cAMP, 
suggesting that glucagon stimulates HNF4a activity and results in increased PEPCK 
transcription. Overexpression of HNF4a, PGC-la and p300 also enhanced PEPCK mRNA 
expression in the presence of 8-Br-cAMP. From these results, it was concluded that cAMP 
(which acts downstream of glucagon) stimulates HNF4a activity and promotes the 
expression of PEPCK and potentially other gluconeogenic enzymes. This finding agrees 
published works, which point to HNF4a as a key player in up-regulation of PEPCK and G-6- 
Pase by glucagon and cAMP (Rliee et ah, 2003; Gautier-Stein et al., 2005). In T2DM 
hepatic glucose output is increased, with one cause being a deficiency in insulin to inliibit 
PEPCK tianscription (Postic et al., 2004). In tliis scenaiio, it is postulated that HNF4a 
would stimulate gluconeogenesis and contribute to increased hepatic glucose output. This 
would be exacerbated by the increased expression of PGC-la observed in the diabetic state 
(Finck and Kelly, 2006).
The results of the current study also led to the conclusion that HNF4a plays a role in the 
inhibition of L-PK mRNA expression by glucagon, as demonstiated by the positive 
correlation between HNF4a and L-PK niRNA levels under 8-Br-cAMP incubation 
conditions (Figure 6.15). In additon, inliibition of L-PK mRNA expression by 8-Br-cAMP 
was overcome by HNF4a, p300 and PGC-la overexpression (Figure 6.22), suggestmg that 
the balance between HNF4a and other transcription factors is important in determining L-PK 
gene repression by cAMP. This finding is in agreement with studies in rat liver which 
demonstrate a role for HNF4a down-regulation of L-PK transcription in the fasting state 
(Viollet et al., 1997; Gourdon et al., 1999). It is hypothesised that increased HNF4a activity 
would result in increased flux through the glycolytic pathway, contributing to substrate 
availability for lipogenesis.
Investigation of the role of HNF4a in lipogenic gene expression focussed on the expression 
of the SREBP-lc and FAS genes, two key regulators of lipogenesis at the transcriptional and 
enzyme levels respectively (Sections 1.3.3 and 1.4.3). As the transcription of these target 
genes is stimulated by insulin (Section 1.8.3 and 1.8.4), the hypothesis that HNF4a 
tianscriptional activity is enhanced by insulin was tested. The stimulation of HNF4a- 
dependent SREBP-lc reporter gene expression by incubation of HepG2 cells with insulin 
provides evidence for this hypothesis (Figures 4.5 and 4.9). On the other hand, results of
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DN-HNF4a overexpression on FAS mRNA expression (Figure 6.12) were relatively 
inconclusive, in that insulin did not robustly induce FAS mRNA expression in HepG2 cells 
(Figure 6.2). Based on the results of SREBP-lc reporter gene studies, it was concluded that 
insulin stimulates HNF4a activity and promotes the expression of SREBP-lc. This finding 
suggests that HNF4a could contribute to the up-regulation of SREBP-lc expression observed 
in insulin resistant states (Shimoimna et ah, 2000) and thereby contribute to increased de 
novo lipogenesis observed in NAFLD (Donnelly et ah, 2005).
The final aim of the current reseaich was to investigate the mechanisms wliich enable 
HNF4a to differentially regulate taiget genes in different metabolic pathways. Further 
elucidation of these mechanisms may form a groundwork for the development of therapies 
targeted to reduce hepatic gluconeogenesis in T2DM or to inliibit hepatic lipogenesis in 
NAFLD. The findings of this project suggest that different protein complexes containing 
different HNF4a co-factors aie involved in the activation of HNF4a target genes in the 
fasting state compar ed to the fed state. A hypothetical series of models was devised in order 
to explain experimental observations (Figure 7.1), which will be elaborated on below.
The co-activator PGC-la is an important HNF4a partner in expression of gluconeogenic 
enzymes, apolipoproteiiis and bile acid synthesis enzymes (Rliee et ah, 2003; Rliee et ah, 
2006; Bhalla et ah, 2004). The findings from this project provide novel evidence that the 
interaction of HNF4a with PGC-la are dependent on metabolic stimuli.
In studying regulation of PEPCK gene expression by HNF4a and PGC-la, it was noted that 
incubation conditions altered the interaction between HNF4a and PGC-la. Co-transfection 
of HepG2 cells with HNF4a and PGC-la followed by incubation with standard culture 
medium repressed PEPCK reporter gene expression compared to HNF4a overepression alone 
(Figure 4.4). On the other hand, HNF4a, PGC-la and p300 overexpression in the presence 
of 8-Br-cAMP enhanced PEPCK mRNA expression (Figure 6.18). In combination, these 
results suggest that increased intracellular' cAMP levels enhance the interaction of HNF4a 
and PGC-la and that this mteraction could be dependent on the phosphorylation state of 
either or both factors. In a dephosphorylated state, a negative regulatory domain of PGC-la 
has been shown to interact with the co-repressor pl60myb (Fan et a l, 2004).
Phosphorylation of PGC-la by p38 MAPK increases its transcriptional activity and relieves
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its interactions with co-repressors (Puigsei-ver et a l, 2001; Fan et a l, 2004). p38 MAPK 
activity has been shown to be stimulated by glucagon signalling in hepatocytes, with 
phosphorylation of PGC-la by p38 MAPK playing a stimulatory role in gluconeogenesis 
(Cao et a l, 2005).
HNF4a is also phosphorylated downstream of glucagon by PKA and also potentially by p38 
MAPK (Viollet et a l, 1997; Guo et a l, 2006). HNF4a phosphorylation by PKA on S129 has 
been linlced to decreased DNA-binding activity, wliilst phosphorylation by p38 MAPK on 
SI58 has been shown to enliance DNA-binding and /ra«5-activation potential, and to stabilise 
HNF4a protein levels (Viollet et a l, 1997; Guo et a l, 2006; Xu et a l, 2007). Therefore, it is 
postulated that a specific HNF4a phosphorylation pattern is brought about in the fasting state 
which facilitates tlie interaction of HNF4a with PGC-la (Figure 7.1 A).
A second stimulus in the fasting state is raised plasma glucocorticoid levels (Section 1.1.2). 
Since activation of PEPCK expression by glucocorticoids was not observed in HepG2 cells 
(as discussed in the first part of this section), it is hypothesised that HNF4a and PGC-la 
form pait of a multi-protein complex with the GR within the GRU of the PEPCK promoter 
(Figure 7.1 A), based on other studies which show that glucocorticoids promote binding of 
HNF4a to the PEPCK promoter (Cassuto et a l , 2005).
Under the opposite metabolic conditions corresponding to the fed state, results of Q-PCR 
analysis indicated that HNF4a and PGC-la do not functionally interact, as a positive 
correlation with PEPCK mRNA expression levels was observed under these conditions for 
PGC-la, but not for HNF4a (Figure 6.21). This result suggests that insulin and high glucose 
concentiation alter the phosphorylation state of HNF4a and potentially disrupt its interactions 
with PGC-la and the GR in tlie fed state.
Results of studying L-PK and SREBP-lc expression also led to the conclusion that PGC-la 
is not the functional partner of HNF4a under fed state conditions. Co-ti’ansfection of 
HNF4a, p300 and PGC-la tended to suppress L-PK mRNA expression under cell cultuie 
conditions mimicking the fed state (Figure 6.22). L-PK reporter gene expression was 
enlianced by high glucose concenhation (Figure 4.1) and insulin enlianced reporter gene 
expression from L-PK promoter constiucts containing HNF4a and ChREBP binding sites
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when HNF4a was overexpressed (Figure 4.2). These results suggest that HNF4a interacts 
with other protein par tners in the fed state at the L-PK promoter. A candidate for the 
interaction with HNF4a at the L-PK promoter is ChREBP, although additional co-activator 
proteins may be involved (Figure 7.IB). In addition to the activation of CliREBP by 
dephosphorylation by glucose (Kawaguchi et a l, 2001), the interaction of HNF4a with 
ChREBP is possibly further enhanced by an altered HNF4a phosphorylation status in the fed 
state. In the absence of glucagon signalling, HNF4a is likely to be dephosphorylated at SI 34 
(Viollet e/fl/., 1997).
The results of SREBP-lc reporter constr uct experiments suggest that insulin enliances 
HNF4a activity in the context of the SREBP-lc promoter. As noted for L-PK above, this 
enhancement of transcriptional activity could be through changes in FINF4a phosphorylation 
state brought about by insulin downstream signalling (Figure 7.1C). Co-transfection of 
HNF4a with PGC-la or p300 repressed SREBP-lc reporter gene expression, (Figure 4.5 to 
4.8), providing frnther evidence that HNF4a:co-activator interactions are dependent on 
promoter context and metabolic stimuli. Another transcription factor or co-activator may be 
a frmctional partner of HNF4a at the SREBP-lc promoter. A possible candidate for 
interaction with HNF4a at the SREBP-lc promoter is a member of the SREBP family, with 
an SRE motif present approximately 400 bp downstr eam of the putative HNF4a binding site 
in the human SREBP-lc promoter (Figure 4.10). HNF4a has been shown to interact in a 
non-DNA binding manner witli SREBP-2 to activate sterol isomerase gene expression 
(Misawa et a l, 2003). On the other hand, the interaction of SREBP-1 with HNF4a prevents 
PGC-la recruitment to the PEPCK and CYP7A1 genes and inliibits their transcription in the 
fed state (Yamamoto et a l , 2004; Li et a l, 2006; Ponugoti et a l, 2007). In the case of the 
SREBP-lc gene promoter, tlie converse scenario could occur: HNF4a and SREBP cooperate 
in activating SREBP-lc transcription, hence overexpressed PGC-la competes with SREBP 
for binding of HNF4a, leading to decreased SREBP-lc gene expression (Figuie 7.1C). As 
noted for PEPCK and L-PK, the phosphorylation state of HNF4a and its protein pai tners 
could determine whether a co-factor such as PGC-la behaves as a co-activator or a co­
repressor.
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Figure 7.1: Model of HNF4a-dependent regulation of (A) PEPCK, (B) L-PK and (C) 
SREBP-lc gene expression in response to metabolic stimuli. (A) HNF4a interactions 
with PGC-la and GR in stimulating PEPCK expression may be dependent on the 
phosphorylation state of HNF4a and PGC-la. (B) HNF4a forms a nucleoprotein 
complex with ChREBP to activate L-PK expression in response to high glucose and 
insulin. (C) HNF4a activates SREBP-lc in response to insulin, potentially through an 
interaction with SREBP, which can be disrupted by PGC-la and p300.
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In siimniary, glucagon was found to activate HNF4a in promoting PEPCK expression 
tlu'ough synergy of HNF4a with PGC-la. Insulin activated HNF4a in promoting the 
expression of the L-PK and SREBP-lc genes, an effect repressed by PGC-la or p300, 
suggesting that alternate protein complexes are central to the role of HNF4a in glycolytic and 
lipogenic gene expression. Overall, the cuiTent research provides new evidence that HNF4a 
activity is modulated by metabolic stimuli and suggests that the balance between insulin and 
glucagon in the circulation impacts on the subset of HNF4a tar get genes which arc activated 
and their dysregulation in metabolic disease states.
7.2 Recommendations for future work
It is planned to publish the results of the current project in a peer-reviewed journal in due 
course. In addition, the current results could be built on using the following approaches:
> Expansion of HNF4a target gene analysis
The proposed model (Figme 7.1) for the regulation of fasting vs. feeding-induced genes by 
HNF4a could be confirmed by extending the tar get genes analysed from the experiment 
where HNF4a, p300 and PGC-la were overexpressed and effects on PEPCK and L-PK 
gene expression studied (Figures 6.16 - 6.25). Target genes which could be analysed by 
quantitative RT-PCR include additional genes of the gluconeogenic pathway (G-6-Pase), 
glycolytic pathway (GK, aldolase B) and lipogenic pathway (FAS, MTP).
> HNF4a knock-down by small-interfering RNA
The role of HNF4a in metabolic regulation of its tar get genes could be further investigated 
by expression of small-interfering RNA (siRNA) against HNF4a, which knocks down gene 
function by inducing cleavage of mRNA coding for the siRNA-tar geted gene. This approach 
has proved useful in demonstrating a role for HNF4a in the induction of FAS mRNA 
expression by carbohydrate in rat hepatocytes (Adamson et aL, 2006). An siRNA approach 
would also lend itself to further investigation of the role of specific HNF4a splice variants in 
target gene expression.
> Further validation of human SREBP-lc as a HNF4a target gene
Since further validation of human SREBP-lc as a HNF4a target gene was not possible due to 
limited SREBP-lc mRNA expression in HepG2 cells (Chapter 5), other approaches could be
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employed. HNF4a binding to the putative HNF4a binding site in the human SREBP-lc 
promoter has yet to be demonstrated (Tarling et a/., 2004). HNF4a binding to the SREBP-1 
promoter could be investigated in vitro by electrophoretic mobility shift assays (EMSA) with 
oligonucleotides corresponding to the HNF4a element in the SREBP-lc promoter. 
Chromatin immunoprécipitation (ChIP) analysis with anti-HNF4a antibodies using primary 
human hepatocytes would demonstrate genomic binding of HNF4a to the SREBP-lc 
promoter.
> Role of HNF4a phosphorylation state in differential regulation
The proposed role of HNF4a phosphorylation status in the regulation of differentially 
expressed target genes (Figure 7.1) could be tested by the utilisation of HNF4a 
phosphorylation site mutants. In tliis approach, the relevant serine (or threonine) residue is 
mutated to an alanine to generate a HNF4a which cannot be phosphorylated at that residue, 
or a phosphomimetic is generated by the mutation from serine to aspartate. Combined with 
inliibitors of the protein kinases of interest {e.g. p38 MAPK), this approach has enabled the 
identification of the HNF4a serine residue (SI 5 8) involved in the activation of target gene 
expression in response to inflammatory redox stimuli (Guo et al., 2006). A larger scale 
analysis of changes in the phosphorylation state of HNF4a, other transcription factors and 
co-factors in response to a pai-ticulai' metabolic stimuli could be undertaken using a 
phosphoproteomics approach (Ptacek and Snyder, 2006).
> HNF4a protein-protein interactions
The potential interactions of HNF4a with protein partners such as PGC-la, CliREBP and 
SREBP under different metabolic conditions (Figme 7.1) could be investigated by cliromatin 
imnimioprecipitation (ChIP) analysis, whereby transcription factors are crosslinked to DNA 
by formaldehyde treatment followed by immmioprecipitatiori with an antibody against the 
protein of interest and PCR with primers specific to elements of the tar get gene promoter 
(Das et al., 2004). Antibodies against the HNF4a protein partner of interest combined with 
PCR primers specific to the HNF4a binding site in the target gene promoter would indicate 
an interaction between HNF4a and a protein partner at the target gene promoter.
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> Metabolite profiling
In order to study the impact of changes in HNF4a activity on flux tlu'ough metabolic 
pathways, a metabolomics approach could be employed combined with HNF4a laiockdown 
or overexpression. The application of metabolomics methods to study metabolite profiles 
related to glucagon function in HepG2 cells has recently been presented (Thuniser et al., 
2007a) (see List of Abstiacts).
2 2 2
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Chapter 8:
8.1 Sequencing of HNF4a splice variant RT-PCR products
SeqA Name 
1 iin f4 a lp ro d
L e n (n t)  SeqB Name L e n (n t)  Score
582 2 h n f4a ïsëq F 2  339 84
CLUSTAL W (1 .8 2 )  m u lt ip le  sequence a lig n m e n t
CTGCTCGGAGCCACCAAGAGATCCATGGTGTTCAAGGACGTGCTGCTCCTAGGCAATGAC 60h n f4 a lp ro d
h nf4a lseq F2
h n f4 a lp ro d
h nf4a lseq F2
h n f4 a lp ro d
h nf4a lseq F2
h n f4 a lp ro d
h nf4a lseq F2
h n f4 a lp ro d
h n f4a lseq F 2
h n f4 a lp ro d
hnf4a lseq F2
h n f4 a lp rc d
hnf4a lseq P 2
h n f4 a lp ro d
hnf4a lseq F2
h n f4 a lp rc d
hn f4a lseq F 2
h n f4 a lp ro d
h n f4a lseq P 2
h n f4 a lp ro d
h nf4a lseq F2
TACATTGTCCCTCGGCACTGCCCGGAGCTGGCGGAGATGAGCCGGGTGTCCATACGCATC 120
CTTGACGAGCTGGTGCTGCCCTTCCAGGAGCTGCAGATCGATGACAATGAGTATGCCTAC 180
CTCAAAGCCATCATCTTCTTTGACCCAGATGCCAAGGGGCTGAGCGATCCAGGGAAGATC 240
AAGCGGCTGCGTTCCCAGGTGCAGGTGAGCTTGGAGGACTACATCAACGACCGCCAGTAT 300 
---------------------------------------------------------------------------------AGANAAACANCTNNN--CAT 18* * * * * *  **
GACTCG-CGTGGCCGC--TTTGGAGAGCTG— CTGCTGCTGCTGCCCACCTTG-CAGAGC 354 
GACTCGGCGTGGCCGACATTTGGAGAGCTNGTCNGCTGCTGCTGCCCACCTTGGCAGAGC 78****** ******** *********** * ******************* ******
ATCACCTGGCAGATGATCGAGCAGATCCAGTTCATCAAGCTCTTCGGCATGGCCAAGATT 414 
ATCACCTGGCAGATGATCGAGCAGATCCAGTTCATCAAGCTCTTCGGCATGGCCAAGATT 138* * * * * * * * * * * * * ****************** * * * * * * * ************** * * * * * * * *
GACAACCTGTTGCAGGAGATGCTGCTGGGAGGGTCCCCCAGCGATGCACCCCATGCCCAC 474 
GACAACCTGTTGCAGGAGATGCTGCTGGGAGGGTCCCCCAGCGATGCACCCCATGCCCAC 198****** is * * * * * * * * * * * * * ******** * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
CACCCCCTGCACCCTCACCTGATGCAGGAACATATGGGAACCAACGTCATCGTTGCCAAC 534 
CACCCCCTGCACCCTCACCTGAT6CAGGAACATATGGGAACCAACGTCATCGTTGCCAAC 258************************************************************
ACAATGCCCACTCACCTCAGCAACGGACAGATGTCCACCCCTGÂiSSCd-  _  582
ACAATGCCCACTCACCTCAGCAACGGACAGATGTCCACCCCfGÂGÂCÂACNNNTNNNNCT 318* * * * * * * ****************************************
TTTNGTCCCCCNCNNNNNNNN 339
Box 8.1: ClustalW comparison of HNF4al sequence and the results of sequencing the 
HNF4al RT-PCR product. HepG2 RNA was used in RT-PCR with primers specific to 
the HNF4al splice variant (Section 2.2.5). The HNF4al RT-PCR product was purified 
and sequenced using primer seqprimerF2 (Section 2.2.9). Results of the sequencing 
reaction {hnf4alseqF2) were compared with sequence based on human HNF4al sequence 
(Genbanlc Accession No.: NM_178849) {hnf4alprod) using ClustalW. Asterisks 
underneath the aligned sequences indicate that the sequences are identical. The 
sequencing results show 100% homology with tlie HNF4al sequence ûom base number 
73 up to and including the final section which is unique to the HNF4al splice variant. The 
yellow/greeh boundary indicates the splice site between exons 9 and 10 of tlie HNF4al 
coding sequence which is unique to this splice variant.
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SeqA Name L e n (n t)  SeqB Name L e n (n t)  score
Ï  HNF4a2RTPCR 594 2 a2resultsF2C 0R R  314 94
A l ignm ent
CLUSTAL W ( 1 .8 3 )  m u lt ip le  sequence a lig n m e n t
HNF4a2RTPCR CTGCTCGGAGCCACCAAGAGATCCATGGTGTTCAAGGACGTGCTGCTCCTAGGCAATGAC 60
a2resultsF2CORR------------ -------------------------------------------------------------------------------------------------------------------------
HNF4a2RTPCR TACATTGTCCCTCGGCACTGCCCGGAGCTGGCGGAGATGAGCCGGGTGTCCATACGCATC 120
a2resultsF2C 0R R --------------------------------------------------------------------------------------------------------------------------------------
HNF4a2RTPCR CTTGACGAGCTGGTGCTGCCCTTCCAGGAGCTGCAGATCGATGACAATGAGTATGCCTAC 180
a2resultsF2C 0R R ------------ --------------------------------------------------------------------------------------------------------------------------
HNF4a2RTPCR CTCAAAGCCATCATCTTCTTTGACCCAGATGCCAAGGGGCTGAGCGATCCAGGGAAGATC 240
a2resultsF2CORR------------ --------------------------------------------------------------------------------------------------------------------------
HNF4a2RTPCR AAGCGGCTGCGTTCCCAGGTGCAGGTGAGCTTGGAGGACTACATCAACGACCGCCAGTAT 300
a2resultsF2CORR  TAGAANNNNNTNNGNCAT 18
HNF4a2RTPCR GACTCGCGTGGCCG-CTTTGGAGAGCTGCTGCTGCTGCTGCCCACCTTGCAGAGCATCAC 359
a2resultSF2C 0R R  GACTCGCGTGGCCGACTTTGGAGAGCTGCTGCTGCTGCTGCCCACCTTGCAGAGCATCAC 78************** *********************************************
HNF4a2RTPCR CTGGCAGATGATCGAGCAGATCCAGTTCATCAAGCTCTTCGGCATGGCCAAGATTGACAA 419
a2resultsF2C 0R R  CTGGCAGATGATCGAGCAGATCCAGTTCATCAAGCTCTTCGGCATGGCCAAGATTGACAA 138* *  *  *  *  * * * * * * * *  * *  * * *  * *  * * *  *  * * * *  * * * * * * *  *  * * * *  * *  *  * *  *  *  * * *  *  * * * * * * *  * i t
HNF4a2RTPCR CCTGTTGCAGGAGATGCTGCTGGGAGGGTCCCCCAGCGATGCACCCCATGCCCACCACCC 479
a2resultSF2C 0R R  CCTGTTGCAGGAGATGCTGCTGGGAGGGTCCCCCAGCGATGCACCCCATGCCCACCACCC 198******* * * * * * * * * ********** * * * * * ******** * * * * * * ************ ****
HNF4a2RTPCR CCTGCACCCTCACCTGATGCAGGAACATATGGGAACCAACGTCATCGTTGCCAACACAAT 5 39
a2resultsF2C 0R R  CCTGCACCCTCACCTGATGCAGGAACATATGGGAACCAACGTCATCGTTGCCAACACAAT 258************************************************************
HNF4a2RTPCR GCCCACTCACCTCAGCAACGGACAGATGT6TGAGTGGCCCCGACCCAGGGGACAG- 594
a2resultSF2C0RR GCCCACTCACCTCAGCAACGGACAGATGTGTGAGTGGCCCCGACCCAGGGGACAGA 314* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
Box 8,2: ClustalW comparison of HNF4a2 sequence and the results of sequencing the 
HNF4a2 RT-PCR product. HepG2 RNA was used in RT-PCR with primers specific to 
the HNF4a2 splice variant (Section 2.2.5). The HNF4a2 RT-PCR product was purified 
and sequenced using primer seqprimerF2 (Section 2.2.9). Results of the sequencing 
reaction (a2resuîtsF2CORR) were compared with sequence based on himian HNF4a2 
sequence (Genbank Accession No.: NM 000457) (HNF4a2RTPCR) using ClustalW. 
Asterisks underneath die aligned sequences indicate that the sequences are identical. The 
sequencing results show 100% homology with die HNF4a2 sequence from base number 
33 (sequencing result) up to and including the final 26 bp section which is unique to the 
HNF4a2 splice variant (highlighted area).
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SeqA Name L e n (n t)  SeqB Name L e n (n t)  Score
1 h n f4a lp h a3p ro d  231 2 s e q r e s u lt  218 93
CLUSTAL W ( 1 .8 2 )  m u lt ip le  sequence a lig n m e n t
h n f4a lp ha3p ro d  -CCTGGCAGATGATCGAGCAGATCCAGTTCATCAAGCTCTTCGGCATGGCCAAGATTGAC 59
s e q re s u lt  tcctggcagatg atcg ag cag atccag ttcatcaag ctcttcg g catg g ccaag attg ac  60***********************************************************
h nf4a lp ha3p ro d  aacctgttgcaggagatgctgctgggaggtccgtgccaagcccaggaggggcggggttgg  119
s e q re s u lt  AACCTGTTGCAGGAGATGCTGCTGGGAGGTCCGTGCCAAGCCCAGGAGGGGCGGGGTTGG 120************************************************************
hnf4alphaB prod  AGTGGGGACTCCCCAGGAGACAGGCCTCACACAGTGAGCTCACCCCTCAGCTCCTTGGCT 179
s e q r e s u lt  AGTGGGGACTCCCCAGGAGACAGGCCTCACACAGTGAGCTCACCCCTCA6CTCCTTGGCT 180* * *** * *** ******* *** ********** * ***** * * * ****** **** ** * ** * *** A**
h n f4a lp h a3p ro d  TCCCCACTGTGCCGCTTTGGGCAAGTTGCTTAACCTGTCTGTGCCTCAGTTT 231
s e q re s u lt  t c c c c a c t g t g n c c n g c t a — t t g g a t a - t c a n c n n n t n a a -----------------------218
Box 8.3: ClustalW comparison of HNF4a3 sequence and the results of sequencing the 
HNF4a3 RT-PCR product. HuH7 RNA was used in RT-PCR with primers specific to 
the HNF4a3 splice variant (Section 2.2.5). The HNF4a3 RT-PCR product was purified 
and sequenced (Section 2.2.9). Results of the sequencing reaction {seqresult) were 
compared with sequence based on human HNF4a3 sequence (Genbanlc Accession No.: 
NM_178850) {HNF4alphaSprod) using ClustalW. Asterisks underneath the sequences 
mdicated sequences are identical. The sequencing results show 100% homology with the 
HNF4a3 sequence up to the last 30 bases where the sequencing reaction breaks down. 
Highlighted ar ea (yellow) indicates the bases which are unique to the HNF4a3 splice 
variant. A similar* ClustalW comparison with the HNF4a2 splice variant yielded a score of 
only 40%.
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S e q A  N am e  
1 H N F 4a7
L e n ( n t )  S e q B  N am e L e n ( n t )  S c o r e
2  s e q r e s u l t  3 5 0  941 3 2 9
H N F 4a7
s e q r e s u l t
------------------ ATGGTCAGCGTGAACGCGCCCCTCGGGGCTCCAGTGGAGAGTTCTTACGACA 5  2
TCTTGGCCATGGTCAGCGTGAACGCGCCCCTCGGGGCTCCAGTGGAGAGTTCTTACGACA 6 0  ****************************************************
H N F 4a7
s e q r e s u l t
CGTCCCCATCAGAAGGCACCAACCTCAACGCGCCCAACAGCCTGGGTGTCAGCGCCCTGT 1 1 2  
CGTCCCCATCAGAAGGCACCAACCTCAACGCGCCCAACAGCCTGGGTGTCAGCGCCCTGT 1 2 0  ** * * * * * * * * * *************************************************
H N F 4a7
s e q r e s u l t
GTGCCATCTGCGGGGACCGGGCCACGGGCAAACACTACGGTGCCTCGAGCTGTGACGGCT 1 7 2  
GTGCCATCTGCGGGGACCGGGCCACGGGCAAACACTACGGTGCCTCGAGCTGTGACGGCT 1 8 0  ************************************************************
H N F 4a7
s e q r e s u l t
GCAAGGGCTTCTTCCGGAGGAGCGTGCGGAAGAACCACATGTACTCCTGCAGATTTAGCC 2 3 2  
GCAAGGGCTTCTTCCGGAGGAGCGTGCGGAAGAACCACATGTACTCCTGCAGATTTAGCC 2 4 0  * * * * * * * * * * * *************************************************
H N F 4a7
s e q r e s u l t
GGCAGTGCGTGGTGGACAAAGACAAGAGGAACCAGTGCCGCTACTGCAGGCTCAAGAAAT 2 9 2  
GGCAGTGCGTGGTGGACAAAGACAAGAGGAACCAGTGCCGCTACTGCAGGCTCAAGAAAT 3 0 0  * * * * * * * * * * * *************************************************
H N F 4a7
s e q r e s u l t
HNF4a7
s e q re s u lt
GCTTCCGGGCTGGCATGAAGAAGGAAGCCGTCCAGAATGAGCGGGACCGGATCAGCACTC 3 5 2
GCTTCCGGGC-GGCAT-AAGAAGGAAGCC-TCCAGAA-GAGCGGACTCACAGCG-------------  3 5 0********** ***** ************  ******* ****** * * *
GAAGGTCAAGCTATGAGGACAGCAGCCTGCCCTCCATCAATGCGCTCCTGCAGGCGGAGG 412
Box 8.4: ClustalW comparison of HNF4a7 sequence and the results of sequencing the 
HNF4a7/8 RT-PCR product. HepG2 RNA was used in RT-PCR with primers specific to 
tlie HNF4a7/8 splice variant (Section 2.2.5). The HNF4a7/8 RT-PCR product was 
purified and sequenced using antisense primer aVprimerRl (underlined bases) (Section 
2.2.9). Results of the sequencing reaction {seqresult) were compaied with sequence based 
on human HNF4a7 sequence (Genbanlc Accession No.: AY680696) {HNF4a7) using 
ClustalW. Asterisks imderneath the sequences indicated sequences are identical, The 
sequencing results show 100% homology with the HNF4a7/8 sequence in exon ID 
(highlighted area) which is unique to the HNF4a7/8 splice vaiiant.
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8,2 Results of statistical analysis (Chapter 4)
8.2.1 Key
Symbol /7-value
N.S. >0.05
<0.05
<0.01* * <0.001
8.2.2 Figure 4.1 : Summary of two-way AN OVA and posthoc analysis
Effect of glucose concentration and hormones on L-PK reporter gene expression in 
HepG2 cells (Figure 4.1);
Results of two-way ANOVA
Source of Variation % of total variation /7-value
Interaction 24.55 /?< 0.0001
Incubation condition 27.09 p < 0.0001
Reporter gene 35.86 /?< 0.0001
Post-hoc analysis (Bonferroni);
Table 8.1: Post-hoc analysis - Incubation condition: Reporter gene: (L4L3)4-54PK
Incubation
condition
5.5 mM 
glucose
25 mM 
glucose
5,5 mM 
glucose + 
Insulin
25 mM 
glucose + 
Insulin
5.5 mM 
glucose + 
HSM
25 mM 
glucose + 
HSM
5.5 mM 
glucose - *** N.S. *** N.S. ***
25 mM 
glucose - *** N.S. N.S.
5.5 mM 
glucose + 
Insulin
N.S. *** - N.S. ***
25 mM 
glucose + 
Insulin
N.S. - *** $
5.5 mM 
glucose + 
HSM
N.S. >1; * N.S. *** -
25 mM 
glucose + 
HSM
*** N.S. *** * *** -
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Table 8.2: Post-hoc analysis - Incubation condition: Reporter gene: (L3)3-54 PK
Incubation
condition
5.5 mM 
glucose
25 mM 
glucose
5.5 mM 
glucose + 
Insulin
25 niM 
glucose + 
Insulin
5.5 mM 
glucose + 
HSM
25 mM 
glucose + 
HSM
5.5 niM 
glucose - N.S. N.S. N.S. N.S. N.S.
25 mM 
glucose N.S. - N.S. N.S. N.S. N.S.
5.5 mM 
glucose + 
Insulin
N.S. N.S. - N.S. N.S. N.S.
25 mM 
glucose + 
Insulin
N.S. N.S. N.S. - N.S. N.S.
5.5 mM 
glucose + 
HSM
N.S. N.S. N.S. N.S. - N.S.
25 mM 
glucose + 
HSM
N.S. N.S. N.S. N.S. N.S. —
Table 8.3: Post-hoc analysis (Reporter gene)
Reporter gene
Incubation condition
(L4L3)4-54PKv5. (L3)3-54PK
5.5 mM glucose N.S.
25 mM glucose ***
5.5 mM glucose + Insulin N.S.
25 mM glucose + Insulin ***
5.5 mM glucose + HSM N.S.
25 mM glucose + HSM ***
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8.2.3 Figure 4.5: Summary of one-way ANOVA and posthoc analysis
Regulation of SREBP-lc reporter gene expression by (A) rat and (B) human HNF4al, 
insulin, glucose concentration and PG C -la (Figure 4.5):
Figure 4.5A
Result of one-way ANOVA: p  < 0.001 
Post-hoc analysis using Tukey’s post-hoc tests:
Table 8.4: Besults of post-hoc analysis: Figure 4.5A (Rat HISF4a overexpression)
Incubation
condition
5.5 mM 
glucose
5.5 mM 
glucose 
+ insulin
5.5 mM 
glucose 
+HNF4a
5.5 mM 
glucose 
+ insulin+
HNF4a
25 niM 
glucose+
HNF4a
25 mM 
glucose 
+ insulin+
HNF4a
5.5 mM 
glucose 
+HNF4a 
+ PGC- 
la
5.5 mM 
glucose 
+ insulin 
+HNF4a 
+ PGC- 
la
5.5 mM 
glucose - N.S. *** *** *** ***
5.5 mM 
glucose + 
insulin
N.S. - *** *** * * * ***
5.5 mM 
glucose 
+HNF4a
- * * * N.S. *** *** * * *
5.5 mM 
glucose + 
insulin + 
HNF4a
*** * * * * *** N.S. *** ***
25 mM 
glucose + 
HNF4a
N.S. *** - *** *** ***
25 mM 
glucose 
+ insulin 
+ HNF4a
H: * ❖ N.S. *** - *** * * *
5.5 mM 
glucose 
+HNF4a + 
PGC-la
^îJîsIj *** *** *** - N.S.
5.5 mM 
glucose + 
insulin 
+HNF4a + 
PGC-la
*** *4(0 * * * *** N.S. -
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Figure 4.5B
Result of one-way ANOVA: p  < 0.001
Table 8.5: Results of 3ost-hoc analysis: Figure 4.51 (Human HNF4a overexpression)
Incubation
condition
5.5 mM 
glucose
5.5 mM 
glucose 
+ insulin
5.5 mM 
glucose 
+HNF4a
5.5 mM 
glucose 
+ insulin+
HNF4a
25 mM 
glucose+
HNF4a
25 mM 
glucose 
+ insulin+
HNF4a
5.5 mM 
glucose 
+HNF4a 
+ PGC- 
la
5.5 mM 
glucose 
+ insulin 
+HNF4a 
+ PGC- 
la
5.5 mM 
glucose - N.S. 0*0 0*0 000 0*0 N.S. *
5.5 mM 
glucose + 
insulin
N.S. - 0*0 0*0 00* 0*0 * 0 0
5.5 mM 
glucose 
+HNF4a
0*0 00* - 0*0 N.S. N.S. N.S. N.S.
5.5 mM 
glucose + 
insulin + 
HNF4a
00 0 00* 00* - 00* N.S. 00* 000
25 mM 
glucose + 
HNF4a
00* *0 0 N.S. 00* - * N.S. N.S.
25 mM 
glucose 
+ insulin 
+ HNF4a
000 00* N.S. N.S. * - 0*0 00*
5.5 mM 
glucose 
+HNF4a + 
PGC-la
N.S. * N.S. 0*0 N.S. 000 - N.S.
5.5 mM 
glucose + 
insulin 
+HNF4a + 
PGC-la
* 0 0 N.S. 00 0 N.S. 0*0 N.S. -
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8 .3  R e s u l t s  o f  s e q u e n c i n g  D N - H N F 4 a  e x p r e s s i o n  v e c t o r
W T-H N F4A
D N -H N F 4A
CTGGACCCAGCCTACACCACCCTGGAATTTGAGAATGTGCAGGTGTTGACGATGGGCAAT
CTGGACCCAGCCTACACCACCCTGGAATTTGAGAATGTGCAGGTGTTGACGATGGGCAAT
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
2 0 3
2 4 0
W T-H N F4A
D N -H N F 4A
GACACGTCCCCATCAGAAGGCACCAACCTCAACGCGCCCAACAGCCTGGGTGTCAGCGCG
GACACGTCCCCATCAGAAGGCACCAACCTCAACGCGCCCAACAGCCTGGGTGTCAGCGCC* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
2 6 3
3 0 0
W T-HNF4A
D N -H N F 4A
CTGTGTGCCATCTGCGGGGACCGGGCCACGGGCAAACACTACGGTGCCTCGAGCTGTGAC
CTGTGTGCCATCTGCGGGGACCGGGCCACGGGCAAACACTACGGTGCCTCGAGCTGTGAC
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
3 2 3
3 6 0
W T-HNF4A
D N -H N F 4A
g g c t g c a a g g g c t t c t t c c g g a g g a g c g t g c g g a a g a a c c a c a t g t a c t c c t g c a g a t t t
GGCTGCAAGGGCTTCTTCCGGAGGAGCGTGCGGAAGAACCACATGTACTCCTGCAGATTT
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
3 8 3
4 2 0
W T-H N F4A
D N -H N F 4A
a g c c g g c a g t g c g t g g t g g a c a a a g a c a a g a g g a a c c a g t g c c g c t a c | g c a g g c t c a a g
AGCCGGCAGTGCGTGGTGGACAAAGACAAGAGGAACCAGTGCCGCTACCGCAGGCTCAAG
* * * * * * * * * * *
4 4 3
4 8 0
W T-HNF4A
D N -H N F 4A
AAATGCTTCCGGGCTGGCATGAAGAAGGAAGCCGTCCAGAATGAGCGGGACCGGATCAGC
AAATGCTTCCGGGCTGGCATGAAGAAGGAAGCCGTCCAGAATGAGCGGGACCGGATCAGC
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
5 0 3
5 4 0
W T-HNF4A
D N -H N F 4A
ACTCGAAGGTCAAGCTATGAGGACAGCAGCCTGCCCTCCATCAATGCGCTCCTGCAGGCG
ACTCGAAGGTCAAGCTATGAGGACAGCAGCCTGCCCTCCATCAATGCGCTCCTGCAGGCG
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
5 6 3
6 0 0
Box 8.5: ClustalW comparison of wild-type HNF4a sequence and the results of 
sequencing the DN-HNF4a expression vector (pDGT23.1). DN-HNF4a expression 
vector was sequenced with T7 promoter primer present in the basic vector (pcDNA3). 
Results of the sequencing reaction (DN-HNF4A) were compar ed with sequence of the 
wild-type human HNF4a2 sequence (WT-HNF4A) (Genbanlc Accession No.: 
NM_000457) using ClustalW sequence aligmnent program. It was confirmed that DN- 
HNF4a differs from wild-type in tliat it contains a T (green) - >  C (red) point mutation, 
as described by Taylor et aL (1996).
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8.4 Further analysis (Chapter 6)
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Figure 8.1: Effect of DN-HNF4a on the regulation of (A) apoCIII and (B) FAS mRNA 
expression by insulin: Linear regression analysis. Linear' regr ession analysis of (A) 
apoCIII or (B) FAS vs. HNF4a mRNA expression levels were performed with data from 
control (closed triangles A ) and insulin (open triangles A ) incubation conditions (from 
both pcDNA3- and DN-HNF4a-transfection conditions), from experiment as described in 
Figure 6.12. Results are presented as individual datapoints with linear regression analyses 
indicated by a dashed line with adjacent R  ^and /7-values. Differences between control and 
insulin incubation conditions were analysed by compar ing the slopes and intercepts of tire 
two linear' regression analyses, as indicated by a double-arrow and adjacent /7-value (N.S., 
not significant).
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X 300% -
n. 200%-
100%-\m m
Incubation condition:
t m  Control (0.04% HOH) 
ESSa Dex.
CS23 8-Br-cAMP + dex.
pcDNA3 HNF4a+p300+PGC-1a 
Transfection condition
500%-c
400% -
300% -
200% -
.£ 100%-
0%
pcDNA3 HNF4a+p300+PGC-1 a.
Incubation condition:
t = n  Control (0.04% EtOH) 
c c z t  8-Br-cAl^P + dex.
Transfection condition
Figure 8.2: Comparison of (A) HNF4a, (B) p300 and (C) endogenous PG C -la 
expression in HepG2 cells between dexamethasone-containing and control (EtOH)-
medium. Experiment described in Figure 6.15. The effect of incubation with 
dexamethasone on gene expression was compaied with control medium (0.04% EtOH) by 
two-way ANOVA with Bonferroni post-hoc tests (*/? < 0.05, ** p  < 0.01, *** p  < 0.001).
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Figure 8.3: Comparison of (A) exogenous PGC-la, (B) PEPCK and (C) L-PK 
expression in HepG2 cells between dexamethasone-containing and control (EtOH) 
medium. Experiment described in Figure 6.15. The effect of incubation with 
dexamethasone on gene expression was compared with control medium (SFM + 0.04% 
EtOH) by two-way ANOVA with Bonferroni post-hoc tests (* p  < 0.05, < 0.01, *** p
<0.001).
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Figure 8.4; Correlation bet^veen expression of PEPCK and (A) IINF4a, (B) p300 (C) 
endogenous PGC-la and (D) exogenous PGC-la mRNA levels under 100 nM insulin 
incubation condition. Analysis of correlation between PEPCK and HNF4a / co-activator 
mRNA expression levels was performed witli data from control (closed triangles A) and 
insulin (open triangles A ) as presented in Figures 6.16 to 6.18. Results are presented as 
individual datapoints with correlation analyses indicated by a dashed line with adjacent 
and values. Differences between the incubation conditions were analysed by comparing 
the lineal' regression analyses and a significant difference between the intercepts or slopes 
of the two lines is indicated by a double-anow and adjacent p-value or N.S. in the case of 
no significant differences. (If the difference relates to the slopes, this is noted; no additional 
notation coixesponds to a difference between the intercepts).
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Figure 8.5: Correlation bet^veen expression of PEPCK and (A) HNF4a, (B) p300 (C) 
endogenous PG C -la and (D) exogenous PG C -la mRNA levels under 25 mM glucose 
incubation condition. Analysis of correlation between PEPCK and HNF4a / co-activator 
mRNA expression levels was performed performed with data from control (closed 
triangles A ) and 25 mM glucose (open triangles A ) as presented in Figures 6.16 to 6.18. 
Results aie presented as individual datapoints with correlation analyses indicated by a 
dashed line with adjacent R  ^andj??-valiies. Differences between the incubation conditions 
were analysed by comparing the linear regression analyses and a significant difference 
between the intercepts or slopes of the two lines is indicated by a double-arrow and 
adjacent p-value or N.S. in the case of no significant differences. (If the difference relates 
to the slopes, this is noted; no additional notation corresponds to a difference between the 
intercepts).
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Figure 8.6: Correlation between expression of L-PK and (A) HNF4a, (B) p300 (C) 
endogenous PG C -la and (D) exogenous PG C -la mRNA levels under 1 pM 
dexamethasone incubation condition. Analysis of correlation between L-PK and HNF4a 
/ co-activator mRNA expression levels was performed performed with data from control 
(closed triangles A )  and dexamethasone (open triangles A) as presented in Figures 6.16, 
6.17 and 6.23. Results are presented as individual datapoints with correlation analyses 
indicated by a dashed line with adjacent R  ^and /7-values. Differences between the 
incubation conditions were analysed by comparing the linear' regression analyses and a 
significant difference between the intercepts or slopes of the two lines is indicated by a 
double-anow and adjacent p-value oï N.S. in the case of no significant differences. (If the 
difference relates to the slopes, this is noted; no additional notation corresponds to a 
difference between the intercepts).
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Figure 8.7: Correlation between expression of L-PK and (A) HNF4a, (B) p300 (C) 
endogenous PGC-la and (D) exogenous PGC-la mRNA levels under 1 inM 8-Br- 
cAMP and 1 pM dexamethasone incubation condition. Analysis of correlation between 
L-PK and HNF4a / co-activator niRNA expression levels was performed with data from 
control (closed triangles A ) and 8-Br-cAMP + dexamethasone (open triangles A) as 
presented in Figures 6.16, 6.17 and 6.23. Results are presented as individual datapoints 
with correlation analyses indicated by a dashed line with adjacent R  ^andp-values. 
Differences between the incubation conditions were analysed by comparing the linear 
regression analyses and a significant difference between the intercepts or slopes of the two 
lines is indicated by a double-aiTOW and adjacent p-value or N.S. in the case of no 
significant differences. (If the difference relates to the slopes, this is noted; no additional 
notation corresponds to a difference between the intercepts).
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Figure 8.8: Correlation between expression of L-PK and (A) HNF4a, (B) p300 (C) 
endogenous PGC-la and (D) exogenous PGC-la mRNA levels under 100 nM insulin 
incubation condition. Analysis of correlation between L-PK and HNF4a / co-activator 
mRNA expression levels was performed with data from control (closed triangles A) and 
insulin (open triangles A) as presented in Figmes 6.16, 6.17 and 6.23. Results are 
presented as individual datapoints with correlation analyses indicated by a dashed line with 
adjacent R  ^and/?-values. Differences between the incubation conditions were analysed by 
comparing the lineai' regression analyses and a significant difference between the intercepts 
or slopes of the two lines is indicated by a double-arrow and adjacent p-value or N.S. in the 
case of no significant differences. (If the difference relates to the slopes, this is noted; no 
additional notation corresponds to a difference between the intercepts).
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